{
    "paper_id": "fa379d78a9adefe07274e654d197681633d28ad6",
    "metadata": {
        "title": "EDITOR-IN-CHIEF EDITORIAL CONSULTANTS CONTINUED SOCIAL MEDIA EDITORS Design of the b3-Adrenergic Agonist Treatment in Chronic Pulmonary Hypertension Secondary to Heart Failure Trial",
        "authors": [
            {
                "first": "Valentin",
                "middle": [],
                "last": "Fuster",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "David",
                "middle": [
                    "J"
                ],
                "last": "Moliterno",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Y",
                "middle": [],
                "last": "Chandrashekhar",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Christopher",
                "middle": [
                    "M"
                ],
                "last": "O&apos;connor",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Jacc",
                "middle": [
                    ":"
                ],
                "last": "Clinical",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Electrophysiology",
                "middle": [],
                "last": "David",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "J",
                "middle": [],
                "last": "Wilber",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Julia",
                "middle": [],
                "last": "Grapsa",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Bonnie",
                "middle": [],
                "last": "Ky",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Brian",
                "middle": [
                    "H"
                ],
                "last": "Annex",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Nanette",
                "middle": [
                    "H"
                ],
                "last": "Bishopric",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Nikolaos",
                "middle": [
                    "G"
                ],
                "last": "Frangogiannis",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Daniel",
                "middle": [
                    "P"
                ],
                "last": "Kelly",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Peter",
                "middle": [],
                "last": "Libby",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "William",
                "middle": [
                    "Robb"
                ],
                "last": "Maclellan",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Geoffrey",
                "middle": [
                    "S"
                ],
                "last": "Pitt",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Eva",
                "middle": [],
                "last": "Van Rooij",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Mark",
                "middle": [],
                "last": "Anderson",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Themistocles",
                "middle": [],
                "last": "Assimes",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Noel",
                "middle": [],
                "last": "Bairey-Merz",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Craig",
                "middle": [],
                "last": "Basson",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Jeffrey",
                "middle": [],
                "last": "Berger",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Don",
                "middle": [],
                "last": "Bers",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Michael",
                "middle": [],
                "last": "Bristow",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Daniel",
                "middle": [],
                "last": "Burkoff",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "John",
                "middle": [],
                "last": "Burnett",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "John",
                "middle": [],
                "last": "Canty",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Barbara",
                "middle": [],
                "last": "Casadei",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Karen",
                "middle": [],
                "last": "Christman",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Peter",
                "middle": [],
                "last": "Crawford",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Craig",
                "middle": [],
                "last": "Emter",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Zahi",
                "middle": [],
                "last": "Fayad",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Glenn",
                "middle": [],
                "last": "Fishman",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Peter",
                "middle": [],
                "last": "Ganz",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Roberta",
                "middle": [],
                "last": "Gottlieb",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Josh",
                "middle": [],
                "last": "Hare",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Douglas",
                "middle": [
                    "L"
                ],
                "last": "Mann",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "L",
                "middle": [
                    "Kristin"
                ],
                "last": "Newby",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Robert",
                "middle": [],
                "last": "Roberts",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Juan",
                "middle": [
                    "F"
                ],
                "last": "Granada",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Cindy",
                "middle": [],
                "last": "Green",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Justine",
                "middle": [
                    "Varieur"
                ],
                "last": "Turco",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "",
                "middle": [],
                "last": "Ma",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Monica",
                "middle": [
                    "R"
                ],
                "last": "Payne-Emmerson",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Kimberly",
                "middle": [],
                "last": "Trevey",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "",
                "middle": [],
                "last": "Ba",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Nandhini",
                "middle": [],
                "last": "Kuntipuram",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Elizabeth",
                "middle": [],
                "last": "Bradtke",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Tamika",
                "middle": [
                    "Edaire"
                ],
                "last": "",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Jennifer",
                "middle": [],
                "last": "Rapp",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Ray",
                "middle": [],
                "last": "Hershberger",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Carolyn",
                "middle": [],
                "last": "Ho",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Jennifer",
                "middle": [],
                "last": "Ho",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Farouc",
                "middle": [],
                "last": "Jaffer",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Tim",
                "middle": [],
                "last": "Kamp",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Walter",
                "middle": [],
                "last": "Koch",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "David",
                "middle": [],
                "last": "Lanfear",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Jin-Moo",
                "middle": [],
                "last": "Lee",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Richard",
                "middle": [],
                "last": "Lee",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Jonathan",
                "middle": [],
                "last": "Lindner",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Peter",
                "middle": [],
                "last": "Liu",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Eduardo",
                "middle": [],
                "last": "Marban",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Ali",
                "middle": [],
                "last": "Marian",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Kenneth",
                "middle": [],
                "last": "Margulies",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Peter",
                "middle": [],
                "last": "Mccullough",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Timothy",
                "middle": [],
                "last": "Mckinsey",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Javid",
                "middle": [],
                "last": "Moslehi",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Jorge",
                "middle": [],
                "last": "Plutzky",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "David",
                "middle": [],
                "last": "Port",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Sumanth",
                "middle": [],
                "last": "Prabhu",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Hani",
                "middle": [],
                "last": "Sabbath",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Paul",
                "middle": [],
                "last": "Simpson",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Mark",
                "middle": [],
                "last": "Sussman",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Jenny",
                "middle": [],
                "last": "Van Eyk",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Richard",
                "middle": [],
                "last": "Vega",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Xander",
                "middle": [],
                "last": "Wehrens",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Arthur",
                "middle": [],
                "last": "Wilde",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Myles",
                "middle": [],
                "last": "Wolf",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Sean",
                "middle": [],
                "last": "Wu",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Amanda",
                "middle": [],
                "last": "Coniglio",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Michelle",
                "middle": [],
                "last": "Kelsey",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Vishal",
                "middle": [],
                "last": "Rao",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Reza",
                "middle": [],
                "last": "Ardehali",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Meena",
                "middle": [
                    "S"
                ],
                "last": "Madhur",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Holly",
                "middle": [],
                "last": "Atkinson",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Lawrence",
                "middle": [
                    "S"
                ],
                "last": "Cohen",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Kim",
                "middle": [],
                "last": "Fox",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Robert",
                "middle": [],
                "last": "Frye",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Philip",
                "middle": [
                    "J"
                ],
                "last": "Landrigan",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Richard",
                "middle": [
                    "L"
                ],
                "last": "Popp",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Eric",
                "middle": [
                    "N"
                ],
                "last": "Prystowsky",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "James",
                "middle": [],
                "last": "Willerson",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Athena",
                "middle": [],
                "last": "Poppas",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Howard",
                "middle": [
                    "&quot;"
                ],
                "last": "Bo",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "&quot;",
                "middle": [
                    "T"
                ],
                "last": "Walpole",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Daniel",
                "middle": [
                    "M"
                ],
                "last": "Philbin",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Viviany",
                "middle": [
                    "R"
                ],
                "last": "Taqueti",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Rhonda",
                "middle": [
                    "M"
                ],
                "last": "Cooper-Dehoff",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Islam",
                "middle": [
                    "Y"
                ],
                "last": "Elgendy",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Prasad",
                "middle": [
                    "C"
                ],
                "last": "Gunasekaran",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Fadi",
                "middle": [
                    "G"
                ],
                "last": "Hage",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Fred",
                "middle": [
                    "M"
                ],
                "last": "Kusumoto",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Renato",
                "middle": [
                    "D"
                ],
                "last": "Lopes",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Sandra",
                "middle": [
                    "M"
                ],
                "last": "Oliver-Mcneil",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Acnp-Bc",
                "middle": [],
                "last": "John",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "U",
                "middle": [],
                "last": "Doherty",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Facc",
                "middle": [],
                "last": "Syed",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Tanveer",
                "middle": [],
                "last": "Rab",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Janice",
                "middle": [
                    "B"
                ],
                "last": "Sibley",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Acc",
                "middle": [],
                "last": "Ma",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Senior",
                "middle": [],
                "last": "Divisional",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "",
                "middle": [],
                "last": "Director",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Ines",
                "middle": [],
                "last": "Garcia-Lunar",
                "suffix": "",
                "affiliation": {
                    "laboratory": "Centro Nacional de Investigaciones Cardiovasculares (CNIC)",
                    "institution": "",
                    "location": {
                        "settlement": "Madrid",
                        "country": "Spain"
                    }
                },
                "email": ""
            },
            {
                "first": "Isabel",
                "middle": [],
                "last": "Blanco",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Hospital Cl\u00ednic-IDIBAPS",
                    "location": {
                        "settlement": "Barcelona",
                        "country": "Spain"
                    }
                },
                "email": ""
            },
            {
                "first": "Leticia",
                "middle": [],
                "last": "Fern\u00e1ndez-Friera",
                "suffix": "",
                "affiliation": {
                    "laboratory": "Centro Nacional de Investigaciones Cardiovasculares (CNIC)",
                    "institution": "",
                    "location": {
                        "settlement": "Madrid",
                        "country": "Spain"
                    }
                },
                "email": ""
            },
            {
                "first": "Susanna",
                "middle": [],
                "last": "Prat-Gonz\u00e0lez",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "University of Barcelona",
                    "location": {
                        "settlement": "Barcelona",
                        "country": "Spain"
                    }
                },
                "email": ""
            },
            {
                "first": "Paloma",
                "middle": [],
                "last": "Jord\u00e0",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "University of Barcelona",
                    "location": {
                        "settlement": "Barcelona",
                        "country": "Spain"
                    }
                },
                "email": ""
            },
            {
                "first": "Javier",
                "middle": [],
                "last": "S\u00e1nchez",
                "suffix": "",
                "affiliation": {
                    "laboratory": "Centro Nacional de Investigaciones Cardiovasculares (CNIC)",
                    "institution": "",
                    "location": {
                        "settlement": "Madrid",
                        "country": "Spain"
                    }
                },
                "email": ""
            },
            {
                "first": "Daniel",
                "middle": [],
                "last": "Pereda",
                "suffix": "",
                "affiliation": {
                    "laboratory": "Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Cardiovasculares (CIBERCV)",
                    "institution": "",
                    "location": {
                        "settlement": "Madrid",
                        "country": "Spain"
                    }
                },
                "email": ""
            },
            {
                "first": "Sandra",
                "middle": [],
                "last": "Pujadas",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Universitat Autonoma de Barcelona",
                    "location": {
                        "addrLine": "Hospital Santa Creu i Sant Pau, IIb-Sant Pau",
                        "settlement": "Barcelona",
                        "country": "Spain"
                    }
                },
                "email": ""
            },
            {
                "first": "Mercedes",
                "middle": [],
                "last": "Rivas",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Universitat Autonoma de Barcelona",
                    "location": {
                        "addrLine": "Hospital Santa Creu i Sant Pau, IIb-Sant Pau",
                        "settlement": "Barcelona",
                        "country": "Spain"
                    }
                },
                "email": ""
            },
            {
                "first": "Eduard",
                "middle": [],
                "last": "Sol\u00e9-Gonzalez",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Jorge",
                "middle": [],
                "last": "V\u00e1zquez",
                "suffix": "",
                "affiliation": {
                    "laboratory": "Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Cardiovasculares (CIBERCV)",
                    "institution": "",
                    "location": {
                        "settlement": "Madrid",
                        "country": "Spain"
                    }
                },
                "email": ""
            },
            {
                "first": "Zorba",
                "middle": [],
                "last": "Bl\u00e1zquez",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "University Hospital",
                    "location": {
                        "addrLine": "12 de Octubre"
                    }
                },
                "email": ""
            },
            {
                "first": "Juan",
                "middle": [],
                "last": "Garc\u00eda-Picart",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Universitat Autonoma de Barcelona",
                    "location": {
                        "addrLine": "Hospital Santa Creu i Sant Pau, IIb-Sant Pau",
                        "settlement": "Barcelona",
                        "country": "Spain"
                    }
                },
                "email": ""
            },
            {
                "first": "Pedro",
                "middle": [],
                "last": "Caravaca",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "University Hospital",
                    "location": {
                        "addrLine": "12 de Octubre"
                    }
                },
                "email": ""
            },
            {
                "first": "Noem\u00ed",
                "middle": [],
                "last": "Escalera",
                "suffix": "",
                "affiliation": {
                    "laboratory": "Centro Nacional de Investigaciones Cardiovasculares (CNIC)",
                    "institution": "",
                    "location": {
                        "settlement": "Madrid",
                        "country": "Spain"
                    }
                },
                "email": ""
            },
            {
                "first": "Pablo",
                "middle": [],
                "last": "Garcia-Pavia",
                "suffix": "",
                "affiliation": {
                    "laboratory": "Centro Nacional de Investigaciones Cardiovasculares (CNIC)",
                    "institution": "",
                    "location": {
                        "settlement": "Madrid",
                        "country": "Spain"
                    }
                },
                "email": ""
            },
            {
                "first": "Juan",
                "middle": [],
                "last": "Delgado",
                "suffix": "",
                "affiliation": {
                    "laboratory": "Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Cardiovasculares (CIBERCV)",
                    "institution": "",
                    "location": {
                        "settlement": "Madrid",
                        "country": "Spain"
                    }
                },
                "email": ""
            },
            {
                "first": "Javier",
                "middle": [],
                "last": "Segovia-Cubero",
                "suffix": "",
                "affiliation": {
                    "laboratory": "Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Cardiovasculares (CIBERCV)",
                    "institution": "",
                    "location": {
                        "settlement": "Madrid",
                        "country": "Spain"
                    }
                },
                "email": ""
            },
            {
                "first": "Valent\u00edn",
                "middle": [],
                "last": "Fuster",
                "suffix": "",
                "affiliation": {
                    "laboratory": "Centro Nacional de Investigaciones Cardiovasculares (CNIC)",
                    "institution": "",
                    "location": {
                        "settlement": "Madrid",
                        "country": "Spain"
                    }
                },
                "email": ""
            },
            {
                "first": "Eulalia",
                "middle": [],
                "last": "Roig",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Universitat Autonoma de Barcelona",
                    "location": {
                        "addrLine": "Hospital Santa Creu i Sant Pau, IIb-Sant Pau",
                        "settlement": "Barcelona",
                        "country": "Spain"
                    }
                },
                "email": ""
            },
            {
                "first": "Joan",
                "middle": [
                    "Albert"
                ],
                "last": "Barber\u00e1",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Hospital Cl\u00ednic-IDIBAPS",
                    "location": {
                        "settlement": "Barcelona",
                        "country": "Spain"
                    }
                },
                "email": ""
            },
            {
                "first": "Borja",
                "middle": [],
                "last": "Ibanez",
                "suffix": "",
                "affiliation": {
                    "laboratory": "Centro Nacional de Investigaciones Cardiovasculares (CNIC)",
                    "institution": "",
                    "location": {
                        "settlement": "Madrid",
                        "country": "Spain"
                    }
                },
                "email": ""
            },
            {
                "first": "Ana",
                "middle": [],
                "last": "Garc\u00eda-\u00c1lvarez",
                "suffix": "",
                "affiliation": {
                    "laboratory": "Centro Nacional de Investigaciones Cardiovasculares (CNIC)",
                    "institution": "",
                    "location": {
                        "settlement": "Madrid",
                        "country": "Spain"
                    }
                },
                "email": ""
            }
        ]
    },
    "abstract": [
        {
            "text": "CpcPH is a relatively common complication of chronic HF, is associated with poor survival, and has no specific pharmacological treatment.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        },
        {
            "text": "\u00df3AR stimulation has shown improvement in pulmonary hemodynamics and RV performance in a translational large animal model mimicking this condition.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        },
        {
            "text": "The SPHERE-HF trial is a Phase II randomized, double-blind clinical trial designed to evaluate the efficacy and safety of mirabegron (oral b3 AR agonist) in patients with CpcPH secondary to HF.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        },
        {
            "text": "The SPHERE-HF trial will include 80 patients treated with mirabegron or placebo for 16 weeks.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        },
        {
            "text": "The main outcome is the change in PVR. Secondary outcomes include changes in RV performance, clinical status, NT-proBNP levels, and additional pulmonary hemodynamic parameters.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        }
    ],
    "body_text": [
        {
            "text": "Combined pre-and post-capillary hypertension (CpcPH) is a relatively common complication of heart failure (HF) associated with a poor prognosis. Currently, there is no specific therapy approved for this entity. Recently, treatment with beta-3 adrenergic receptor (b3AR) agonists was able to improve pulmonary hemodynamics and right ventricular (RV) performance in a translational, large animal model of chronic PH. The authors present the design of a phase II randomized clinical trial that tests the benefits of mirabegron (a clinically available b3AR agonist) in patients with CpcPH due to HF. The effect of b3AR treatment will be evaluated on pulmonary hemodynamics, as well as clinical, biochemical, and advanced cardiac imaging parameters. (1, 2) that results in more severe symptoms, worse exercise tolerance, and increased risk of death (3) (4) (5) . Initially, this isolated post-capillary PH (IpcPH) is purely passive but has the potential to progress to combined pre-and post-capillary PH (CpcPH), a progressive disease characterized by significant vasoconstriction and vascular remodeling with a worse prognosis than IpcPH (6, 7) . Although IpcPH can be treated by focusing only on the underlying condition (8) , CpcPH requires treatment of both pulmonary vascular remodeling and the primary heart disease.",
            "cite_spans": [
                {
                    "start": 745,
                    "end": 748,
                    "text": "(1,",
                    "ref_id": null
                },
                {
                    "start": 749,
                    "end": 751,
                    "text": "2)",
                    "ref_id": null
                },
                {
                    "start": 844,
                    "end": 847,
                    "text": "(3)",
                    "ref_id": null
                },
                {
                    "start": 848,
                    "end": 851,
                    "text": "(4)",
                    "ref_id": null
                },
                {
                    "start": 852,
                    "end": 855,
                    "text": "(5)",
                    "ref_id": null
                },
                {
                    "start": 1134,
                    "end": 1137,
                    "text": "(6,",
                    "ref_id": null
                },
                {
                    "start": 1138,
                    "end": 1140,
                    "text": "7)",
                    "ref_id": null
                },
                {
                    "start": 1218,
                    "end": 1221,
                    "text": "(8)",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "SUMMARY"
        },
        {
            "text": "Currently, there are no specific pharmacological therapies approved for patients with CpcPH (8, 9) . Clinical studies performed with specific pulmonary vasodilators [i.e., prostanoids (10) and endothelin receptor blockers (11, 12) ] in cohorts with HF or PH secondary to HF have not shown positive results, primarily because of concomitant systemic hypotension and hepatic toxicity. Although preliminary data from small singlecenter studies (13, 14) that tested phosphodiesterase type 5 inhibitors in PH secondary to HF were promising, more recent evidence (15) (16) (17) strongly discourages their use in this setting. In addition, neutral findings have been reported for cyclic guanosine monophosphate (cGMP) stimulation in PH secondary to HF, either with preserved or reduced left ventricular ejection fraction (LVEF) (18, 19) . Therefore, new treatments are needed for CpcPH. The sympathetic nervous system is central to the neurohumoral regulation of cardiovascular function and is implicated in many cardiopulmonary diseases. (20, 21) . Like other adrenoreceptors, b3ARs are coupled to G proteins, and the downstream activated pathway includes nitric oxide synthase, nitric oxide-activated guanylyl cyclase, and cGMP synthesis, as well as increased cyclic adenosine monophosphate synthesis (22) . Loss of cGMP and cyclic adenosine monophosphate signaling represents a hallmark in PH. It is known that within the pulmonary circulation, cyclic nucleotides exert several favorable effects, including vasodilatation, inhibition of smooth muscle cell proliferation, and prevention of platelet aggregation (23) .",
            "cite_spans": [
                {
                    "start": 92,
                    "end": 95,
                    "text": "(8,",
                    "ref_id": null
                },
                {
                    "start": 96,
                    "end": 98,
                    "text": "9)",
                    "ref_id": null
                },
                {
                    "start": 184,
                    "end": 188,
                    "text": "(10)",
                    "ref_id": null
                },
                {
                    "start": 222,
                    "end": 226,
                    "text": "(11,",
                    "ref_id": null
                },
                {
                    "start": 227,
                    "end": 230,
                    "text": "12)",
                    "ref_id": null
                },
                {
                    "start": 441,
                    "end": 445,
                    "text": "(13,",
                    "ref_id": null
                },
                {
                    "start": 446,
                    "end": 449,
                    "text": "14)",
                    "ref_id": null
                },
                {
                    "start": 557,
                    "end": 561,
                    "text": "(15)",
                    "ref_id": null
                },
                {
                    "start": 562,
                    "end": 566,
                    "text": "(16)",
                    "ref_id": null
                },
                {
                    "start": 567,
                    "end": 571,
                    "text": "(17)",
                    "ref_id": null
                },
                {
                    "start": 821,
                    "end": 825,
                    "text": "(18,",
                    "ref_id": null
                },
                {
                    "start": 826,
                    "end": 829,
                    "text": "19)",
                    "ref_id": null
                },
                {
                    "start": 1032,
                    "end": 1036,
                    "text": "(20,",
                    "ref_id": null
                },
                {
                    "start": 1037,
                    "end": 1040,
                    "text": "21)",
                    "ref_id": null
                },
                {
                    "start": 1296,
                    "end": 1300,
                    "text": "(22)",
                    "ref_id": null
                },
                {
                    "start": 1606,
                    "end": 1610,
                    "text": "(23)",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "SUMMARY"
        },
        {
            "text": "In recent years, several publications have demonstrated the cardioprotective effect of b3AR stimulation in different experimental models of ischemia-reperfusion injury (24) (25) (26) and HF (27) (28) (29) .",
            "cite_spans": [
                {
                    "start": 168,
                    "end": 172,
                    "text": "(24)",
                    "ref_id": null
                },
                {
                    "start": 173,
                    "end": 177,
                    "text": "(25)",
                    "ref_id": null
                },
                {
                    "start": 178,
                    "end": 182,
                    "text": "(26)",
                    "ref_id": null
                },
                {
                    "start": 190,
                    "end": 194,
                    "text": "(27)",
                    "ref_id": null
                },
                {
                    "start": 195,
                    "end": 199,
                    "text": "(28)",
                    "ref_id": null
                },
                {
                    "start": 200,
                    "end": 204,
                    "text": "(29)",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "Beta-3 adrenoreceptor (b3AR) expression has been"
        },
        {
            "text": "Therefore, b3ARs have emerged as a potential thera- Table 1 .",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 52,
                    "end": 59,
                    "text": "Table 1",
                    "ref_id": "TABREF0"
                }
            ],
            "section": "Beta-3 adrenoreceptor (b3AR) expression has been"
        },
        {
            "text": "At the first protocol, an exclusion criterium of QTc interval on ECG >430 ms in men and >450 in women was included as a general safety standard. This criterion was later modified by an amendment to QTc Participants will be assigned, on an individual basis, to mirabegron or placebo using randomly selected block sizes stratified by center using the Blockrand package (R Foundation). The randomization list will be provided exclusively to the pharmacy department responsible for the medication preparation, which Informed consent X will prepare the medication kits by identifying them with a unique sequential number for the entire study and will provide the kits to the centers. Researchers will assign received medication kits in a sequential order and record the kit number provided to each patient in the data collection system. Baseline descriptive statistics will be calculated according to standard methods on the ITT and PP populations. Qualitative variables will be described as absolute number (n) and frequency (%), whereas quantitative variables will be described by mean AE SD Normal BP (systolic BP $95 and #135 mm Hg) AND HR #90 beats/min AND QTc interval* <430 ms in men or <450 ms in women AND blood analysis within normality AND patient asymptomatic Up titrate study medication in 50 mg/day",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Beta-3 adrenoreceptor (b3AR) expression has been"
        },
        {
            "text": "If the patient develops any of the following: significant hypotension (systolic BP <80 mm Hg) or hypertension (systolic BP >145 mm Hg) OR tachycardia (HR >100 beat/min) OR prolonged QTc interval* (>430 ms in men or >450 ms in women) OR worsening of renal function/transaminase elevation on blood analysis OR symptoms associated with medication or median (interquartile range), depending on normality (assessed using the Shapiro-Wilk test). Efficacy measures will be calculated on the ITT and PP analyses. The treatment effect on the primary outcome measure will be analyzed using a linear regression model that includes the baseline value, treatment, baseline \u00c2 treatment interaction, center, and center \u00c2 treatment interaction. Interaction terms will be removed if the Wald test is not statistically significant (p > 0.10). The efficacy analyses done on the PP set will be considered confirmatory (main analyses). For the ITT population, in those cases with missing final values of the primary outcome measure, these values will be replaced by the baseline data (last observation carried forward).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Beta-3 adrenoreceptor (b3AR) expression has been"
        },
        {
            "text": "The following exploratory analyses of the primary outcome measure will be contemplated: LVEF (LVEF <40% vs. $40%); and the maximum tolerated dose (mg/d) subgroups and their interaction with treatment. Secondary outcome measures will be analyzed similarly using linear models for quantitative normal variables or generalized models for quantitative non-normal variables and logistic regression for dichotomous values. The analysis of the secondary variables will be carried out using the available information, without missing imputation techniques.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Beta-3 adrenoreceptor (b3AR) expression has been"
        },
        {
            "text": "A descriptive analysis will be performed to evaluate safety of the treatment using the safety population. No interim analyses are planned. A 2-tailed p value < 0.05 will be considered statistically significant, unless otherwise specified.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Beta-3 adrenoreceptor (b3AR) expression has been"
        },
        {
            "text": "EXAMINATIONS. R i g h t h e a r t c a t h e t e r i z a t i o n . The procedure will be performed using a Swan-Ganz catheter introduced via the internal jugular vein using a standard methodology. Hemodynamic measurements will include right atrial pressure, systolic, diastolic, and mean PAP, as well as pulmonary capillary wedge pressure at end-expiration. Zero level will be set at the level of the anterior axillar line while lying flat; 2 different mean PAP values will be registered over a 5-to 10-min period, and the average calculated. Cardiac output will be quantified by the thermodilution method (5 measurements, average of 3, excluding the highest and lowest values).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "DESCRIPTION OF THE STUDY PROCEDURES AND"
        },
        {
            "text": "6 -m i n w a l k i n g t e s t . Tests will be carried out following the recommendations of the American and European Respiratory Societies (40) . Patients will be instructed to walk along a 30-m long corridor and to walk as far as possible for 6 min. Tests will be supervised by a nurse, and heart rate and oxygen saturation will be recorded. Cardiomyopathy Questionnaire, which has been validated in the Spanish population, will be used to assess quality of life.",
            "cite_spans": [
                {
                    "start": 140,
                    "end": 144,
                    "text": "(40)",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "DESCRIPTION OF THE STUDY PROCEDURES AND"
        },
        {
            "text": "P h y s i c a l e x a m i n a t i o n . Blood pressure will be measured at every visit using an automated sphygmomanometer in a quiet room. Three measurements will be performed over a 10-min period, and the average between the second and third measurement will be registered. Heart rate and oxygen saturation (using a pulse oxymeter) will be also entered into the electronic case report form. Patients will be weighed on every study visit, and functional class (following the NYHA classification), as well as HF signs and symptoms will be recorded.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "DESCRIPTION OF THE STUDY PROCEDURES AND"
        },
        {
            "text": "B l o o d s a m p l e s . A venous sample will be obtained at visits 0, 3, 4, 5, 6, and 8 and tested for complete blood count, serum glucose, as well as renal and liver function. NT-proBNP measurement will also be performed at visits 0 and 8.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "DESCRIPTION OF THE STUDY PROCEDURES AND"
        },
        {
            "text": "E C G . Heart rhythm, heart rate, QT, and QTc interval will be measured. C M R a n a l y s i s . Cine, 2-dimensional flow imaging and delayed enhancement will be analyzed using specialized software (IntelliSpacePortal v9.0, Philips) by blinded investigators in the Imaging Core Laboratory at CNIC. On cine images, end-diastolic and endsystolic frames will be selected based on visual assessment of largest and smallest LV volumes, respectively, and on the opening or closing of atrioventricular and semilunar valves. Biventricular endocardial contours will be manually traced in enddiastole and end-systole, and Simpson's method will be used to automatically calculate end-diastolic volumes, end-systolic volumes, and ejection fractions.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "DESCRIPTION OF THE STUDY PROCEDURES AND"
        },
        {
            "text": "RV trabeculations will be adjudicated to the blood pool ( Figures 2B and 2C) . Similarly, the inner contours of the main pulmonary artery cross section will be outlined in each cardiac phase. Through integration of pulmonary artery areas and flow, the following parameters will be quantified: peak velocity; average velocity during the complete cardiac cycle; minimum and maximum areas; and pulmonary artery net forward volume. RV-arterial coupling (the ratio of pulmonary artery effective elastance to RV maximal end-systolic elastance) will be estimated as (endsystolic volume/stroke volume) (47) . Regions of interest will be drawn on T1 maps in the myocardial anterior and inferior RV insertion points, interventricular septum, LV lateral wall and LV cavity blood pool before and after contrast administration for estimation of the extracellular volume, as previously described ( Figures 2D and 2E ) (48) . ",
            "cite_spans": [
                {
                    "start": 594,
                    "end": 598,
                    "text": "(47)",
                    "ref_id": null
                },
                {
                    "start": 904,
                    "end": 908,
                    "text": "(48)",
                    "ref_id": null
                }
            ],
            "ref_spans": [
                {
                    "start": 58,
                    "end": 76,
                    "text": "Figures 2B and 2C)",
                    "ref_id": "FIGREF6"
                },
                {
                    "start": 884,
                    "end": 901,
                    "text": "Figures 2D and 2E",
                    "ref_id": "FIGREF6"
                }
            ],
            "section": "DESCRIPTION OF THE STUDY PROCEDURES AND"
        },
        {
            "text": "A P R I L 2 0 2 0 : 3 1 7 -2 7",
            "cite_spans": [],
            "ref_spans": [],
            "section": "SPHERE-HF Trial Design"
        },
        {
            "text": "PH associated with HF has repeatedly been shown to decrease survival, particularly in patients with CpcPH (6, 39) . Although IpcPH is entirely reversible when pulmonary arterial wedge pressure is normalized by medical or surgical interventions, this is not the case for CpcPH, due to associated pulmonary arterial remodeling. The latter correlates with pulmonary vascular gradients and increased PVR (49) . Approximately 12% to 14% of patients with PH and HF present with CpcPH, a prevalence similarly distributed in reduced or preserved HF (6) . As underlined by Van- derpool and Naeije (50) , knowledge of the specific phenotype of CpcPH is of great importance to the design of future trials of targeted therapies for PH and HF. Several randomized controlled trials tested the effect of pulmonary vasodilators in HF but few of them focused in patients with confirmed PH and only a minority of studies focused on CpcPH.",
            "cite_spans": [
                {
                    "start": 106,
                    "end": 109,
                    "text": "(6,",
                    "ref_id": null
                },
                {
                    "start": 110,
                    "end": 113,
                    "text": "39)",
                    "ref_id": null
                },
                {
                    "start": 400,
                    "end": 404,
                    "text": "(49)",
                    "ref_id": null
                },
                {
                    "start": 541,
                    "end": 544,
                    "text": "(6)",
                    "ref_id": null
                },
                {
                    "start": 564,
                    "end": 568,
                    "text": "Van-",
                    "ref_id": null
                },
                {
                    "start": 588,
                    "end": 592,
                    "text": "(50)",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "DISCUSSION"
        },
        {
            "text": "Studies that evaluated the effect of prostanoids (epoprostenol) (10) and endothelin-1 receptor antagonists (bosentan) (11, 51) in patients with advanced HF and severe LV systolic dysfunction were terminated early due to an increased rate of adverse events in the investigational drug group compared with the control group. In the recent MELODY (Macitentan in Pulmonary Hypertension due to Left Ventricular Dysfunction) trial (12) , which randomized 63 patients with CpcPH to macitentan or placebo, there were no differences in the main endpoint (composite of fluid retention or worsening in NYHA functional class) between groups. Phosphodiesterase-type 5 inhibitors also failed to show a consistent effect in PH secondary to HF (13) (14) (15) (16) (17) . Moreover, in the recent Spanish multicenter SIOVAC (Sildenafil for Improving Outcomes After Valvular Correction) trial that included 200 patients with residual PH after surgically treated valvular heart disease, sildenafil was associated with worse outcomes than placebo (17) .",
            "cite_spans": [
                {
                    "start": 118,
                    "end": 122,
                    "text": "(11,",
                    "ref_id": null
                },
                {
                    "start": 123,
                    "end": 126,
                    "text": "51)",
                    "ref_id": null
                },
                {
                    "start": 425,
                    "end": 429,
                    "text": "(12)",
                    "ref_id": null
                },
                {
                    "start": 728,
                    "end": 732,
                    "text": "(13)",
                    "ref_id": null
                },
                {
                    "start": 733,
                    "end": 737,
                    "text": "(14)",
                    "ref_id": null
                },
                {
                    "start": 738,
                    "end": 742,
                    "text": "(15)",
                    "ref_id": null
                },
                {
                    "start": 743,
                    "end": 747,
                    "text": "(16)",
                    "ref_id": null
                },
                {
                    "start": 748,
                    "end": 752,
                    "text": "(17)",
                    "ref_id": null
                },
                {
                    "start": 1026,
                    "end": 1030,
                    "text": "(17)",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "DISCUSSION"
        },
        {
            "text": "Regarding soluble guanylate cyclase stimulators (riociguat), neutral findings were reported in PH secondary to HF with preserved and reduced LVEFs (18, 19) . Several limitations of the previous trials should be noted: 1) in most of them, the target population was not selected based on the pulmonary hemodynamic status (confirmed diagnosis of PH) but included the full spectrum of patients with LHD, and only a minority were targeted at patients with CpcPH; 2) most studies were single center, and mortality, will be undertaken.",
            "cite_spans": [
                {
                    "start": 147,
                    "end": 151,
                    "text": "(18,",
                    "ref_id": null
                },
                {
                    "start": 152,
                    "end": 155,
                    "text": "19)",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "DISCUSSION"
        },
        {
            "text": "Garcia-Lunar et al. ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "DISCUSSION"
        },
        {
            "text": "Recognizing that guideline-directed histologic grading of endomyocardial biopsy tissue samples for rejection surveillance has limited diagnostic accuracy, quantitative, in situ characterization was performed of several important immune cell types in a retrospective cohort of clinical endomyocardial tissue samples. Differences between cases were identified and were grouped by histologic grade versus clinical rejection trajectory, with significantly increased programmed death ligand 1\u00fe, forkhead box P3\u00fe, and cluster of differentiation 68\u00fe cells suppressed in clinically evident rejections, especially cases with marked clinical-histologic discordance. Programmed death ligand 1\u00fe, forkhead box P3\u00fe, and cluster of differentiation 68\u00fe cell proportions are also significantly higher in \"never-rejection\" when compared with \"future-rejection.\" These findings suggest that in Unfortunately, the guideline-recommended ISHLT grading scheme suffers from a lack of prognostic accuracy, correlating poorly with the clinical trajectory of a current rejection event and lacking the ability to stratify patients by future CAR risk (1) (2) (3) (4) Improving Diagnostic Accuracy and Rejection Risk Stratification inflammatory infiltrate\" to extract additional clinically relevant information from EMB samples (5) . Despite this 15-year-old call to action, there has been very limited application of tissue-level immune phenotyping in human heart transplant tissues. This stands in contrast to oncologic and rheumatologic medicine, where deeper phenotyping of immune populations and immune effector pathways have resulted in improved risk stratification and better targeting of therapeutic strategies (6) (7) (8) (9) (10) (11) (12) .",
            "cite_spans": [
                {
                    "start": 1122,
                    "end": 1125,
                    "text": "(1)",
                    "ref_id": null
                },
                {
                    "start": 1126,
                    "end": 1129,
                    "text": "(2)",
                    "ref_id": null
                },
                {
                    "start": 1130,
                    "end": 1133,
                    "text": "(3)",
                    "ref_id": null
                },
                {
                    "start": 1134,
                    "end": 1137,
                    "text": "(4)",
                    "ref_id": null
                },
                {
                    "start": 1298,
                    "end": 1301,
                    "text": "(5)",
                    "ref_id": null
                },
                {
                    "start": 1689,
                    "end": 1692,
                    "text": "(6)",
                    "ref_id": null
                },
                {
                    "start": 1693,
                    "end": 1696,
                    "text": "(7)",
                    "ref_id": null
                },
                {
                    "start": 1697,
                    "end": 1700,
                    "text": "(8)",
                    "ref_id": null
                },
                {
                    "start": 1701,
                    "end": 1704,
                    "text": "(9)",
                    "ref_id": null
                },
                {
                    "start": 1705,
                    "end": 1709,
                    "text": "(10)",
                    "ref_id": null
                },
                {
                    "start": 1710,
                    "end": 1714,
                    "text": "(11)",
                    "ref_id": null
                },
                {
                    "start": 1715,
                    "end": 1719,
                    "text": "(12)",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "SUMMARY"
        },
        {
            "text": "In this paper, we report novel proof-of-concept studies applying a state-of-the-art, fully quantita- Specifically, the cohort of 46 transplant EMB described in this paper was selected to permit assessments of how immune cell populations differ between tissues with low versus high ISHLT grades, between tissues corresponding to clinically silent versus clinically evident rejection trajectories, and between tissues from patients who will go on to experience serious rejection (future rejection) versus those who will not (never rejection). The retrospective chart review and analysis of archived tissue specimens employed in this research were approved by the Institutional Review Board at the University of Pennsylvania.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "SUMMARY"
        },
        {
            "text": "For these retrospective cases, the ISHLT histologic grade assigned by the attending pathologist at the time of the EMB procedure was used as the reference standard for rejection diagnosis. These grades were further simplified by assigning a binary histologic grade label:",
            "cite_spans": [],
            "ref_spans": [],
            "section": "SUMMARY"
        },
        {
            "text": "\"low-grade\" rejection was defined as ISHLT 2004 consensus criteria histologic grades 0R or 1R and \"high-grade\" rejection was defined as ISHLT histologic grade 2R or 3R. This grouping typically defines the distinction used to determine whether augmented immunosuppressive therapy is prescribed (34) .",
            "cite_spans": [
                {
                    "start": 293,
                    "end": 297,
                    "text": "(34)",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "SUMMARY"
        },
        {
            "text": "For the same 46 EMB events, the distinction between \"clinically silent\" and \"clinically evident\" rejection was made based on a set of major and minor criteria to determine whether allograft injury was present. Clinical metadata from within 7 days of each EMB event were collected to allow for determination of clinical trajectory. These data were derived from electronic health record-documented symptoms, physical exam findings, lab results, echocardiographic parameters, electrocardiogram findings, and invasive hemodynamic data. The major criteria in Table 1 for differentiating clinically evident from clinically silent rejection trajectories are based on definitions of \"hemodynamic compromise\" in previous prospective investigations of allograft rejection (35) (36) (37) and provide high specificity for clinically significant rejection. The minor criteria in Table 1 Finally, the 19 EMB in this cohort that were categorized as low ISHLT grade and clinically silent were further classified by the patient-level incidence of future serious CAR events. These EMB were assigned a binary label as either \"future rejection\" or \"never rejection,\" based on whether a serious CAR event occurred within the first 3 years post-transplantation.",
            "cite_spans": [
                {
                    "start": 762,
                    "end": 766,
                    "text": "(35)",
                    "ref_id": null
                },
                {
                    "start": 767,
                    "end": 771,
                    "text": "(36)",
                    "ref_id": null
                },
                {
                    "start": 772,
                    "end": 776,
                    "text": "(37)",
                    "ref_id": null
                }
            ],
            "ref_spans": [
                {
                    "start": 554,
                    "end": 561,
                    "text": "Table 1",
                    "ref_id": "TABREF0"
                },
                {
                    "start": 866,
                    "end": 873,
                    "text": "Table 1",
                    "ref_id": "TABREF0"
                }
            ],
            "section": "SUMMARY"
        },
        {
            "text": "These cases allow for assessment of whether Corp., Radnor, Pennsylvania) used for immunohistochemistry, with 1 section per slide. All cut, unstained tissue sections were stored in a nitrogen chamber to minimize oxidation and degradation of tissue epitopes. In addition to EMB slides, 2 slides from native (nontransplant) heart tissue obtained from cadaveric organ donors and 1 slide from human lymph node tissue were used as \"negative\" and \"positive\" staining controls, respectively.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "SUMMARY"
        },
        {
            "text": "The cytotoxic T-cell marker CD8 was selected due to recognition that this cell population is a primary effector of myocyte injury during cellular rejection (18) (19) (20) . Regulatory T-cell transcription factor FoxP3 was selected due to the immune-modulatory, antiinflammatory effects these interleukin-10 and transforming growth factor-bsecreting cells are thought to exert in renal allografts (21) (22) (23) and animal models of heart transplantation (24, 25) . The monocyte lineage marker CD68 is used in the diagnosis of antibodymediated rejection, but it has also been implicated in cellular rejection, albeit with conflicting results on the effects these cells exert (26, 27) . Finally, PD-L1 is 1 component of the PD-L1/PD1 immune \"checkpoint\" molecules that interact to suppress cytotoxic actions of activated T cells. Though checkpoint inhibitors used in cancer immunotherapy have been implicated in myocarditis, a role for checkpoint molecules in human heart transplantation has included only case reports of severe rejection following oncologic PD1/ PD-L1 inhibitor treatment (28) (29) (30) annotated for each sample to conduct quantitative image analysis. Some samples were unable to yield 5 regions of interest due to confounding factors, such as tissue folds, small tissue biopsy size, or large areas without myocardium (e.g., vessels, fibrosis, fat).",
            "cite_spans": [
                {
                    "start": 156,
                    "end": 160,
                    "text": "(18)",
                    "ref_id": null
                },
                {
                    "start": 161,
                    "end": 165,
                    "text": "(19)",
                    "ref_id": null
                },
                {
                    "start": 166,
                    "end": 170,
                    "text": "(20)",
                    "ref_id": null
                },
                {
                    "start": 396,
                    "end": 400,
                    "text": "(21)",
                    "ref_id": null
                },
                {
                    "start": 401,
                    "end": 405,
                    "text": "(22)",
                    "ref_id": null
                },
                {
                    "start": 406,
                    "end": 410,
                    "text": "(23)",
                    "ref_id": null
                },
                {
                    "start": 454,
                    "end": 458,
                    "text": "(24,",
                    "ref_id": null
                },
                {
                    "start": 459,
                    "end": 462,
                    "text": "25)",
                    "ref_id": null
                },
                {
                    "start": 674,
                    "end": 678,
                    "text": "(26,",
                    "ref_id": null
                },
                {
                    "start": 679,
                    "end": 682,
                    "text": "27)",
                    "ref_id": null
                },
                {
                    "start": 1088,
                    "end": 1092,
                    "text": "(28)",
                    "ref_id": null
                },
                {
                    "start": 1093,
                    "end": 1097,
                    "text": "(29)",
                    "ref_id": null
                },
                {
                    "start": 1098,
                    "end": 1102,
                    "text": "(30)",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "TARGET SELECTION FOR MULTIPLEX IMMUNOFLUORESCENCE."
        },
        {
            "text": "Q u a n t i t a t i v e m u l t i s p e c t r a l i m a g e a n a l y s i s . A spectral library was created from the stained library slides, and the autofluorescence spectrum was isolated using the autofluorescence slide. All annotated regions of interest were imported into a new project in inForm Tissue Finder (Akoya Biosciences) and",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TARGET SELECTION FOR MULTIPLEX IMMUNOFLUORESCENCE."
        },
        {
            "text": "were spectrally unmixed using the generated spectral library. Of note, the image analyst was blinded to the slide cohort categories to avoid bias. The flow diagram depicts the study cohort with subgroups. CAR \u00bc cardiac allograft rejection; EMB \u00bc endomyocardial biopsy;",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TARGET SELECTION FOR MULTIPLEX IMMUNOFLUORESCENCE."
        },
        {
            "text": "ISHLT \u00bc International Society for Heart and Lung Transplantation; QC \u00bc quality control.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TARGET SELECTION FOR MULTIPLEX IMMUNOFLUORESCENCE."
        },
        {
            "text": "Peyster et al. Table 2 . Even more striking, PD-L1\u00fe cells were more than 4-fold more abundant in clinically silent cases compared with clinically evident cases, regardless of ISHLT grade. Table 4 and Figure 2B highlight the strong, grade-independent correlation of FoxP3 and Immunophenotyping future-and never-rejection cases. To assess whether immune phenotypes differ between patients who will suffer important rejection events in the future and those who will not, we analyzed the subset of cases in which serial, concor- Despite relatively few cases, every QmIF marker except CD68 displayed statistically significant differences between future-rejection cases and neverrejection cases, as shown in Table 5 . Though these analyses were performed on biopsies that were uniformly of low-histologic grade at a time when there was no evidence of allograft dysfunction or injury, the future-rejection group more closely resembles the clinically evident and high-grade rejection groups than it does the clinically silent or low-grade groups.",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 15,
                    "end": 22,
                    "text": "Table 2",
                    "ref_id": "TABREF1"
                },
                {
                    "start": 188,
                    "end": 195,
                    "text": "Table 4",
                    "ref_id": "TABREF17"
                },
                {
                    "start": 200,
                    "end": 209,
                    "text": "Figure 2B",
                    "ref_id": "FIGREF7"
                },
                {
                    "start": 702,
                    "end": 709,
                    "text": "Table 5",
                    "ref_id": "TABREF18"
                }
            ],
            "section": "TARGET SELECTION FOR MULTIPLEX IMMUNOFLUORESCENCE."
        },
        {
            "text": "When the future-rejection group is analyzed by temporal proximity to the incident severe rejection event, an apparent progression emerges: compared with never-rejection cases, future-rejection cases at >6 months prior to rejection have a moderately reduced proportion of FoxP3\u00fe and PD-L1\u00fe cells. By 3 to 6 weeks before clinically evident rejection, there is a dramatic and statistically significant drop-off to extremely low levels for FoxP3\u00fe, CD68\u00fe, and the PD-L1\u00fe cells ( Table 5 , Figure 4 ).",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 474,
                    "end": 481,
                    "text": "Table 5",
                    "ref_id": "TABREF18"
                },
                {
                    "start": 484,
                    "end": 492,
                    "text": "Figure 4",
                    "ref_id": "FIGREF63"
                }
            ],
            "section": "TARGET SELECTION FOR MULTIPLEX IMMUNOFLUORESCENCE."
        },
        {
            "text": "These proof-of-concept studies applying QmIF technology within the cardiac transplantation population provide compelling evidence for the feasibility and utility of immune phenotyping to improve the diagnostic and prognostic value of allograft EMB specimens. First, using archived formalin-fixed, paraffin-embedded tissue blocks-some more than 10 Peyster et al. Table 1 ). Figure 1 . Peyster et al. Overall, the QmIF results of EMB cases grouped by clinical trajectory support the hypothesis that to accurately assess the threat to allograft function, Images are from a discordant low ISHLT grade EMB, with low-histologic grade but clinically evident allograft injury. Images are from a discordant high ISHLT grade EMB (C) and from a concordant high ISHLT grade EMB (D). Although rough estimates of basophilic cellular infiltrates due not appear markedly different within grade in H and E slides (A1 vs. B1, and C1 vs. D1), multiplex IF profiles within grade visibly differ between cases with and without evident allograft injury. Note diffuse PD-L1 (green) staining within myocardium of patients with clinically silent CAR (A5, C5), in comparison to clinically evident CAR (B5, D5). Also note profound PD-L1 and CD68 within cellular infiltrate in discordant high-grade EMB (C4), as well as the higher proportion (albeit overall low density) of FoxP3 cells when compared with the concordant high grade EMB (C6 vs. D6).",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 362,
                    "end": 369,
                    "text": "Table 1",
                    "ref_id": "TABREF0"
                },
                {
                    "start": 373,
                    "end": 381,
                    "text": "Figure 1",
                    "ref_id": "FIGREF5"
                }
            ],
            "section": "DISCUSSION"
        },
        {
            "text": "The scale bar is 50 um for panels in rows A, C, and D, and 100 um for panels in row B. Phrased differently, panels in rows A, C, and D are 500 um in total width, while panels in row B are 750 um in total width. DAPI \u00bc 4 0 ,6-diamidino-2-phenylindole; other abbreviations as in Figures 1 and 2 . Abbreviations as in Tables 2 and 3 . has been the focus of significant biomedical research, though rarely in the context of organ transplantation (40) (41) (42) (43) (44) (45) (46) (47) . The binding of PD-L1 to PD1 on helper T cells, beyond simple \"inactivation\" with consequent decreases in inflammatory cytokine production, has been shown to stimulate FoxP3\u00fe expression and effector T-cell differentiation into regulatory T cells (41, 42, 44, 45 Peyster et al. margulies@uphs.upenn.edu. Go to http://www.acc.org/ jacc-journals-cme to take the CME/MOC/ECME quiz for this article. (2). Surprisingly, we could reproducibly observe real-time thrombus formation within minutes without any treatment with chemical agent for thrombus induction ( Figure 1D , Video 1), indicating that observation by fluorescence microscopy triggered thrombus formation at ligated femoral/ saphenous vein. We also confirmed thrombus was formed in both female C57BL/6J mice and ICR mice (a strain of albino mice) in the same manner (n \u00bc 5, respectively), indicating thrombus induction was sex-, strain-, and melamine-independent (data not shown).",
            "cite_spans": [
                {
                    "start": 441,
                    "end": 445,
                    "text": "(40)",
                    "ref_id": null
                },
                {
                    "start": 446,
                    "end": 450,
                    "text": "(41)",
                    "ref_id": null
                },
                {
                    "start": 451,
                    "end": 455,
                    "text": "(42)",
                    "ref_id": null
                },
                {
                    "start": 456,
                    "end": 460,
                    "text": "(43)",
                    "ref_id": null
                },
                {
                    "start": 461,
                    "end": 465,
                    "text": "(44)",
                    "ref_id": null
                },
                {
                    "start": 466,
                    "end": 470,
                    "text": "(45)",
                    "ref_id": null
                },
                {
                    "start": 471,
                    "end": 475,
                    "text": "(46)",
                    "ref_id": null
                },
                {
                    "start": 476,
                    "end": 480,
                    "text": "(47)",
                    "ref_id": null
                },
                {
                    "start": 728,
                    "end": 732,
                    "text": "(41,",
                    "ref_id": null
                },
                {
                    "start": 733,
                    "end": 736,
                    "text": "42,",
                    "ref_id": null
                },
                {
                    "start": 737,
                    "end": 740,
                    "text": "44,",
                    "ref_id": null
                },
                {
                    "start": 741,
                    "end": 743,
                    "text": "45",
                    "ref_id": null
                }
            ],
            "ref_spans": [
                {
                    "start": 277,
                    "end": 292,
                    "text": "Figures 1 and 2",
                    "ref_id": "FIGREF5"
                },
                {
                    "start": 315,
                    "end": 329,
                    "text": "Tables 2 and 3",
                    "ref_id": "TABREF1"
                },
                {
                    "start": 1037,
                    "end": 1046,
                    "text": "Figure 1D",
                    "ref_id": "FIGREF5"
                }
            ],
            "section": "DISCUSSION"
        },
        {
            "text": "We hypothesized that thrombus formation in this Table 1 ). Both platelet-and neutrophil-depletion did not prevent thrombus formation and did not change thrombus size acutely (p \u00bc NS, respectively) ( Figures 4B and 4C ).",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 48,
                    "end": 55,
                    "text": "Table 1",
                    "ref_id": "TABREF0"
                },
                {
                    "start": 199,
                    "end": 216,
                    "text": "Figures 4B and 4C",
                    "ref_id": "FIGREF6"
                }
            ],
            "section": "DISCUSSION"
        },
        {
            "text": "Neutrophil extracellular traps are also reported as a key player of DVT initiation (2, 17) ; however, pretreatment with deoxyribonuclease also did not affect the DVT size in our model ( Figure 4D ). As oxidative stress is considered as a major contributor to the formation of DVT in models such as the laser- Figure 6C ). This might explain why DVT exhibits an annual ringlike structure. We also observed the leukocytes migrating into the DVT accompanied with platelets. As Recent studies reported in vivo thrombosis imaging systems available for high-resolution microscopic imaging (2, 11, 12, 24) . However, these thrombus models are injury-induced (laser-induced or electrolytic) platelet thrombus-based, not a fibrinand erythrocyte-rich thrombus, which is visualized in our study. Furthermore, most of these models use small vessels such as cremaster muscle and mesentery vessels. These microvascular thrombosis models are related with pathological thrombus that occurs during sepsis and other inflammatory disorders, but that is not relevant to large vessels such as jugular and femoral vein, as observed in human VTE (25) .",
            "cite_spans": [
                {
                    "start": 83,
                    "end": 86,
                    "text": "(2,",
                    "ref_id": null
                },
                {
                    "start": 87,
                    "end": 90,
                    "text": "17)",
                    "ref_id": null
                },
                {
                    "start": 583,
                    "end": 586,
                    "text": "(2,",
                    "ref_id": null
                },
                {
                    "start": 587,
                    "end": 590,
                    "text": "11,",
                    "ref_id": null
                },
                {
                    "start": 591,
                    "end": 594,
                    "text": "12,",
                    "ref_id": null
                },
                {
                    "start": 595,
                    "end": 598,
                    "text": "24)",
                    "ref_id": null
                },
                {
                    "start": 1123,
                    "end": 1127,
                    "text": "(25)",
                    "ref_id": null
                }
            ],
            "ref_spans": [
                {
                    "start": 186,
                    "end": 195,
                    "text": "Figure 4D",
                    "ref_id": "FIGREF63"
                },
                {
                    "start": 309,
                    "end": 318,
                    "text": "Figure 6C",
                    "ref_id": "FIGREF30"
                }
            ],
            "section": "DISCUSSION"
        },
        {
            "text": "In terms of thrombus induction on the stage of microscopy, our model is similar with the conventional laser-induced in vivo imaging models (11) (12) (13) 26) ; however, we succeeded in thrombus induction in femoral/saphenous vein, where is literally a deep vein, as opposed to cremaster and mesenteric arterioles in the previous laser-induced model. Second, we used filtered white light (mainly through FITC filter in the microscope) produced from a mercury lamp, not a nitrogen or helium-neon laser as used in past studies (11) (12) (13) 26) . We believe that weaker light stimulation and larger vein size are the reasons that thrombus could not be formed by light irradiation alone and that the formed thrombus was not a platelet-rich thrombus.",
            "cite_spans": [
                {
                    "start": 139,
                    "end": 143,
                    "text": "(11)",
                    "ref_id": null
                },
                {
                    "start": 144,
                    "end": 148,
                    "text": "(12)",
                    "ref_id": null
                },
                {
                    "start": 149,
                    "end": 153,
                    "text": "(13)",
                    "ref_id": null
                },
                {
                    "start": 154,
                    "end": 157,
                    "text": "26)",
                    "ref_id": null
                },
                {
                    "start": 524,
                    "end": 528,
                    "text": "(11)",
                    "ref_id": null
                },
                {
                    "start": 529,
                    "end": 533,
                    "text": "(12)",
                    "ref_id": null
                },
                {
                    "start": 534,
                    "end": 538,
                    "text": "(13)",
                    "ref_id": null
                },
                {
                    "start": 539,
                    "end": 542,
                    "text": "26)",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "DISCUSSION"
        },
        {
            "text": "A recent study succeeded in applying the IVC ste- ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "DISCUSSION"
        },
        {
            "text": "Phosphorylcholine is a pro-inflammatory epitope in atherogenic oxidized phospholipids.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "HIGHLIGHTS"
        },
        {
            "text": "This study investigated effects of a novel monoclonal IgG1 antibody against PC on vascular function and atherosclerotic inflammation.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "HIGHLIGHTS"
        },
        {
            "text": "Treatment with phosphorylcholine antibody preserved coronary flow reserve and decreased uptake of 18 F-FDG in atherosclerotic lesions in hypercholesterolemic mice.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "HIGHLIGHTS"
        },
        {
            "text": "Noninvasive imaging techniques represent translational tools to assess the efficacy of phosphorylcholine-targeted therapy on coronary artery function and atherosclerosis.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "HIGHLIGHTS"
        },
        {
            "text": "This study showed that treatment with a therapeutic monoclonal immunoglobulin-G1 antibody against phosphorylcholine on oxidized phospholipids preserves coronary flow reserve and attenuates atherosclerotic inflammation as determined by the uptake of 18 Table 1 ",
            "cite_spans": [
                {
                    "start": 249,
                    "end": 251,
                    "text": "18",
                    "ref_id": null
                }
            ],
            "ref_spans": [
                {
                    "start": 252,
                    "end": 259,
                    "text": "Table 1",
                    "ref_id": "TABREF0"
                }
            ],
            "section": "SUMMARY"
        },
        {
            "text": "Treatment with X19-mu was well tolerated, with the antibody remaining present in the blood until the end of the intervention; the average plasma X19-mu concentration 5 to 7 days after the last injection was 14 AE 9.8 mg/ml. One mouse was excluded due to a failure in the dosing of X19-mu (no detectable levels of X19-mu in plasma), and 1 mouse due to failure in dosing of 18 F-FDG. Thus, the final study group consisted of 16 mice in the vehicle group and 16 mice in the X19-mu group.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "RESULTS"
        },
        {
            "text": "As shown in Table 1 (Figures 2A and 2B, respectively) . nonspecific IgG) ( Figure 5A) . VCAM1, ICAM1, and IL8",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 12,
                    "end": 19,
                    "text": "Table 1",
                    "ref_id": "TABREF0"
                },
                {
                    "start": 20,
                    "end": 53,
                    "text": "(Figures 2A and 2B, respectively)",
                    "ref_id": "FIGREF6"
                },
                {
                    "start": 75,
                    "end": 85,
                    "text": "Figure 5A)",
                    "ref_id": "FIGREF29"
                }
            ],
            "section": "RESULTS"
        },
        {
            "text": "gene-expression tended to be lower in the presence of PC-mAb than nonspecific IgG but were not statistically significant. IL6 gene-expression as well as IL-6 and IL-8 protein levels were similar in the presence of PC-mAb and nonspecific IgG antibodies ( Figure 5B ). Table 3 .",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 254,
                    "end": 263,
                    "text": "Figure 5B",
                    "ref_id": "FIGREF29"
                },
                {
                    "start": 267,
                    "end": 274,
                    "text": "Table 3",
                    "ref_id": "TABREF3"
                }
            ],
            "section": "RESULTS"
        },
        {
            "text": "Our results revealed that 6-week treatment with an exogenous antibody targeting PC epitope on OxPLs preserved CFR and reduced 18 (3, 27) . In patients with stable coronary artery disease, levels of the PC epitope in LDL particles were shown to be significantly related to the severity of endothelial dysfunction after lipidlowering therapy (2) . Furthermore, a negative correlation between OxLDL levels and CFR, an integrated measure of coronary reactivity (18) , was found in young individuals with hypercholesterolemia (28).",
            "cite_spans": [
                {
                    "start": 126,
                    "end": 128,
                    "text": "18",
                    "ref_id": null
                },
                {
                    "start": 129,
                    "end": 132,
                    "text": "(3,",
                    "ref_id": null
                },
                {
                    "start": 133,
                    "end": 136,
                    "text": "27)",
                    "ref_id": null
                },
                {
                    "start": 340,
                    "end": 343,
                    "text": "(2)",
                    "ref_id": null
                },
                {
                    "start": 457,
                    "end": 461,
                    "text": "(18)",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "DISCUSSION"
        },
        {
            "text": "Our results extended the previous findings by Despite reduced 18 F-FDG uptake, we did not find a reduction in overall lesion macrophage quantity, the proportions of M1/M2 polarized macrophages, the lesion collagen content, or the atherosclerosis burden. Based on our previous validation study (24) , mice that showed extensive pre-existing atherosclerosis at the beginning of therapy were studied, and therefore, it was unlikely that major plaque regression or changes in plaque cellular composition would have occurred within short-term treatment. Previous studies indicated that a metabolic marker such as 18 F-FDG uptake was sensitive to changes caused by short-term interventions, despite changes in plaque burden, and aortic 18 F-FDG signal provided an independent predictor of future cardiovascular events (16, 17) . There are also regional differences in the driving forces of atherogenesis in mice. Although histology was analyzed in the aortic root, 18 tsiantoulas@meduniwien.ac.at.",
            "cite_spans": [
                {
                    "start": 293,
                    "end": 297,
                    "text": "(24)",
                    "ref_id": null
                },
                {
                    "start": 812,
                    "end": 816,
                    "text": "(16,",
                    "ref_id": null
                },
                {
                    "start": 817,
                    "end": 820,
                    "text": "17)",
                    "ref_id": null
                },
                {
                    "start": 959,
                    "end": 961,
                    "text": "18",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "DISCUSSION"
        },
        {
            "text": "Combining CHD phenotype-driven gene set enrichment and CRISPR knockdown screening in zebrafish is an effective approach to identifying novel CHD genes.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "R E F E R E N C E S HIGHLIGHTS"
        },
        {
            "text": "Mutations affecting genes coding for the WAVE2 protein complex and small GTPase-mediated signaling are associated with LVOTO lesions.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "R E F E R E N C E S HIGHLIGHTS"
        },
        {
            "text": "WAVE2 complex genes brk1, nckap1, and wasf2 and regulators of small GTPase signaling cul3a and racgap1",
            "cite_spans": [],
            "ref_spans": [],
            "section": "R E F E R E N C E S HIGHLIGHTS"
        },
        {
            "text": "are critical to zebrafish heart development.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "R E F E R E N C E S HIGHLIGHTS"
        },
        {
            "text": "Genetic variants are the primary driver of congenital heart disease (CHD) pathogenesis. However, our ability to identify causative variants is limited. To identify causal CHD genes that are associated with specific molecular functions, the study used prior knowledge to filter de novo variants from 2,881 probands with sporadic severe CHD. This approach enabled the authors to identify an association between left ventricular outflow tract obstruction lesions and genes associated with the WAVE2 complex and regulation of small GTPase-mediated signal transduction. Using CRISPR zebrafish knockdowns, the study confirmed that WAVE2 complex proteins Three independent analysis pipelines were used to process reads and were mapped to hg19 using Table 3 ). For LVOTO, the highestranked CORUM protein complex identified by Enrichr was WAVE2. One GOBP term was consistently enriched using both tools: regulation of small GTPase-mediated signal transduction ( Table 2) . (33) (34) (35) . Therefore, we selected the 5 WAVE2 complex genes, cul3a, and racgap1 for further validation in zebrafish embryos. Gene set enrichment was performed using HHE and MGI library in silico-filtered genes with the hypergeometric overrepresentation test implemented using Enrichr and WebGestalt. Terms were filtered for statistical significance if Benjamini-Hochberg-adjusted p < 0.05 using both tools. *Combined score derived from Enrichr, which is a unique ranking system that combines the adjusted p value with a deviation from expected ranking for each term based on inputting random gene sets. \u2020Fold enrichment and adjusted p values presented from WebGestalt using background gene list correction.",
            "cite_spans": [
                {
                    "start": 964,
                    "end": 968,
                    "text": "(33)",
                    "ref_id": null
                },
                {
                    "start": 969,
                    "end": 973,
                    "text": "(34)",
                    "ref_id": null
                },
                {
                    "start": 974,
                    "end": 978,
                    "text": "(35)",
                    "ref_id": null
                }
            ],
            "ref_spans": [
                {
                    "start": 742,
                    "end": 749,
                    "text": "Table 3",
                    "ref_id": "TABREF3"
                },
                {
                    "start": 953,
                    "end": 961,
                    "text": "Table 2)",
                    "ref_id": "TABREF1"
                }
            ],
            "section": "SUMMARY"
        },
        {
            "text": "CORUM \u00bc Comprehensive Resource of Mammalian Protein Complexes; GOBP \u00bc Gene Ontology biological processes; other abbreviations as in Table 1 .",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 132,
                    "end": 139,
                    "text": "Table 1",
                    "ref_id": "TABREF0"
                }
            ],
            "section": "SUMMARY"
        },
        {
            "text": "EMBRYOS. Zebrafish was selected for gene knockdown as its ability to survive via oxygen diffusion in the absence of a functional cardiovascular system permits the study of lethal cardiac defects later in development (36) . Using CRISPR-guided knockdown, we observed cardiac phenotypes in F0 embryos with mosaic loss of brk1, cul3a, nckap1, racgap1, and wasf2",
            "cite_spans": [
                {
                    "start": 216,
                    "end": 220,
                    "text": "(36)",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "MODELING LOSS OF CANDIDATE GENES IN ZEBRAFISH"
        },
        {
            "text": "( Table 3) . Reversed cardiac looping was observed in brk1, cul3a, nckap1, and wasf2 knockdown embryos, while racgap1 knockdown resulted in zebrafish embryos with a small, poorly contractile ventricle often Of the genes associated with consistently enriched terms and not previously implicated in structural heart defects, CUL3 and RACGAP1 are the most strongly connected.",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 2,
                    "end": 10,
                    "text": "Table 3)",
                    "ref_id": "TABREF3"
                }
            ],
            "section": "MODELING LOSS OF CANDIDATE GENES IN ZEBRAFISH"
        },
        {
            "text": "Edwards et al. with associated atrial dilation ( Figure 2) . Notably, all 7 of these genes are both highly expressed in the developing heart and brain of the mouse, but a brain phenotype was only observed in racgap1 knockdown embryos (6) . The direct link between planar cell polarity and WAVE2 complex signaling is the RhoGTPase RAC1.",
            "cite_spans": [
                {
                    "start": 234,
                    "end": 237,
                    "text": "(6)",
                    "ref_id": null
                }
            ],
            "ref_spans": [
                {
                    "start": 49,
                    "end": 58,
                    "text": "Figure 2)",
                    "ref_id": "FIGREF7"
                }
            ],
            "section": "MODELING LOSS OF CANDIDATE GENES IN ZEBRAFISH"
        },
        {
            "text": "Early lethality has prohibited studying global loss of Rac1, but second heart field-specific knockdown of Taken together, these studies illustrate how altered signaling via planar cell polarity/Rac1/ WAVE2 can disrupt normal mammalian heart development.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "DISCUSSION"
        },
        {
            "text": "In addition to contributing to small GTPasemediated signaling, loss of CUL3 may also contribute to CHD through its role in ubiquitination (45) . In HEK293 cells, SAP130, a regulator of Edwards et al. Another potentially important advantage of in silico testing is its potential to identify areas for rescue or repurposing of existing drugs (14) . Rescue refers to redirecting drugs that have already failed efficacy trials for one application, but then can be successfully Engineered 3D constructs of heart muscle permit measurement of virtually all parameters of heart function, including twitch force, kinetics, beating rate, rhythm, diastolic tension, and intracellular calcium movement (39) (40) (41) (42) (43) . Engineered cardiac tissue has the potential for use as a research tool, as a replacement for animal toxicity testing of therapeutic agents, and as a therapy unto itself. The models are easy manipulated genetically, and they behave quantitatively much like native muscle, making them reasonable platforms for disease modeling and toxicity testing. In 2018, for example, Truitt et al. (52) . Bear in mind that for all of these drugs, Before the FDA and other regulatory bodies will agree to allow OC technology to replace any phases of animal testing, the technology will have to be proven at least as accurate, if not more so than current testing. Early data are scarce but promising.",
            "cite_spans": [
                {
                    "start": 138,
                    "end": 142,
                    "text": "(45)",
                    "ref_id": null
                },
                {
                    "start": 340,
                    "end": 344,
                    "text": "(14)",
                    "ref_id": null
                },
                {
                    "start": 690,
                    "end": 694,
                    "text": "(39)",
                    "ref_id": null
                },
                {
                    "start": 695,
                    "end": 699,
                    "text": "(40)",
                    "ref_id": null
                },
                {
                    "start": 700,
                    "end": 704,
                    "text": "(41)",
                    "ref_id": null
                },
                {
                    "start": 705,
                    "end": 709,
                    "text": "(42)",
                    "ref_id": null
                },
                {
                    "start": 710,
                    "end": 714,
                    "text": "(43)",
                    "ref_id": null
                },
                {
                    "start": 1100,
                    "end": 1104,
                    "text": "(52)",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "DISCUSSION"
        },
        {
            "text": "In a pulmonary edema model created in an OC, the response to a low-molecular-weight pulmonary edema therapeutic was shown to be similar in the OC to results obtained in animal models (65) . InSpheroAG Medicines Agency has also put forth guidelines to eliminate or significantly restrict animal testing for certain human medicine products in order to reduce animal use in drug regulatory approvals (74) (75) (76) . ",
            "cite_spans": [
                {
                    "start": 183,
                    "end": 187,
                    "text": "(65)",
                    "ref_id": null
                },
                {
                    "start": 397,
                    "end": 401,
                    "text": "(74)",
                    "ref_id": null
                },
                {
                    "start": 402,
                    "end": 406,
                    "text": "(75)",
                    "ref_id": null
                },
                {
                    "start": 407,
                    "end": 411,
                    "text": "(76)",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "DISCUSSION"
        },
        {
            "text": "Vascular calcification is a highly regulated, cell-mediated process that is strongly associated with CKD and confers increased risk for incident CV events.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "HIGHLIGHTS"
        },
        {
            "text": "Multiple pathways link vascular calcification with CKD; however, they remain incompletely understood, and the development of targeted therapies has been underwhelming.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "HIGHLIGHTS"
        },
        {
            "text": "Illumination of the causal steps and natural history that link vascular calcification to CV events will affirm its role as a CV risk factor and accelerate drug discovery and therapeutic translation. (4), and the global burden of kidney disease continues to rise (5) . In this context, cardiovascular disease (CVD) is a significant contributor to the high morbidity experienced by patients with CKD and CV death is the most common cause of death in this population ( Figure 1 ).",
            "cite_spans": [
                {
                    "start": 262,
                    "end": 265,
                    "text": "(5)",
                    "ref_id": null
                }
            ],
            "ref_spans": [
                {
                    "start": 466,
                    "end": 474,
                    "text": "Figure 1",
                    "ref_id": "FIGREF5"
                }
            ],
            "section": "HIGHLIGHTS"
        },
        {
            "text": "shown linear relations between CV mortality and reduced eGFR and proteinuria or albuminuria (6) . The effect is most pronounced for those with end-stage kidney disease (ESKD) in whom 85% of adults commencing dialysis at older than 45 years of age will have some form of CVD and experience a relative risk of CV death that exceeds 20 times that of the general population (7) . In adults younger than 30 years of age, the relative risk is even more dramatic; incident ESKD confers a >150-fold risk of CV death compared with an age-matched population (8) . Expressed another way, persons with mild to moderate (stages 1",
            "cite_spans": [
                {
                    "start": 92,
                    "end": 95,
                    "text": "(6)",
                    "ref_id": null
                },
                {
                    "start": 370,
                    "end": 373,
                    "text": "(7)",
                    "ref_id": null
                },
                {
                    "start": 548,
                    "end": 551,
                    "text": "(8)",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "Large contemporary datasets have repeatedly"
        },
        {
            "text": "to 3) CKD are at higher risk of CV events and CV mortality than they are for progression to ESKD (9,10).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Large contemporary datasets have repeatedly"
        },
        {
            "text": "CKD imparts increased risk for a wide array of CVDs ( Figure 2 ). Although atherosclerotic CVD is the most frequent manifestation, leading some to consider CKD a coronary-artery risk equivalent (11), rates of heart failure (12), stroke (13), valvular heart disease (14), arrhythmia (15) , and sudden cardiac death (16) (35) ( Figure 3 ). This is a finding observed in up to 75% of patients with higher than or equal to stage 3 CKD (36), providing a mechanistic basis to the increased rates of heart failure (37) and atrial fibrillation observed in CKD (38) . (42). VHD \u00bc valvular heart disease; other abbreviations as in Figure 1 . ",
            "cite_spans": [
                {
                    "start": 282,
                    "end": 286,
                    "text": "(15)",
                    "ref_id": null
                },
                {
                    "start": 552,
                    "end": 556,
                    "text": "(38)",
                    "ref_id": null
                }
            ],
            "ref_spans": [
                {
                    "start": 54,
                    "end": 62,
                    "text": "Figure 2",
                    "ref_id": "FIGREF7"
                },
                {
                    "start": 326,
                    "end": 334,
                    "text": "Figure 3",
                    "ref_id": "FIGREF26"
                },
                {
                    "start": 621,
                    "end": 629,
                    "text": "Figure 1",
                    "ref_id": "FIGREF5"
                }
            ],
            "section": "Large contemporary datasets have repeatedly"
        },
        {
            "text": "viewed on a lateral lumbar spine plane radiograph (40) . Although the score has reasonable interobserver reproducibility, the progressive reduction in ",
            "cite_spans": [
                {
                    "start": 50,
                    "end": 54,
                    "text": "(40)",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "Vascular Calcification in CKD"
        },
        {
            "text": "A P R I L 2 0 2 0 : 3 9 Vascular calcification at the carotid vessels is associated with increased risk of stroke (141) . Involvement of the proximal aorta can cause a porcelain aorta that can prohibit cardiothoracic surgery (142) . Calcification of the coronary arteries has been linked to increased cardiovascular and all-cause mortality and locally may cause increased atherothrombosis. Calcification of the aorta and the distal vessels is associated with increased arterial stiffness. Calcification of the iliofemoral vessels at the site of anastomosis has been associated with graft failure and worse transplantation outcomes (143, 144) . Calcification of the radial artery and fistula site is more generally associated with early fistula failure (145, 146) . Calcification of the lower limb arteries is associated with the development of peripheral arterial disease (PAD) (claudication, limb ischemia) as well as arterial stiffness (147, 148) . Calciphylaxis is a severe and accelerated form of calcification, predominantly localized in the medial layer of skin arterioles and commonly affects the lower limbs but can occur anywhere. CAC \u00bc coronary artery calcification.",
            "cite_spans": [
                {
                    "start": 114,
                    "end": 119,
                    "text": "(141)",
                    "ref_id": "BIBREF287"
                },
                {
                    "start": 225,
                    "end": 230,
                    "text": "(142)",
                    "ref_id": "BIBREF288"
                },
                {
                    "start": 631,
                    "end": 636,
                    "text": "(143,",
                    "ref_id": "BIBREF289"
                },
                {
                    "start": 637,
                    "end": 641,
                    "text": "144)",
                    "ref_id": "BIBREF290"
                },
                {
                    "start": 752,
                    "end": 757,
                    "text": "(145,",
                    "ref_id": "BIBREF291"
                },
                {
                    "start": 758,
                    "end": 762,
                    "text": "146)",
                    "ref_id": null
                },
                {
                    "start": 938,
                    "end": 943,
                    "text": "(147,",
                    "ref_id": "BIBREF292"
                },
                {
                    "start": 944,
                    "end": 948,
                    "text": "148)",
                    "ref_id": "BIBREF293"
                }
            ],
            "ref_spans": [],
            "section": "Vascular Calcification in CKD"
        },
        {
            "text": "to what is now regarded as a pathological, tightly regulated, and cell-mediated process that resembles bone formation and turnover. Despite this growth in understanding, the temporal sequence of events and the exact cellular steps remain incompletely understood and the focus of ongoing research. Moreover, the observed events are unlikely to occur in a stepwise manner and instead are more likely to represent synchronous and interrelated processes ( Table 1) . (74) . Supporting data in patients with CKD suggest levels of fetuin-A are inversely associated with vascular calcification (75) , and low levels have been linked to inflammation and all-cause mortality in the dialysis population (76) .",
            "cite_spans": [
                {
                    "start": 463,
                    "end": 467,
                    "text": "(74)",
                    "ref_id": null
                },
                {
                    "start": 587,
                    "end": 591,
                    "text": "(75)",
                    "ref_id": null
                },
                {
                    "start": 693,
                    "end": 697,
                    "text": "(76)",
                    "ref_id": null
                }
            ],
            "ref_spans": [
                {
                    "start": 452,
                    "end": 460,
                    "text": "Table 1)",
                    "ref_id": "TABREF0"
                }
            ],
            "section": "Vascular Calcification in CKD"
        },
        {
            "text": "MGP is a widely expressed protein and has been shown to accumulate in calcified tissue. Its precise role remains unconfirmed; however, the two prevailing, potentially synergistic, theories are that MGP may bind calcium ions and calcium crystals, thereby inhibiting crystal growth (77) , or that MGP may interfere with bone morphogenic protein(s) signaling and prevent unwanted cell-induced mineralization (78) . Animal MGP-knockout models developed rapid and extensive aortic medial calcification, which is associated with rupture and early hemorrhagic death (79) . In vitro studies showed that MGP was down- Etelcalcetide, an intravenous calcimimetic that acts at a different site on the CaR, was highly efficacious at lowering PTH and FGF-23 in placebocontrolled trials (115, 116) , and in a head-to-head study, was more effective than cinacalcet on biochemical endpoints (117) . The effects of etelcalcetide on vascular calcification or clinical events have not been evaluated.",
            "cite_spans": [
                {
                    "start": 280,
                    "end": 284,
                    "text": "(77)",
                    "ref_id": "BIBREF220"
                },
                {
                    "start": 405,
                    "end": 409,
                    "text": "(78)",
                    "ref_id": "BIBREF221"
                },
                {
                    "start": 559,
                    "end": 563,
                    "text": "(79)",
                    "ref_id": "BIBREF222"
                },
                {
                    "start": 772,
                    "end": 777,
                    "text": "(115,",
                    "ref_id": "BIBREF260"
                },
                {
                    "start": 778,
                    "end": 782,
                    "text": "116)",
                    "ref_id": "BIBREF261"
                },
                {
                    "start": 874,
                    "end": 879,
                    "text": "(117)",
                    "ref_id": "BIBREF262"
                }
            ],
            "ref_spans": [],
            "section": "Vascular Calcification in CKD"
        },
        {
            "text": "VITAMIN K. As previously described, vitamin K is required to decarboxylate MGP to obtain its calcification inhibitory capacity. Consistent with this physiology, both vitamin K antagonism and vitamin K deficiency have been linked to vascular calcification (118, 119) . In a biochemical proof-of-concept study conducted in 53 patients who underwent hemodialysis, daily supplementation of vitamin K was safe and resulted in a significant increase in MGP activation (120) . Whether increased MGP activation translates into slowing of calcification is being tested in the VitaVasK study. This trial enrolled 348 patients who underwent hemodialysis with a CAC score of at least 100 and randomized them to either oral vitamin K1 orally thrice weekly supplementation or placebo (121) . Because this was an open label trial that was halted early and included <100 participants, larger studies are required to confirm and progress these findings. A combination of these predominantly intimal versus predominantly medial modalities will provide unique insights into natural history, relative modifiability and potential differential drug efficacy.",
            "cite_spans": [
                {
                    "start": 255,
                    "end": 260,
                    "text": "(118,",
                    "ref_id": "BIBREF263"
                },
                {
                    "start": 261,
                    "end": 265,
                    "text": "119)",
                    "ref_id": "BIBREF264"
                },
                {
                    "start": 462,
                    "end": 467,
                    "text": "(120)",
                    "ref_id": "BIBREF265"
                },
                {
                    "start": 770,
                    "end": 775,
                    "text": "(121)",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "Vascular Calcification in CKD"
        },
        {
            "text": "Furthermore, conventional thinking about vascular calcification has been relatively uni-dimensional, aiming to restore or reverse components of the uremic milieu in individuals in whom calcification is established, and inhibitory mechanisms exhausted.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Vascular Calcification in CKD"
        },
        {
            "text": "The underwhelming results may be due to late inter- Nelson et al. ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Vascular Calcification in CKD"
        }
    ],
    "bib_entries": {
        "BIBREF0": {
            "ref_id": "b0",
            "title": "Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL",
            "authors": [
                {
                    "first": "C",
                    "middle": [
                        "J"
                    ],
                    "last": "Binder",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "H\u00f6rkk\u00f6",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Dewan",
                    "suffix": ""
                }
            ],
            "year": 2003,
            "venue": "Nat Med",
            "volume": "9",
            "issn": "",
            "pages": "736--779",
            "other_ids": {}
        },
        "BIBREF1": {
            "ref_id": "b1",
            "title": "Human oxidation-specific antibodies reduce foam cell formation and atherosclerosis progression",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "Tsimikas",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Miyanohara",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Hartvigsen",
                    "suffix": ""
                }
            ],
            "year": 2011,
            "venue": "J Am Coll Cardiol",
            "volume": "58",
            "issn": "",
            "pages": "1715--1742",
            "other_ids": {}
        },
        "BIBREF2": {
            "ref_id": "b2",
            "title": "Oxidized phospholipids are proinflammatory and proatherogenic in hypercholesterolaemic mice",
            "authors": [
                {
                    "first": "X",
                    "middle": [],
                    "last": "Que",
                    "suffix": ""
                },
                {
                    "first": "M-Y",
                    "middle": [],
                    "last": "Hung",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Yeang",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "Nature",
            "volume": "558",
            "issn": "",
            "pages": "301--307",
            "other_ids": {}
        },
        "BIBREF3": {
            "ref_id": "b3",
            "title": "Thresholds for arterial wall inflammation quantified by 18F-FDG PET imaging: implications for vascular interventional studies",
            "authors": [
                {
                    "first": "M",
                    "middle": [
                        "R"
                    ],
                    "last": "Dweck",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [],
                    "last": "Aikawa",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "E"
                    ],
                    "last": "Newby",
                    "suffix": ""
                }
            ],
            "year": 2016,
            "venue": "J Am Coll Cardiol Img",
            "volume": "119",
            "issn": "",
            "pages": "1198--207",
            "other_ids": {}
        },
        "BIBREF4": {
            "ref_id": "b4",
            "title": "Cardiac PET imaging for the detection",
            "authors": [
                {
                    "first": "T",
                    "middle": [
                        "H"
                    ],
                    "last": "Schindler",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [
                        "R"
                    ],
                    "last": "Schelbert",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Quercioli",
                    "suffix": ""
                },
                {
                    "first": "V",
                    "middle": [],
                    "last": "Dilsizian",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF5": {
            "ref_id": "b5",
            "title": "for the CANTOS Trial Group. Antiinflammatory therapy with canakinumab for atherosclerotic disease",
            "authors": [
                {
                    "first": "P",
                    "middle": [
                        "M"
                    ],
                    "last": "Ridker",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [
                        "M"
                    ],
                    "last": "Everett",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Thuren",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF7": {
            "ref_id": "b7",
            "title": "Innate sensing of oxidation-specific epitopes in health and disease",
            "authors": [
                {
                    "first": "C",
                    "middle": [
                        "J"
                    ],
                    "last": "Binder",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "Papac-Milicevic",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "L"
                    ],
                    "last": "Witztum",
                    "suffix": ""
                }
            ],
            "year": 2016,
            "venue": "Nat Rev Immunol",
            "volume": "16",
            "issn": "",
            "pages": "485--97",
            "other_ids": {}
        },
        "BIBREF8": {
            "ref_id": "b8",
            "title": "Oxidized phospholipids are proinflammatory and proatherogenic in hypercholesterolaemic mice",
            "authors": [
                {
                    "first": "X",
                    "middle": [],
                    "last": "Que",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "Y"
                    ],
                    "last": "Hung",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Yeang",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "Nature",
            "volume": "558",
            "issn": "",
            "pages": "301--307",
            "other_ids": {}
        },
        "BIBREF9": {
            "ref_id": "b9",
            "title": "The role of B cells in atherosclerosis",
            "authors": [
                {
                    "first": "A",
                    "middle": [
                        "P"
                    ],
                    "last": "Sage",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Tsiantoulas",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "J"
                    ],
                    "last": "Binder",
                    "suffix": ""
                },
                {
                    "first": "Z",
                    "middle": [],
                    "last": "Mallat",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "Nat Rev Cardiol",
            "volume": "16",
            "issn": "",
            "pages": "180--96",
            "other_ids": {}
        },
        "BIBREF10": {
            "ref_id": "b10",
            "title": "Therapeutic antibody against phosphorylcholine preserves coronary function and attenuates Vascular 18 F-FDG uptake in atherosclerotic mice",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "St\u00e5hle",
                    "suffix": ""
                },
                {
                    "first": "Jmu",
                    "middle": [],
                    "last": "Silvola",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Hellberg",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "J Am Coll Cardiol Basic Trans Science",
            "volume": "5",
            "issn": "",
            "pages": "360--73",
            "other_ids": {}
        },
        "BIBREF11": {
            "ref_id": "b11",
            "title": "B cells and humoral immunity in atherosclerosis",
            "authors": [
                {
                    "first": "D",
                    "middle": [],
                    "last": "Tsiantoulas",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "J"
                    ],
                    "last": "Diehl",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "L"
                    ],
                    "last": "Witztum",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "J"
                    ],
                    "last": "Binder",
                    "suffix": ""
                }
            ],
            "year": 2014,
            "venue": "Circ Res",
            "volume": "114",
            "issn": "",
            "pages": "1743--56",
            "other_ids": {}
        },
        "BIBREF13": {
            "ref_id": "b13",
            "title": "Long-term outcomes in children with congenital heart disease: National Health Interview Survey",
            "authors": [
                {
                    "first": "H",
                    "middle": [],
                    "last": "Razzaghi",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Oster",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Reefhuis",
                    "suffix": ""
                }
            ],
            "year": 2015,
            "venue": "J Pediatr",
            "volume": "166",
            "issn": "",
            "pages": "119--143",
            "other_ids": {}
        },
        "BIBREF14": {
            "ref_id": "b14",
            "title": "Genetic Basis for Congenital Heart Disease: Revisited: A Scientific Statement From the American Heart Association",
            "authors": [
                {
                    "first": "M",
                    "middle": [
                        "E"
                    ],
                    "last": "Pierpont",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Brueckner",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [
                        "K"
                    ],
                    "last": "Chung",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "Circulation",
            "volume": "138",
            "issn": "",
            "pages": "653--711",
            "other_ids": {}
        },
        "BIBREF15": {
            "ref_id": "b15",
            "title": "Recurrence of discordant congenital heart defects in families",
            "authors": [
                {
                    "first": "N",
                    "middle": [],
                    "last": "Oyen",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Poulsen",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Wohlfahrt",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [
                        "A"
                    ],
                    "last": "Boyd",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [
                        "K"
                    ],
                    "last": "Jensen",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Melbye",
                    "suffix": ""
                }
            ],
            "year": 2010,
            "venue": "Circ Cardiovasc Genet",
            "volume": "3",
            "issn": "",
            "pages": "122--130",
            "other_ids": {}
        },
        "BIBREF16": {
            "ref_id": "b16",
            "title": "De novo mutations in histone-modifying genes in congenital heart disease",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "Zaidi",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Choi",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Wakimoto",
                    "suffix": ""
                }
            ],
            "year": 2013,
            "venue": "Nature",
            "volume": "498",
            "issn": "",
            "pages": "220--223",
            "other_ids": {}
        },
        "BIBREF17": {
            "ref_id": "b17",
            "title": "Reduced penetrance, variable expressivity, and genetic heterogeneity of familial atrial septal defects",
            "authors": [
                {
                    "first": "D",
                    "middle": [
                        "W"
                    ],
                    "last": "Benson",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Sharkey",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Fatkin",
                    "suffix": ""
                }
            ],
            "year": 1998,
            "venue": "Circulation",
            "volume": "97",
            "issn": "",
            "pages": "2043--2051",
            "other_ids": {}
        },
        "BIBREF18": {
            "ref_id": "b18",
            "title": "De novo mutations in congenital heart disease with neurodevelopmental and other congenital anomalies",
            "authors": [
                {
                    "first": "J",
                    "middle": [],
                    "last": "Homsy",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Zaidi",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Shen",
                    "suffix": ""
                }
            ],
            "year": 2015,
            "venue": "Science",
            "volume": "350",
            "issn": "",
            "pages": "1262--1268",
            "other_ids": {}
        },
        "BIBREF19": {
            "ref_id": "b19",
            "title": "Contribution of rare inherited and de novo variants in 2,871 congenital heart disease probands",
            "authors": [
                {
                    "first": "S",
                    "middle": [
                        "C"
                    ],
                    "last": "Jin",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Homsy",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Zaidi",
                    "suffix": ""
                }
            ],
            "year": 2017,
            "venue": "Nat Genet",
            "volume": "49",
            "issn": "",
            "pages": "1593--601",
            "other_ids": {}
        },
        "BIBREF20": {
            "ref_id": "b20",
            "title": "A framework for variation discovery and genotyping using next-generation DNA sequencing data",
            "authors": [
                {
                    "first": "M",
                    "middle": [
                        "A"
                    ],
                    "last": "Depristo",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [],
                    "last": "Banks",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Poplin",
                    "suffix": ""
                }
            ],
            "year": 2011,
            "venue": "Nat Genet",
            "volume": "43",
            "issn": "",
            "pages": "491--499",
            "other_ids": {}
        },
        "BIBREF21": {
            "ref_id": "b21",
            "title": "Fast and accurate long-read alignment with Burrows-Wheeler transform",
            "authors": [
                {
                    "first": "H",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Durbin",
                    "suffix": ""
                }
            ],
            "year": 2010,
            "venue": "Bioinformatics",
            "volume": "26",
            "issn": "",
            "pages": "589--95",
            "other_ids": {}
        },
        "BIBREF22": {
            "ref_id": "b22",
            "title": "PredictSNP2: a unified platform for accurately evaluating SNP effects by exploiting the different characteristics of variants in distinct genomic regions",
            "authors": [
                {
                    "first": "J",
                    "middle": [],
                    "last": "Bendl",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Musil",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Stourac",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Zendulka",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Damborsky",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Brezovsky",
                    "suffix": ""
                }
            ],
            "year": 2016,
            "venue": "PLoS Comput Biol",
            "volume": "12",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF23": {
            "ref_id": "b23",
            "title": "A general framework for estimating the relative pathogenicity of human genetic variants",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Kircher",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "M"
                    ],
                    "last": "Witten",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Jain",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [
                        "J"
                    ],
                    "last": "O&apos;roak",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [
                        "M"
                    ],
                    "last": "Cooper",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Shendure",
                    "suffix": ""
                }
            ],
            "year": 2014,
            "venue": "Nat Genet",
            "volume": "46",
            "issn": "",
            "pages": "310--315",
            "other_ids": {}
        },
        "BIBREF24": {
            "ref_id": "b24",
            "title": "Mouse Genome Database G. The Mouse Genome Database: integration of and access to knowledge about the laboratory mouse",
            "authors": [
                {
                    "first": "J",
                    "middle": [
                        "A"
                    ],
                    "last": "Blake",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "J"
                    ],
                    "last": "Bult",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "T"
                    ],
                    "last": "Eppig",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "A"
                    ],
                    "last": "Kadin",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "E"
                    ],
                    "last": "Richardson",
                    "suffix": ""
                }
            ],
            "year": 2014,
            "venue": "Nucleic Acids Res",
            "volume": "42",
            "issn": "",
            "pages": "810--817",
            "other_ids": {}
        },
        "BIBREF25": {
            "ref_id": "b25",
            "title": "The Congenital Heart Disease Genetic Network Study: rationale, design, and early results",
            "authors": [
                {
                    "first": "C",
                    "middle": [],
                    "last": "Pediatric Cardiac Genomics",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Gelb",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Brueckner",
                    "suffix": ""
                }
            ],
            "year": 2013,
            "venue": "Circ Res",
            "volume": "112",
            "issn": "",
            "pages": "698--706",
            "other_ids": {}
        },
        "BIBREF26": {
            "ref_id": "b26",
            "title": "Enrichr: a comprehensive gene set enrichment analysis web server 2016 update",
            "authors": [
                {
                    "first": "M",
                    "middle": [
                        "V"
                    ],
                    "last": "Kuleshov",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "R"
                    ],
                    "last": "Jones",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "D"
                    ],
                    "last": "Rouillard",
                    "suffix": ""
                }
            ],
            "year": 2016,
            "venue": "Nucleic Acids Res",
            "volume": "44",
            "issn": "",
            "pages": "90--97",
            "other_ids": {}
        },
        "BIBREF27": {
            "ref_id": "b27",
            "title": "WebGestalt 2019: gene set analysis toolkit with revamped UIs and APIs",
            "authors": [
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Liao",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [
                        "J"
                    ],
                    "last": "Jaehnig",
                    "suffix": ""
                },
                {
                    "first": "Z",
                    "middle": [],
                    "last": "Shi",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "Nucleic Acids Res",
            "volume": "47",
            "issn": "",
            "pages": "199--205",
            "other_ids": {}
        },
        "BIBREF28": {
            "ref_id": "b28",
            "title": "CRISPR/Cas9-Directed Gene Editing for the Generation of Loss-of-Function Mutants in High-Throughput Zebrafish F0 Screens",
            "authors": [
                {
                    "first": "S",
                    "middle": [
                        "S"
                    ],
                    "last": "Shankaran",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [
                        "J"
                    ],
                    "last": "Dahlem",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [
                        "W"
                    ],
                    "last": "Bisgrove",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [
                        "J"
                    ],
                    "last": "Yost",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Tristani-Firouzi",
                    "suffix": ""
                }
            ],
            "year": 2017,
            "venue": "Curr Protoc Mol Biol",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF29": {
            "ref_id": "b29",
            "title": "A rapid and efficient method of genotyping zebrafish mutants",
            "authors": [
                {
                    "first": "J",
                    "middle": [
                        "M"
                    ],
                    "last": "Parant",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "A"
                    ],
                    "last": "George",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Pryor",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "T"
                    ],
                    "last": "Wittwer",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [
                        "J"
                    ],
                    "last": "Yost",
                    "suffix": ""
                }
            ],
            "year": 2009,
            "venue": "Dev Dyn",
            "volume": "238",
            "issn": "",
            "pages": "3168--74",
            "other_ids": {}
        },
        "BIBREF30": {
            "ref_id": "b30",
            "title": "WAVE signalling: from biochemistry to biology",
            "authors": [
                {
                    "first": "S",
                    "middle": [
                        "H"
                    ],
                    "last": "Soderling",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "D"
                    ],
                    "last": "Scott",
                    "suffix": ""
                }
            ],
            "year": 2006,
            "venue": "Biochem Soc Trans",
            "volume": "34",
            "issn": "",
            "pages": "73--79",
            "other_ids": {}
        },
        "BIBREF31": {
            "ref_id": "b31",
            "title": "Abi1 is essential for the formation and activation of a WAVE2 signalling complex",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Innocenti",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Zucconi",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Disanza",
                    "suffix": ""
                }
            ],
            "year": 2004,
            "venue": "Nat Cell Biol",
            "volume": "6",
            "issn": "",
            "pages": "319--346",
            "other_ids": {}
        },
        "BIBREF32": {
            "ref_id": "b32",
            "title": "GeNets: a unified web platform for network-based genomic analyses",
            "authors": [
                {
                    "first": "T",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Kim",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Rosenbluh",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "Nat Methods",
            "volume": "15",
            "issn": "",
            "pages": "543--549",
            "other_ids": {}
        },
        "BIBREF33": {
            "ref_id": "b33",
            "title": "Genetics of congenital heart disease",
            "authors": [
                {
                    "first": "A",
                    "middle": [
                        "A"
                    ],
                    "last": "Richards",
                    "suffix": ""
                },
                {
                    "first": "V",
                    "middle": [],
                    "last": "Garg",
                    "suffix": ""
                }
            ],
            "year": 2010,
            "venue": "Curr Cardiol Rev",
            "volume": "6",
            "issn": "",
            "pages": "91--98",
            "other_ids": {}
        },
        "BIBREF34": {
            "ref_id": "b34",
            "title": "Rac1 signaling is critical to cardiomyocyte polarity and embryonic heart development",
            "authors": [
                {
                    "first": "C",
                    "middle": [],
                    "last": "Leung",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Lu",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "Q",
                    "middle": [],
                    "last": "Feng",
                    "suffix": ""
                }
            ],
            "year": 2014,
            "venue": "J Am Heart Assoc",
            "volume": "3",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF36": {
            "ref_id": "b36",
            "title": "Cardiovascular disease in neurofibromatosis 1: report of the NF1 Cardiovascular Task Force",
            "authors": [],
            "year": 2002,
            "venue": "",
            "volume": "4",
            "issn": "",
            "pages": "105--116",
            "other_ids": {}
        },
        "BIBREF37": {
            "ref_id": "b37",
            "title": "Functional dysregulation of CDC42 causes diverse developmental phenotypes",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "Martinelli",
                    "suffix": ""
                },
                {
                    "first": "Ohf",
                    "middle": [],
                    "last": "Krumbach",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Pantaleoni",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "Am J Hum Genet",
            "volume": "102",
            "issn": "",
            "pages": "309--329",
            "other_ids": {}
        },
        "BIBREF38": {
            "ref_id": "b38",
            "title": "Deletion of Cdc42 in embryonic cardiomyocytes results in right ventricle hypoplasia",
            "authors": [
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                }
            ],
            "year": 2017,
            "venue": "Clin Transl Med",
            "volume": "6",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF41": {
            "ref_id": "b41",
            "title": "Cullin-3 targets cyclin E for ubiquitination and controls S phase in mammalian cells",
            "authors": [
                {
                    "first": "J",
                    "middle": [
                        "D"
                    ],
                    "last": "Singer",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Gurian-West",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Clurman",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "M"
                    ],
                    "last": "Roberts",
                    "suffix": ""
                }
            ],
            "year": 1999,
            "venue": "Genes Dev",
            "volume": "13",
            "issn": "",
            "pages": "2375--87",
            "other_ids": {}
        },
        "BIBREF42": {
            "ref_id": "b42",
            "title": "Cullin-3-RING ubiquitin ligase activity is required for striated muscle function in mice",
            "authors": [
                {
                    "first": "J",
                    "middle": [
                        "B"
                    ],
                    "last": "Papizan",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "H"
                    ],
                    "last": "Vidal",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Bezprozvannaya",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Bassel-Duby",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [
                        "N"
                    ],
                    "last": "Olson",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "J Biol Chem",
            "volume": "293",
            "issn": "",
            "pages": "8802--8813",
            "other_ids": {}
        },
        "BIBREF43": {
            "ref_id": "b43",
            "title": "Abl-interactor-1 (Abi1) has a role in cardiovascular and placental development and is a binding partner of the alpha4 integrin",
            "authors": [
                {
                    "first": "P",
                    "middle": [
                        "M"
                    ],
                    "last": "Dubielecka",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [
                        "I"
                    ],
                    "last": "Ladwein",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Xiong",
                    "suffix": ""
                }
            ],
            "year": 2011,
            "venue": "Proc Natl Acad Sci U S A",
            "volume": "108",
            "issn": "",
            "pages": "149--54",
            "other_ids": {}
        },
        "BIBREF44": {
            "ref_id": "b44",
            "title": "Brick1 is an essential regulator of actin cytoskeleton required for embryonic development and cell transformation",
            "authors": [
                {
                    "first": "B",
                    "middle": [],
                    "last": "Escobar",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "De Carcer",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Fernandez-Miranda",
                    "suffix": ""
                }
            ],
            "year": 2010,
            "venue": "Cancer Res",
            "volume": "70",
            "issn": "",
            "pages": "9349--59",
            "other_ids": {}
        },
        "BIBREF46": {
            "ref_id": "b46",
            "title": "Axis specification and morphogenesis in the mouse embryo require Nap1, a regulator of WAVE-mediated actin branching",
            "authors": [
                {
                    "first": "A",
                    "middle": [
                        "S"
                    ],
                    "last": "Rakeman",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [
                        "V"
                    ],
                    "last": "Anderson",
                    "suffix": ""
                }
            ],
            "year": 2006,
            "venue": "Development",
            "volume": "133",
            "issn": "",
            "pages": "3075--83",
            "other_ids": {}
        },
        "BIBREF47": {
            "ref_id": "b47",
            "title": "WAVE2 deficiency reveals distinct roles in embryogenesis and Rac-mediated actin-based motility",
            "authors": [
                {
                    "first": "C",
                    "middle": [],
                    "last": "Yan",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "Martinez-Quiles",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Eden",
                    "suffix": ""
                }
            ],
            "year": 2003,
            "venue": "EMBO J",
            "volume": "22",
            "issn": "",
            "pages": "3602--3614",
            "other_ids": {}
        },
        "BIBREF48": {
            "ref_id": "b48",
            "title": "WAVE2 is required for directed cell migration and cardiovascular development",
            "authors": [
                {
                    "first": "D",
                    "middle": [],
                    "last": "Yamazaki",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Suetsugu",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Miki",
                    "suffix": ""
                }
            ],
            "year": 2003,
            "venue": "Nature",
            "volume": "424",
            "issn": "",
            "pages": "452--458",
            "other_ids": {}
        },
        "BIBREF49": {
            "ref_id": "b49",
            "title": "Ontogeny of cardiovascular and respiratory physiology in lower vertebrates",
            "authors": [
                {
                    "first": "W",
                    "middle": [
                        "W"
                    ],
                    "last": "Burggren",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "W"
                    ],
                    "last": "Pinder",
                    "suffix": ""
                }
            ],
            "year": 1991,
            "venue": "Annu Rev Physiol",
            "volume": "53",
            "issn": "",
            "pages": "107--142",
            "other_ids": {}
        },
        "BIBREF50": {
            "ref_id": "b50",
            "title": "A guide to analysis of cardiac phenotypes in the zebrafish embryo",
            "authors": [
                {
                    "first": "G",
                    "middle": [
                        "I"
                    ],
                    "last": "Miura",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Yelon",
                    "suffix": ""
                }
            ],
            "year": 2011,
            "venue": "Methods Cell Biol",
            "volume": "101",
            "issn": "",
            "pages": "161--80",
            "other_ids": {}
        },
        "BIBREF51": {
            "ref_id": "b51",
            "title": "Global ge",
            "authors": [
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [
                        "T"
                    ],
                    "last": "Klena",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [
                        "C"
                    ],
                    "last": "Gabriel",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF52": {
            "ref_id": "b52",
            "title": "The complex genetics of hypoplastic left heart syndrome",
            "authors": [
                {
                    "first": "X",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Yagi",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Saeed",
                    "suffix": ""
                }
            ],
            "year": 2017,
            "venue": "Nat Genet",
            "volume": "49",
            "issn": "",
            "pages": "1152--1161",
            "other_ids": {}
        },
        "BIBREF53": {
            "ref_id": "b53",
            "title": "SCAR/WAVE is activated at mitosis and drives myosin-independent cytokinesis",
            "authors": [
                {
                    "first": "J",
                    "middle": [
                        "S"
                    ],
                    "last": "King",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "M"
                    ],
                    "last": "Veltman",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Georgiou",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Baum",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "H"
                    ],
                    "last": "Insall",
                    "suffix": ""
                }
            ],
            "year": 2010,
            "venue": "J Cell Sci",
            "volume": "123",
            "issn": "",
            "pages": "2246--55",
            "other_ids": {}
        },
        "BIBREF54": {
            "ref_id": "b54",
            "title": "The WAVE/SCAR complex promotes polarized cell movements and actin enrichment in epithelia during C. elegans embryogenesis",
            "authors": [
                {
                    "first": "F",
                    "middle": [
                        "B"
                    ],
                    "last": "Patel",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [
                        "Y"
                    ],
                    "last": "Bernadskaya",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [],
                    "last": "Chen",
                    "suffix": ""
                }
            ],
            "year": 2008,
            "venue": "Dev Biol",
            "volume": "324",
            "issn": "",
            "pages": "297--309",
            "other_ids": {}
        },
        "BIBREF55": {
            "ref_id": "b55",
            "title": "Planar cell polarity signaling: from fly development to human disease",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Simons",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Mlodzik",
                    "suffix": ""
                }
            ],
            "year": 2008,
            "venue": "Annu Rev Genet",
            "volume": "42",
            "issn": "",
            "pages": "517--557",
            "other_ids": {}
        },
        "BIBREF56": {
            "ref_id": "b56",
            "title": "Getting to the heart of planar cell polarity signaling",
            "authors": [
                {
                    "first": "D",
                    "middle": [
                        "J"
                    ],
                    "last": "Henderson",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Chaudhry",
                    "suffix": ""
                }
            ],
            "year": 2011,
            "venue": "Birth -Defects Res A Clin Mol Teratol",
            "volume": "91",
            "issn": "",
            "pages": "460--467",
            "other_ids": {}
        },
        "BIBREF57": {
            "ref_id": "b57",
            "title": "Disheveled mediated planar cell polarity signaling is required in the second heart field lineage for outflow tract morphogenesis",
            "authors": [
                {
                    "first": "T",
                    "middle": [],
                    "last": "Sinha",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Evans",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Wynshaw-Boris",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                }
            ],
            "year": 2012,
            "venue": "Dev Biol",
            "volume": "370",
            "issn": "",
            "pages": "135--179",
            "other_ids": {}
        },
        "BIBREF58": {
            "ref_id": "b58",
            "title": "The Cullin3 ubiquitin ligase functions as a Nedd8-bound heterodimer",
            "authors": [
                {
                    "first": "W",
                    "middle": [],
                    "last": "Wimuttisuk",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "D"
                    ],
                    "last": "Singer",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF60": {
            "ref_id": "b60",
            "title": "Regulation of Cullin-RING ubiquitin ligase 1 by Spliceosomeassociated protein 130 (SAP130)",
            "authors": [
                {
                    "first": "L",
                    "middle": [],
                    "last": "Cordero-Espinoza",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Hagen",
                    "suffix": ""
                }
            ],
            "year": 2013,
            "venue": "Biol Open",
            "volume": "2",
            "issn": "",
            "pages": "838--882",
            "other_ids": {}
        },
        "BIBREF61": {
            "ref_id": "b61",
            "title": "Dominant Noonan syndrome-causing LZTR1 mutations specifically affect the Kelch domain substrate-recognition surface and enhance RAS-MAPK signaling",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Motta",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Fidan",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [],
                    "last": "Bellacchio",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "Hum Mol Genet",
            "volume": "28",
            "issn": "",
            "pages": "1007--1029",
            "other_ids": {}
        },
        "BIBREF62": {
            "ref_id": "b62",
            "title": "LZTR1 drive human disease by dysre",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Steklov",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Pandolfi",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "F"
                    ],
                    "last": "Baietti",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF63": {
            "ref_id": "b63",
            "title": "Limitations of animal studies for predicting toxicity in clinical trials: is it time to rethink our current approach?",
            "authors": [
                {
                    "first": "G",
                    "middle": [],
                    "last": "Van Norman",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "J Am Coll Cardiol Basic Trans Science",
            "volume": "4",
            "issn": "",
            "pages": "845--54",
            "other_ids": {}
        },
        "BIBREF64": {
            "ref_id": "b64",
            "title": "Communicating about animal research with the public",
            "authors": [
                {
                    "first": "Macarthur",
                    "middle": [],
                    "last": "Clark",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "",
                    "suffix": ""
                },
                {
                    "first": "Clifford",
                    "middle": [
                        "P"
                    ],
                    "last": "Jarrett",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [],
                    "last": "Pekow",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "ILAR J",
            "volume": "60",
            "issn": "",
            "pages": "34--42",
            "other_ids": {}
        },
        "BIBREF66": {
            "ref_id": "b66",
            "title": "Older Americans' moral attitudes changing",
            "authors": [
                {
                    "first": "J",
                    "middle": [],
                    "last": "Wilke",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Saad",
                    "suffix": ""
                }
            ],
            "year": 2013,
            "venue": "Gallup.com",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF67": {
            "ref_id": "b67",
            "title": "Directive 2003/15/EC of the European Parliament and of the Council of 27 February",
            "authors": [
                {
                    "first": "",
                    "middle": [],
                    "last": "Eur-Lex",
                    "suffix": ""
                }
            ],
            "year": 2003,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF68": {
            "ref_id": "b68",
            "title": "National Institutes of Health. NIH to reduce significantly the use of chimpanzees in research (news release)",
            "authors": [],
            "year": 2018,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF70": {
            "ref_id": "b70",
            "title": "NIH will no longer support biomedical research on chimpanzees",
            "authors": [],
            "year": 2015,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF71": {
            "ref_id": "b71",
            "title": "Dog research at U.S. Department of Veterans Affairs gets formal review",
            "authors": [
                {
                    "first": "D",
                    "middle": [],
                    "last": "Grimm",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF72": {
            "ref_id": "b72",
            "title": "Public perceptions of animal experimentation across Europe",
            "authors": [
                {
                    "first": "F",
                    "middle": [
                        "C"
                    ],
                    "last": "Von Roten",
                    "suffix": ""
                }
            ],
            "year": 2013,
            "venue": "Public Underst Sci",
            "volume": "22",
            "issn": "",
            "pages": "691--703",
            "other_ids": {}
        },
        "BIBREF73": {
            "ref_id": "b73",
            "title": "Alternative animal and nonanimal models for drug discovery and development: bonus or burden?",
            "authors": [
                {
                    "first": "I",
                    "middle": [
                        "A"
                    ],
                    "last": "Freires",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "De Cassia Orlandi",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Sardi",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Dias De Castro",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [
                        "L"
                    ],
                    "last": "Rosalen",
                    "suffix": ""
                }
            ],
            "year": 2017,
            "venue": "Pharmaceut Res",
            "volume": "34",
            "issn": "",
            "pages": "681--687",
            "other_ids": {}
        },
        "BIBREF74": {
            "ref_id": "b74",
            "title": "Current trends in in silico, in vitro toxicology and safety biomarkers in early drug development",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "Loiodice",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Nogueira De Costa",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Atienzar",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "Drug Chem Tox",
            "volume": "42",
            "issn": "",
            "pages": "113--134",
            "other_ids": {}
        },
        "BIBREF75": {
            "ref_id": "b75",
            "title": "An introduction to computational modeling of cardiac electrophysiology and arrhythmogenicity",
            "authors": [
                {
                    "first": "J",
                    "middle": [],
                    "last": "Mayourian",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [
                        "A"
                    ],
                    "last": "Sobie",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [
                        "D"
                    ],
                    "last": "Costa",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "17--35",
            "other_ids": {}
        },
        "BIBREF76": {
            "ref_id": "b76",
            "title": "In silico toxicology-non-testing methods",
            "authors": [
                {
                    "first": "H",
                    "middle": [],
                    "last": "Raunio",
                    "suffix": ""
                }
            ],
            "year": 2011,
            "venue": "Front Pharmacol",
            "volume": "2",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF77": {
            "ref_id": "b77",
            "title": "Drug repurposing from the perspective of pharmaceutical companies",
            "authors": [
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Cha",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Erez",
                    "suffix": ""
                },
                {
                    "first": "I",
                    "middle": [
                        "J"
                    ],
                    "last": "Reynolds",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "Br J Pharmacol",
            "volume": "175",
            "issn": "",
            "pages": "168--80",
            "other_ids": {}
        },
        "BIBREF78": {
            "ref_id": "b78",
            "title": "Drug repositioning: identifying and developing new uses for existing drugs",
            "authors": [
                {
                    "first": "T",
                    "middle": [
                        "T"
                    ],
                    "last": "Ashburn",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [
                        "B"
                    ],
                    "last": "Thor",
                    "suffix": ""
                }
            ],
            "year": 2014,
            "venue": "Nat Rev Drug Discov",
            "volume": "3",
            "issn": "",
            "pages": "673--83",
            "other_ids": {}
        },
        "BIBREF79": {
            "ref_id": "b79",
            "title": "Inventing new therapies without reinventing the wheel: the power of drug repurposing",
            "authors": [
                {
                    "first": "A",
                    "middle": [],
                    "last": "Papapetropoulos",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Szabo",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "Br J Pharmacol",
            "volume": "175",
            "issn": "",
            "pages": "165--172",
            "other_ids": {}
        },
        "BIBREF80": {
            "ref_id": "b80",
            "title": "Understanding unapproved use of approved drugs \"off label",
            "authors": [],
            "year": 2020,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF81": {
            "ref_id": "b81",
            "title": "Large-scale prediction and testing of drug activity on side-effect targets",
            "authors": [
                {
                    "first": "E",
                    "middle": [],
                    "last": "Lounkine",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "J"
                    ],
                    "last": "Keiser",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Whitebread",
                    "suffix": ""
                }
            ],
            "year": 2012,
            "venue": "Nature",
            "volume": "486",
            "issn": "",
            "pages": "361--369",
            "other_ids": {}
        },
        "BIBREF82": {
            "ref_id": "b82",
            "title": "Machine learning of toxicological big data enables read-across structure activity relationship (RASAR) outperforming animal test reproducibility",
            "authors": [
                {
                    "first": "T",
                    "middle": [],
                    "last": "Luechtefeld",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Marsh",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Rowlands",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Hartung",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "Toxicol Sci",
            "volume": "165",
            "issn": "",
            "pages": "198--212",
            "other_ids": {}
        },
        "BIBREF83": {
            "ref_id": "b83",
            "title": "Drug-induced QT interval prolongation: does ethnicity of the thorough QT study population matter?",
            "authors": [
                {
                    "first": "R",
                    "middle": [
                        "R"
                    ],
                    "last": "Shah",
                    "suffix": ""
                }
            ],
            "year": 2013,
            "venue": "Br J Clin Pharacol",
            "volume": "75",
            "issn": "",
            "pages": "347--58",
            "other_ids": {}
        },
        "BIBREF84": {
            "ref_id": "b84",
            "title": "Guidance for industry: E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs",
            "authors": [
                {
                    "first": "U",
                    "middle": [
                        "S"
                    ],
                    "last": "",
                    "suffix": ""
                }
            ],
            "year": 2005,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF85": {
            "ref_id": "b85",
            "title": "An evaluation of hERG current assay performance: translating preclinical safety studies of clinical QT prolongation",
            "authors": [
                {
                    "first": "G",
                    "middle": [],
                    "last": "Gintant",
                    "suffix": ""
                }
            ],
            "year": 2011,
            "venue": "Pharmacol Ther",
            "volume": "129",
            "issn": "",
            "pages": "109--128",
            "other_ids": {}
        },
        "BIBREF86": {
            "ref_id": "b86",
            "title": "Improved prediction of drug-induced torsades de pointes through simulations of dynamics and machine learning algorithms",
            "authors": [
                {
                    "first": "M",
                    "middle": [
                        "C"
                    ],
                    "last": "Lancaster",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [
                        "A"
                    ],
                    "last": "Sobie",
                    "suffix": ""
                }
            ],
            "year": 2016,
            "venue": "Clin Pharm Therapeut",
            "volume": "100",
            "issn": "",
            "pages": "371--380",
            "other_ids": {}
        },
        "BIBREF87": {
            "ref_id": "b87",
            "title": "Human in silico drug trials demonstrate higher accuracy than animal models in predicting clinical proarrhythmic cardiotoxicity",
            "authors": [
                {
                    "first": "E",
                    "middle": [],
                    "last": "Passini",
                    "suffix": ""
                },
                {
                    "first": "O",
                    "middle": [
                        "J"
                    ],
                    "last": "Britton",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [
                        "R"
                    ],
                    "last": "Lu",
                    "suffix": ""
                }
            ],
            "year": 2017,
            "venue": "Front Physiol",
            "volume": "8",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF88": {
            "ref_id": "b88",
            "title": "Computer model predicts side effects",
            "authors": [
                {
                    "first": "K",
                    "middle": [],
                    "last": "Kolaja",
                    "suffix": ""
                }
            ],
            "year": 2012,
            "venue": "Nature",
            "volume": "486",
            "issn": "",
            "pages": "326--333",
            "other_ids": {}
        },
        "BIBREF89": {
            "ref_id": "b89",
            "title": "A molecularly detailed Nav1.5 model reveals a new class I antiarrhythmic target",
            "authors": [
                {
                    "first": "J",
                    "middle": [
                        "D"
                    ],
                    "last": "Moreno",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [],
                    "last": "Zhu",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Mangold",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [],
                    "last": "Chung",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "R"
                    ],
                    "last": "Silva",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "J Am Coll Cardiol Basic Trans Science",
            "volume": "4",
            "issn": "",
            "pages": "736--51",
            "other_ids": {}
        },
        "BIBREF91": {
            "ref_id": "b91",
            "title": "New drug, old drug, no drug; uses of spectral data-activity relationships (SDAR) modeling. U.S. Food and Drug Administration",
            "authors": [
                {
                    "first": "W",
                    "middle": [
                        "B"
                    ],
                    "last": "Mattes",
                    "suffix": ""
                }
            ],
            "year": 2015,
            "venue": "Science Writers Symposium",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF92": {
            "ref_id": "b92",
            "title": "How simulation can transform regulatory pathways",
            "authors": [
                {
                    "first": "U",
                    "middle": [
                        "S"
                    ],
                    "last": "",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF93": {
            "ref_id": "b93",
            "title": "Reporting of computational modeling studies in medical device submissions: guidance for industry and Food and Drug Administration staff",
            "authors": [
                {
                    "first": "U",
                    "middle": [
                        "S"
                    ],
                    "last": "",
                    "suffix": ""
                }
            ],
            "year": 2016,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF94": {
            "ref_id": "b94",
            "title": "Safety testing of drug metabolites: guidance for industry",
            "authors": [
                {
                    "first": "U",
                    "middle": [
                        "S"
                    ],
                    "last": "",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF95": {
            "ref_id": "b95",
            "title": "Blame it on the antibodies",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Baker",
                    "suffix": ""
                }
            ],
            "year": 2015,
            "venue": "Nature",
            "volume": "521",
            "issn": "",
            "pages": "274--280",
            "other_ids": {}
        },
        "BIBREF97": {
            "ref_id": "b97",
            "title": "The potential of tissue engineering or developing alternatives to animal experiments: a systematic review",
            "authors": [
                {
                    "first": "Rbm",
                    "middle": [],
                    "last": "De Vries",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Leenaars",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Tra",
                    "suffix": ""
                }
            ],
            "year": 2015,
            "venue": "J Tissue Regen Med",
            "volume": "9",
            "issn": "",
            "pages": "771--779",
            "other_ids": {}
        },
        "BIBREF98": {
            "ref_id": "b98",
            "title": "A first vascularized skin equivalent as an alternative to animal experimentation",
            "authors": [
                {
                    "first": "F",
                    "middle": [],
                    "last": "Groeber",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Englehardt",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Lange",
                    "suffix": ""
                }
            ],
            "year": 2016,
            "venue": "ALTEX",
            "volume": "33",
            "issn": "",
            "pages": "415--437",
            "other_ids": {}
        },
        "BIBREF99": {
            "ref_id": "b99",
            "title": "A new method to measure isometric force of contraction in embryonic cardiac myocytes",
            "authors": [
                {
                    "first": "T",
                    "middle": [],
                    "last": "Eschenhagen",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Wakatsuki",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [
                        "L"
                    ],
                    "last": "Elson",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "Second International Conference on Cellular Engineering",
            "volume": "",
            "issn": "",
            "pages": "96--113",
            "other_ids": {}
        },
        "BIBREF100": {
            "ref_id": "b100",
            "title": "Tissues from dissociated cells",
            "authors": [
                {
                    "first": "A",
                    "middle": [
                        "A"
                    ],
                    "last": "Moscona",
                    "suffix": ""
                }
            ],
            "year": 1959,
            "venue": "Sci Am",
            "volume": "200",
            "issn": "",
            "pages": "132--136",
            "other_ids": {}
        },
        "BIBREF101": {
            "ref_id": "b101",
            "title": "Cardiac tissue engineering. State of the art",
            "authors": [
                {
                    "first": "M",
                    "middle": [
                        "N"
                    ],
                    "last": "Hirt",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Hansen",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Echenhagen",
                    "suffix": ""
                }
            ],
            "year": 2014,
            "venue": "Circ Res",
            "volume": "2",
            "issn": "",
            "pages": "354--67",
            "other_ids": {}
        },
        "BIBREF102": {
            "ref_id": "b102",
            "title": "Cardiovascular organ-on-a-chip platforms for drug discovery and development",
            "authors": [
                {
                    "first": "J",
                    "middle": [],
                    "last": "Ribas",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Sadeghi",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Manbaci",
                    "suffix": ""
                }
            ],
            "year": 2016,
            "venue": "Appl In Vitro Tech",
            "volume": "2",
            "issn": "",
            "pages": "82--96",
            "other_ids": {}
        },
        "BIBREF103": {
            "ref_id": "b103",
            "title": "Bioengineering an electro-mechanically functional miniature ventricular heart chamber from human pluripotent stem cells",
            "authors": [
                {
                    "first": "R",
                    "middle": [
                        "A"
                    ],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [],
                    "last": "Keung",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [
                        "J"
                    ],
                    "last": "Cashman",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "Biomaterials",
            "volume": "163",
            "issn": "",
            "pages": "116--143",
            "other_ids": {}
        },
        "BIBREF104": {
            "ref_id": "b104",
            "title": "Human cardiac organoids for disease modeling",
            "authors": [
                {
                    "first": "B",
                    "middle": [],
                    "last": "Nugraha",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Buiono",
                    "suffix": ""
                },
                {
                    "first": "Von",
                    "middle": [],
                    "last": "Boehmenr",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Hoerstrup",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "P"
                    ],
                    "last": "Emmert",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "Y"
                    ],
                    "last": "",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "Clin Pharmacol Ther",
            "volume": "206",
            "issn": "",
            "pages": "79--85",
            "other_ids": {}
        },
        "BIBREF105": {
            "ref_id": "b105",
            "title": "Myocardial tissue engineering: in vitro models",
            "authors": [
                {
                    "first": "G",
                    "middle": [
                        "V"
                    ],
                    "last": "Novakovi",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Eschenhagen",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Mummery",
                    "suffix": ""
                }
            ],
            "year": 2014,
            "venue": "Cold Spring Harb Perspect Med",
            "volume": "4",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF106": {
            "ref_id": "b106",
            "title": "In vitro cardiac tissue models: current status and future prospects",
            "authors": [
                {
                    "first": "A",
                    "middle": [],
                    "last": "Mathur",
                    "suffix": ""
                },
                {
                    "first": "Z",
                    "middle": [],
                    "last": "Ma",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Loskill",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Jeeawoody",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [
                        "E"
                    ],
                    "last": "Healy",
                    "suffix": ""
                }
            ],
            "year": 2016,
            "venue": "Adv Drug Deliv Rev",
            "volume": "96",
            "issn": "",
            "pages": "203--216",
            "other_ids": {}
        },
        "BIBREF107": {
            "ref_id": "b107",
            "title": "Increased afterload augments sunitinib-induced cardiotoxicity in an engineered cardiac mouse microtissue model",
            "authors": [
                {
                    "first": "R",
                    "middle": [],
                    "last": "Truitt",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Mu",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [
                        "A"
                    ],
                    "last": "Corbin",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "J Am Coll Cardiol Basic Trans Science",
            "volume": "3",
            "issn": "",
            "pages": "265--76",
            "other_ids": {}
        },
        "BIBREF108": {
            "ref_id": "b108",
            "title": "Guidance document: regulatory considerations for human cells, tissues, and cellular and tissue-based products: minimal manipulation and homologous use",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF110": {
            "ref_id": "b110",
            "title": "Evaluation of devices used with regenerative medicine advanced therapies: guidance for industry",
            "authors": [
                {
                    "first": "U",
                    "middle": [
                        "S"
                    ],
                    "last": "",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF111": {
            "ref_id": "b111",
            "title": "cellular-gene-therapy-products/ regenerative-medicine-advanced-therapydesignation",
            "authors": [
                {
                    "first": "U",
                    "middle": [
                        "S"
                    ],
                    "last": "",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF112": {
            "ref_id": "b112",
            "title": "Expedited programs for regenerative medicine therapies for serious conditions: guidance for industry",
            "authors": [
                {
                    "first": "U",
                    "middle": [
                        "S"
                    ],
                    "last": "",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF113": {
            "ref_id": "b113",
            "title": "Available at: https:// wyss.harvard",
            "authors": [],
            "year": 2020,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF114": {
            "ref_id": "b114",
            "title": "Organ/body-on-achip based on microfluidic technology for drug discovery",
            "authors": [
                {
                    "first": "H",
                    "middle": [],
                    "last": "Kimura",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Sakai",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Fujii",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "Drug Metab Pharmacokin",
            "volume": "33",
            "issn": "",
            "pages": "43--51",
            "other_ids": {}
        },
        "BIBREF115": {
            "ref_id": "b115",
            "title": "FDA researchers to evaluate 'organs-on-chips' technology",
            "authors": [],
            "year": 2017,
            "venue": "Constituent Update",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF116": {
            "ref_id": "b116",
            "title": "Drug compound screening in single and integrated multi-organoid body-on-a-chip systems",
            "authors": [
                {
                    "first": "A",
                    "middle": [],
                    "last": "Skardal",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Aleman",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Forsythe",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Biofabrication",
            "volume": "12",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF117": {
            "ref_id": "b117",
            "title": "Heart disease and stroke statistics-2020 update: a report from the",
            "authors": [
                {
                    "first": "S",
                    "middle": [
                        "S"
                    ],
                    "last": "Virani",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Alonso",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [],
                    "last": "Benjamin",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "American Heart Association. Circulation",
            "volume": "141",
            "issn": "",
            "pages": "139--596",
            "other_ids": {}
        },
        "BIBREF118": {
            "ref_id": "b118",
            "title": "Temporal trends and factors associated with cardiovascular drug development",
            "authors": [
                {
                    "first": "T",
                    "middle": [
                        "J"
                    ],
                    "last": "Hwang",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "C"
                    ],
                    "last": "Lauffenburger",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "M"
                    ],
                    "last": "Franklin",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "S"
                    ],
                    "last": "Kesselheim",
                    "suffix": ""
                }
            ],
            "year": 1990,
            "venue": "J Am Coll Cardiol Basic Trans Science",
            "volume": "1",
            "issn": "",
            "pages": "301--309",
            "other_ids": {}
        },
        "BIBREF119": {
            "ref_id": "b119",
            "title": "New drug therapy approvals 2019. Advancing health through innovation",
            "authors": [
                {
                    "first": "U",
                    "middle": [
                        "S"
                    ],
                    "last": "",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF121": {
            "ref_id": "b121",
            "title": "Heart disease and stroke statistics-2016 Update: a report from the",
            "authors": [
                {
                    "first": "D",
                    "middle": [],
                    "last": "Mozaffarian",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [
                        "J"
                    ],
                    "last": "Benjamin",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "S"
                    ],
                    "last": "Go",
                    "suffix": ""
                }
            ],
            "year": 2016,
            "venue": "American Heart Association. Circulation",
            "volume": "133",
            "issn": "",
            "pages": "38--360",
            "other_ids": {}
        },
        "BIBREF122": {
            "ref_id": "b122",
            "title": "WITHDRAWN-a resource for withdrawn and discontinued drugs",
            "authors": [
                {
                    "first": "B",
                    "middle": [
                        "V"
                    ],
                    "last": "Siramshetty",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Nickel",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Omieczynski",
                    "suffix": ""
                }
            ],
            "year": 2016,
            "venue": "Nucl Acids Res",
            "volume": "44",
            "issn": "",
            "pages": "1080--1086",
            "other_ids": {}
        },
        "BIBREF123": {
            "ref_id": "b123",
            "title": "Engineered in vitro disease models",
            "authors": [
                {
                    "first": "K",
                    "middle": [
                        "H"
                    ],
                    "last": "Benam",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Dauth",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Hassell",
                    "suffix": ""
                }
            ],
            "year": 2015,
            "venue": "Annu Rev Pathol",
            "volume": "10",
            "issn": "",
            "pages": "195--262",
            "other_ids": {}
        },
        "BIBREF124": {
            "ref_id": "b124",
            "title": "Towards chamber specific heart-on-a-ship for drug testing applications",
            "authors": [
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Zhao",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "Rafatian",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [
                        "Y"
                    ],
                    "last": "Wang",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Adv Drug Deliv Rev",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF125": {
            "ref_id": "b125",
            "title": "Ensembles of engineered cardiac tissues for physiological and pharmacological study: heart on a chip",
            "authors": [
                {
                    "first": "A",
                    "middle": [],
                    "last": "Grosberg",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [
                        "W"
                    ],
                    "last": "Alford",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "L"
                    ],
                    "last": "Mccain",
                    "suffix": ""
                }
            ],
            "year": 2011,
            "venue": "Lab Chip",
            "volume": "11",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF126": {
            "ref_id": "b126",
            "title": "Microfluidic heart on a chip for higher throughput pharmacological studies",
            "authors": [
                {
                    "first": "A",
                    "middle": [],
                    "last": "Agarwal",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "A"
                    ],
                    "last": "Goss",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Cho",
                    "suffix": ""
                }
            ],
            "year": 2013,
            "venue": "Lab Chip",
            "volume": "13",
            "issn": "",
            "pages": "3599--608",
            "other_ids": {}
        },
        "BIBREF127": {
            "ref_id": "b127",
            "title": "Recapitulating maladaptive, multiscale remodeling of failing myocardium on a chip",
            "authors": [
                {
                    "first": "M",
                    "middle": [
                        "L"
                    ],
                    "last": "Mccain",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "P"
                    ],
                    "last": "Sheehy",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Grosberg",
                    "suffix": ""
                }
            ],
            "year": 2013,
            "venue": "Proc Natl Acad Sci U S A",
            "volume": "110",
            "issn": "",
            "pages": "9770--9775",
            "other_ids": {}
        },
        "BIBREF128": {
            "ref_id": "b128",
            "title": "Investigation of hypoxia-induced myocardial injury dynamics in a tissue interface mimicking microfluidic device",
            "authors": [
                {
                    "first": "L",
                    "middle": [],
                    "last": "Ren",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                }
            ],
            "year": 2013,
            "venue": "Anal Chem",
            "volume": "85",
            "issn": "",
            "pages": "235--279",
            "other_ids": {}
        },
        "BIBREF129": {
            "ref_id": "b129",
            "title": "Modeling the mitochondrial cardiomyopathy of Barth syndrome with induced pluripotent stem cell and heart-on-chip technologies",
            "authors": [
                {
                    "first": "G",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "L"
                    ],
                    "last": "Mccain",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Yang",
                    "suffix": ""
                }
            ],
            "year": 2014,
            "venue": "Nat Med",
            "volume": "20",
            "issn": "",
            "pages": "616--639",
            "other_ids": {}
        },
        "BIBREF130": {
            "ref_id": "b130",
            "title": "A human disease model of drug toxicity-induced pulmonary edema in a lung-on-a-chip microdevice",
            "authors": [
                {
                    "first": "D",
                    "middle": [],
                    "last": "Huh",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "D"
                    ],
                    "last": "Leslie",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [
                        "D"
                    ],
                    "last": "Matthews",
                    "suffix": ""
                }
            ],
            "year": 2012,
            "venue": "Sci Transl Med",
            "volume": "4",
            "issn": "",
            "pages": "159--206",
            "other_ids": {}
        },
        "BIBREF131": {
            "ref_id": "b131",
            "title": "Organs on a chip! FDA's predictive toxicology roadmap. Update Magazine",
            "authors": [
                {
                    "first": "J",
                    "middle": [],
                    "last": "Rein",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF132": {
            "ref_id": "b132",
            "title": "Onchip recapitulation of clinical bone marrow toxicities and patient-specific pathophysiology",
            "authors": [
                {
                    "first": "D",
                    "middle": [
                        "B"
                    ],
                    "last": "Chou",
                    "suffix": ""
                },
                {
                    "first": "V",
                    "middle": [],
                    "last": "Frismantas",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Milton",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Nat Biomed Eng",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF133": {
            "ref_id": "b133",
            "title": "Reproducing human and cross-species drug toxicities using a liver-chip",
            "authors": [
                {
                    "first": "K",
                    "middle": [
                        "J"
                    ],
                    "last": "Jang",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "A"
                    ],
                    "last": "Otieno",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Ronxhi",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "Sci Transl Med",
            "volume": "11",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF134": {
            "ref_id": "b134",
            "title": "National Institutes of Health National Center for Advancing Translational Sciences. Tissue chip funding information",
            "authors": [
                {
                    "first": "K",
                    "middle": [
                        "E"
                    ],
                    "last": "Lasser",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [
                        "D"
                    ],
                    "last": "Allen",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "J"
                    ],
                    "last": "Whoolhandler",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "U"
                    ],
                    "last": "Himmelstein",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "M"
                    ],
                    "last": "Wolfe",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "H"
                    ],
                    "last": "Bor",
                    "suffix": ""
                }
            ],
            "year": 2002,
            "venue": "JAMA",
            "volume": "287",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF135": {
            "ref_id": "b135",
            "title": "FDA's predictive technology roadmap",
            "authors": [
                {
                    "first": "U",
                    "middle": [
                        "S"
                    ],
                    "last": "",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF136": {
            "ref_id": "b136",
            "title": "Accessed March 3, 2020. 73. 21st Century Cures Act. Public Law 114-255. 114th Congress",
            "authors": [
                {
                    "first": "J",
                    "middle": [],
                    "last": "Rein",
                    "suffix": ""
                },
                {
                    "first": "Drug",
                    "middle": [],
                    "last": "Food",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Law Institute",
                    "suffix": ""
                }
            ],
            "year": 2016,
            "venue": "Organs on chip! FDA's predictive toxicology roadmap",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF137": {
            "ref_id": "b137",
            "title": "Regulation (EC) No 1907/2006 -Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH)",
            "authors": [],
            "year": 2020,
            "venue": "European Commission",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF139": {
            "ref_id": "b139",
            "title": "of the European Parliament and the Council on the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH)",
            "authors": [],
            "year": 1907,
            "venue": "/2008 -laying down test methods pursuant to Regulation",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF140": {
            "ref_id": "b140",
            "title": "Reflection paper providing an overview of the current regulatory testing requirements for medicinal products for human use and opportunities for implementation of the 3Rs",
            "authors": [],
            "year": 2018,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF141": {
            "ref_id": "b141",
            "title": "Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO)",
            "authors": [
                {
                    "first": "A",
                    "middle": [
                        "S"
                    ],
                    "last": "Levey",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [
                        "U"
                    ],
                    "last": "Eckardt",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Tsukamoto",
                    "suffix": ""
                }
            ],
            "year": 2005,
            "venue": "Kidney Int",
            "volume": "67",
            "issn": "",
            "pages": "2089--100",
            "other_ids": {}
        },
        "BIBREF142": {
            "ref_id": "b142",
            "title": "The global burden of kidney disease and the sustainable development goals",
            "authors": [
                {
                    "first": "V",
                    "middle": [
                        "A"
                    ],
                    "last": "Luyckx",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Tonelli",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "W"
                    ],
                    "last": "Stanifer",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "Bull World Health Organ",
            "volume": "96",
            "issn": "",
            "pages": "414--436",
            "other_ids": {}
        },
        "BIBREF143": {
            "ref_id": "b143",
            "title": "A systematic analysis of worldwide population-based data on the global burden of chronic kidney disease in 2010",
            "authors": [
                {
                    "first": "K",
                    "middle": [
                        "T"
                    ],
                    "last": "Mills",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Xu",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                }
            ],
            "year": 2015,
            "venue": "Kidney Int",
            "volume": "88",
            "issn": "",
            "pages": "950--957",
            "other_ids": {}
        },
        "BIBREF144": {
            "ref_id": "b144",
            "title": "Chronic kidney disease and life expectancy",
            "authors": [
                {
                    "first": "T",
                    "middle": [
                        "C"
                    ],
                    "last": "Turin",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Tonelli",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [
                        "J"
                    ],
                    "last": "Manns",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Ravani",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "B"
                    ],
                    "last": "Ahmed",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [
                        "R"
                    ],
                    "last": "Hemmelgarn",
                    "suffix": ""
                }
            ],
            "year": 2012,
            "venue": "Nephrol Dial Transplant",
            "volume": "27",
            "issn": "",
            "pages": "3182--3188",
            "other_ids": {}
        },
        "BIBREF145": {
            "ref_id": "b145",
            "title": "Analysis of the Global Burden of Disease study highlights the global, regional, and national trends of chronic kidney disease epidemiology from",
            "authors": [
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Xie",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Bowe",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "H"
                    ],
                    "last": "Mokdad",
                    "suffix": ""
                }
            ],
            "year": 1990,
            "venue": "Kidney Int",
            "volume": "94",
            "issn": "",
            "pages": "567--81",
            "other_ids": {}
        },
        "BIBREF146": {
            "ref_id": "b146",
            "title": "Subclinical atherosclerosis measures for cardiovascular prediction in CKD",
            "authors": [
                {
                    "first": "K",
                    "middle": [],
                    "last": "Matsushita",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Sang",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "H"
                    ],
                    "last": "Ballew",
                    "suffix": ""
                }
            ],
            "year": 2015,
            "venue": "J Am Soc Nephrol",
            "volume": "26",
            "issn": "",
            "pages": "439--486",
            "other_ids": {}
        },
        "BIBREF147": {
            "ref_id": "b147",
            "title": "Cardiovascular disease in dialysis patients",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Cozzolino",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Mangano",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Stucchi",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Ciceri",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Conte",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Galassi",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "Nephrol Dial Transplant",
            "volume": "33",
            "issn": "",
            "pages": "28--34",
            "other_ids": {}
        },
        "BIBREF148": {
            "ref_id": "b148",
            "title": "Risk of cardiovascular disease and mortality in young adults with endstage renal disease: an analysis of the US Renal Data System",
            "authors": [
                {
                    "first": "Z",
                    "middle": [
                        "J"
                    ],
                    "last": "Modi",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Lu",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "Ji",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "JAMA Cardiol",
            "volume": "4",
            "issn": "",
            "pages": "353--62",
            "other_ids": {}
        },
        "BIBREF149": {
            "ref_id": "b149",
            "title": "Cardiovascular disease and chronic kidney disease",
            "authors": [
                {
                    "first": "R",
                    "middle": [],
                    "last": "Gargiulo",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Suhail",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [
                        "V"
                    ],
                    "last": "Lerma",
                    "suffix": ""
                }
            ],
            "year": 2015,
            "venue": "Dis Mon",
            "volume": "61",
            "issn": "",
            "pages": "403--416",
            "other_ids": {}
        },
        "BIBREF150": {
            "ref_id": "b150",
            "title": "Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization",
            "authors": [
                {
                    "first": "D",
                    "middle": [
                        "S"
                    ],
                    "last": "Keith",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [
                        "A"
                    ],
                    "last": "Nichols",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "M"
                    ],
                    "last": "Gullion",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "B"
                    ],
                    "last": "Brown",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "H"
                    ],
                    "last": "Smith",
                    "suffix": ""
                }
            ],
            "year": 2004,
            "venue": "Arch Intern Med",
            "volume": "164",
            "issn": "",
            "pages": "659--63",
            "other_ids": {}
        },
        "BIBREF151": {
            "ref_id": "b151",
            "title": "Chronic kidney disease as a coronary artery disease risk equivalent",
            "authors": [
                {
                    "first": "A",
                    "middle": [],
                    "last": "Briasoulis",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [
                        "L"
                    ],
                    "last": "Bakris",
                    "suffix": ""
                }
            ],
            "year": 2013,
            "venue": "Curr Cardiol Rep",
            "volume": "15",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF152": {
            "ref_id": "b152",
            "title": "Epidemiology of cardio-renal syndromes: workgroup statements from the 7th ADQI Consensus Conference",
            "authors": [
                {
                    "first": "S",
                    "middle": [
                        "M"
                    ],
                    "last": "Bagshaw",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "N"
                    ],
                    "last": "Cruz",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "Aspromonte",
                    "suffix": ""
                }
            ],
            "year": 2010,
            "venue": "",
            "volume": "25",
            "issn": "",
            "pages": "1406--1422",
            "other_ids": {}
        },
        "BIBREF153": {
            "ref_id": "b153",
            "title": "Stroke and chronic kidney disease: epidemiology, pathogenesis, and management across kidney disease stages",
            "authors": [
                {
                    "first": "T",
                    "middle": [],
                    "last": "Dad",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "E"
                    ],
                    "last": "Weiner",
                    "suffix": ""
                }
            ],
            "year": 2015,
            "venue": "Semin Nephrol",
            "volume": "35",
            "issn": "",
            "pages": "311--333",
            "other_ids": {}
        },
        "BIBREF154": {
            "ref_id": "b154",
            "title": "Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO)",
            "authors": [
                {
                    "first": "C",
                    "middle": [
                        "A"
                    ],
                    "last": "Herzog",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "W"
                    ],
                    "last": "Asinger",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "K"
                    ],
                    "last": "Berger",
                    "suffix": ""
                }
            ],
            "year": 2011,
            "venue": "Kidney Int",
            "volume": "80",
            "issn": "",
            "pages": "572--86",
            "other_ids": {}
        },
        "BIBREF155": {
            "ref_id": "b155",
            "title": "Increased prevalence of coronary artery disease, silent myocardial ischemia, complex ventricular arrhythmias, atrial fibrillation, left ventricular hypertrophy, mitral annular calcium, and aortic valve calcium in patients with chronic renal insufficiency",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Das",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [
                        "S"
                    ],
                    "last": "Aronow",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "A"
                    ],
                    "last": "Mcclung",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "N"
                    ],
                    "last": "Belkin",
                    "suffix": ""
                }
            ],
            "year": 2006,
            "venue": "Cardiol Rev",
            "volume": "14",
            "issn": "",
            "pages": "14--21",
            "other_ids": {}
        },
        "BIBREF156": {
            "ref_id": "b156",
            "title": "Chronic kidney disease is associated with increased risk of sudden cardiac death among patients with coronary artery disease",
            "authors": [
                {
                    "first": "P",
                    "middle": [
                        "H"
                    ],
                    "last": "Pun",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [
                        "R"
                    ],
                    "last": "Smarz",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [
                        "F"
                    ],
                    "last": "Honeycutt",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [
                        "K"
                    ],
                    "last": "Shaw",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "M"
                    ],
                    "last": "Al-Khatib",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "P"
                    ],
                    "last": "Middleton",
                    "suffix": ""
                }
            ],
            "year": 2009,
            "venue": "Kidney Int",
            "volume": "76",
            "issn": "",
            "pages": "652--660",
            "other_ids": {}
        },
        "BIBREF157": {
            "ref_id": "b157",
            "title": "Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis",
            "authors": [
                {
                    "first": "C",
                    "middle": [
                        "S"
                    ],
                    "last": "Fox",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Matsushita",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Woodward",
                    "suffix": ""
                }
            ],
            "year": 2012,
            "venue": "Lancet",
            "volume": "380",
            "issn": "",
            "pages": "1662--73",
            "other_ids": {}
        },
        "BIBREF158": {
            "ref_id": "b158",
            "title": "Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a metaanalysis",
            "authors": [
                {
                    "first": "B",
                    "middle": [
                        "K"
                    ],
                    "last": "Mahmoodi",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Matsushita",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Woodward",
                    "suffix": ""
                }
            ],
            "year": 2012,
            "venue": "Lancet",
            "volume": "380",
            "issn": "",
            "pages": "1649--61",
            "other_ids": {}
        },
        "BIBREF159": {
            "ref_id": "b159",
            "title": "The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial",
            "authors": [
                {
                    "first": "C",
                    "middle": [],
                    "last": "Baigent",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "J"
                    ],
                    "last": "Landray",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Reith",
                    "suffix": ""
                }
            ],
            "year": 2011,
            "venue": "Lancet",
            "volume": "377",
            "issn": "",
            "pages": "2181--92",
            "other_ids": {}
        },
        "BIBREF160": {
            "ref_id": "b160",
            "title": "Rosuvastatin and cardiovascular events in patients undergoing hemodialysis",
            "authors": [
                {
                    "first": "B",
                    "middle": [
                        "C"
                    ],
                    "last": "Fellstrom",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "G"
                    ],
                    "last": "Jardine",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "E"
                    ],
                    "last": "Schmieder",
                    "suffix": ""
                }
            ],
            "year": 2009,
            "venue": "N Engl J Med",
            "volume": "360",
            "issn": "",
            "pages": "1395--407",
            "other_ids": {}
        },
        "BIBREF161": {
            "ref_id": "b161",
            "title": "Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis",
            "authors": [
                {
                    "first": "C",
                    "middle": [],
                    "last": "Wanner",
                    "suffix": ""
                },
                {
                    "first": "V",
                    "middle": [],
                    "last": "Krane",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [],
                    "last": "Marz",
                    "suffix": ""
                }
            ],
            "year": 2005,
            "venue": "N Engl J Med",
            "volume": "353",
            "issn": "",
            "pages": "238--286",
            "other_ids": {}
        },
        "BIBREF162": {
            "ref_id": "b162",
            "title": "Vascular calcification and cardiovascular function in chronic kidney disease",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Sigrist",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Bungay",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "W"
                    ],
                    "last": "Taal",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "W"
                    ],
                    "last": "Mcintyre",
                    "suffix": ""
                }
            ],
            "year": 2006,
            "venue": "Nephrol Dial Transplant",
            "volume": "21",
            "issn": "",
            "pages": "707--721",
            "other_ids": {}
        },
        "BIBREF163": {
            "ref_id": "b163",
            "title": "Prevalence and associations of coronary artery calcification in patients with stages 3 to 5 CKD without cardiovascular disease",
            "authors": [
                {
                    "first": "J",
                    "middle": [
                        "S"
                    ],
                    "last": "Garland",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "M"
                    ],
                    "last": "Holden",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [
                        "A"
                    ],
                    "last": "Groome",
                    "suffix": ""
                }
            ],
            "year": 2008,
            "venue": "Am J Kidney Dis",
            "volume": "52",
            "issn": "",
            "pages": "849--58",
            "other_ids": {}
        },
        "BIBREF164": {
            "ref_id": "b164",
            "title": "All-cause mortality in hemodialysis patients with heart valve calcification",
            "authors": [
                {
                    "first": "P",
                    "middle": [],
                    "last": "Raggi",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Bellasi",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Gamboa",
                    "suffix": ""
                }
            ],
            "year": 2011,
            "venue": "Clin J Am Soc Nephrol",
            "volume": "6",
            "issn": "",
            "pages": "1990--1995",
            "other_ids": {}
        },
        "BIBREF165": {
            "ref_id": "b165",
            "title": "Regulatory mechanisms in vascular calcification",
            "authors": [
                {
                    "first": "A",
                    "middle": [
                        "P"
                    ],
                    "last": "Sage",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Tintut",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [
                        "L"
                    ],
                    "last": "Demer",
                    "suffix": ""
                }
            ],
            "year": 2010,
            "venue": "Nat Rev Cardiol",
            "volume": "7",
            "issn": "",
            "pages": "528--564",
            "other_ids": {}
        },
        "BIBREF166": {
            "ref_id": "b166",
            "title": "Media calcification and intima calcification are distinct entities in chronic kidney disease",
            "authors": [
                {
                    "first": "K",
                    "middle": [],
                    "last": "Amann",
                    "suffix": ""
                }
            ],
            "year": 2008,
            "venue": "Clin J Am Soc Nephrol",
            "volume": "3",
            "issn": "",
            "pages": "1599--605",
            "other_ids": {}
        },
        "BIBREF167": {
            "ref_id": "b167",
            "title": "Mechanistic insights into vascular calcification in CKD",
            "authors": [
                {
                    "first": "R",
                    "middle": [],
                    "last": "Shroff",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "A"
                    ],
                    "last": "Long",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Shanahan",
                    "suffix": ""
                }
            ],
            "year": 2013,
            "venue": "J Am Soc Nephrol",
            "volume": "24",
            "issn": "",
            "pages": "179--89",
            "other_ids": {}
        },
        "BIBREF168": {
            "ref_id": "b168",
            "title": "Arterial disease in chronic renal failure-an experimental study in the rabbit",
            "authors": [
                {
                    "first": "E",
                    "middle": [],
                    "last": "Tvedegaard",
                    "suffix": ""
                }
            ],
            "year": 1987,
            "venue": "Acta Pathol Microbiol Immunol Scand A",
            "volume": "290",
            "issn": "",
            "pages": "1--28",
            "other_ids": {}
        },
        "BIBREF169": {
            "ref_id": "b169",
            "title": "Arterial and cellular inflammation in patients with CKD",
            "authors": [
                {
                    "first": "S",
                    "middle": [
                        "J"
                    ],
                    "last": "Bernelot Moens",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "L"
                    ],
                    "last": "Verweij",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [
                        "M"
                    ],
                    "last": "Van Der Valk",
                    "suffix": ""
                }
            ],
            "year": 2017,
            "venue": "J Am Soc Nephrol",
            "volume": "28",
            "issn": "",
            "pages": "1278--85",
            "other_ids": {}
        },
        "BIBREF170": {
            "ref_id": "b170",
            "title": "Coronary artery calcification and its progression: what does it really mean?",
            "authors": [
                {
                    "first": "H",
                    "middle": [],
                    "last": "Mori",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Torii",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Kutyna",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Sakamoto",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "V"
                    ],
                    "last": "Finn",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Virmani",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "J Am Coll Cardiol Img",
            "volume": "11",
            "issn": "",
            "pages": "127--169",
            "other_ids": {}
        },
        "BIBREF171": {
            "ref_id": "b171",
            "title": "Coronary plaque composition, morphology, and outcomes in patients with and without chronic kidney disease presenting with acute coronary syndromes",
            "authors": [
                {
                    "first": "U",
                    "middle": [],
                    "last": "Baber",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [
                        "W"
                    ],
                    "last": "Stone",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Weisz",
                    "suffix": ""
                }
            ],
            "year": 2012,
            "venue": "J Am Coll Cardiol Img",
            "volume": "5",
            "issn": "",
            "pages": "53--61",
            "other_ids": {}
        },
        "BIBREF172": {
            "ref_id": "b172",
            "title": "Mechanisms of vascular calcification in CKD-evidence for premature ageing?",
            "authors": [
                {
                    "first": "C",
                    "middle": [
                        "M"
                    ],
                    "last": "Shanahan",
                    "suffix": ""
                }
            ],
            "year": 2013,
            "venue": "Nat Rev Nephrol",
            "volume": "9",
            "issn": "",
            "pages": "661--70",
            "other_ids": {}
        },
        "BIBREF173": {
            "ref_id": "b173",
            "title": "Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease",
            "authors": [
                {
                    "first": "J",
                    "middle": [],
                    "last": "Blacher",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "P"
                    ],
                    "last": "Guerin",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Pannier",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "J"
                    ],
                    "last": "Marchais",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [
                        "M"
                    ],
                    "last": "London",
                    "suffix": ""
                }
            ],
            "year": 2001,
            "venue": "Hypertension",
            "volume": "38",
            "issn": "",
            "pages": "938--980",
            "other_ids": {}
        },
        "BIBREF174": {
            "ref_id": "b174",
            "title": "Arterial stiffening and vascular calcifications in end-stage renal disease",
            "authors": [
                {
                    "first": "A",
                    "middle": [
                        "P"
                    ],
                    "last": "Guerin",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [
                        "M"
                    ],
                    "last": "London",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "J"
                    ],
                    "last": "Marchais",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Metivier",
                    "suffix": ""
                }
            ],
            "year": 2000,
            "venue": "Nephrol Dial Transplant",
            "volume": "15",
            "issn": "",
            "pages": "1014--1035",
            "other_ids": {}
        },
        "BIBREF175": {
            "ref_id": "b175",
            "title": "Cardiovascular magnetic resonance-derived aortic distensibility: validation and observed regional differences in the elderly",
            "authors": [
                {
                    "first": "A",
                    "middle": [
                        "J"
                    ],
                    "last": "Nelson",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "G"
                    ],
                    "last": "Worthley",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "D"
                    ],
                    "last": "Cameron",
                    "suffix": ""
                }
            ],
            "year": 2009,
            "venue": "J Hypertens",
            "volume": "27",
            "issn": "",
            "pages": "535--577",
            "other_ids": {}
        },
        "BIBREF176": {
            "ref_id": "b176",
            "title": "Left ventricular hypertrophy in nondiabetic predialysis CKD",
            "authors": [
                {
                    "first": "E",
                    "middle": [],
                    "last": "Paoletti",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Bellino",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Cassottana",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Rolla",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Cannella",
                    "suffix": ""
                }
            ],
            "year": 2005,
            "venue": "Am J Kidney Dis",
            "volume": "46",
            "issn": "",
            "pages": "320--327",
            "other_ids": {}
        },
        "BIBREF177": {
            "ref_id": "b177",
            "title": "Left ventricular hypertrophy in renal disease: beyond preload and afterload",
            "authors": [
                {
                    "first": "E",
                    "middle": [],
                    "last": "Ritz",
                    "suffix": ""
                }
            ],
            "year": 2009,
            "venue": "Kidney Int",
            "volume": "75",
            "issn": "",
            "pages": "771--774",
            "other_ids": {}
        },
        "BIBREF178": {
            "ref_id": "b178",
            "title": "Association of chronic kidney disease with atrial fibrillation among adults in the United States: REasons for Geographic and Racial Differences in Stroke (REGARDS) Study",
            "authors": [
                {
                    "first": "U",
                    "middle": [],
                    "last": "Baber",
                    "suffix": ""
                },
                {
                    "first": "V",
                    "middle": [
                        "J"
                    ],
                    "last": "Howard",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "L"
                    ],
                    "last": "Halperin",
                    "suffix": ""
                }
            ],
            "year": 2011,
            "venue": "Circ Arrhythm Electrophysiol",
            "volume": "4",
            "issn": "",
            "pages": "26--32",
            "other_ids": {}
        },
        "BIBREF179": {
            "ref_id": "b179",
            "title": "Quantification of coronary artery calcium using ultrafast computed tomography",
            "authors": [
                {
                    "first": "A",
                    "middle": [
                        "S"
                    ],
                    "last": "Agatston",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [
                        "R"
                    ],
                    "last": "Janowitz",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [
                        "J"
                    ],
                    "last": "Hildner",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [
                        "R"
                    ],
                    "last": "Zusmer",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Viamonte",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Detrano",
                    "suffix": ""
                }
            ],
            "year": 1990,
            "venue": "J Am Coll Cardiol",
            "volume": "15",
            "issn": "",
            "pages": "827--859",
            "other_ids": {}
        },
        "BIBREF180": {
            "ref_id": "b180",
            "title": "New indices to classify location, severity and progression of calcific lesions in the abdominal aorta: a 25-year follow-up study",
            "authors": [
                {
                    "first": "L",
                    "middle": [
                        "I"
                    ],
                    "last": "Kauppila",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "F"
                    ],
                    "last": "Polak",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [
                        "A"
                    ],
                    "last": "Cupples",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "T"
                    ],
                    "last": "Hannan",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "P"
                    ],
                    "last": "Kiel",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [
                        "W"
                    ],
                    "last": "Wilson",
                    "suffix": ""
                }
            ],
            "year": 1997,
            "venue": "Atherosclerosis",
            "volume": "132",
            "issn": "",
            "pages": "245--50",
            "other_ids": {}
        },
        "BIBREF181": {
            "ref_id": "b181",
            "title": "A plain X-ray vascular calcification score is associated with arterial stiffness and mortality in dialysis patients",
            "authors": [
                {
                    "first": "T",
                    "middle": [],
                    "last": "Adragao",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Pires",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Birne",
                    "suffix": ""
                }
            ],
            "year": 2009,
            "venue": "Nephrol Dial Transplant",
            "volume": "24",
            "issn": "",
            "pages": "997--1002",
            "other_ids": {}
        },
        "BIBREF182": {
            "ref_id": "b182",
            "title": "Arterial stiffness in CKD: a review",
            "authors": [
                {
                    "first": "R",
                    "middle": [
                        "R"
                    ],
                    "last": "Townsend",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "Am J Kidney Dis",
            "volume": "73",
            "issn": "",
            "pages": "240--247",
            "other_ids": {}
        },
        "BIBREF183": {
            "ref_id": "b183",
            "title": "Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediaterisk individuals",
            "authors": [
                {
                    "first": "J",
                    "middle": [],
                    "last": "Yeboah",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "L"
                    ],
                    "last": "Mcclelland",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [
                        "S"
                    ],
                    "last": "Polonsky",
                    "suffix": ""
                }
            ],
            "year": 2012,
            "venue": "JAMA",
            "volume": "308",
            "issn": "",
            "pages": "788--95",
            "other_ids": {}
        },
        "BIBREF184": {
            "ref_id": "b184",
            "title": "Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients",
            "authors": [
                {
                    "first": "J",
                    "middle": [],
                    "last": "Braun",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Oldendorf",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [],
                    "last": "Moshage",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Heidler",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [],
                    "last": "Zeitler",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [
                        "C"
                    ],
                    "last": "Luft",
                    "suffix": ""
                }
            ],
            "year": 1996,
            "venue": "Am J Kidney Dis",
            "volume": "27",
            "issn": "",
            "pages": "394--401",
            "other_ids": {}
        },
        "BIBREF185": {
            "ref_id": "b185",
            "title": "Relationship of estimated GFR and coronary artery calcification in the CRIC (Chronic Renal Insufficiency Cohort) Study",
            "authors": [
                {
                    "first": "M",
                    "middle": [
                        "J"
                    ],
                    "last": "Budoff",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "J"
                    ],
                    "last": "Rader",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "P"
                    ],
                    "last": "Reilly",
                    "suffix": ""
                }
            ],
            "year": 2011,
            "venue": "Am J Kidney Dis",
            "volume": "58",
            "issn": "",
            "pages": "519--545",
            "other_ids": {}
        },
        "BIBREF186": {
            "ref_id": "b186",
            "title": "Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease?",
            "authors": [
                {
                    "first": "P",
                    "middle": [],
                    "last": "Raggi",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Boulay",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Chasan-Taber",
                    "suffix": ""
                }
            ],
            "year": 2002,
            "venue": "J Am Coll Cardiol",
            "volume": "39",
            "issn": "",
            "pages": "695--701",
            "other_ids": {}
        },
        "BIBREF187": {
            "ref_id": "b187",
            "title": "Coronary artery calcium assessment in CKD: utility in cardiovascular disease risk assessment and treatment?",
            "authors": [
                {
                    "first": "A",
                    "middle": [],
                    "last": "Bashir",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [
                        "E"
                    ],
                    "last": "Moody",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [
                        "C"
                    ],
                    "last": "Edwards",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "J"
                    ],
                    "last": "Ferro",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "N"
                    ],
                    "last": "Townend",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "P"
                    ],
                    "last": "Steeds",
                    "suffix": ""
                }
            ],
            "year": 2015,
            "venue": "Am J Kidney Dis",
            "volume": "65",
            "issn": "",
            "pages": "937--985",
            "other_ids": {}
        },
        "BIBREF188": {
            "ref_id": "b188",
            "title": "Coronary artery calcification and risk of cardiovascular disease and death among patients with chronic kidney disease",
            "authors": [
                {
                    "first": "J",
                    "middle": [],
                    "last": "Chen",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "J"
                    ],
                    "last": "Budoff",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "P"
                    ],
                    "last": "Reilly",
                    "suffix": ""
                }
            ],
            "year": 2017,
            "venue": "JAMA Cardiol",
            "volume": "2",
            "issn": "",
            "pages": "635--678",
            "other_ids": {}
        },
        "BIBREF189": {
            "ref_id": "b189",
            "title": "The addition of vascular calcification scores to traditional risk factors improves cardiovascular risk assessment in patients with chronic kidney disease",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "Liabeuf",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Desjardins",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Diouf",
                    "suffix": ""
                }
            ],
            "year": 2015,
            "venue": "PLoS One",
            "volume": "10",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF190": {
            "ref_id": "b190",
            "title": "Coronary calcification in patients with chronic kidney disease and coronary artery disease",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "Nakamura",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Ishibashi-Ueda",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Niizuma",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Yoshihara",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Horio",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Kawano",
                    "suffix": ""
                }
            ],
            "year": 2009,
            "venue": "Clin J Am Soc Nephrol",
            "volume": "4",
            "issn": "",
            "pages": "1892--900",
            "other_ids": {}
        },
        "BIBREF191": {
            "ref_id": "b191",
            "title": "Correlation of simple imaging tests and coronary artery calcium measured by computed tomography in hemodialysis patients",
            "authors": [
                {
                    "first": "A",
                    "middle": [],
                    "last": "Bellasi",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [],
                    "last": "Ferramosca",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Muntner",
                    "suffix": ""
                }
            ],
            "year": 2006,
            "venue": "Kidney Int",
            "volume": "70",
            "issn": "",
            "pages": "1623--1631",
            "other_ids": {}
        },
        "BIBREF192": {
            "ref_id": "b192",
            "title": "Abdominal aortic calcification can predict all-cause mortality and CV events in dialysis patients: a systematic review and meta-analysis",
            "authors": [
                {
                    "first": "Q",
                    "middle": [],
                    "last": "Niu",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Hong",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "H"
                    ],
                    "last": "Lee",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Men",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Zhao",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Zuo",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "PLoS One",
            "volume": "13",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF193": {
            "ref_id": "b193",
            "title": "Vascular calcification in patients with nondialysis CKD over 3 years",
            "authors": [
                {
                    "first": "J",
                    "middle": [
                        "L"
                    ],
                    "last": "Gorriz",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Molina",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "J"
                    ],
                    "last": "Cerveron",
                    "suffix": ""
                }
            ],
            "year": 2015,
            "venue": "Clin J Am Soc Nephrol",
            "volume": "10",
            "issn": "",
            "pages": "654--66",
            "other_ids": {}
        },
        "BIBREF194": {
            "ref_id": "b194",
            "title": "Progression of medial arterial calcification in CKD",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "Manzoor",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Ahmed",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Ali",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "Kidney Int Rep",
            "volume": "3",
            "issn": "",
            "pages": "1328--1363",
            "other_ids": {}
        },
        "BIBREF195": {
            "ref_id": "b195",
            "title": "Breast arterial calcification: a marker of medial vascular calcification in chronic kidney disease",
            "authors": [
                {
                    "first": "V",
                    "middle": [],
                    "last": "Duhn",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "&apos;orsi",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [
                        "T"
                    ],
                    "last": "",
                    "suffix": ""
                },
                {
                    "first": "Johnson",
                    "middle": [
                        "S"
                    ],
                    "last": "",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "&apos;orsi",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "J"
                    ],
                    "last": "Adams",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "L"
                    ],
                    "last": "",
                    "suffix": ""
                },
                {
                    "first": "O",
                    "middle": [],
                    "last": "Neill",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [
                        "C"
                    ],
                    "last": "",
                    "suffix": ""
                }
            ],
            "year": 2011,
            "venue": "Clin J Am Soc Nephrol",
            "volume": "6",
            "issn": "",
            "pages": "377--82",
            "other_ids": {}
        },
        "BIBREF196": {
            "ref_id": "b196",
            "title": "The clinical significance of medial arterial calcification in end-stage renal disease in women",
            "authors": [
                {
                    "first": "N",
                    "middle": [],
                    "last": "Abou-Hassan",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [],
                    "last": "Tantisattamo",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "&apos;orsi",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [
                        "T"
                    ],
                    "last": "",
                    "suffix": ""
                },
                {
                    "first": "O",
                    "middle": [],
                    "last": "Neill",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [
                        "C"
                    ],
                    "last": "",
                    "suffix": ""
                }
            ],
            "year": 2015,
            "venue": "Kidney Int",
            "volume": "87",
            "issn": "",
            "pages": "195--204",
            "other_ids": {}
        },
        "BIBREF197": {
            "ref_id": "b197",
            "title": "KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD)",
            "authors": [],
            "year": 2017,
            "venue": "Kidney Disease: Improving Global Outcomes CKD-MBD Update Work Group",
            "volume": "7",
            "issn": "",
            "pages": "1--59",
            "other_ids": {}
        },
        "BIBREF198": {
            "ref_id": "b198",
            "title": "KDOQI US commentary on the 2009 KDIGO Clinical practice guideline for the diagnosis, evaluation, and treatment of ckd-mineral and bone disorder (CKD-MBD)",
            "authors": [
                {
                    "first": "K",
                    "middle": [],
                    "last": "Uhlig",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "S"
                    ],
                    "last": "Berns",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Kestenbaum",
                    "suffix": ""
                }
            ],
            "year": 2010,
            "venue": "Am J Kidney Dis",
            "volume": "55",
            "issn": "",
            "pages": "773--99",
            "other_ids": {}
        },
        "BIBREF199": {
            "ref_id": "b199",
            "title": "Kidney Disease: Improving Global Outcomes CKD-MBD Update Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF201": {
            "ref_id": "b201",
            "title": "Association of serum phosphate with vascular and valvular calcification in moderate CKD",
            "authors": [
                {
                    "first": "K",
                    "middle": [
                        "L"
                    ],
                    "last": "Adeney",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "S"
                    ],
                    "last": "Siscovick",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "H"
                    ],
                    "last": "Ix",
                    "suffix": ""
                }
            ],
            "year": 2009,
            "venue": "J Am Soc Nephrol",
            "volume": "20",
            "issn": "",
            "pages": "381--388",
            "other_ids": {}
        },
        "BIBREF202": {
            "ref_id": "b202",
            "title": "Mineral metabolism, mortality, and morbidity in maintenance hemodialysis",
            "authors": [
                {
                    "first": "G",
                    "middle": [
                        "A"
                    ],
                    "last": "Block",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [
                        "S"
                    ],
                    "last": "Klassen",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "M"
                    ],
                    "last": "Lazarus",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "Ofsthun",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [
                        "G"
                    ],
                    "last": "Lowrie",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [
                        "M"
                    ],
                    "last": "Chertow",
                    "suffix": ""
                }
            ],
            "year": 2004,
            "venue": "J Am Soc Nephrol",
            "volume": "15",
            "issn": "",
            "pages": "2208--2226",
            "other_ids": {}
        },
        "BIBREF203": {
            "ref_id": "b203",
            "title": "Determinants of progressive vascular calcification in haemodialysis patients",
            "authors": [
                {
                    "first": "G",
                    "middle": [
                        "M"
                    ],
                    "last": "Chertow",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Raggi",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Chasan-Taber",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Bommer",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Holzer",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "K"
                    ],
                    "last": "Burke",
                    "suffix": ""
                }
            ],
            "year": 2004,
            "venue": "Nephrol Dial Transplant",
            "volume": "19",
            "issn": "",
            "pages": "1489--96",
            "other_ids": {}
        },
        "BIBREF204": {
            "ref_id": "b204",
            "title": "Arterial calcification in chronic kidney disease: key roles for calcium and phosphate",
            "authors": [
                {
                    "first": "C",
                    "middle": [
                        "M"
                    ],
                    "last": "Shanahan",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "H"
                    ],
                    "last": "Crouthamel",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Kapustin",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "M"
                    ],
                    "last": "Giachelli",
                    "suffix": ""
                }
            ],
            "year": 2011,
            "venue": "Circ Res",
            "volume": "109",
            "issn": "",
            "pages": "697--711",
            "other_ids": {}
        },
        "BIBREF205": {
            "ref_id": "b205",
            "title": "Phosphate regulation of vascular smooth muscle cell calcification",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "Jono",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "D"
                    ],
                    "last": "Mckee",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "E"
                    ],
                    "last": "Murry",
                    "suffix": ""
                }
            ],
            "year": 2000,
            "venue": "Circ Res",
            "volume": "87",
            "issn": "",
            "pages": "10--17",
            "other_ids": {}
        },
        "BIBREF206": {
            "ref_id": "b206",
            "title": "Characterization of phosphate transport in rat vascular smooth muscle cells: implications for vascular calcification",
            "authors": [
                {
                    "first": "R",
                    "middle": [],
                    "last": "Villa-Bellosta",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [
                        "E"
                    ],
                    "last": "Bogaert",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Levi",
                    "suffix": ""
                },
                {
                    "first": "V",
                    "middle": [],
                    "last": "Sorribas",
                    "suffix": ""
                }
            ],
            "year": 2007,
            "venue": "Arterioscler Thromb Vasc Biol",
            "volume": "27",
            "issn": "",
            "pages": "1030--1036",
            "other_ids": {}
        },
        "BIBREF207": {
            "ref_id": "b207",
            "title": "Increased levels of serum parathyroid hormone and fibroblast growth factor-23 are the main factors associated with the progression of vascular calcification in long-hour hemodialysis patients",
            "authors": [
                {
                    "first": "G",
                    "middle": [],
                    "last": "Jean",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [],
                    "last": "Bresson",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Lorriaux",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF209": {
            "ref_id": "b209",
            "title": "Vascular calcification: contribution of parathyroid hormone in renal failure",
            "authors": [
                {
                    "first": "K",
                    "middle": [
                        "R"
                    ],
                    "last": "Neves",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [
                        "G"
                    ],
                    "last": "Graciolli",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [
                        "M"
                    ],
                    "last": "Dos Reis",
                    "suffix": ""
                }
            ],
            "year": 2007,
            "venue": "Kidney Int",
            "volume": "71",
            "issn": "",
            "pages": "1262--70",
            "other_ids": {}
        },
        "BIBREF210": {
            "ref_id": "b210",
            "title": "Submaximal suppression of parathyroid hormone ameliorates calcitriolinduced aortic calcification and remodeling and myocardial fibrosis in uremic rats",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "Jung",
                    "suffix": ""
                },
                {
                    "first": "U",
                    "middle": [],
                    "last": "Querfeld",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Muller",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Rudolph",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Peters",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Kramer",
                    "suffix": ""
                }
            ],
            "year": 2012,
            "venue": "J Hypertens",
            "volume": "30",
            "issn": "",
            "pages": "2182--91",
            "other_ids": {}
        },
        "BIBREF211": {
            "ref_id": "b211",
            "title": "Decrease in thoracic vertebral bone attenuation with calciumbased phosphate binders in hemodialysis",
            "authors": [
                {
                    "first": "P",
                    "middle": [],
                    "last": "Raggi",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "James",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "K"
                    ],
                    "last": "Burke",
                    "suffix": ""
                }
            ],
            "year": 2005,
            "venue": "J Bone Miner Res",
            "volume": "20",
            "issn": "",
            "pages": "764--72",
            "other_ids": {}
        },
        "BIBREF212": {
            "ref_id": "b212",
            "title": "Vascular calcification and bone disease: the calcification paradox",
            "authors": [
                {
                    "first": "V",
                    "middle": [],
                    "last": "Persy",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "&apos;haese",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "",
                    "suffix": ""
                }
            ],
            "year": 2009,
            "venue": "Trends Mol Med",
            "volume": "15",
            "issn": "",
            "pages": "405--421",
            "other_ids": {}
        },
        "BIBREF213": {
            "ref_id": "b213",
            "title": "characteristics, mapping, and catheter ablation of potential rotors in nonparoxysmal atrial fibrillation",
            "authors": [
                {
                    "first": "Y",
                    "middle": [
                        "J"
                    ],
                    "last": "Lin",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "T"
                    ],
                    "last": "Lo",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Lin",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF215": {
            "ref_id": "b215",
            "title": "Fetuin-A is a mineral carrier protein: small angle neutron scattering provides new insight on fetuin-A controlled calcification inhibition",
            "authors": [
                {
                    "first": "A",
                    "middle": [],
                    "last": "Heiss",
                    "suffix": ""
                },
                {
                    "first": "V",
                    "middle": [],
                    "last": "Pipich",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [],
                    "last": "Jahnen-Dechent",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Schwahn",
                    "suffix": ""
                }
            ],
            "year": 2010,
            "venue": "Biophys J",
            "volume": "99",
            "issn": "",
            "pages": "3986--95",
            "other_ids": {}
        },
        "BIBREF216": {
            "ref_id": "b216",
            "title": "The serum protein alpha 2-Heremans-Schmid glycoprotein/ fetuin-A is a systemically acting inhibitor of ectopic calcification",
            "authors": [
                {
                    "first": "C",
                    "middle": [],
                    "last": "Schafer",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Heiss",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Schwarz",
                    "suffix": ""
                }
            ],
            "year": 2003,
            "venue": "J Clin Invest",
            "volume": "112",
            "issn": "",
            "pages": "357--66",
            "other_ids": {}
        },
        "BIBREF217": {
            "ref_id": "b217",
            "title": "Role of calcification inhibitors in the pathogenesis of vascular calcification in chronic kidney disease (CKD)",
            "authors": [
                {
                    "first": "S",
                    "middle": [
                        "M"
                    ],
                    "last": "Moe",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Reslerova",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Ketteler",
                    "suffix": ""
                }
            ],
            "year": 2005,
            "venue": "Kidney Int",
            "volume": "67",
            "issn": "",
            "pages": "2295--304",
            "other_ids": {}
        },
        "BIBREF218": {
            "ref_id": "b218",
            "title": "Dialysis accelerates medial vascular calcification in part by triggering smooth muscle cell apoptosis",
            "authors": [
                {
                    "first": "R",
                    "middle": [
                        "C"
                    ],
                    "last": "Shroff",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Mcnair",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "Figg",
                    "suffix": ""
                }
            ],
            "year": 2008,
            "venue": "Circulation",
            "volume": "118",
            "issn": "",
            "pages": "1748--57",
            "other_ids": {}
        },
        "BIBREF219": {
            "ref_id": "b219",
            "title": "Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Ketteler",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Bongartz",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Westenfeld",
                    "suffix": ""
                }
            ],
            "year": 2003,
            "venue": "Lancet",
            "volume": "361",
            "issn": "",
            "pages": "827--860",
            "other_ids": {}
        },
        "BIBREF220": {
            "ref_id": "b220",
            "title": "Matrix Gla protein, a new gamma-carboxyglutamic acidcontaining protein which is associated with the organic matrix of bone",
            "authors": [
                {
                    "first": "P",
                    "middle": [
                        "A"
                    ],
                    "last": "Price",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "R"
                    ],
                    "last": "Urist",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Otawara",
                    "suffix": ""
                }
            ],
            "year": 1983,
            "venue": "Biochem Biophys Res Commun",
            "volume": "117",
            "issn": "",
            "pages": "765--71",
            "other_ids": {}
        },
        "BIBREF221": {
            "ref_id": "b221",
            "title": "Matrix GLA protein, a regulatory protein for bone morphogenetic protein-2",
            "authors": [
                {
                    "first": "A",
                    "middle": [
                        "F"
                    ],
                    "last": "Zebboudj",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Imura",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Bostrom",
                    "suffix": ""
                }
            ],
            "year": 2002,
            "venue": "J Biol Chem",
            "volume": "277",
            "issn": "",
            "pages": "4388--94",
            "other_ids": {}
        },
        "BIBREF222": {
            "ref_id": "b222",
            "title": "Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein",
            "authors": [
                {
                    "first": "G",
                    "middle": [],
                    "last": "Luo",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Ducy",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "D"
                    ],
                    "last": "Mckee",
                    "suffix": ""
                }
            ],
            "year": 1997,
            "venue": "Nature",
            "volume": "386",
            "issn": "",
            "pages": "78--81",
            "other_ids": {}
        },
        "BIBREF223": {
            "ref_id": "b223",
            "title": "A current understanding of vascular calcification in CKD",
            "authors": [
                {
                    "first": "N",
                    "middle": [
                        "J"
                    ],
                    "last": "Paloian",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "M"
                    ],
                    "last": "Giachelli",
                    "suffix": ""
                }
            ],
            "year": 2014,
            "venue": "Am J Physiol Renal Physiol",
            "volume": "307",
            "issn": "",
            "pages": "891--900",
            "other_ids": {}
        },
        "BIBREF224": {
            "ref_id": "b224",
            "title": "Matrix Gla protein binding to hydroxyapatite is dependent on the ionic environment: calcium enhances binding affinity but phosphate and magnesium decrease affinity",
            "authors": [
                {
                    "first": "M",
                    "middle": [
                        "E"
                    ],
                    "last": "Roy",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "K"
                    ],
                    "last": "Nishimoto",
                    "suffix": ""
                }
            ],
            "year": 2002,
            "venue": "Bone",
            "volume": "31",
            "issn": "",
            "pages": "296--302",
            "other_ids": {}
        },
        "BIBREF225": {
            "ref_id": "b225",
            "title": "Warfarin induces cardiovascular damage in mice",
            "authors": [
                {
                    "first": "T",
                    "middle": [],
                    "last": "Kruger",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Oelenberg",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "Kaesler",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF227": {
            "ref_id": "b227",
            "title": "Chronic coumarin treatment is associated with increased extracoronary arterial calcification in humans",
            "authors": [
                {
                    "first": "R",
                    "middle": [
                        "J"
                    ],
                    "last": "Rennenberg",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [
                        "J"
                    ],
                    "last": "Van Varik",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [
                        "J"
                    ],
                    "last": "Schurgers",
                    "suffix": ""
                }
            ],
            "year": 2010,
            "venue": "Blood",
            "volume": "115",
            "issn": "",
            "pages": "5121--5124",
            "other_ids": {}
        },
        "BIBREF228": {
            "ref_id": "b228",
            "title": "Can biological calcification occur in the presence of pyrophosphate?",
            "authors": [
                {
                    "first": "J",
                    "middle": [
                        "L"
                    ],
                    "last": "Meyer",
                    "suffix": ""
                }
            ],
            "year": 1984,
            "venue": "Arch Biochem Biophys",
            "volume": "231",
            "issn": "",
            "pages": "1--8",
            "other_ids": {}
        },
        "BIBREF229": {
            "ref_id": "b229",
            "title": "Regulation of vascular calcification: roles of phosphate and osteopontin",
            "authors": [
                {
                    "first": "C",
                    "middle": [
                        "M"
                    ],
                    "last": "Giachelli",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "Y"
                    ],
                    "last": "Speer",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "M"
                    ],
                    "last": "Rajachar",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Yang",
                    "suffix": ""
                }
            ],
            "year": 2005,
            "venue": "Circ Res",
            "volume": "96",
            "issn": "",
            "pages": "717--739",
            "other_ids": {}
        },
        "BIBREF230": {
            "ref_id": "b230",
            "title": "Prognostic implication of plasma osteopontin levels in patients with chronic kidney disease",
            "authors": [
                {
                    "first": "D",
                    "middle": [
                        "V"
                    ],
                    "last": "Barreto",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Lenglet",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Liabeuf",
                    "suffix": ""
                }
            ],
            "year": 2011,
            "venue": "Nephron Clin Pract",
            "volume": "117",
            "issn": "",
            "pages": "363--72",
            "other_ids": {}
        },
        "BIBREF231": {
            "ref_id": "b231",
            "title": "Initiation and propagation of vascular calcification is regulated by a concert of platelet-and smooth muscle cellderived extracellular vesicles",
            "authors": [
                {
                    "first": "L",
                    "middle": [
                        "J"
                    ],
                    "last": "Schurgers",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "C"
                    ],
                    "last": "Akbulut",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "M"
                    ],
                    "last": "Kaczor",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Halder",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "R"
                    ],
                    "last": "Koenen",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Kramann",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "Front Cardiovasc Med",
            "volume": "5",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF232": {
            "ref_id": "b232",
            "title": "Vascular smooth muscle cell calcification is mediated by regulated exosome secretion",
            "authors": [
                {
                    "first": "A",
                    "middle": [
                        "N"
                    ],
                    "last": "Kapustin",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "L"
                    ],
                    "last": "Chatrou",
                    "suffix": ""
                },
                {
                    "first": "I",
                    "middle": [],
                    "last": "Drozdov",
                    "suffix": ""
                }
            ],
            "year": 2015,
            "venue": "Circ Res",
            "volume": "116",
            "issn": "",
            "pages": "1312--1335",
            "other_ids": {}
        },
        "BIBREF234": {
            "ref_id": "b234",
            "title": "A novel role of cellular interactions in vascular calcification",
            "authors": [
                {
                    "first": "Asa",
                    "middle": [],
                    "last": "Bardeesi",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Gao",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                }
            ],
            "year": 2017,
            "venue": "J Transl Med",
            "volume": "15",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF235": {
            "ref_id": "b235",
            "title": "Micro-RNA in cardiovascular calcification: focus on targets and extracellular vesicle delivery mechanisms",
            "authors": [
                {
                    "first": "C",
                    "middle": [],
                    "last": "Goettsch",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "D"
                    ],
                    "last": "Hutcheson",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [],
                    "last": "Aikawa",
                    "suffix": ""
                }
            ],
            "year": 2013,
            "venue": "Circ Res",
            "volume": "112",
            "issn": "",
            "pages": "1073--84",
            "other_ids": {}
        },
        "BIBREF236": {
            "ref_id": "b236",
            "title": "Oligogalacturonic acid inhibits vascular calcification by two mechanisms: inhibition of vascular smooth muscle cell osteogenic conversion and interaction with collagen",
            "authors": [
                {
                    "first": "A",
                    "middle": [],
                    "last": "Hodroge",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [],
                    "last": "Trecherel",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Cornu",
                    "suffix": ""
                }
            ],
            "year": 2017,
            "venue": "Arterioscler Thromb Vasc Biol",
            "volume": "37",
            "issn": "",
            "pages": "1391--401",
            "other_ids": {}
        },
        "BIBREF237": {
            "ref_id": "b237",
            "title": "Matrix remodeling in vascular calcification associated with chronic kidney disease",
            "authors": [
                {
                    "first": "A",
                    "middle": [
                        "S"
                    ],
                    "last": "Pai",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "M"
                    ],
                    "last": "Giachelli",
                    "suffix": ""
                }
            ],
            "year": 2010,
            "venue": "J Am Soc Nephrol",
            "volume": "21",
            "issn": "",
            "pages": "1637--1677",
            "other_ids": {}
        },
        "BIBREF238": {
            "ref_id": "b238",
            "title": "Mineralized tissue cells are a principal source of FGF23",
            "authors": [
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Yoshiko",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Minamizaki",
                    "suffix": ""
                }
            ],
            "year": 2007,
            "venue": "Bone",
            "volume": "40",
            "issn": "",
            "pages": "1565--73",
            "other_ids": {}
        },
        "BIBREF239": {
            "ref_id": "b239",
            "title": "Regulation and function of the FGF23/klotho endocrine pathways",
            "authors": [
                {
                    "first": "A",
                    "middle": [],
                    "last": "Martin",
                    "suffix": ""
                },
                {
                    "first": "V",
                    "middle": [],
                    "last": "David",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [
                        "D"
                    ],
                    "last": "Quarles",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF242": {
            "ref_id": "b242",
            "title": "Effect of ferric citrate on serum phosphate and fibroblast growth factor 23 among patients with nondialysisdependent chronic kidney disease: path analyses",
            "authors": [
                {
                    "first": "G",
                    "middle": [
                        "A"
                    ],
                    "last": "Block",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [
                        "E"
                    ],
                    "last": "Pergola",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Fishbane",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "Nephrol Dial Transplant",
            "volume": "34",
            "issn": "",
            "pages": "1115--1139",
            "other_ids": {}
        },
        "BIBREF243": {
            "ref_id": "b243",
            "title": "FGF23 at the crossroads of phosphate, iron economy and erythropoiesis",
            "authors": [
                {
                    "first": "D",
                    "middle": [],
                    "last": "Edmonston",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Wolf",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Nat Rev Nephrol",
            "volume": "16",
            "issn": "",
            "pages": "7--19",
            "other_ids": {}
        },
        "BIBREF244": {
            "ref_id": "b244",
            "title": "Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [],
                    "last": "Tang",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Zhou",
                    "suffix": ""
                }
            ],
            "year": 2006,
            "venue": "J Am Soc Nephrol",
            "volume": "17",
            "issn": "",
            "pages": "1305--1320",
            "other_ids": {}
        },
        "BIBREF245": {
            "ref_id": "b245",
            "title": "Update on fibroblast growth factor 23 in chronic kidney disease",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Wolf",
                    "suffix": ""
                }
            ],
            "year": 2012,
            "venue": "Kidney Int",
            "volume": "82",
            "issn": "",
            "pages": "737--784",
            "other_ids": {}
        },
        "BIBREF246": {
            "ref_id": "b246",
            "title": "alpha-Klotho is a non-enzymatic molecular scaffold for FGF23 hormone signalling",
            "authors": [
                {
                    "first": "G",
                    "middle": [],
                    "last": "Chen",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Goetz",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "Nature",
            "volume": "553",
            "issn": "",
            "pages": "461--467",
            "other_ids": {}
        },
        "BIBREF247": {
            "ref_id": "b247",
            "title": "FGF23 and Klotho in chronic kidney disease",
            "authors": [
                {
                    "first": "H",
                    "middle": [],
                    "last": "Olauson",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [
                        "E"
                    ],
                    "last": "Larsson",
                    "suffix": ""
                }
            ],
            "year": 2013,
            "venue": "Curr Opin Nephrol Hypertens",
            "volume": "22",
            "issn": "",
            "pages": "397--404",
            "other_ids": {}
        },
        "BIBREF248": {
            "ref_id": "b248",
            "title": "Fibroblast growth factor 23 accelerates phosphate-induced vascular calcification in the absence of klotho deficiency",
            "authors": [
                {
                    "first": "R",
                    "middle": [],
                    "last": "Jimbo",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Kawakami-Mori",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Mu",
                    "suffix": ""
                }
            ],
            "year": 2014,
            "venue": "Kidney Int",
            "volume": "85",
            "issn": "",
            "pages": "1103--1114",
            "other_ids": {}
        },
        "BIBREF249": {
            "ref_id": "b249",
            "title": "Vascular klotho deficiency potentiates the development of human artery calcification and mediates resistance to fibroblast growth factor 23",
            "authors": [
                {
                    "first": "K",
                    "middle": [],
                    "last": "Lim",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [
                        "S"
                    ],
                    "last": "Lu",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Molostvov",
                    "suffix": ""
                }
            ],
            "year": 2012,
            "venue": "Circulation",
            "volume": "125",
            "issn": "",
            "pages": "2243--55",
            "other_ids": {}
        },
        "BIBREF250": {
            "ref_id": "b250",
            "title": "Arterial klotho expression and FGF23 effects on vascular calcification and function",
            "authors": [
                {
                    "first": "K",
                    "middle": [],
                    "last": "Lindberg",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Olauson",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Amin",
                    "suffix": ""
                }
            ],
            "year": 2013,
            "venue": "PLoS One",
            "volume": "8",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF251": {
            "ref_id": "b251",
            "title": "Fibroblast growth factor 23 is not associated with and does not induce arterial calcification",
            "authors": [
                {
                    "first": "J",
                    "middle": [
                        "J"
                    ],
                    "last": "Scialla",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [
                        "L"
                    ],
                    "last": "Lau",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "P"
                    ],
                    "last": "Reilly",
                    "suffix": ""
                }
            ],
            "year": 2013,
            "venue": "Kidney Int",
            "volume": "83",
            "issn": "",
            "pages": "1159--68",
            "other_ids": {}
        },
        "BIBREF252": {
            "ref_id": "b252",
            "title": "A protective role for FGF-23 in local defence against disrupted arterial wall integrity?",
            "authors": [
                {
                    "first": "D",
                    "middle": [],
                    "last": "Zhu",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [
                        "C"
                    ],
                    "last": "Mackenzie",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "L"
                    ],
                    "last": "Millan",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Farquharson",
                    "suffix": ""
                },
                {
                    "first": "V",
                    "middle": [
                        "E"
                    ],
                    "last": "Macrae",
                    "suffix": ""
                }
            ],
            "year": 2013,
            "venue": "Mol Cell Endocrinol",
            "volume": "372",
            "issn": "",
            "pages": "1--11",
            "other_ids": {}
        },
        "BIBREF253": {
            "ref_id": "b253",
            "title": "Klotho deficiency causes vascular calcification in chronic kidney disease",
            "authors": [
                {
                    "first": "M",
                    "middle": [
                        "C"
                    ],
                    "last": "Hu",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Shi",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                }
            ],
            "year": 2011,
            "venue": "J Am Soc Nephrol",
            "volume": "22",
            "issn": "",
            "pages": "124--160",
            "other_ids": {}
        },
        "BIBREF254": {
            "ref_id": "b254",
            "title": "Persistence of vascular calcification after reversal of uremia",
            "authors": [
                {
                    "first": "K",
                    "middle": [
                        "A"
                    ],
                    "last": "Lomashvili",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [
                        "E"
                    ],
                    "last": "Manning",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "N"
                    ],
                    "last": "Weitzmann",
                    "suffix": ""
                },
                {
                    "first": "V",
                    "middle": [],
                    "last": "Nelea",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "D"
                    ],
                    "last": "Mckee",
                    "suffix": ""
                },
                {
                    "first": "O",
                    "middle": [],
                    "last": "Neill",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [
                        "C"
                    ],
                    "last": "",
                    "suffix": ""
                }
            ],
            "year": 2017,
            "venue": "Am J Pathol",
            "volume": "187",
            "issn": "",
            "pages": "332--340",
            "other_ids": {}
        },
        "BIBREF255": {
            "ref_id": "b255",
            "title": "Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study",
            "authors": [
                {
                    "first": "J",
                    "middle": [
                        "S"
                    ],
                    "last": "Lindberg",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Culleton",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Wong",
                    "suffix": ""
                }
            ],
            "year": 2005,
            "venue": "J Am Soc Nephrol",
            "volume": "16",
            "issn": "",
            "pages": "800--807",
            "other_ids": {}
        },
        "BIBREF256": {
            "ref_id": "b256",
            "title": "Calcification is associated with loss of functional calcium-sensing receptor in vascular smooth muscle cells",
            "authors": [
                {
                    "first": "M",
                    "middle": [
                        "U"
                    ],
                    "last": "Alam",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "P"
                    ],
                    "last": "Kirton",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [
                        "L"
                    ],
                    "last": "Wilkinson",
                    "suffix": ""
                }
            ],
            "year": 2009,
            "venue": "Cardiovasc Res",
            "volume": "81",
            "issn": "",
            "pages": "260--268",
            "other_ids": {}
        },
        "BIBREF257": {
            "ref_id": "b257",
            "title": "The calcimimetic R-568 retards uremia-enhanced vascular calcification and atherosclerosis in apolipoprotein E deficient (apoE-/-) mice",
            "authors": [
                {
                    "first": "O",
                    "middle": [],
                    "last": "Ivanovski",
                    "suffix": ""
                },
                {
                    "first": "I",
                    "middle": [
                        "G"
                    ],
                    "last": "Nikolov",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "Joki",
                    "suffix": ""
                }
            ],
            "year": 2009,
            "venue": "Atherosclerosis",
            "volume": "205",
            "issn": "",
            "pages": "55--62",
            "other_ids": {}
        },
        "BIBREF258": {
            "ref_id": "b258",
            "title": "The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis",
            "authors": [
                {
                    "first": "P",
                    "middle": [],
                    "last": "Raggi",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [
                        "M"
                    ],
                    "last": "Chertow",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [
                        "U"
                    ],
                    "last": "Torres",
                    "suffix": ""
                }
            ],
            "year": 2011,
            "venue": "Nephrol Dial Transplant",
            "volume": "26",
            "issn": "",
            "pages": "1327--1366",
            "other_ids": {}
        },
        "BIBREF259": {
            "ref_id": "b259",
            "title": "Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis",
            "authors": [
                {
                    "first": "E",
                    "middle": [
                        "T"
                    ],
                    "last": "Investigators",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [
                        "M"
                    ],
                    "last": "Chertow",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [
                        "A"
                    ],
                    "last": "Block",
                    "suffix": ""
                }
            ],
            "year": 2012,
            "venue": "N Engl J Med",
            "volume": "367",
            "issn": "",
            "pages": "2482--94",
            "other_ids": {}
        },
        "BIBREF260": {
            "ref_id": "b260",
            "title": "Effect of etelcalcetide vs placebo on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: two randomized clinical trials",
            "authors": [
                {
                    "first": "G",
                    "middle": [
                        "A"
                    ],
                    "last": "Block",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "A"
                    ],
                    "last": "Bushinsky",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Cunningham",
                    "suffix": ""
                }
            ],
            "year": 2017,
            "venue": "JAMA",
            "volume": "317",
            "issn": "",
            "pages": "146--55",
            "other_ids": {}
        },
        "BIBREF261": {
            "ref_id": "b261",
            "title": "Effects of etelcalcetide on fibroblast growth factor 23 in patients with secondary hyperparathyroidism receiving hemodialysis",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Wolf",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [
                        "A"
                    ],
                    "last": "Block",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [
                        "M"
                    ],
                    "last": "Chertow",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Clin Kidney J",
            "volume": "13",
            "issn": "",
            "pages": "75--84",
            "other_ids": {}
        },
        "BIBREF262": {
            "ref_id": "b262",
            "title": "Effect of etelcalcetide vs cinacalcet on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: a randomized clinical trial",
            "authors": [
                {
                    "first": "G",
                    "middle": [
                        "A"
                    ],
                    "last": "Block",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "A"
                    ],
                    "last": "Bushinsky",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Cheng",
                    "suffix": ""
                }
            ],
            "year": 2017,
            "venue": "JAMA",
            "volume": "317",
            "issn": "",
            "pages": "156--64",
            "other_ids": {}
        },
        "BIBREF263": {
            "ref_id": "b263",
            "title": "The circulating inactive form of matrix gla protein is a surrogate marker for vascular calcification in chronic kidney disease: a preliminary report",
            "authors": [
                {
                    "first": "L",
                    "middle": [
                        "J"
                    ],
                    "last": "Schurgers",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "V"
                    ],
                    "last": "Barreto",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [
                        "C"
                    ],
                    "last": "Barreto",
                    "suffix": ""
                }
            ],
            "year": 2010,
            "venue": "Clin J Am Soc Nephrol",
            "volume": "5",
            "issn": "",
            "pages": "568--75",
            "other_ids": {}
        },
        "BIBREF264": {
            "ref_id": "b264",
            "title": "Vitamin K status and vascular calcification: evidence from observational and clinical studies",
            "authors": [
                {
                    "first": "M",
                    "middle": [
                        "K"
                    ],
                    "last": "Shea",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "M"
                    ],
                    "last": "Holden",
                    "suffix": ""
                }
            ],
            "year": 2012,
            "venue": "Adv Nutr",
            "volume": "3",
            "issn": "",
            "pages": "158--65",
            "other_ids": {}
        },
        "BIBREF265": {
            "ref_id": "b265",
            "title": "Effect of vitamin K2 supplementation on functional vitamin K deficiency in hemodialysis patients: a randomized trial",
            "authors": [
                {
                    "first": "R",
                    "middle": [],
                    "last": "Westenfeld",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Krueger",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Schlieper",
                    "suffix": ""
                }
            ],
            "year": 2012,
            "venue": "Am J Kidney Dis",
            "volume": "59",
            "issn": "",
            "pages": "186--95",
            "other_ids": {}
        },
        "BIBREF267": {
            "ref_id": "b267",
            "title": "Vitamin K1 to slow vascular calcification in haemodialysis patients (VitaVasK trial): a rationale and study protocol",
            "authors": [],
            "year": 2014,
            "venue": "Nephrol Dial Transplant",
            "volume": "29",
            "issn": "",
            "pages": "1633--1641",
            "other_ids": {}
        },
        "BIBREF268": {
            "ref_id": "b268",
            "title": "Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients",
            "authors": [
                {
                    "first": "G",
                    "middle": [
                        "M"
                    ],
                    "last": "Chertow",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "K"
                    ],
                    "last": "Burke",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Raggi",
                    "suffix": ""
                }
            ],
            "year": 2002,
            "venue": "Kidney Int",
            "volume": "62",
            "issn": "",
            "pages": "245--52",
            "other_ids": {}
        },
        "BIBREF269": {
            "ref_id": "b269",
            "title": "Mortality in kidney disease patients treated with phosphate binders: a randomized study",
            "authors": [
                {
                    "first": "Di",
                    "middle": [],
                    "last": "Iorio",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Bellasi",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Russo",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "",
                    "suffix": ""
                }
            ],
            "year": 2012,
            "venue": "Clin J Am Soc Nephrol",
            "volume": "7",
            "issn": "",
            "pages": "487--93",
            "other_ids": {}
        },
        "BIBREF270": {
            "ref_id": "b270",
            "title": "Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis",
            "authors": [
                {
                    "first": "S",
                    "middle": [
                        "A"
                    ],
                    "last": "Jamal",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Vandermeer",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Raggi",
                    "suffix": ""
                }
            ],
            "year": 2013,
            "venue": "Lancet",
            "volume": "382",
            "issn": "",
            "pages": "1268--77",
            "other_ids": {}
        },
        "BIBREF271": {
            "ref_id": "b271",
            "title": "Effects of phosphate binders in moderate CKD",
            "authors": [
                {
                    "first": "G",
                    "middle": [
                        "A"
                    ],
                    "last": "Block",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "C"
                    ],
                    "last": "Wheeler",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "S"
                    ],
                    "last": "Persky",
                    "suffix": ""
                }
            ],
            "year": 2012,
            "venue": "J Am Soc Nephrol",
            "volume": "23",
            "issn": "",
            "pages": "1407--1422",
            "other_ids": {}
        },
        "BIBREF272": {
            "ref_id": "b272",
            "title": "Can we IMPROVE cardiovascular outcomes through phosphate lowering in CKD? Rationale and protocol for the IMpact of Phosphate Reduction On Vascular End-points in Chronic Kidney Disease (IMPROVE-CKD) study",
            "authors": [
                {
                    "first": "N",
                    "middle": [],
                    "last": "Lioufas",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [
                        "D"
                    ],
                    "last": "Toussaint",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [],
                    "last": "Pedagogos",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "BMJ Open",
            "volume": "9",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF273": {
            "ref_id": "b273",
            "title": "Rationale and approaches to phosphate and fibroblast growth factor 23 reduction in CKD",
            "authors": [
                {
                    "first": "T",
                    "middle": [],
                    "last": "Isakova",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "H"
                    ],
                    "last": "Ix",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "M"
                    ],
                    "last": "Sprague",
                    "suffix": ""
                }
            ],
            "year": 2015,
            "venue": "J Am Soc Nephrol",
            "volume": "26",
            "issn": "",
            "pages": "2328--2367",
            "other_ids": {}
        },
        "BIBREF274": {
            "ref_id": "b274",
            "title": "Magnesium reduces calcification in bovine vascular smooth muscle cells in a dose-dependent manner",
            "authors": [
                {
                    "first": "F",
                    "middle": [],
                    "last": "Kircelli",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "E"
                    ],
                    "last": "Peter",
                    "suffix": ""
                },
                {
                    "first": "Sevinc",
                    "middle": [],
                    "last": "Ok",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [],
                    "last": "",
                    "suffix": ""
                }
            ],
            "year": 2012,
            "venue": "Nephrol Dial Transplant",
            "volume": "27",
            "issn": "",
            "pages": "514--535",
            "other_ids": {}
        },
        "BIBREF275": {
            "ref_id": "b275",
            "title": "Magnesium prevents phosphate-induced calcification in human aortic vascular smooth muscle cells",
            "authors": [
                {
                    "first": "L",
                    "middle": [],
                    "last": "Louvet",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Buchel",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Steppan",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Passlick-Deetjen",
                    "suffix": ""
                },
                {
                    "first": "Z",
                    "middle": [
                        "A"
                    ],
                    "last": "Massy",
                    "suffix": ""
                }
            ],
            "year": 2013,
            "venue": "Nephrol Dial Transplant",
            "volume": "28",
            "issn": "",
            "pages": "869--78",
            "other_ids": {}
        },
        "BIBREF276": {
            "ref_id": "b276",
            "title": "Magnesium modulates the expression levels of calcification-associated factors to inhibit calcification in a time-dependent manner",
            "authors": [
                {
                    "first": "J",
                    "middle": [],
                    "last": "Xu",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Bai",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Jin",
                    "suffix": ""
                }
            ],
            "year": 2015,
            "venue": "Exp Ther Med",
            "volume": "9",
            "issn": "",
            "pages": "1028--1062",
            "other_ids": {}
        },
        "BIBREF277": {
            "ref_id": "b277",
            "title": "Dietary magnesium supplementation prevents and reverses vascular and soft tissue calcifications in uremic rats",
            "authors": [
                {
                    "first": "J",
                    "middle": [
                        "M"
                    ],
                    "last": "Diaz-Tocados",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Peralta-Ramirez",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "E"
                    ],
                    "last": "Rodriguez-Ortiz",
                    "suffix": ""
                }
            ],
            "year": 2017,
            "venue": "Kidney Int",
            "volume": "92",
            "issn": "",
            "pages": "1084--99",
            "other_ids": {}
        },
        "BIBREF278": {
            "ref_id": "b278",
            "title": "Oral magnesium supplementation in chronic kidney disease stages 3 and 4: efficacy, safety, and effect on serum calcification propensity-a prospective randomized double-blinded placebo-controlled clinical trial",
            "authors": [
                {
                    "first": "I",
                    "middle": [],
                    "last": "Bressendorff",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Hansen",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Schou",
                    "suffix": ""
                }
            ],
            "year": 2017,
            "venue": "Kidney Int Rep",
            "volume": "2",
            "issn": "",
            "pages": "380--389",
            "other_ids": {}
        },
        "BIBREF279": {
            "ref_id": "b279",
            "title": "Long-term effects of magnesium carbonate on coronary artery calcification and bone mineral density in hemodialysis patients: a pilot study",
            "authors": [
                {
                    "first": "D",
                    "middle": [
                        "M"
                    ],
                    "last": "Spiegel",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Farmer",
                    "suffix": ""
                }
            ],
            "year": 2009,
            "venue": "Hemodial Int",
            "volume": "13",
            "issn": "",
            "pages": "453--462",
            "other_ids": {}
        },
        "BIBREF280": {
            "ref_id": "b280",
            "title": "Magnesium retards the progress of the arterial calcifications in hemodialysis patients: a pilot study",
            "authors": [
                {
                    "first": "I",
                    "middle": [
                        "P"
                    ],
                    "last": "Tzanakis",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [
                        "E"
                    ],
                    "last": "Stamataki",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "N"
                    ],
                    "last": "Papadaki",
                    "suffix": ""
                }
            ],
            "year": 2014,
            "venue": "Int Urol Nephrol",
            "volume": "46",
            "issn": "",
            "pages": "2199--205",
            "other_ids": {}
        },
        "BIBREF281": {
            "ref_id": "b281",
            "title": "A Randomized trial of magnesium oxide and oral carbon adsorbent for coronary artery calcification in predialysis CKD",
            "authors": [
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Sakaguchi",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Hamano",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Obi",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "J Am Soc Nephrol",
            "volume": "30",
            "issn": "",
            "pages": "1073--85",
            "other_ids": {}
        },
        "BIBREF282": {
            "ref_id": "b282",
            "title": "Effect of crystallization inhibitors on vascular calcifications induced by vitamin D: a pilot study in Sprague-Dawley rats",
            "authors": [
                {
                    "first": "F",
                    "middle": [],
                    "last": "Grases",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Sanchis",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Perello",
                    "suffix": ""
                }
            ],
            "year": 2007,
            "venue": "Circ J",
            "volume": "71",
            "issn": "",
            "pages": "1152--1158",
            "other_ids": {}
        },
        "BIBREF283": {
            "ref_id": "b283",
            "title": "Characterization of SNF472 pharmacokinetics and efficacy in uremic and non-uremic rats models of cardiovascular calcification",
            "authors": [
                {
                    "first": "M",
                    "middle": [
                        "D"
                    ],
                    "last": "Ferrer",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Ketteler",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Tur",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "PLoS One",
            "volume": "13",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF284": {
            "ref_id": "b284",
            "title": "Slowing progression of cardiovascular calcification with SNF472 in patients on hemodialysis: results of a randomized, phase 2b study",
            "authors": [
                {
                    "first": "P",
                    "middle": [],
                    "last": "Raggi",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Bellasi",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Bushinsky",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Circulation",
            "volume": "141",
            "issn": "",
            "pages": "728--767",
            "other_ids": {}
        },
        "BIBREF285": {
            "ref_id": "b285",
            "title": "Development of a novel chronic kidney disease mouse model to evaluate the progression of hyperphosphatemia and associated mineral bone disease",
            "authors": [
                {
                    "first": "T",
                    "middle": [],
                    "last": "Tani",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Orimo",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Shimizu",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Tsuruoka",
                    "suffix": ""
                }
            ],
            "year": 2017,
            "venue": "Sci Rep",
            "volume": "7",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF286": {
            "ref_id": "b286",
            "title": "Cause-specific deaths in nondialysis-dependent CKD",
            "authors": [
                {
                    "first": "S",
                    "middle": [
                        "D"
                    ],
                    "last": "Navaneethan",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "D"
                    ],
                    "last": "Schold",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Arrigain",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "E"
                    ],
                    "last": "Jolly",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "V"
                    ],
                    "last": "Nally",
                    "suffix": ""
                }
            ],
            "year": 2015,
            "venue": "J Am Soc Nephrol",
            "volume": "26",
            "issn": "",
            "pages": "2512--2532",
            "other_ids": {}
        },
        "BIBREF287": {
            "ref_id": "b287",
            "title": "Chronic kidney disease is linked to carotid nodular calcification, an unstable plaque not correlated to inflammation",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Cardellini",
                    "suffix": ""
                },
                {
                    "first": "V",
                    "middle": [],
                    "last": "Rovella",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Scimeca",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "Aging Dis",
            "volume": "10",
            "issn": "",
            "pages": "71--81",
            "other_ids": {}
        },
        "BIBREF288": {
            "ref_id": "b288",
            "title": "Porcelain aorta: a comprehensive review",
            "authors": [
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Abramowitz",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Jilaihawi",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Chakravarty",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "J"
                    ],
                    "last": "Mack",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "R"
                    ],
                    "last": "Makkar",
                    "suffix": ""
                }
            ],
            "year": 2015,
            "venue": "Circulation",
            "volume": "131",
            "issn": "",
            "pages": "827--863",
            "other_ids": {}
        },
        "BIBREF289": {
            "ref_id": "b289",
            "title": "The prognostic significance of iliac vessel calcification in renal transplantation",
            "authors": [
                {
                    "first": "E",
                    "middle": [],
                    "last": "Aitken",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Ramjug",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Buist",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Kingsmore",
                    "suffix": ""
                }
            ],
            "year": 2012,
            "venue": "Transplant Proc",
            "volume": "44",
            "issn": "",
            "pages": "2925--2956",
            "other_ids": {}
        },
        "BIBREF290": {
            "ref_id": "b290",
            "title": "Consequences of iliac arterial atheroma on renal transplantation",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "Droupy",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Eschwege",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Hammoudi",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Durrbach",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Charpentier",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Benoit",
                    "suffix": ""
                }
            ],
            "year": 2006,
            "venue": "J Urol",
            "volume": "175",
            "issn": "",
            "pages": "1036--1045",
            "other_ids": {}
        },
        "BIBREF291": {
            "ref_id": "b291",
            "title": "Correlation of pre-existing radial artery macrocalcifications with late patency of primary radiocephalic fistulas in diabetic hemodialysis patients",
            "authors": [
                {
                    "first": "S",
                    "middle": [
                        "J"
                    ],
                    "last": "Choi",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [
                        "E"
                    ],
                    "last": "Yoon",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [
                        "S"
                    ],
                    "last": "Kim",
                    "suffix": ""
                }
            ],
            "year": 2014,
            "venue": "J Vasc Surg",
            "volume": "28",
            "issn": "",
            "pages": "462--70",
            "other_ids": {}
        },
        "BIBREF292": {
            "ref_id": "b292",
            "title": "Comparison of atherosclerotic calcification in major vessel beds on the risk of all-cause and causespecific mortality: the Rotterdam Study",
            "authors": [
                {
                    "first": "D",
                    "middle": [],
                    "last": "Bos",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "J"
                    ],
                    "last": "Leening",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Kavousi",
                    "suffix": ""
                }
            ],
            "year": 2015,
            "venue": "Circ Cardiovasc Imaging",
            "volume": "8",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF293": {
            "ref_id": "b293",
            "title": "Prevalence of nonatheromatous le",
            "authors": [
                {
                    "first": "W",
                    "middle": [
                        "C"
                    ],
                    "last": "O&apos;neill",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [
                        "H"
                    ],
                    "last": "Han",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [
                        "M"
                    ],
                    "last": "Schneider",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "A"
                    ],
                    "last": "Hennigar",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF294": {
            "ref_id": "b294",
            "title": "Meditation. In: Devotions Upon Emergent Occasions",
            "authors": [
                {
                    "first": "J",
                    "middle": [],
                    "last": "Donne",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Xvii",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF295": {
            "ref_id": "b295",
            "title": "Emerging coronaviruses: genome structure, replication",
            "authors": [
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Chen",
                    "suffix": ""
                },
                {
                    "first": "Q",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Guo",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF297": {
            "ref_id": "b297",
            "title": "Doctors and Nurses Fighting Coronavirus in China Die of Both Infection and Fatigue",
            "authors": [
                {
                    "first": "A",
                    "middle": [],
                    "last": "Su",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Los Angeles Times",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF298": {
            "ref_id": "b298",
            "title": "Mining for Augustinian gold in John Donne's \"Meditation 17",
            "authors": [
                {
                    "first": "R",
                    "middle": [],
                    "last": "Jungman",
                    "suffix": ""
                }
            ],
            "year": 2007,
            "venue": "Am Notes Queries",
            "volume": "20",
            "issn": "",
            "pages": "16--20",
            "other_ids": {}
        },
        "BIBREF300": {
            "ref_id": "b300",
            "title": "35 years old, ophthalmologist, Central Hospital of Wuhan",
            "authors": [
                {
                    "first": "Wenliang",
                    "middle": [],
                    "last": "Dr",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF301": {
            "ref_id": "b301",
            "title": "57 years old, ophthalmologist, Central Hospital of Wuhan",
            "authors": [
                {
                    "first": "Zhongming",
                    "middle": [],
                    "last": "Dr",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Mei",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF302": {
            "ref_id": "b302",
            "title": "Heping Zhu, ophthalmologist, Central Hospital of Wuhan",
            "authors": [
                {
                    "first": "",
                    "middle": [],
                    "last": "Dr",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF303": {
            "ref_id": "b303",
            "title": "Xueqing Jiang, 56 years old, thyroid and breast surgeon, Central Hospital of Wuhan",
            "authors": [
                {
                    "first": "",
                    "middle": [],
                    "last": "Dr",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF304": {
            "ref_id": "b304",
            "title": "Zhengbin Lin, 62 years old, kidney transplant surgeon",
            "authors": [
                {
                    "first": "",
                    "middle": [],
                    "last": "Dr",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF305": {
            "ref_id": "b305",
            "title": "Yinhua Peng, 29 years old, pulmonary physician, First People's Hospital of Jiangxia District",
            "authors": [
                {
                    "first": "",
                    "middle": [],
                    "last": "Dr",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF306": {
            "ref_id": "b306",
            "title": "Sisi Xia, 29 years old, gastroenterologist, Xiehe Jiangbei Hospital",
            "authors": [
                {
                    "first": "",
                    "middle": [],
                    "last": "Dr",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF307": {
            "ref_id": "b307",
            "title": "Wenjun Huang, 42 years old, pulmonary physician",
            "authors": [
                {
                    "first": "",
                    "middle": [],
                    "last": "Dr",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF308": {
            "ref_id": "b308",
            "title": "51 years old, Dean of Wuchang Hospital",
            "authors": [
                {
                    "first": "Zhiming",
                    "middle": [],
                    "last": "Dr",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF309": {
            "ref_id": "b309",
            "title": "51 years old, Vice Dean of Nanjing Hospital of Chinese Medicine",
            "authors": [
                {
                    "first": "Hui",
                    "middle": [],
                    "last": "Dr",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Xu",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF310": {
            "ref_id": "b310",
            "title": "50 years old, general surgeon, Red Cross Hospital of Wuhan",
            "authors": [
                {
                    "first": "",
                    "middle": [],
                    "last": "Dr",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Junxiao",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF311": {
            "ref_id": "b311",
            "title": "52 years old, Vice Dean of Xianyang Central Health Center",
            "authors": [
                {
                    "first": "Yanghong",
                    "middle": [],
                    "last": "Dr",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Mao",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF312": {
            "ref_id": "b312",
            "title": "52 years old, infectious physician, Taizhou People's Hospital",
            "authors": [
                {
                    "first": "Jijun",
                    "middle": [],
                    "last": "Dr",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Jiang",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF313": {
            "ref_id": "b313",
            "title": "58 years old",
            "authors": [
                {
                    "first": "Jinbo",
                    "middle": [],
                    "last": "Dr",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Jiang",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "Disease Control Center of Dayu",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF314": {
            "ref_id": "b314",
            "title": "Nurse Fan Yang, 55 years old",
            "authors": [],
            "year": null,
            "venue": "Wuchang Hospital Community Health Service Center",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF315": {
            "ref_id": "b315",
            "title": "69 years old",
            "authors": [
                {
                    "first": "Debu",
                    "middle": [],
                    "last": "Dr",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Wu",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "Ezhou Hospital of Traditional Chinese Medicine",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF316": {
            "ref_id": "b316",
            "title": "Yingjie Song, 28 years old",
            "authors": [
                {
                    "first": "",
                    "middle": [],
                    "last": "Dr",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF318": {
            "ref_id": "b318",
            "title": "Zhengrong Zhu, 48 years old",
            "authors": [
                {
                    "first": "",
                    "middle": [],
                    "last": "Dr",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "Nanyang Community Health Service Center",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF319": {
            "ref_id": "b319",
            "title": "Xiansheng Du, 55 years old, Yangjiang Hospital of Li Autonomous County",
            "authors": [
                {
                    "first": "",
                    "middle": [],
                    "last": "Dr",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF320": {
            "ref_id": "b320",
            "title": "Wuche Liang, 62 years old, Hubei Hospital of Integrated Traditional Chinese and Western Medicine",
            "authors": [
                {
                    "first": "",
                    "middle": [],
                    "last": "Dr",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF322": {
            "ref_id": "b322",
            "title": "36 years old, Baofeng Hospital of Traditional Chinese Medicine",
            "authors": [
                {
                    "first": "Yangyang",
                    "middle": [],
                    "last": "Dr",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Yuan",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF323": {
            "ref_id": "b323",
            "title": "Jinxing Yuan, 32 years old",
            "authors": [
                {
                    "first": "",
                    "middle": [],
                    "last": "Dr",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "Jinlingfeng Town Health Center",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        }
    },
    "ref_entries": {
        "FIGREF0": {
            "text": "Chronic Pulmonary Hypertension Secondary to Heart Failure [SPHERE-HF]; NCT02775539) (J Am Coll Cardiol Basic Trans Science 2020;5:317-27) \u00a9 2020 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). P ulmonary hypertension (PH) is a common complication of heart failure (HF)",
            "latex": null,
            "type": "figure"
        },
        "FIGREF1": {
            "text": "the a Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain; b Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain; c Hospital Universitario Quir\u00f3nsalud Madrid, UEM, Madrid, Spain; d demonstrated in the human myocardium and vessels, and it has been described to be upregulated in left heart disease (LHD)",
            "latex": null,
            "type": "figure"
        },
        "FIGREF2": {
            "text": "peutic target in cardiovascular diseases. Recent experimental research has demonstrated that treatment with b3AR agonists produces a beneficial effect on hemodynamics, right ventricular (RV) remodeling, and pulmonary vascular proliferation in a translational porcine model of post-capillary chronic PH (30). In addition, several Phase II and III randomized clinical trials (31-37) have already confirmed the good safety profile of the oral b3AR agonist mirabegron in healthy subjects and in patients with overactive bladder syndrome. Mirabegron, the selective oral b3AR agonist tested in the present trial, is currently approved for the treatment of overactive bladder syndrome in Europe, Japan, and America. A recent study has also demonstrated a good safety profile of mirabegron in patients with HF and reduced LVEF (38). Based on the previously described concepts and evidence and the positive results of pre-clinical research, we designed a multicenter placebocontrolled Phase II randomized clinical trial to evaluate the efficacy and safety of mirabegron in patients with chronic CpcPH secondary to HF. METHODS STUDY HYPOTHESIS. The main hypothesis of the SPHERE-HF (b3 Adrenergic Agonist Treatment in Chronic Pulmonary Hypertension Secondary to Heart Failure) trial is that maintenance treatment with a selective b3AR agonist (mirabegron) in patients with PH secondary to HF compared with placebo will result in a beneficial effect due to: 1) a reduction in pulmonary vascular resistance (PVR); 2) an increase in RV performance; 3) improvement in clinical status; and 4) no increase in adverse events. STUDY ENDPOINTS. E f fi c a c y m e a s u r e s . The primary outcome is the change in PVR on right heart catheterization, calculated in Wood units as: (mean pulmonary artery pressure (PAP) [mm Hg] \u00c0 pulmonary capillary wedge pressure [mm Hg])/cardiac output [l/min]) from baseline to week 16. Secondary outcomes are change from baseline to week 16 in clinical status (measured by 6-min walk distance, New York Heart Association [NYHA] functional class, quality of life evaluated with the Spanish version of the Kansas City Cardiomyopathy Questionnaire, and the dyspnea Borg scale score), other hemodynamic variables assessed by right heart catheterization (mean PAP, transpulmonary gradient, diastolic pressure gradient, and cardiac output), RV performance (RV ejection fraction and cardiac output by cardiac magnetic resonance [CMR] or cardiac computed tomography [CCT]), as well as plasmatic levels of Nterminal pro-hormone of brain natriuretic peptide (NT-proBNP). Safety measures include hospital admissions for HF or respiratory failure, death, urgent heart transplantation, initiation of intravenous therapy due to worsening HF (diuretics or inotropic drugs), adverse events, and adverse drug reactions, as well as monitorization of heart rate and the QTc interval on electrocardiography (ECG) (by Framingham method). External monitoring of all clinical events and ECG acquisitions will be performed. STUDY POPULATION AND INCLUSION/EXCLUSION CRITERIA. Patients have been identified and recruited from 4 different tertiary hospitals across Spain, all of which have a reference HF Unit. Inclusion and exclusion criteria are presented on",
            "latex": null,
            "type": "figure"
        },
        "FIGREF3": {
            "text": ">480 ms, based on the high percentage of patients with CpcPH who were excluded at baseline and the absence of data that suggested that mirabegron significantly increased QTc.written informed consent, patients undergo the following baseline procedures and assessments (all must be completed within 4 weeks before random allocation): demographic and medical history data collection; physical examination (including blood pressure, heart rate, and pulse oximetry); NYHA functional class; blood sample analysis including NT-proBNP; ECG; echocardiography; right heart catheterization; 6-min walking test, and CMR. Thosepatients with formal contraindications for CMR can undergo a dedicated CCT examination to measure RV volumes and function (Table 2, Figure 2). Patients who fulfill all inclusion criteria and none of the exclusion criteria are randomized to receive either mirabegron (50 mg) or placebo once daily in a blinded fashion (visit 0). Visit 1 represents the day of the first study medication dose and must take place in the 5 days after visit 0. A safety visit is performed 1 week after initiation of therapy (visit 2) because, according to the medication technical sheet, steadystate concentrations are achieved at 7 days of once-daily dosing with mirabegron. Thereafter, medication dose is titrated every 2 weeks for 8 weeks (visits 3, 4, and 5) based on patients' monitoring of blood pressure, heart rate, QTc interval, blood analysis, and clinical status assessed at that visit (Table 3 shows the recommended titration algorithm). At the end of the dose titration phase (visit 6), all patients are expected to have reached their optimal dose. To assure blinding of the treatment arms, patients allocated to the placebo group undergo titration from visit 3 onwards, following the same algorithm. During the maintenance phase (8 weeks), patients continue receiving the same dose assigned at visit 6, unless a decrease in dose is required for safety purposes. An intermediate clinical visit is performed halfway through the maintenance phase (visit 7). At visit 8 (end of the study), patients undergo all study examinations performed at baseline and stop the study medication. The last visit (visit 9) takes place 30 days after the last study medication dose for",
            "latex": null,
            "type": "figure"
        },
        "FIGREF4": {
            "text": "Manufacturing of study medication. Manufacturing of mirabegron and placebo is carried out in the pharmaceutical area of the Hospital Cl\u00ednic Pharmacy department. The excipient for placebo capsules (mixture of microcrystalline cellulose and colloidal silica) is received with the corresponding certificate of analysis from the manufacturer (Fagron Iberica S.A.U, Tarrasa, Spain). The material the lot number and expiration date are verified for each entry, and the corresponding certificate of analysis is archived. Similarly, at the reception of mirabegron (Betmiga; bought from Astelas Pharma [Chuo, Tokyo, Japan] for 28.9V/box containing 30 pills of 50 mg of Betmiga), the batch and expiration date are checked and recorded. Betmiga pills are taken out of the blisters and automatically encapsulated (a single pill into a capsule). Similarly, the excipient is included in the capsules. Immediately, capsules including mirabegron or excipient are introduced in polyethylene bottles (30 capsules each) that are labeled as study medication, including the batch number and expiration. The bottles are kept in the clinical trials area in conservation conditions (atmosphere temperature <25 o C). Polyethylene bottles containing 30 capsules of mirabegron or placebo are labeled in a blinded manner, so both the physicians and patients are blinded to the study medication. Thereby, titration is performed in the same way for both active drug and placebo by increasing the number of capsules a day, and there is no option that unblinding is lost in the up titration phase. STATISTICAL METHODS. Randomization procedure.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF5": {
            "text": "Summary of the Study Conduct",
            "latex": null,
            "type": "figure"
        },
        "FIGREF6": {
            "text": "The following analysis populations are pre-defined for this study: intention to treat (ITT) populationdall randomized patients; per protocol (PP) populationdpatients from the ITT group who have the final (16-week) measurement of the primary outcome and who have taken at least 80% of all the medication doses; and safety populationdall patients who have taken $1 doses of the assigned treatment.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF7": {
            "text": "Multimodality Imaging Evaluation of RV Performance in SPHERE-HF Trial (A) Right ventricular (RV) speckle tracking\u00c0derived strain from an apical 4-chamber view on echocardiography. (B and C) End-diastolic and end-systolic frames from the cine sequence at the mid-ventricular level to calculate biventricular volumes and ejection fraction with cardiac magnetic resonance (CMR). (D and E) T1 maps before (D) and 15 min after contrast administration (E) for estimation of extracellular volume using CMR. (F and G) Cardiac computed tomographic images from enddiastolic and end-systolic frames to calculate biventricular volumes and ejection fraction in a patient who could not undergo CMR due to an implantable cardiac resynchronization therapy device. SPHERE-HF \u00bc b3 Adrenergic Agonist Treatment in Chronic Pulmonary Hypertension Secondary to Heart Failure.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF9": {
            "text": "Studies will be performed according to standard American Society of Echocardiography and European Association of Cardiovascular Imaging guidelines, with special dedication to the evaluation of RV performance(41,42). The acquisition protocol is standardized across all centers, and studies are digitally stored for dedicated offline analysis at the Imaging Core Laboratory located at Centro Nacional de Investigaciones Cardiovasculares.Left ventricular (LV) volumes and ejection fractions will be measured using the modified Simpson rule (biplane method). Left and right atrial areas will be obtained at ventricular end-systole, excluding the pulmonary vein confluence and the left atrial appendage. RV dimensions, end-systolic and enddiastolic RV areas, and the tricuspid annular plane systolic excursion will be measured from a RVfocused apical 4-chamber view. Fractional area change will be calculated as the difference in RV enddiastolic area and RV end-systolic area divided by the RV end-systolic area. RV index of myocardial performance (Tei index) and the tricuspid lateral annular systolic velocity wave (S') will be measured using Doppler tissue imaging velocity of the lateral tricuspid annulus. Valvular disease and diastolic function will be graded according to the American Society of Echocardiography and European Association of Cardiovascular Imaging standards(43)(44)(45). A 3-beat 2-dimensional digital clip of a RV-focused, 4-chamber view will be acquired for quantification of RV strain by speckle tracking echocardiography (Figure 2A). All analyses will be performed using the CMR studies will be performed with either 1.5-or 3.0-T magnets, using dedicated surface coils for cardiac studies and retrospective electrocardiographic gating. The acquisition protocol is standardized across all centers, and all studies are digitally stored for dedicated offline analysis at the Imaging Core Laboratory located at Centro Nacional de Investigaciones Cardiovasculares (CNIC) (Madrid, Spain). The CMR examination includes the following sequences. A steady-state free precession cine sequence is used to acquire 15 contiguous short-axis slices covering both ventricles from base to apex and reconstructed into 25 cardiac phases each for the evaluation of biventricular volumes and function. Two-dimensional flow imaging (phase contrast) is performed perpendicular to the main pulmonary artery with a velocity-encoded gradient echo sequence and an upper velocity limit of 100 cm/s (with further increases for any signal aliasing). For this purpose, 2 double-oblique orthogonal views oriented along the main axis of the pulmonary artery trunk are acquired with a standard steady-state free precession cine sequence and used as the reference to prescribe a plane truly perpendicular to the main pulmonary artery for the acquisition of phase contrast images. Care is taken to ensure that the imaging plane remains between the pulmonary valve and pulmonary artery bifurcation throughout the cardiac cycle. In addition, aortic velocity and LV cardiac output are systematically measured (46). For delayed gadolinium enhancement imaging, patients receive an intravenous bolus of 0.125 mmol/kg of gadolinium followed by 20 ml of saline. After 5 to 10 min, contiguous shortaxis views matching the cine images are acquired using a phase-sensitive inversion\u00c0recovery fast gradient echo sequence for the evaluation of delayed gadolinium enhancement. Typical breath-hold times range from 8 to 14 s. In patients with an inability to perform such breath-holds, delayed gadolinium enhancement images are repeated with a single-shot inversion\u00c0recovery steady-state free precession sequence during free breathing. T1 mapping sequences will be acquired just before contrast administration and 15 min after contrast administration in a short-axis view at the level of the papillary muscles for estimation of the extracellular volume fraction.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF10": {
            "text": "C T . CCT studies are performed using at least a 64slice scanner with retrospective electrocardiographic gating mode acquisition (ideally with modulation dose). CCT images are acquired from the level of the aortic arch to the dome of the diaphragm in a breathhold mode. Nonionic iodinated contrast agent (approximately 80 ml) is injected at a rate of 5 ml/s with a power injector, followed by a saline 40 ml flush. A bolus tracking technique is used to trigger image acquisition once attenuation in a region of interest placed in the descending aorta has reached a pre-set threshold of 100 HU. Axial images are reconstructed with an image matrix of 512 \u00c2 512 pixels and a slice thickness of 1.25 mm from 0% to 90% of the cardiac cycle to calculate RV function. Post-processing of CCT images will be performed on a dedicated workstation with specific RV function quantification package (IntelliSpacePortal v9.0, Philips) (Figures 2F and 2G). DURATION OF THE STUDY. The SPHERE-HF clinical trial started recruitment in June 2017, and it is expected that the inclusion phase will end by June 2020. As of December 18, 2019, a total of 61 patients have been included in the study.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF12": {
            "text": "situ immune modulators regulate the severity of cardiac allograft rejection. (J Am Coll Cardiol Basic Trans Science 2020;5:328-40) \u00a9 2020 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license (http://creativecommons. org/licenses/by-nc-nd/4.0/).",
            "latex": null,
            "type": "figure"
        },
        "FIGREF13": {
            "text": "ardiac allograft rejection (CAR) is a serious concern among transplant recipients, occurring in roughly one-third of patients in the first year post-transplantation and conferring an increased risk of short-and long-term graft failure. Because of the high morbidity and mortality associated with CAR, the International Society for Heart and Lung Transplantation (ISHLT) has recommended regular surveillance endomyocardial biopsy (EMB) with standardized histologic grading for CAR since 1990.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF15": {
            "text": "tive, multiplex immunofluorescence (QmIF) methodology on archived clinical EMB tissue samples, with a focus on uncovering immune phenotypes that can improve the diagnostic and prognostic performance of histologic analysis for CAR. Using a custom panel of IF markers focused on cell-mediated immune responses and modified from commercially available panels validated in multiple oncologic publications (13-17), we performed in situ identification and quantification of cluster of differentiation 3 (CD3), CD8, CD68, forkhead box P3 (FoxP3), and programmed death ligand 1 (PD-L1). Due to limited research in human heart transplant tissues, the rationale for the markers selected for this cellmediated rejection panel comes predominantly from animal models and renal transplantation (18-33). T cells are implicated in most cases of CAR, but are in actuality a heterogeneous group of cells capable of exerting pro-inflammatory and anti-inflammatory effects under different conditions. As a result, quantification of the pan-T-cell marker CD3 in addition to markers of T-cell subtypes and effectors was the objective of this proof-of-concept work. Within this context, our novel application of QmIF demonstrated striking new diagnostic and prognostic insights beyond the standard ISHLT grade, supporting potential benefits from further application and refinement of the immune-phenotyping panel. METHODS COHORT CONSIDERATIONS. The study cohort was selected from the transplant records at the Hospital of the University of Pennsylvania and consisted of biopsy events that occurred between 2007 and 2013. Cases were manually selected to allow for exploration of the potential diagnostic and prognostic implications of performing immune phenotyping within EMB tissue.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF16": {
            "text": "occur in IF markers in advance of a serious CAR event. RETROSPECTIVE SAMPLE ACQUISITION AND PREPARATION. All EMB tissues analyzed for this study had been sampled using a standard percutaneous method, fixed in 4% paraformaldehyde, and embedded in paraffin wax as per usual post-transplantation clinical care and pathology laboratory workflows at the Hospital of the University of Pennsylvania. Five, 4-mm thick serial sections were cut from formalin-fixed paraffinembedded blocks and mounted onto positively charged glass microscope slides (48382-119; VWR",
            "latex": null,
            "type": "figure"
        },
        "FIGREF17": {
            "text": "Individual fluorophore signal intensities, in normalized counts, were assessed on the multiplex imagery following spectral unmixing to confirm proper staining intensity levels and absence of residual cross talk.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF18": {
            "text": "fl o w . The Trainable Tissue Segmentation module was used to automatically segment all samples into total cardiac tissue and background based on hand-drawn training regions. Cell segmentation was conducted using the Adaptive Cell Segmentation, which uses algorithms to account for variations in staining and background levels within and across images to identify cellular compartments from multiple image planes. The algorithm first identifies the cell nuclei (via 4 0 ,6diamidino-2-phenylindole staining), followed by the cell membrane and cytoplasm for each, and has further settings for cell splitting and staining quality. The Phenotyping module, which utilizes a user-trainable random forest classifier, learned and phenotyped all markers, except for PD-L1, in which the staining intensity was scored per cell on a 0 to 3\u00fe scale using thresholding to enable histology score (H-score) calculations. All cell segmentation and scoring data and imagery were exported for further analysis. STATISTICAL METHODS. Raw cell count (and PD-L1 intensity) data generated by inForm quantitative image analysis were sent to the University of Pennsylvania for further analysis. Cases were analyzed by pre-specified groups as described in \"cohort considerations.\" For CD3\u00fe, CD8\u00fe, CD68\u00fe, and PD-L1 cell count data, values were normalized by total cell counts to account for differences in tissue size and myocardial area. FoxP3 \u00fe cells were normalized by the total T-cell (CD3\u00fe) cell count. Groupwise chi-squared testing was performed on the normalized cell count data. Comparisons included cases grouped by high versus low ISHLT histologic grade, by clinically evident versus clinically silent rejection determination, and by patient-level future-rejection versus never-rejection label. Cases were also analyzed by",
            "latex": null,
            "type": "figure"
        },
        "FIGREF19": {
            "text": "Diagram of Study Cohort, With Subgroups",
            "latex": null,
            "type": "figure"
        },
        "FIGREF20": {
            "text": "e.g., \"concordant positive\" \u00bc high ISHLT grade/clinically evident CAR, \"concordant negative\" \u00bc low ISHLT grade/clinically silent CAR, \"discordant positive\" \u00bc high ISHLT grade/clinically silent CAR, and \"discordant negative\" \u00bc low ISHLT grade/clinically evident CAR). Semiquantitative analysis of PD-L1 staining intensity was also performed, with PD-L1\u00fe status placed into 1 of 4 categories based on intensity (level 0 \u00bc no PD-L1, level 1 \u00bc low intensity, level 2 \u00bc moderate intensity, level 3 \u00bc high intensity). PD-L1 H-scores were based on a method described previously (38). Briefly, the total number of cells and the percentage of cells in each PD-L1-staining level were counted in 3 randomly selected fields under high magnification. PD-L1 H-score was then calculated for each case according to the following formula: Hscore \u00bc 0 \u00c2 % of level-0 cells \u00fe 1 \u00c2 % of level-1 intensity cells \u00fe 2 \u00c2 % of level-2 intensity cells \u00fe 3 \u00c2 % of level-3 intensity cells. Because H-scores were tabulated on a per-patient basis rather than a per-cell basis, a per-patient analysis of this metric was per-",
            "latex": null,
            "type": "figure"
        },
        "FIGREF21": {
            "text": "provides a compelling visual demonstration of how these conventional T-cell markers correlate predominantly with grade classification and provide little help for discriminating between cases with versus without serious clinical rejection syndromes. High-grade EMB also have significantly higher proportions of macrophage marker CD68 when compared with low-grade EMB (p < 0.001), but unlike the traditional T-cell markers CD3 and CD8, the opposite relationship is seen when cases are grouped by the severity of the clinical rejection syndrome. Clinically silent rejection events have a significantly higher proportion of CD68\u00fe cells than do clinically evident rejection events (p < 0.001). An examination of the results from EMB with clinical-histologic discordance provides the explanation for these opposing results (Table 4, Figure 2B), with discordant high-grade cases manifesting by far the highest proportion of CD68\u00fe cells (5.45%; p < 0.001) whereas discordant low-grade cases manifest the lowest (0.14%; p < 0.001). Cells expressing the regulatory T-cell marker FoxP3 are twice as abundant in clinically silent rejection events, as compared with clinically evident rejection both within the low-histologic grade and the high-histologic grade cohort (p < 0.001 for both).",
            "latex": null,
            "type": "figure"
        },
        "FIGREF22": {
            "text": "L1, with similarly high proportions found either in low-or high-grade clinically silent EMB and similarly low proportions found in either low-or high-grade clinically evident EMB.The per-patient PD-L1 H-score, a composite measure incorporating both PD-L1 staining prevalence and signal intensity, is strongly associated with clinical rejection syndrome but not with histologic grade (Tables 3 and 4,Figure 3B). Patients with clinically silent rejection syndromes, whether the EMB received a high or low grade, manifest PD-L1 H-scores that are at least 4\u00c2 higher than those seen for clinically evident rejection events of either grade class.Illustrative hematoxylin and eosin-and QmIFstained digital slides for high and low ISHLT grades with both concordant and discordant clinical rejection syndromes are shown inFigure 3.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF23": {
            "text": "QmIF Results Grouped by ISHLT Grade and Clinical Status(A) Quantitative multiplex immunofluorescence (QmIF) results for cluster of differentiation 3\u00fe (CD3\u00fe) and CD8\u00fe cells, grouped by ISHLT grade and subgrouped based on concordance or discordance between ISHLT grade and clinical evidence of rejection (see",
            "latex": null,
            "type": "figure"
        },
        "FIGREF25": {
            "text": "the most extreme proportions of these potentially allograft-protective markers, with the discordant high-grade cases containing the highest proportions and the discordant low-grade cases containing the lowest. Visual inspection of QmIF slides further highlights the potential importance of PD-L1, with a diffuse PD-L1\u00fe (green) staining pattern seen throughout the myocardium in clinically silent biopsies (Figures 3A5 and 3C5) that is conspicuously absent in clinically evident rejection cases (Figures 3B5 and 3D5). It is also worth highlighting the particularly dense PD-L1 staining seen within the cellular infiltrate of the discordant high ISHLT grade slide (Figure 3C5), which may suggest an active and dynamic PD-L1 presence at the site of an acute immune response.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF26": {
            "text": "Representative EMB Cases, With H and E Stained, 7-IF Marker Composite, and Select Single IF Marker Digital Slides Hematoxylin and eosin (H and E)-stained (A1, B1, C1, D1), 7-immunofluorescence (IF) marker multiplex composite (A2, B2, C2, D2), and selected single IF marker (A3 to A6, B3 to B6, C3 to C6, D3 to D6) EMB slides. (A) Images are a representative concordant low ISHLT grade EMB with low ISHLT grade and no clinical evidence of allograft injury. (B)",
            "latex": null,
            "type": "figure"
        },
        "FIGREF27": {
            "text": "more than just a rough count of basophilic immune cells as performed in conventional ISHLT grading is required. This hypothesis is reinforced when the concordant low ISHLT grade EMB are differentiated from one another as futurerejection cases versus never-rejection cases, based on whether the patient experiences a serious rejection event in the first 3 years post-transplantation. The immune profiles of never-rejection EMB are defined by particularly high proportions of PD-L1\u00fe and FoxP3\u00fe cells. In contrast, future-rejection EMB as a whole exhibit lower levels of these alloprotective markers, with striking reductions observed by 3 to 6 weeks prior to an upcoming clinically evident rejection. The nearly complete loss of FoxP3\u00fe and PD-L1\u00fe cells in the weeks preceding clinically evident rejection supports both their potential utility as biomarkers for identifying patients at high risk for significant rejection events, as well as the need to further investigate potential allo-protective role of these markers in heart transplantation. Mechanistically, the interplay between monocyte lineage cells (CD68\u00fe), regulatory T cells (FoxP3\u00fe), and PD-L1-expressing cells suggested by our results",
            "latex": null,
            "type": "figure"
        },
        "FIGREF28": {
            "text": "for CAR. Certainly, future research can apply additional QmIF antibody panels to further explore mechanisms of interest. Additionally, the present research does not fully leverage the available tools for quantitative image analysis in modern digital pathology. Spatial relationships between markers and infiltration patterns can be quantified using modern computer algorithms (48,49) and may provide additional layers of detail that enhance our understanding of disease while also boosting diagnostic and predictive performance. Finally, the present work may be enhanced by integrating complementary molecular technologies to better characterize the allograft-specific antigen targets of T-cell immunity that may play a role in determining CAR severity and future risk. The checkpoint inhibitor therapies and engineered cell therapies that have revolutionized oncologic medicine are based on 2 fundamental immunologic concepts: that cells have the ability to evade T-cell immune responses utilizing inhibitory surface receptors (e.g., PD-L1), and that a detailed molecular understanding of antigen immunogenicity can permit robust in vivo targeting of specific tissues via engineered T cells. Whereas our present work closely resembles the early in situ research that elucidated the role of checkpoint molecules in tumor tissues (50), future efforts should also focus on characterizing which allograft antigens play a role in determining the allograft fate via T-cell receptor sequencing. CONCLUSIONS Although there is indeed important additional work to be performed, the present research represents an important step toward precision diagnosis and risk stratification in cardiac transplantation. Our results demonstrate the feasibility and translational potential of the QmIF methodology, while identifying several key, and potentially targetable, mechanisms involved in determining the severity of an alloimmune response. ADDRESS FOR CORRESPONDENCE: Dr. Kenneth B. Margulies, Perelman School of Medicine, University of Pennsylvania, Translational Research Center, Room 11-101, 3400 Civic Center Boulevard, Building 421, Philadelphia, Pennsylvania 19104. E-mail: ken.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF29": {
            "text": "Stewart S, Winters GL, Fishbein MC, et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant 2005; 24:1710-20.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF30": {
            "text": "Wang C, Gong J, Tu TY, Lee PP, Fakih M. Immune profiling of microsatellite instability-high and polymerase \u03b5 (POLE)-mutated metastatic colorectal tumors identifies predictors of response to anti-PD-1 therapy. J Gastrointest Oncol 2018;9: 404-15.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF31": {
            "text": "7. van den Berg TK, Valerius T. Myeloid immune-checkpoint inhibition enters the clinical stage. Nat Rev Clin Oncol 2019;16: 275-6.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF32": {
            "text": "Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov 2019;18: 197-218. 9. Wang YL, Gao JM, Xing LZ. Therapeutic potential of Oroxylin A in rheumatoid arthritis. Int Immunopharmacol 2016;40:294-9. PERSPECTIVES COMPETENCY IN MEDICAL KNOWLEDGE: Clinically, these proof-of-concept studies support the feasibility and clinical benefits of applying immune-phenotyping for characterization of cardiac allograft biopsies. Specifically, the findings that the abundance of regulatory T cells and PD-L1 expression is linked to clinical allograft status suggests that native rejection suppressing processes may contribute to the discordance frequently observed between patients' clinical trajectory and ISHLT biopsy grade. The findings that suppressed PD-L1 is linked to clinically significant allo-immunity is a relevant extension of recent reports that checkpoint molecule inhibitors can induce severe myocarditis. TRANSLATIONAL OUTLOOK: From a translational perspective, the implicated allo-protective actions of CD68-expressing macrophages, FoxP3-expressing regulatory T cells, and PD-L1 expression merit both further mechanistic investigation in preclinical animal models and clinical investigation in larger retrospective and prospective cohorts, including a greater emphasis on time-course studies. Enhanced mechanistic clarity will ultimately enable more precise immune-suppressive strategies with superior performance for recipients of solid organ transplants. Kim N, Kim HS. Targeting checkpoint receptors and molecules for therapeutic modulation of natural killer cells. Front Immunol 2018;9:2041. 12. Burugu S, Dancsok AR, Nielsen TO. Emerging targets in cancer immunotherapy. Semin Cancer Biol 2018;52:39-52. 13. Stack EC, Wang C, Roman KA, Hoyt CC. Multiplexed immunohistochemistry, imaging, and quantitation: a review, with an assessment of Tyramide signal amplification, multispectral imaging and multiplex analysis. Methods 2014;70: 46-58.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF33": {
            "text": "Parra ER, Uraoka N, Jiang M, et al. Validation of multiplex immunofluorescence panels using multispectral microscopy for immune-profiling of formalin-fixed and paraffin-embedded human tumor tissues. Sci Rep 2017;7:13380. 15. Blom S, Paavolainen L, Bychkov D, et al. Systems pathology by multiplexed immunohistochemistry and whole-slide digital image analysis. Sci Rep 2017;7:15580. 16. Galetta H, Mansfield J, Richard B, et al. Validation of multiplex immunofluorescence for use in analysis of tumour infiltrating lymphocytes. J Immunotherapy Cancer 2015;3:P411. 17. Gorris MAJ, Halilovic A, Rabold K, et al. Eightcolor multiplex immunohistochemistry for simultaneous detection of multiple immune checkpoint molecules within the tumor microenvironment. J Immunol 2018;200:347-54.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF34": {
            "text": "Harper SJ, Ali JM, Wlodek E, et al. CD8 T-cell recognition of acquired alloantigen promotes acute allograft rejection. Proc Natl Acad Sci U S A 2015;112:12788-93. 19. Rocha PN, Plumb TJ, Crowley SD, Coffman TM. Effector mechanisms in transplant rejection. Immunol Rev 2003;196:51-64.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF35": {
            "text": "Le Moine A, Goldman M, Abramowicz D. Multiple pathways to allograft rejection. Transplantation 2002;73:1373-81.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF36": {
            "text": "Bestard O, Cruzado JM, Rama I, et al. Presence of FoxP3\u00fe regulatory T cells predicts outcome of subclinical rejection of renal allografts. J Am Soc Nephrol 2008;19:2020-6.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF37": {
            "text": "Chung BH, Oh HJ, Piao SG, et al. Clinical significance of the ratio between FOXP3 positive regulatory T cell and interleukin-17 secreting cell in renal allograft biopsies with acute T-cellmediated rejection. Immunology 2012;136:344-51.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF38": {
            "text": "Hua J, Inomata T, Chen Y, et al. Pathological conversion of regulatory T cells is associated with loss of allotolerance. Sci Rep 2018;8:7059.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF39": {
            "text": "Raimondi G, Sumpter TL, Matta BM, et al. Mammalian target of rapamycin inhibition and alloantigen-specific regulatory T cells synergize to promote long-term graft survival in immunocompetent recipients. J Immunol 2010;184:624-36.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF40": {
            "text": "Liao T, Xue Y, Zhao D, et al. In vivo attenuation of antibody-mediated acute renal allograft rejection by ex vivo TGF-b-induced CD4(\u00fe)Foxp3(\u00fe) regulatory T cells. Front Immunol 2017;8:1334.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF41": {
            "text": "Girlanda R, Kleiner DE, Duan Z, et al. Monocyte infiltration and kidney allograft dysfunction during acute rejection. Am J Transplant 2008;8:600-7. 28. Alhamad T, Venkatachalam K, Linette GP, Brennan DC. Checkpoint inhibitors in kidney transplant recipients and the potential risk of rejection. Am J Transplant 2016;16:1332-3.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF42": {
            "text": "Goldman JW, Abdalla B, Mendenhall MA, et al. PD 1 checkpoint inhibition in solid organ transplants: 2 sides of a coin-case report. BMC Nephrol 2018;19:210.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF43": {
            "text": "Lipson EJ, Bagnasco SM, Moore J Jr., et al. Tumor regression and allograft rejection after administration of anti-PD-1. N Engl J Med 2016; 374:896-8.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF44": {
            "text": "Pilat N, Sayegh MH, Wekerle T. Costimulatory pathways in transplantation. Semin Immunol 2011; 23:293-303.32. Tanaka K, Albin MJ, Yuan X, et al. PDL1 is required for peripheral transplantation tolerance and protection from chronic allograft rejection. J Immunol 2007;179:5204-10. 33. Sch\u00fctte-N\u00fctgen K, Boenisch O, Harrach H, et al. Divergent function of programmed deathligand 1 in donor tissue versus recipient immune system in a murine model of bronchiolitis obliterans. Am J Pathol 2017;187:1368-79.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF45": {
            "text": "Costanzo MR, Dipchand A, Starling R, et al. The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. J Heart Lung Transplant 2010;29:914-56. 35. Kobashigawa JA, Miller LW, Russell SD, et al. Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report. Am J Transplant 2006;6:1377-86. 36. Eisen HJ, Tuzcu EM, Dorent R, et al., for the RAD B253 Study Group. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003; 349:847-58.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF46": {
            "text": "Kobashigawa J, Patel J, Azarbal B, et al. Randomized pilot trial of gene expression profiling versus heart biopsy in the first year after heart transplant: early invasive monitoring attenuation through gene expression trial. Circ Heart Fail 2015; 8:557-64.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF47": {
            "text": "Igarashi T, Teramoto K, Ishida M, Hanaoka J, Daigo Y. Scoring of PD-L1 expression intensity on pulmonary adenocarcinomas and the correlations with clinicopathological factors. ESMO Open 2016; 1:e000083.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF48": {
            "text": "Berry GJ, Burke MM, Andersen C, et al. The 2013 International Society for Heart and Lung Transplantation Working Formulation for the standardization of nomenclature in the pathologic diagnosis of antibody-mediated rejection in heart transplantation. J Heart Lung Transplant 2013;32:1147-62.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF49": {
            "text": "Amarnath S, Magnus CW, Wang JC, et al. The PDL1-PD1 axis converts human TH1 cells into regulatory T cells. Sci Transl Med 2011;3:111ra120. 42. Francisco LM, Salinas VH, Brown KE, et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med 2009;206:3015-29.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF50": {
            "text": "Romano M, Fanelli G, Tan N, et al. Expanded regulatory T cells induce alternatively activated monocytes with a reduced capacity to expand T helper-17 cells. Front Immunol 2018;9:1625. 44. Gianchecchi E, Fierabracci A. Inhibitory receptors and pathways of lymphocytes: the role of PD-1 in Treg development and their involvement in autoimmunity onset and cancer progression. Front Immunol 2018;9:2374. 45. Miao X, Xu R, Fan B, et al. PD-L1 reverses depigmentation in Pmel-1 vitiligo mice by increasing the abundance of Tregs in the skin. Sci Rep 2018;8:1605. 46. Zhao Y, Chen S, Lan P, et al. Macrophage subpopulations and their impact on chronic allograft rejection versus graft acceptance in a mouse heart transplant model. Am J Transplant 2018;18: 604-16.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF51": {
            "text": "Grabie N, Lichtman AH, Padera R. T cell checkpoint regulators in the heart. Cardiovasc Res 2019;115:869-77.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF52": {
            "text": "Nirschl JJ, Janowczyk A, Peyster EG, et al. A deep-learning classifier identifies patients with clinical heart failure using whole-slide images of H&E tissue. PLoS One 2018;13: e0192726. 49. Peyster EG, Madabhushi A, Margulies KB. Advanced morphologic analysis for diagnosing allograft rejection: the case of cardiac transplant rejection. Transplantation 2018;102:1230-9.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF53": {
            "text": "Hutloff A, Dittrich AM, Beier KC, et al. ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. Nature 1999;397: 263-6. KEY WORDS allograft rejection, immune checkpoint molecules, immune regulation, quantitative immunohistochemistry APPENDIX For supplemental tables, please see the online version of this paper.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF54": {
            "text": "ong-term graft failure is the major hurdle in human cardiac transplantation. Advanced immunosuppressive therapies have substantially decreased the risk of acute graft failure but have limited efficacy in preventing graft failure from allograft coronary artery disease or chronic heart failure. In this proof of concept study in this issue of JACC: Basic to Translational Science, Peyster et al. (1) have applied quantitative multiplexed immunofluorescence (QmIF) microscopy for immunophenotyping of mononuclear immune cell types in a selective retrospective cohort of cardiac transplant biopsies. Three-year outcomes based on histologic classification were compared to clinical rejection trajectories by using multiple parameters of clinical worsening of cardiac performance. Immune modulators of CD8-positive cytotoxic T cells (regulatory T-cell transcription factor FoxP3 and programmed death ligand [PD-L1]) and a marker of macrophage lineage (CD68) were chosen as test markers. QmIF identified discrepancies between histologic and clinical predictions of long-term cardiac failure based on those markers. The proportion of PD-L1-and FoxP3-expressing cells were dynamic within cardiac allografts, and reduced levels of these cells predicted future allograft failure better than histologic grading. The QmIF methodology applied is robust and may hold promise for prognosticating outcomes based on endomyocardial biopsy. The study design could be a useful model to understand the failings of histologic grading in predicting outcome. As a proof of concept study, the statistical design was adequate. Unfortunately, there was a high failure rate (26%) of application of the method to retrospective biopsies which may have produced a serious sampling error. No table was provided to rule out this potential source of error based on comparison of the included and excluded cases. For future comparisons, it will be important to use the most recent validated International Society of Heart Lung Transplantation (ISHLT) histologic grading schema (established in 2013), so that antibody-mediated rejection (AMR) can be carefully evaluated in such investigations (2). The current study was based on the ISHLT schema from 2005, in which AMR was only loosely defined. Studies of longterm outcomes of cardiac allograft recipients have shown that AMR, detected by routine surveillance biopsies, even when clinically silent, strongly predicted adverse long-term outcomes for the recipients (3). The most recent schema emphasizes the histologic features of AMR including endothelial activation, adherence of macrophages to capillary walls, and the presence of interstitial edema. In fact, recent publications have emphasized the value of histologic features as diagnostic criteria for AMR. A validation study showed that chronic cardiovascular mortality after cardiac transplant was predicted equally by either immunopathologic or histologic features of ISSN 2452-302X https://doi.org/10.1016/j.jacbts.2020.03.001 *Editorials published in JACC: Basic to Translational Science reflect the views of the authors and do not necessarily represent the views of JACC: Basic to Translational Science or the American College of Cardiology. From the a U.T.A.H. Cardiac Transplant Program, Salt Lake City, Utah; b Division of Heart Failure and Cardiac Transplant, University of Utah School of Medicine, Salt Lake City, Utah; and the c Division of Heart Failure and Cardiac Transplant, Intermountain Healthcare, Salt Lake City, Utah. Dr. Hammond is supported by A. Lee Christensen Fund, Intermountain Healthcare Foundation, Salt Lake City, Utah. The author attests she is in compliance with human studies committees and animal welfare regulations of the author's institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the JACC: Basic to Translational Science author instructions page.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF55": {
            "text": "would enhance the diagnostic value. For example, the high-grade lesions illustrated (1) are histologically different and may be from very different post-transplantation time points. The infiltrate in the clinically silent high-grade rejection (case C1) consisted mostly of activated lymphocytes and macrophages in what appeared to be an early acute cellular rejection (1). The second case (D1), from an endomyocardial biopsy with significant longstanding myocyte injury and repair, is likely from a later posttransplantation time point (1). The infiltrate in the latter biopsy is composed of a more pleomorphic population of cells and appears to also involve capillary injury and repair. Based only on histologic features, the immunophenotypes would be expected to vary. Comparing cases serially and at similar posttransplantation intervals would add precision to the QmIF study. In the 2013 ISHLT schema, the role of macrophages in AMR is highlighted by the inclusion of CD68-positive macrophages within capillaries as part of the grading schema. In this pilot study (1), there is no mention of the location of the CD68-positive cells. The study found discordance of CD68-positive cells in a comparison between clinically silent and clinically evident rejection and in cases with clinical pathologic discordance. Macrophages are pivotal cells in innate immune responses and adapt phenotypically and functionally based on local circumstances. It is likely that the macrophages detected in this study represent diverse populations. In view of recent reports of the heterogeneity of macrophage populations in allograft injury, future studies should include markers of both pro-inflammatory (case M1) and anti-inflammatory pro-fibrogenic (case M2) subtypes of macrophages, both of which were detected by the CD68 marker (1). A recent report in a mouse cardiac transplant model demonstrated that M2 cells were critical components of the response to chronic allograft injury. Such cells, when exposed to mTOR deletion, express PD-L1 and exert potent immune regulatory functions, mediating long-term graft survival rather than graft loss (5). Although immune mechanisms in mouse models with knock-out population designs are not exactly analogous to human allograft immune processes, several important elements should be considered. mTOR deletion in macrophages and T lymphocytes is likely commonly operative in human cardiac transplantation because of the widespread use of rapamycin, a potent mTOR inhibitor. Using QmIF, the impact of mTOR deletion on macrophage subpopulations and PD-L1 expression could be explored. PD-L1 was investigated in the current study only by quantification and not cellular localization. Doublelabeling methods would shed important light on which cells are PD-L1-positive, some of which are likely macrophages or dendritic cells. Another critical addition to QmIF studies will be markers to detect innate immune cell contributions, such as the role of complement components, inhibitors of complement activation, and NK cells. Innate immune responses likely mediate some aspects of chronic allograft failure (6). Investigation of these elements, along with those of adaptive immune responses, especially if carried out in time-course studies, could shed light on these various mechanisms. Antibody-mediated and cell-mediated rejection often occur together, and it is unknow if this cooccurrence is related to mere association or to different mechanisms at play in such circumstances. Innate immune mechanisms may be operative in different ways in these situations. In addition, studies using QmIF should also include comparison with molecular studies of endomyocardial biopsies, which are now being increasingly investigated to predict outcome as complements to histologic testing (7). Exploration of molecular pathways in addition to histologic and immunopathologic features will help to clarify the mechanisms underlying chronic allograft failure, especially if correlated with histologic and immunopathologic features. ADDRESS FOR CORRESPONDENCE: Dr. M. Elizabeth H. Hammond, Division of Heart Failure and Cardiac Peyster EG, Wang C, Ishola F, et al. In situ immune profiling of heart transplant biopsies improves diagnostic accuracy and rejection risk stratification. J Am Coll Cardiol Basic Trans Science 2020;5:328-40. 2. Berry GJ, Burke MM, Andersen C, et al. The 2013 International Society for Heart and Lung Transplantation Working Formulation for the standardization of nomenclature in the pathologic diagnosis of antibody-mediated rejection in heart transplantation. J Heart Lung Transplant 2013;32: 1147-62. 3. Kfoury AG, Snow GL, Budge D, et al. A longitudinal study of the course of asymptom-atic antibody-mediated rejection in heart transplantation. J Heart Lung Transplant 2012;31: 46-51. 4. Hammond MEH, Revelo MP, Miller DV, et al. ISHLT pathology antibody mediated rejection score correlates with increased risk of cardiovascular mortality: a retrospective validation analysis. J Heart Lung Transplant 2016;35: 320-5.5. Zhao Y, Chen S, Lan P, et al. Macrophage subpopulations and their impact on chronic allograft rejection versus graft acceptance in a mouse heart transplant model. Am J Transplant 2018;, MD, a Tetsuya Hara, MD, PHD, a Makoto Nishimori, MD, a Yasuhiro Irino, PHD, b Seimi Satomi-Kobayashi, MD, PHD, a Masakazu Shinohara, MD, PHD, c Ryuji Toh, MD, PHD, b Farouc A. Jaffer, MD, PHD, d Tatsuro Ishida, MD, PHD, a Ken-ichi Hirata, MD, PHD a,b VISUAL ABSTRACT Okano, M. et al. J Am Coll Cardiol Basic Trans Science. 2020;5(4):344-56.ISSN 2452-302X https://doi.org/10.1016/j.jacbts.2020.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF56": {
            "text": "a novel clinically relevant murine DVT model at femoral/saphenous vein induced by flow restriction and light illumination. Our model newly succeeded in inducing DVT in a valve pocket and enabled spontaneous pulmonary embolism of fibrin-rich thrombus from lower extremity vein, reproducing the clinical VTE scenario. This model is suitable for motion-free in vivo high-resolution imaging of fibrin-rich DVT development and organization using 2-photon microscopy, enabling the real-time imaging of migration of platelets and leukocytes into the erythrocyte-rich DVT. SUMMARY This work established a new murine venous thromboembolism (VTE) model. This model has multiple novel features representing clinical VTE that include the following: 1) deep venous thrombosis (DVT) was formed and extended in the long axis of femoral/saphenous vein; 2) thrombus was formed in a venous valve pocket; 3) deligation of suture-induced spontaneous pulmonary emboli of fibrin-rich DVT; and 4) cardiac motion-free femoral/saphenous vein allowed high-resolution intravital microscopic imaging of fibrin-rich DVT. This new model requires only commercially available epifluorescence microscopy. Therefore, this model has significant potential for better understanding of VTE pathophysiology. (J Am Coll Cardiol Basic Trans Science 2020;5:344-56) \u00a9 2020 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/ by-nc-nd/4.0/). V enous thromboembolism (VTE), including the following 2 sequential clinical situations, deep venous thrombosis (DVT) and pulmonary embolism (PE), is responsible for a significant number of cardiovascular deaths (1). Studies have shown that leukocytes and platelets play a major role in the pathogenesis of DVT (2-4). Recent advances in molecular imaging techniques allowed visualization of dynamic behavior of inflammatory cells at a single-cell level in living organs; however, the dynamic movement of inflammatory cells in fibrin-rich DVT has not been visualized due to the lack of appropriate animal models suitable for in vivo imaging. There are several issues associated with the already established murine DVT models that they are inappropriate for in vivo imaging and unable to mimic clinical VTE features including spontaneous PE from lower extremity vein and common site of DVT (valvular pocket) (5,6). Ligature-based inferior vena cava (IVC) models, which include stasis and stenosis models, are most commonly used and have clinical features of DVT (2,7); however, these models are not suitable for in vivo imaging owing to their location in the body and their large thrombus size for microscopic the a Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan; b Division of Evidence-based Laboratory Medicine, Kobe University Graduate School of Medicine, Kobe, Japan; c Division of Epidemiology, Kobe University Graduate School of Medicine, Kobe, Japan; and the d Cardiovascular Research Center, Cardiology Division, Massachusetts General Hospital, Boston, Massachusetts. This study was supported by Grants-In-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan (19K08516), the Mochida Memorial Foundation for Medical and Pharmaceutical Research, and National Institutes of Health's National Heart, Lung, and Blood Institute grant R01HL137913. Drs. Toh and Irino have reported that the Division of Evidence-based Laboratory Medicine was established by an endowment fund from the Sysmex Corporation. Dr. Jaffer has received research grants from Canon and Siemens; has served as a proctor for and on the Advisory Boards of Abbott Vascular and Boston Scientific; has consulted for Acrostak; and is a shareholder in Intravascular Imaging, Inc. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors' institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the JACC: Basic to Translational Science author instructions page.Manuscript received October 11, 2019; revised manuscript received January 8, 2020, accepted January 8, 2020.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF57": {
            "text": "Induction of Stasis-and Irradiation-Induced DVT in the Murine Femoral/Saphenous Vein (A) Surgical ligation of the femoral vein induced flow restriction. Dotted white line indicates the femoral vein. Bars \u00bc 5 mm. (B) Venous flow velocity at the saphenous vein in ligated mice showed significant decrease compared with in nonligated mice (median: 2.27 [interquartile range (IQR): 1.86 to 2.59] vs. 0.35 [IQR: 0.20 to 0.61] mm/s; p < 0.001; n \u00bc 8 to 16 per group). ***p < 0.001. Box-and-whisker plot: middle line represents median value, box indicates IQR (25th, 75th percentiles), and range bars show maximum and minimum. (C) Even after ligation of the femoral vein (V), venous flow in the saphenous vein persisted at a low level as flow diverted (white arrows) into its side branches. Bars \u00bc 500 mm. (D) Imaging of real-time thrombus formation (visualized as a filling defect [*] in fluorescein isothiocyanate [FITC]-dextran-based venography) in the flow-restricted saphenous vein following the light irradiation through excitation filter in FITC channel (475/35 nm). Thrombus formation was initiated from the downstream of blood flow within seconds after the irradiation and extended distally in the long-axis direction of the vessel. See also Video 1. Without ligation, thrombus was not formed during the observation. Bars \u00bc 500 mm. (C,D) White arrows indicate venous flow direction. Prox \u00bc proximal. for all protocols, antibodies, labeling agents, and imaging systems used in this study are provided in the Supplemental Methods. SURGICAL LIGATION OF THE FEMORAL VEIN. The anesthetized mice were immobilized on a plastic board in a dorsal position. Simple skin incisions permitted vessel exposures of femoral/saphenous vein and artery. The femoral vein at the proximal site of venous bifurcation was separated carefully from the femoral artery, and surgically ligated with 7-0 nylon sutures to induce complete vessel occlusion as shown in Figure 1A, resulting in significant decrease of venous flow at saphenous vein (median: 2.27 [interquartile range (IQR): 1.86 to 2.59] vs. 0.35 [IQR: 0.20 to 0.61] mm/s; p < 0.001). Unlike the IVC, venous flow was restored even after the complete ligation at femoral vein (Figure 1B) through the backflow into the side branch (Figure 1C). All mice with bleedings of the femoral vein during surgery were excluded from further experiments. STATISTICAL ANALYSIS. All statistical analyses were performed using GraphPad Prism 7 software (La Jolla, California",
            "latex": null,
            "type": "figure"
        },
        "FIGREF58": {
            "text": "We assessed the relationship between venous flow velocity and thrombus area. We measured thrombus area in nonligated, partially ligated (to achieve middle range of flow velocity), and totally ligated femoral vein after exposure of fluorescein isothiocyanate (FITC)-channel filtered light (475/35 nm) for 60 s. The results showed that reduction of blood flow increased thrombus area and formation rate (Supplemental Figure 1A). Without ligation to reduce blood flow, thrombus never formed during the observation for several minutes (Figure 1D, bottom). Next, to clarify the required conditions of light irradiation of thrombus formation in this model, we assessed the light intensity, light exposure time, and wavelength of excitation light in the thrombus formation. Higher light intensity and longer light exposure time induced larger thrombus area, indicating that thrombus formation is light flux irradiationdependent (Supplemental Figures 1B and 1C). We generally use the FITC filter to observe thrombus as a negative area of FITC dextran; however, other wavelengths such as 350/50 nm (4 0 ,6-diamidino-2phenylindole channel) and 542/20 nm (tetramethyl rhodamine iso-thiocyanate channel) could also induce thrombus formation, suggesting that wavelength of irradiation light did not affect thrombus formation (Supplemental Figure 1D). To rule out the effect of fluorescence reaction between FITC-filtered excitation light and FITC dextran, we confirmed that thrombus could be induced with other blood flow imaging dyes including Evans blue dye (Wako Pure Chemical Industries, Osaka, Japan) and Tracer-653 probe (Molecular Targeting Technologies, Inc., West Chester, Pennsylvania) (SupplementalFigure 1E). We also tested FITC-filtered light exposure without FITC dextran. Although real-time thrombus formation was not visualized, injection of FITC dextran after light",
            "latex": null,
            "type": "figure"
        },
        "FIGREF59": {
            "text": "in our model exhibited multiple common features with human DVT in morphology, histology, and common sites. Unlike the conventional thrombus imaging models such as ferric chloride and rose bengal models, formed thrombus in our model showed a large mass of elliptical shape that extended and elongated in a long-axis direction of the vessel without occlusion, similar to clinical DVT (5). Both ferric chloride and rose bengal models exhibited a small dot pattern that mainly consisted of platelets and few erythrocytes, similar to arterial thrombosis (Figure 2A). Although excitation light-irradiation alone without ligation failed DVT formation within minutes, longer (>10 min) continuous light illumination resulted in platelet-rich thrombus, similar to a previous laser-induced thrombus model (Figure 2A, bottom). It is well recognized that a clinical DVT mainly consists of erythrocytes and fibrin network with less platelet aggregation. Thrombus in our model allowed in vivo multicolor imaging to visualize thrombus components such as, for example, fibrin, erythrocytes, and platelets. Mice were injected with FITC dextran, rhodamine 6G (platelets and leukocytes) and human fibrinogen or anti-glycophorin A antibody (erythrocytes) before light irradiation. The multicolor imaging revealed the fibrinand erythrocyte-rich thrombus with low accumulation of platelets and leukocytes (Figure 2B), recapitulating clinical DVT components. Real-time imaging of thrombus formation using FITC-labeled red blood cells also supports the formation of erythrocyte-2C), indicating a significant role of erythrocytes in this DVT model. In vivo photomicrograph of thrombus represented red-white thrombus, similar to clinical DVT. Intravital microscopy of the same thrombus precisely visualized the localization of platelet-rich white thrombus lesion as a rhodamine 6G-positive area (Figure 2D). Pathological analyses of formed thrombus in our model confirmed erythrocyte-and fibrin-rich thrombus with infiltrating leukocytes, similar to clinical DVT (5) (Figure 2E). Furthermore, our DVT model could reproduce several features of clinical DVT for the first time. DVT was formed at a frequent site, such as the venous valve pocket and venous confluences, indicating the similarity of rheological effects in human DVT (15,16) (Figures 2F and 2G). Additionally, DVT in our model enabled spontaneous embolization, allowing real-Video 3). Lastly, this model enabled monitoring of pharmacological effects of antithrombotic drugs. Similar to clinical DVT, thrombus development in our model was prevented by preinjection of unfractionated heparin (2IBecause the current DVT model allows spontaneous detachment of lowerextremity DVT, we tested whether this model can generate acute PE. After DVT formation in the femoral vein, we deligated the suture to allow embolization of thrombi. Alexa Fluor 647 conjugated fibrinogen (fibrinogen-AF647) was pre-injected to visualize thrombi. A large fibrin-rich DVT was visualized by in vivo fluorescence microscopy (Figure 3A). Although DVT was not embolized just after the deligation, most",
            "latex": null,
            "type": "figure"
        },
        "FIGREF60": {
            "text": "Continued (A) Thrombus positive for glycophorin A (red blood cell [RBC] marker) with low accumulation of rhodamine 6G indicates the erythrocyte-and fibrin-rich DVT. Both ferric chloride and rose bengal models induced dotlike platelet (Plt)-rich thrombus, indicating arterial thrombus. Continuous (>10 min) excitation light irradiation without ligation induced platelet-rich thrombus, similar to a previous laser-induced thrombus model (bottom). Real-time imaging of thrombus formation using FITC-labeled RBC is shown in Video 2. (B) Fibrin-rich thrombus with few platelets was observed in our new model.(C) Phlebotomy-induced anemic mice exhibited decreased thrombus size (median: 0.31 [IQR: 0.22, 0.48] vs. 0.19 [IQR: 0.14, 0.31] mm 2 ; p \u00bc 0.017, n \u00bc 10 to 12 per group). (D) Macroscopic image of thrombus represented red-white thrombus, similar to clinical DVT. In vivo fluorescence imaging of same thrombus precisely visualized the localization of platelet-rich white thrombus lesion as rhodamine 6G-positive area. (E) Pathological analyses of formed thrombus in our model confirmed the erythrocyte-and fibrin-rich thrombus with infiltrating leukocytes, mimicking clinical DVT. DVT was formed at clinically relevant sites, specifically with (F) venous valve pocket and (G) venous confluences, indicating the similarity of rheological effects in human DVT. (H) DVT in our model enabled spontaneous embolization, allowing real-time visualization at the moment of thromboembolism (Video 3). Arrowheads indicate the broken site of DVT. Dotted circle indicates emboli. (I) Thrombus resolution was augmented by unfractionated heparin (median initial thrombus area: 53.8% [IQR: 29.4%, 69.7%] vs. 26.6% [IQR: 0%, 48.0%]; p \u00bc 0.047; n \u00bc 10 per group). Bars \u00bc 200 mm. *p < 0.05. White arrows indicate venous flow direction. Dex \u00bc dextran; FM \u00bc fluorescence microscopy; HE \u00bc hematoxylin and eosin; WBC \u00bc white blood cells; RBC \u00bc red blood cells; other abbreviations as in Figure 1. femoral DVT had disappeared within 30 min after the deligation, indicating that thrombi had spontaneously embolized to the pulmonary artery. Resected lungs exhibited strong fibrinogen-AF647based fluorescence (Figure 3B, top). Images of the resected lungs from fibrinogen-AF647-injected mice without DVT were also taken to exclude the postmortem clot formation at pulmonary artery, and these mice showed no evidence of fluorescence signal (Figure 3B, bottom). To confirm that fluorescence signal is produced by embolized thrombus, histological assessment was performed. Hematoxylin and eosin staining of resected lungs showed fibrinrich thrombus with inflammatory cells in the pulmonary artery. Carstairs staining showed that fibrinogen-AF647-positive structures imaged by fluorescence microscopy are fibrin-rich thrombus (Figure 3C). These data indicate that our DVT model can be used as a novel PE model.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF61": {
            "text": "Spontaneous DVT Embolization to Pulmonary Artery, as a Novel PE Model (A) Femoral vein was ligated and illuminated by excitation light to induce large thrombus size. DVT was visualized by pre-injection of fibrinogen-AF647 (red, left panel). Thirty min after the deligation of the femoral vein suture, the formed DVT had disappeared, indicating embolization (right panel). Bar \u00bc 500 mm. Dotted line indicates femoral vein. X indicates ligation site. (B) To confirm the femoral DVT embolized to the lungs, resected lungs were imaged using in vivo imaging system fluorescence reflectance imaging. Spotted fluorescence signal indicated embolized fibrin-rich DVT. Fibrinogen-AF647-injected mice without DVT exhibited no apparent fluorescent signal, suggesting fibrin-rich signal was not a postmortem clot. Bars \u00bc 2 mm. (C) HE staining of resected lung showed inflammatory cells infiltrated thrombus in the pulmonary artery. Right panel shows magnified image of dotted area in the left panel. Subsets of lung tissues were processed for frozen sections to visualize in vivo-injected fibrinogen-AF647 by fluorescence microscopy, confirming fluorescence signal (arrows) was fibrin-rich embolized DVT from lower extremity. Bars \u00bc 200 mm. auto \u00bc auto-fluorescence; fibrinogen-AF647 \u00bc fibrinogen, Alexa Fluor 647 Conjugate; other abbreviations as in Figures 1 and 2. demonstrated the significant role of platelets and neutrophils in the initiation of DVT formation in the IVC-ligature model (2). To elucidate the role of these cells in the DVT formation in our model, we imaged leukocytes and platelets during DVT formation. Multicolor real-time imaging of DVT formation revealed that rhodamine 6G-labeled leukocytes and platelets did not clearly accumulate and attach to the vein wall prior to DVT formation, unlike the IVC-ligature model (Figure 4A). We then imaged and compared the DVT formation in the platelet-and neutrophil-depleted mice by pre-treatment with an antiplatelet antibody and antineutrophil antibody, which dramatically decreased circulating platelet and neutrophil counts (Supplemental",
            "latex": null,
            "type": "figure"
        },
        "FIGREF62": {
            "text": "induced thrombus model and the rose bengal model, we then assessed the role of oxidative stress in our model. To visualize reactive oxygen species (ROS) during DVT formation, 3 0 -(p-aminophenyl) fluorescein was administered before DVT initiation. However, ROS signal was not shown in thrombus area in our model, whereas laser/ROS model using hematoporphyrin (12) showed ROS-positive platelet",
            "latex": null,
            "type": "figure"
        },
        "FIGREF63": {
            "text": "Platelet-, Neutrophil-, and Oxidative Stress-Independent Thrombus Formation (A) Time-lapse multicolor real-time imaging of DVT formation revealed that rhodamine 6G-labeled leukocytes and platelets did not clearly accumulate and attach to the venous wall prior to DVT formation (arrows). Leukocytes and platelets (rhodamine 6G) accumulated after 30 s of irradiation, whereas DVT formed within 15 s. Bars \u00bc 200 mm. Delayed platelet accumulation was confirmed using antiplatelet antibody (right panel). Neither platelet-depletion (B) nor neutrophil-depletion (C) prevented thrombus formation nor changed thrombus size (median: 0.42 [IQR: 0.21 to 0.62] vs. 0.38 [IQR: 0.26 to 0.61]; p \u00bc NS; n \u00bc 10 per group for platelet depletion; and median: 0.34 [IQR: 0.26, 0.45] vs. 0.34 [IQR: 0.26, 0.55]; p \u00bc not significant [NS]; n \u00bc 6 per group for neutrophil depletion, respectively). (D) Pretreatment with deoxyribonuclease also did not affect the DVT formation in our model, indicating neutrophil extracellular traps-independent thrombus initiation in this model (median: 0.39 [IQR: 0.30, 0.60] vs. 0.45 [IQR: 0.33, 0.61]; p \u00bc NS; n \u00bc 5 per group). (E) Reactive oxygen species (ROS) did not localize within the thrombus area in our model (upper panel), whereas laser/ROS model using hematoporphyrin (lower panel) showed ROS-positive (arrowheads) platelet-rich thrombus. Bars \u00bc 500 mm. (F) The antioxidant and ROS scavenger, N-acetylcysteine failed to block DVT formation in our model, indicating a ROS-independent mechanism of DVT formation (median: 0.36 [IQR: 0.26, 0.54] vs. 0.33 [IQR: 0.26, 0.48]; p \u00bc NS; n \u00bc 6 per group). DNAse \u00bc deoxyribonuclease; NAC \u00bc N-acetylcysteine; other Abbreviations as in Figure 1. 4E). In addition, an antioxidant and ROS scavenger, N-acetylcysteine failed to block DVT formation in our model, indicating the mechanism of DVT formation in our model is ROS-independent (Figure 4F). These results collectively suggest that DVT formation in our model is platelet-, neutrophil-, and ROS-independent, unlike previous animal thrombosis models.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF64": {
            "text": "Multiphoton Imaging of Formed DVT and Venous Valve Pocket (A) Representative image of DVT formed at saphenous vein. The vessel wall can be visualized by second harmonic generation (blue) without the need for exogenous labeling agents. (B) Magnified image of dotted line from A is shown. Rhodamine 6G-labeled leukocyte and platelets can be distinguished by their size. (C) Venous valve leaflets were also visualized by second harmonic generation (blue, arrows). Sagittal image (D) and 3-dimensional image (E) confirmed that DVT formed within the valvular pocket sinus, which is the common DVT site in clinical situation. Bars \u00bc 50 mm. Abbreviations as in Figures 1 and 2. PLATELETS AND LEUKOCYTES IN DVT ORGANIZATION PROCESS. Serial imaging of DVT by epifluorescence microscopy easily allows visualization of dynamics of rhodamine 6G-positive area in whole thrombus; however, distinction between platelets and leukocytes is not possible because of insufficient resolution (Figure 6A). High-resolution 4dimensional imaging by multiphoton microscopy enables clear discrimination of and visualizes dynamics of both leukocytes and platelets during the thrombus organization process (Figure 6B). Although recent studies suggest the role of platelets in the initiation of DVT (2), the comprehensive role and dynamics of platelets in the DVT developing and organization process are unknown. Whole thrombus imaging with multiphoton microscopy showed that platelet accumulation within DVT is proximal sidedominant, and resolution is distal side-dominant (Supplemental Figure 2A). We newly observed the platelets' accumulation and deposition on the surface of the DVT, resulting in changing the rheology of blood flow and showing multiple layers of plateletrich and erythrocyte-rich layers (",
            "latex": null,
            "type": "figure"
        },
        "FIGREF65": {
            "text": "Spatiotemporal Dynamics of Inflammatory Cells and Platelets in the DVT Organization (A) Serial imaging of DVT by epifluorescence allows visualization of rhodamine 6G-positive cells (leukocytes and platelets) infiltrating into DVT; however, discrimination between leukocytes and platelets is not possible due to low resolution. Bars \u00bc 100 mm. (B) Multiphoton imaging of DVT enabled clear visualization of spatiotemporal dynamics of leukocytes and platelets. Top left square shows magnified images from dotted line. Bars \u00bc 100 mm. (C) Zones of platelets aggregate in the circulating blood near the DVT (arrows), followed by platelets depositing at the edge of erythrocyte-rich DVT. The deposition of the platelets changed the rheology, resulting in the formation of multiples of platelet layers and erythrocyte layers (dotted line). Bar \u00bc 10 mm. (D) Blood-based leukocytes migrate into the DVT accompanied by platelets (Video 4). Lower panels show dynamics of leukocytes and platelets in dotted area in upper panel. Bars \u00bc 10 mm. (E) Tracked paths of migrating leukocytes over 30 min. White circle indicates tracking leukocytes, and white line shows tracked path (Video 4). Lower panel shows the moving direction in x-axis of each initial x-position. Positive value indicates leukocytes moved toward the right direction, and negative indicates left direction. Leukocytes are moving toward the center of DVT, indicating leukocytes are being recruited into the DVT, rather than random migration occurring. Bar \u00bc 10 mm. Abbreviations as in Figures 1 and 2.neutrophil-platelet interaction is recently reported as facilitators of inflammation(20,21), the accumulation of platelets on the formed DVT might play a role in the initiation of inflammation process, which is not a hemostatic role. Leukocyte migration can also be imaged and analyzed via ImageJ (National Institutes of Health, Bethesda, Maryland) (Figures 6D and 6E, Video 4). Tracking of rhodamine 6G-positive leukocytes shows directional migration of leukocytes toward the center of DVT, suggesting that leukocytes are actively recruited to DVT (Figure 6E). Those migrating leukocytes were confirmed as mainly Ly-6G-positive neutrophils (SupplementalFigure 2B), which has been reported in past histological analyses(14).DISCUSSION Coagulation factors and platelet activation have been thought to be key elements of venous thrombosis until recent discoveries using a murine DVT model, which showed that activation of immune responses strongly influence blood coagulation and pathological thrombus formation (2,22). Although murine ligaturebased models at IVC are widely used, an opposite scenario is seen in clinical DVT. Clinical DVT forms mainly in flow-maintained veins, followed by flow restriction after initial thrombus development, whereas ligature-based models induced flowrestriction first. The other limitation of the IVCbased model is the lack of venous valve. Venous valve pockets and venous confluence in the lower extremity veins are reported as frequent sites of DVT initiation(15,16,23).",
            "latex": null,
            "type": "figure"
        },
        "FIGREF66": {
            "text": "nosis model for in vivo imaging using 2-photon microscopy (2). The study elegantly showed the recruitment of leukocytes and platelets at venous vessel wall as an initiation of DVT. However, formed DVT was too large to visualize the immune cell recruitment from circulating blood flow by intravital fluorescence microscopy. Therefore, visualization of immune cell behavior after DVT formation has been technically limited. To the best of our knowledge, our model, for the first time, enabled visualization of realtime imaging of erythrocyte-rich thrombus formation and organization process in vivo. Furthermore, our model enabled us to visualize the initiation of thromboembolism and induce pulmonary embolization after DVT formation. PE is a common and fatal complication of DVT. Repeated PE triggers the pulmonary hypertension, which is known as chronic thromboembolic pulmonary hypertension. Although there are murine models of PE in the past, the pathophysiology is quite different from the clinical PE. Systemic administration of coagulation factors such as thrombin (27) and thromboplastin (28) and exogenous clot injection (29) are commonly used to induce PE, but the occurrence of pulmonary thrombus is not clearly related and embolized from pre-existed DVT in the lower extremity. The photochemical injury model using rose bengal (30) and the ferric chloride model (31) could induce PE after DVT formation in large vessels, but the main components of thrombus are platelets. Therefore, to the best of our knowledge, this is the first clinically relevant PE model as a consequence of erythrocyte-and fibrin-rich DVT formed in the femoral/saphenous vein, which is the common source of clinical PE. Because our model allows repeated small DVT induction and embolization, our PE model has the potential to be a novel chronic thromboembolic pulmonary hypertension model and further evaluation is desired. STUDY LIMITATIONS. The intravascular infusion of rhodamine 6G labels both platelets and leukocytes; study, the use of the large vessels limits imaging area to the upper surface of the vein (100-to 200-mm depth). Thus, we could not perform a full 3-dimensional thrombus volume measurement. Third, wavelength of infrared laser in our 2-photon microscopy system is limited: from 700 to 1080 nm. Using other systems with wider wavelength (700 to 1,300 nm) or with single-photon imaging laser, 3 or more multicolor imaging could be performed and would expand our study. Lastly, the precise mechanism of thrombus formation in our model is still unclear. Thus, we cannot yet confirm whether this model is useful to investigate the mechanisms of human DVT initiation. CONCLUSIONS Our newly established DVT model enables real-time in vivo imaging of erythrocyte-rich DVT formation and organization process in the murine femoral vein. The formed DVT in this model reproduces several common features of clinical DVT. We propose the utility of our model for better understanding of the pathophysiology of clinical DVT using the highresolution visualization of the DVT organization process such as the dynamic recruitment of platelets and leukocytes to erythrocyte-rich thrombus. ACKNOWLEDGMENTS The authors would like to thank Koichiro Haruwaka, Yoshihisa Tachibana, and Hiroaki Wake for providing technical support in 2photon microscopy imaging.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF67": {
            "text": "Flaumenhaft R, Tanaka E, Graham GJ, et al. Localization and quantification of platelet-rich thrombi in large blood vessels with near-infrared fluorescence imaging. Circulation 2007;115:84-93.11. Falati S, Gross P, Merrill-Skoloff G, Furie BC, Furie B. Real-time in vivo imaging of platelets, tissue factor and fibrin during arterial thrombus formation in the mouse. Nat Med 2002;8: 1175-81.12. Nishimura S, Manabe I, Nagasaki M, et al. In vivo imaging visualizes discoid platelet aggregations without endothelium disruption and implicates contribution of inflammatory cytokine and integrin signaling. Blood 2012;119:e45-56.13. Kov\u00e1cs IB, Tigyi-Sebes A, Trombit\u00e1s K, G\u00f6r\u00f6g P. Evans blue: an ideal energy-absorbing material to produce intravascular microinjury by He-Ne gas laser. Microvasc Res 1975;10: 107-24.14. Hara T, Truelove J, Tawakol A, et al. 18F-fluorodeoxyglucose positron emission tomography/ computed tomography enables the detection of PERSPECTIVES COMPETENCY IN MEDICAL KNOWLEDGE: There are several animal models of thrombosis. However, all of the models have advantages and disadvantages. For instance, the ferric chloride model does not need complicated surgical techniques and is applicable for in vivo microscopic imaging. However, it induces platelet-rich thrombus, thereby the ferric chloride model is not appropriate for DVT experimental study. The IVC-ligature model is currently the most used fibrinand erythrocyte-rich DVT model. However, its location and large thrombus size are inappropriate for in vivo microscopic imaging and inducing pulmonary emboli. TRANSLATIONAL OUTLOOK: Thromboembolic events mostly occur only once throughout the 70 to 90 years of human life, and it only takes several seconds from the initiation of thrombus detachment to complete embolization. Therefore, understanding and visualizing such a quick event has been technically challenging even in animal models. Here, we newly succeeded in inducing and visualizing thrombus formation in vivo, and furthermore, we visualized the moment of thromboembolic event. Our model has significant potential for better understanding of VTE pathophysiology.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF68": {
            "text": "Fuchs TA, Brill A, Duerschmied D, et al. Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci U S A 2010;107:15880-5.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF69": {
            "text": "Rubart M. Two-photon microscopy of cells and tissue. Circ Res 2004;95:1154-66.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF70": {
            "text": "Li W, Luehmann HP, Hsiao HM, et al. Visualization of monocytic cells in regressing atherosclerotic plaques by intravital 2-photon and positron emission tomography-based imagingbrief report. Arterioscler Thromb Vasc Biol 2018; 38:1030-6.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF71": {
            "text": "Lisman T. Platelet-neutrophil interactions as drivers of inflammatory and thrombotic disease. Cell Tissue Res 2018;371:567-76.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF72": {
            "text": "Swystun LL, Liaw PC. The role of leukocytes in thrombosis. Blood 2016;128:753-62. 23. Sevitt S. The structure and growth of valvepocket thrombi in femoral veins. J Clin Pathol 1974;27:517-28. 24. Cooley BC. In vivo fluorescence imaging of large-vessel thrombosis in mice. Arterioscler Thromb Vasc Biol 2011;31:1351-6.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF73": {
            "text": "Fay WP. Intravital fluorescence microscopy improves thrombosis phenotype scoring in mice. Arterioscler Thromb Vasc Biol 2011;31: 1253-4.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF74": {
            "text": "Erhardt JA, Toomey JR, Douglas SA, Johns DG. P2X1 stimulation promotes thrombin receptormediated platelet aggregation. J Thromb Haemost 2006;4:882-90.27. Kumada T, Dittman WA, Majerus PW. A role for thrombomodulin in the pathogenesis of thrombininduced thromboembolism in mice. Blood 1988;71: 728-33. 28. Page MJ, Lourenco AL, David T, et al. Noninvasive imaging and cellular tracking of pulmo-nary emboli by near-infrared fluorescence and positron-emission tomography. Nat Commun 2015;6:8448. 29. Singh S, Houng A, Reed GL. Releasing the brakes on the fibrinolytic system in pulmonary emboli: unique effects of plasminogen activation and alpha2-antiplasmin inactivation. Circulation 2017;135:1011-20.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF76": {
            "text": "Shaya SA, Gani DM, Weitz JI, Kim PY, Gross PL. Factor XIII prevents pulmonary emboli in mice by stabilizing deep vein thrombi. Thromb Haemost 2019;119:992-9. KEY WORDS 2-photon microscopy, deep vein thrombosis, imaging, pulmonary embolism, venous thromboembolism APPENDIX For an expanded Methods section, and supplemental figures, a table, and videos, please see the online version of , MD, a Aditya Sharma, MD b P reclinical studies are important grounds to develop and test hypotheses and novel approaches for translation to human disease. A number of distinct pathologic processes can result in venous thromboembolism. Studies using murine models have shed light on contributions from multiple cell types. Roles have been identified for endothelial and platelet activation, neutrophil extracellular trap generation, myeloid-derived tissue factor release, and erythrocyte-mediated thrombus stabilization. Critical roles have also been described for activation of the inflammasome resulting in maturation of the paradigmatic inflammatory cytokine, interleukin-1b, in venous thrombogenesis (1). Several models to examine venous thrombogenesis and resolution have been described, each with strengths and limitations. To help investigators select an appropriate model to test their hypotheses, several professional societies recently published a consensus statement with detailed methodologies, advantages, and disadvantages of the most widely used models of deep vein thrombosis (DVT) (2). In this issue of JACC: Basic to Translational Science, Okano et al. (3) describe an intriguing new model of venous thromboembolism in the femoral and saphenous veins. The most commonly used murine models of DVT involve manipulation of the infrarenal inferior vena cava (IVC) by stopping or altering blood flow or inducing free radical generation. Studying thrombosis in IVC provides sufficient tissue to examine both the vein wall and thrombus itself. However, the IVC lacks valves and does not replicate flow dynamics seen in human superficial and deep veins with valves where thrombosis often occurs. Initial DVT models involve interrupting blood flow in the infrarenal IVC by complete ligation of the vein and all branch vessels (1,2). The static column of blood generated coagulates upstream of the ligation site. Thrombi generated by this \"stasis\" model are rich in erythrocytes and fibrin and are reproducible in size. This model can be used to study coagulation in gene-modified mice and for following pharmacologic interventions for thrombus resolution days-to-weeks after surgery. Although this model of stasis DVT in mice does not typically result in pulmonary thromboembolism, rats subjected to IVC ligation under hypoxic, hyperbaric conditions developed thrombi downstream of the ligature in the direction of flow with embolism to the lungs. Specific cell-depletion experiments to date suggest that platelets, neutrophils, and monocytes may not play significant roles in thrombogenesis in this model of DVT. Therefore, investigators interested in these cellular inputs to thrombosis should consider an alternate approach. A modification of this model involves restricting but not occluding the IVC to reduce vein diameter to approximately 10% of its normal size while ISSN 2452-302X https://doi.org/10.1016/j.jacbts.2020.03.004 *Editorials published in JACC: Basic to Translational Science reflect the views of the authors and do not necessarily represent the views of JACC: Basic to Translational Science or the American College of Cardiology. From the a Frankel Cardiovascular Center, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan; and the b Division of Cardiovascular Medicine, Department of Internal Medicine, University of Virginia, Charlottesville, Virginia. Dr. Kanthi has received funding from the National Institutes of Health/National Heart, Lung, and Blood Institute (HL150392 and HL131993), Jobst American Venous Forum Award, Falk Medical Research Trust, University of Michigan BioInterfaces Institute, Bo Schembechler Heart of a Champion Foundation, and the University of Michigan Frankel Cardiovascular Center; has received consulting fees from Surface Oncology and Acer Therapeutics; and has a patent pending on the use of carbon monoxide-derived therapeutics in vascular disease. Dr. Sharma has received research funding from the National Heart, Lung, and Blood Institute, DalCor Pharma UK Ltd., and Vascular Medcure Inc. The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors' institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the JACC: Basic to Translational Science author instructions page. of extracellular chromatin traps and reactive oxygen species generation. This \"stenosis\" model of DVT has inherent variability in thrombus frequency and size, recapitulating the clinical condition. It is typically used to study thrombus accretion and propagation beyond the first several hours of thrombogenesis. Thrombus and vessel tissue is sufficiently sized for analysis. Notably, these DVTs have histologic features characteristic of human thrombi, with alternating layers of erythrocyte-rich \"red\" and fibrinand platelet-rich \"white,\" typically described as \"lines of Zahn.\" Intravital microscopy following IVC restriction can help shed light on cellular recruitment and interactions during initial thrombogenesis. Significant limitations include the large number of animals needed for studies due to variability in thrombus incidence and size and the need for sophisticated equipment for image acquisition due to the depth of the IVC. This model has also recently been suggested to result in pulmonary artery thrombi, although it is unclear whether this is a result of thromboembolism from the IVC or in situ pulmonary arterial coagulation, which may result from procoagulant microvesicles or soluble mediators. Free radical-induced thrombosis models using chemical or electrical triggers have been used in large and small veins. Application of iron(III) chloride to the adventitial surface of the vein can be used to trigger thrombosis, although this may cause vessel wall tissue damage. Alternate models deliver a small 1.5 to 3 volt current directly to the external surface of the saphenous or femoral veins for short periods of time. This rapidly induces thrombosis in these valve-containing veins, which can be used for acute or chronic thrombus formation and resolution. Another advantage of this model is the small vein diameter that makes these vessels well-suited for application of real-time intravital microscopy to study cellular and thrombus dynamics. A limitation of this method of DVT formation is that the thrombi generated are rich in platelets and fibrin, reminiscent of \"white clot\" observed in arterial thrombi rather than those seen in DVT. Another recently developed model involving electrolytic injury involves running a current through a needle inserted into the IVC to generate intraluminal free radicals and subsequent thrombosis. Side branches are ligated for consistent flow dynamics. This model has several advantages, including thrombus formation in all experiments, which reduces the number of animals required for each experiment. In addition, thrombus size can be controlled by altering current and time of exposure, which gives investigators significant flexibility to test prothrombotic conditions and antithrombotic interventions. As with other surgical models, the electrolytic IVC injury model requires technical proficiency for consistent results. Each model carries strengths and weaknesses, making model selection critical to test specific hypotheses. Okano et al. (3) describe a new method of venous thrombosis that starts with ligation of the femoral vein to create disturbed flow. The investigators discovered that whereas disturbed flow alone did not generate a thrombus, intravital imaging with fluorescein isothiocyanate-dextran and filtered epifluorescent light triggered coagulation in the imaged segments within minutes. They also found no contribution to thrombogenesis from fluorescent dyes with differing quantum efficiencies as thrombi were seen even if dye was added after light exposure. Clots formed in vein valves, where disturbed flow dominated after downstream ligation. These thrombi were predominantly composed of erythrocytes and fibrin. Although neutrophils and platelets were also recruited to the thrombotic milieu, their role is unclear. Neutrophils were recruited to the center of the thrombus. Treatment with deoxyribonuclease did not alter thrombus size, leading the investigators to conclude that neutrophil extracellular traps are not pathogenic in this model of DVT. However, it is unclear whether deoxyribonuclease can passively penetrate thrombi, and the granulocyte and antimicrobial proteins decorating neutrophil extracellular traps may still be local effectors. Platelet deposition likely alters local flow dynamics and increases thrombus accretion. The presented data also suggest DVT size can be modified by varying light intensity and duration. Notably, thrombosis in the veins could be triggered by longer light exposure even in the absence of flow disturbance. Although the mechanism for filtered light-induced thrombosis in this model is unknown, it has several advantages. First, DVT can be induced in limb veins without chemical or laser-induced injury of the vessel wall. Second, intravital visualization of thrombus dynamics in the earliest stages of DVT is an important strength of this model. Although thrombosis in the mesenteric and cremasteric venules is an excellent tool for intravital differences in gene expression and flow dynamic patterns in these microvascular beds limit extrapolation of observations to larger veins of interest. Third, investigators can use the \"tunability\" of thrombus size by light exposure to study prothrombotic conditions or therapeutic interventions. Fourth, deligation of the femoral vein led to restored venous return and embolization of the thrombi to the lungs providing a much-needed model to study acute pulmonary embolism. Several questions remain about this platform that investigators will note, including the lack of mechanism by which filtered light induces thrombosis. Light at many spectral wavelengths is known to induce changes in cellular processes, which have not yet been elucidated in this model. Photocoagulation with lasers has been used to treat retinal and other diseases, presumably by thermal injury. Erythrocytes have been found to contribute to venous thromboembolism in several ways, including supporting thrombin generation, expression of surface phosphatidylserine, interacting with other cells, and altering fibrin structure and stability (5). It is unclear whether these cellular processes are enrolled in this erythrocyte-dependent model. Furthermore, low-resolution imaging with epifluorescence precludes real-time individual cell tracking although these can be defined ex vivo. Finally, the significance of engagement by neutrophils and platelets remain unknown in this model of thrombosis.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF77": {
            "text": "Okano M, Hara T, Nishimori M, et al. In vivo imaging of venous thrombus and pulmonary embolism using novel murine venous thromboembolism model. St\u00e5hle, MSC, a Johanna M.U. Silvola, PHD, a Sanna Hellberg, PHD, a Margreet de Vries, PHD, b Paul H.A. Quax, PHD, b Jeffrey Kroon, PHD, c Petteri Rinne, PHD, d,e Alwin de Jong, MSC, b Heidi Liljenb\u00e4ck, MSC, a,e Nina Savisto, PHD, a Anna Wickman, PHD, f Erik S.G. Stroes, MD, PHD, c,g Seppo Yl\u00e4-Herttuala, MD, PHD, h Pekka Saukko, MD, PHD, i Tommy Abrahamsson, MD, PHD, j Knut Pettersson, PHD, j Juhani Knuuti, MD, PHD, a,k Anne Roivainen, PHD, a,e Antti Saraste, MD, PHD a,k,l,m VISUAL ABSTRACT St\u00e5hle, M. et al. J Am Coll Cardiol Basic Trans Science. 2020;5(4):360-73.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF78": {
            "text": "F-fluorodeoxyglucose in atherosclerotic mice. The noninvasive imaging techniques represent translational tools to assess the efficacy of phosphorylcholine-targeted therapy on coronary artery function and atherosclerosis in clinical studies. (J Am Coll Cardiol Basic Trans Science 2020;5:360-73) \u00a9 2020 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/ by-nc-nd/4.0/).O xidized phospholipids (OxPLs) mediate many atherogenic processes, including endothelial dysfunction, the accumulation of inflammatory cells into the vessel wall, and the uptake of oxidized low-density lipoprotein (OxLDL) cholesterol by macrophages, thereby promoting foam cell formation and atheroma growth (1-3). Phosphorylcholine (PC) is the polar headgroup of the membrane phospholipid phosphatidylcholine. It is a pro-inflammatory epitope in OxPLs that is recognized as a danger-associated molecular pattern by the innate immune system (1). Human serum contains endogenous antibodies against oxidized epitopes, with the predominant antibody being immunoglobulin (Ig)-M antibody against PC (4-6). Low levels of IgM anti-PC are associated with an increased risk of atherosclerotic cardiovascular events in different patient populations (4,7-10). In subjects with elevated lipoprotein(a) [Lp(a)] and increased inflammatory activity in the arterial wall, activation of circulating monocytes by OxPLs can be inhibited by the IgM E06 antibody, the prototypic murine antibody against PC (11). Experimental studies have indicated that this antibody blocks the scavenger receptormediated uptake of OxLDL on macrophages in vitro (5), and that induction of the PC antibody formation by immunization (12,13) or direct infusion (14) is atheroprotective in mice. In transgenic mice, a single-chain variable fragment of E06 counteracts with OxPLs in vivo, attenuating inflammation and progression of atherosclerosis (15). Accordingly, the available evidence suggests that OxPLs that contain PC are a risk factor for atherosclerosis-related diseases and that a therapeutic antibody against PC may represent an mAb = human PC antibody VCAM = vascular cell adhesion molecule From the a Turku PET Centre, University of Turku, Turku, Finland; b Einthoven Laboratory for Experimental Vascular Medicine, Department of Surgery, Leiden University Medical Center, Leiden, the Netherlands; c Department of Experimental Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Center (UMC), University of Amsterdam,",
            "latex": null,
            "type": "figure"
        },
        "FIGREF79": {
            "text": "18 F-FDG) is a noninvasive tool to measure inflammation in atherosclerotic lesions because18  F-FDG accumulates in inflammatory cells(16,17). Coronary flow reserve (CFR) in response to vasodilator stress is an integrated measure of blood flow through both the epicardial coronary arteries and microvasculature(18). Impaired CFR is a strong predictor of cardiovascular mortality in patients with suspected coronary artery disease(19). Both 18 F-FDG uptake and CFR can serve as translational tools to assess the effects of anti-atherosclerotic therapy.In the present study, we investigated whether anovel exogenous monoclonal IgG1 antibody against PC (designated X19-mu, with similar properties to the endogenous IgM E06 anti-PC) improves vascular function and reduces atherosclerotic inflammation in hypercholesterolemic low-density lipoprotein receptor deficient mice, expressing only apolipoprotein B100 (LDLR \u00c0/\u00c0 ApoB 100/100 ). Vascular function was studied by measuring CFR in response to adenosine with Doppler ultrasound and endothelium-mediated vasodilatation in response to methacholine. Inflammation in aortic atherosclerotic lesions was determined by the uptake of 18 F-FDG and histological stainings of inflammatory markers. The effect of human PC antibody (PC-mAb) on human aortic endothelial cells (HAECs) stimulated with Lp(a) was studied in vitro. METHODS X19-mu AND HUMAN PC-mAb. The antigen-binding sequences of the X19-mu antibody were identified from a phage display library on the basis of their binding ability to PC and were converted to full IgG1 antibodies as part of the work that identified PC-mAb, a fully human monoclonal antibody against PC. This therapeutic, exogenous PC-mAb (Clone X19-A05, Athera Biotechnologies AB, Stockholm, Sweden) showed similar properties to the IgM E06 antibody in inhibiting OxLDL uptake in macrophages, binding to apoptotic cells, blocking OxLDL-induced release of monocyte chemoattractant protein 1 from monocytes, binding to inflammatory cells in human aortic atherosclerotic lesions, and preventing inflammation-driven vascular remodeling in mice (20,21). X19-mu (Athera Biotechnologies AB) differs from the fully human PC-mAb in that it has a murine Fc fraction to lower the risk of an immune reaction to the treatment, but it has identical antigen-binding sequences. The binding affinity to PC is similar between the fully human PC-mAb and the X19-mu antibody (Supplemental Figure 1). ANIMALS AND INTERVENTIONS. The national Animal Experiment Board in Finland and the Regional State Administrative Agency for Southern Finland approved the studies (license ESAVI/2163/04.10.07/ 2015). They were carried out in compliance with European Union laws related to the conduct of animal experimentation. The animals were housed under standard conditions with a 12-h light\u00c0dark cycle with ad libitum access to water and food. LDLR \u00c0/\u00c0 ApoB 100/100 mice (n \u00bc 45; strain #003000, The Jackson Laboratory, Bar Harbor, Maine) were fed a high-fat diet (0.2% total cholesterol, TD 88137, Harlan Teklad, Harlan Laboratories, Madison, Wisconsin) for 12 weeks, starting at the age of 8 weeks, to induce atherosclerosis. After 12 weeks on the high-fat diet, 34 mice were continued on a regular chow diet; after sex and sibling matching, they were randomized to receive intraperitoneal injections containing either 0.9% saline solution as a vehicle (n \u00bc 17) or 10 mg/kg X19-mu (n \u00bc 17), once a week, for 6 weeks. A separate group of mice (n \u00bc 11) was studied at week 0, after the 12-week high-fat diet. CFR was assessed repeatedly before and after 6 week treatments in a randomly selected, prespecified subgroup of mice (n \u00bc 10/treatment) and also in a separate group of healthy C57BL/6 mice (n \u00bc 11; age: 6.5 months). Aortic histology and 18 F-FDG uptake were assessed at the end of the 6-week treatments, and also at week 0, in a separate group of mice. Endothelium-mediated vasodilatory response to methacholine was studied in a separate group of atherosclerotic mice after treatment with vehicle (n \u00bc 8) or X19-mu antibody (n \u00bc 7). For euthanasia in aortic histology and 18 F-FDG studies, mice were anesthetized with isoflurane (2% to 3% inhalation), and blood was collected by cardiac puncture followed by cervical dislocation. BLOOD SAMPLES. For details of the measurement of blood glucose, lipids and X19-mu antibody levels, see the Supplemental Appendix. HISTOLOGY AND IMMUNOFLUORESCENCE. The aortic root was fixed with 10% formalin, embedded in paraffin, and cut into serial 5 mm cross sections at the level of the coronary ostium. Sections were stained with Movat's pentachrome for measurement of the atherosclerotic lesion area and with Masson's trichrome (Sigma-Aldrich, St. Louis, Missouri) for quantification of lesion collagen content. Macrophages were detected by double immunofluorescence detected by immunofluorescence. The presence of PC epitope in atherosclerotic lesions was detected by immunofluorescence using the fully human PC-mAb directly labeled with Cy5 and co-stained with the Mac-3 antibody and CD31 antibody that detected endothelial cells (Supplemental",
            "latex": null,
            "type": "figure"
        },
        "FIGREF80": {
            "text": "CFR AND ENDOTHELIUM-MEDIATED VASODILATATION. A dedicated small animal Doppler ultrasound device (Vevo 2100, VisualSonics Inc., Toronto, Ontario, Canada) with a linear 22-to 55-MHz (MS550D) transducer was used to assess CFR as previously described(22,23).Mice were anesthetized with an intraperitoneal injection of midazolam (8 mg/kg; Hameln Pharmaceuticals GmbH, Hameln, Germany) and ketamine (60 mg/kg; Intervet International BV, Boxmeer, the Netherlands).A tail vein was cannulated, and body temperature was maintained with a heating pad. Blood flow in the middle left coronary artery was localized under color Doppler mapping using modified long-axis views, and the flow velocity spectrum was recorded by pulsedwave Doppler, both at rest and during infusion (maximum of 2 min) of adenosine (140 mg/kg/min; Life Medical Sweden AB, Stocksund, Sweden). Anesthesia was reversed with a subcutaneous injection of flumazenil (0.5 mg/kg; Hameln Pharmaceuticals GmbH). CFR was calculated as the ratio of the mean diastolic flow velocity during maximal adenosine-induced hyperemia to that during rest. The mice were allowed to recover for a minimum of 72 h between ultrasound and 18 F-FDG studies. Endothelium-mediated vasodilatation was studied by measuring arterial blood pressure response to intravenous injection of methacholine in apolipoprotein E deficient (ApoE \u00c0/\u00c0 ) mice (Supplemental Appendix). STIMULATION OF HAECs WITH DONOR-DERIVED LP(a). To study the effect of PC-mAb on endothelial nitric oxide (NO) production and inflammatory responses, HAECs were stimulated with 1 mg/ml of Lp(a) for 24 h in the presence of fully human PC-mAb or a non-specific IgG. Thereafter, cells were processed for gene expression measurements of VCAM1, ICAM1, IL6, and IL8, as well as protein measurements of IL-18 F-FDG (11 AE 0.38 MBq) via the tail vein. At 90 min post-injection, the thoracic aorta from the sinotubular junction to the level of the diaphragm was excised and rinsed with saline. The aorta was frozen in cooled isopentane and cut into sequential longitudinal cryosections of 20 and 8 mm, which provided sections throughout the region on a single slide (n \u00bc 6 to 8 intervals per aorta). Digital autoradiography was performed using the previously described method (24,25). Cryosections were apposed to an imaging plate (Fuji Imaging Plate BAS-TR2025, Fuji Photo Film Co., Ltd., Tokyo, Japan) for 4 h and then scanned with a Fuji Analyser BAS-5000 (internal resolution of 25 mm, Fuji). Then, sections were stained with hematoxylin and eosin (20 mm) or immunohistochemically with Mac-3 antibody (8 mm), scanned with a slide scanner, and co-registered with autoradiographs. 18 F-FDG accumulation was measured as photo-stimulated luminescence per square millimeter in regions of interest placed on the atherosclerotic lesions (n \u00bc 22/mouse) and vessel walls without lesions (n \u00bc 16/mouse), using Tina 2.1 software (Raytest Isotopenmessger\u00e4te, GmbH, Straubenhardt, Germany). To assess the treatment effects, the average 18 F-FDG uptake within all atherosclerotic lesions in 20-mm sections was calculated and divided by the average uptake in lesion-free vessel walls (expressed as lesion-to-wall ratio) in each mouse. To assess the effects of treatment on 18 F-FDG uptake in atherosclerotic lesions with different macrophage densities, percentage of Mac-3-positive staining within the lesions was measured with Image J software and compared with the 18 F-FDG uptake (lesionto-wall ratio) in the same lesions in 8 mm sections (n \u00bc 7 randomly chosen mice/treatment; 8 lesions/ mouse) as previously described (25). Measurement of 18 F-FDG uptake in other organs is described in the Supplemental Appendix. STATISTICAL ANALYSIS. Results are presented as individual data points with mean AE SD, unless otherwise indicated. Data were analyzed using SPSS Statistics software 22 (IBM, Armonk, New York). Normality was examined by a Shapiro-Wilk test, and equality of variances was tested with Levene's test. Multiple comparisons were made by 1-way analysis of variance (ANOVA) followed by Dunnett's post hoc test for the week 0 group. Student's t-test for unpaired or paired data was used for comparisons between intervention groups. Fisher's exact test was used to evaluate",
            "latex": null,
            "type": "figure"
        },
        "FIGREF81": {
            "text": ", the body weights and fasting blood glucose levels were comparable between the vehicle-and X19-mu\u00c0treated groups. Compared with the mice studied at week 0, plasma levels of cholesterol, LDL, and high-density lipoprotein were lower (p # 0.001) after 6 weeks on normal mouse chow in both the vehicle and X19-mu groups, with the X19-mu treatment not showing any incremental effect on lipids in comparison with vehicle. LESION HISTOLOGY. All LDLR \u00c0/\u00c0 ApoB 100/100 mice showed prominent macrophage-rich atherosclerotic lesions in the aortic root (Figures 1 and 2). Compared with mice studied at week 0, the absolute lesion area in the aortic root was larger after the 6-week treatment in both the vehicle-(0.32 AE 0.23 mm 2 vs. 0.68 AE 0.28 mm 2 ; p \u00bc 0.004) and X19-mu\u00c0treated (0.32 AE 0.23 mm 2 vs. 0.62 AE 0.28 mm 2 ; p \u00bc 0.017) mice. However, the lesion areas were similar after treatment with either vehicle or X19-mu (p \u00bc 0.57). At week 0, the intimal area positive for Mac-3 staining was 25 AE 8.2%. In comparison with this initial value, the intimal area positive for Mac-3 did not differ after the 6-week treatment with vehicle (19 AE 8.7%; p \u00bc 0.19) or X19-mu (19 AE 10%; p \u00bc 0.21). X19-mu treatment had no effect in comparison with vehicle (p \u00bc 0.93) (Figure 1G). The expression of the M1 macrophage marker CCR2 after vehicle treatment was comparable to that in the X19-mu\u00c0treated group (44 AE 13% vs. 43 AE 13% of the Mac-3 positive area; p \u00bc 0.87) (Figure 1H), as was the expression of the M2 macrophage marker CD206 (48 AE 26% vs. 60 AE 24% of the Mac-3 positive area; p \u00bc 0.23) (Figure 1H), which resulted in a comparable ratio of M2 and M1 macrophages (1.4 AE 1.1 vs. 1.7 AE 1.3; p \u00bc 0.55). At week 0, the percentages of M1 and M2 macrophages were 41 AE 9.2% and 50 AE 13%, respectively. These values were similar after 6-week treatment with either vehicle (p \u00bc 0.84 and p \u00bc 0.96, respectively) or X19-mu (p \u00bc 0.91 and p \u00bc 0.60, respectively). The extent of lesion endothelium positive for VCAM-1 or ICAM-1 did not show significant differences after treatment with vehicle or X19-mu (",
            "latex": null,
            "type": "figure"
        },
        "FIGREF82": {
            "text": "Compared with vehicle, treatment with X19-mu reduced the intimal area positive for IL-1b (24 AE 1.0% vs. 21 AE 0.83%; p \u00bc 0.044) (Figure 2C) but not for monocyte chemoattractant protein 1 (10 AE 1.0% vs. 10 AE 0.60%; p \u00bc 0.82) (Figure 2D). The number of macrophages containing cleaved caspase-3 was similar after treatment with vehicle or X19-mu (220 AE 65 cells/mm 2 vs. 230 AE 72 cells/mm 2 ; p \u00bc 0.61) (Figure 2E). The lesion collagen content was similar after treatment with vehicle or X19-mu (39 AE 5.6% vs. 40 AE 7.9%; p \u00bc 0.68) (Figure 2F).",
            "latex": null,
            "type": "figure"
        },
        "FIGREF84": {
            "text": "Macrophage Proportion or Phenotype in Atherosclerotic Lesions Is Not Affected by X19-mu Treatment An atherosclerotic lesion from serial sections of the aortic root stained with (A) Movat's pentachrome, (B) antibodies against Mac-3 in macrophages, (C) CCR2 in M1 polarized macrophages, and (D) CD206 in M2 polarized macrophages, as well as double immunofluorescence stainings with (E) Mac-3 and CCR2, or (F) Mac-3 and CD206. The percentage of intimal area (G) stained with Mac-3 and the (H) proportions of CCR2-and CD206-positive macrophages within the Mac-3 area shown as individual data points with mean AE SD. Student's t-test for unpaired and paired (CCR2 vs. CD206) measurements; n \u00bc 10 to 16/staining/group. Scale bar \u00bc 100 mm (10 mm in inserts in E and F).",
            "latex": null,
            "type": "figure"
        },
        "FIGREF86": {
            "text": "The Effect of X19-mu Treatment on Lesion Histology in Aortic Root Sections (A) Atherosclerotic lesions in the aortic root stained with vascular cell adhesion molecule (VCAM)-1 (green), (B) intracellular cell adhesion molecule (ICAM)-1 (green), (C) interleukin (IL)-1b (red), (D) monocyte chemoattractant protein (MCP)-1 (red), as well as (E) Mac-3 and cleaved caspase-3 (yellow). All sections are counterstained with 4',6-diamino-2-phenylindole (blue, nuclei). (F) Lesion collagen content is quantified from Masson's trichrome stainings (blue). Quantitative results are shown as individual data points in addition to mean AE SD in histograms; Fisher's exact test for histological scores(A and B), and Student's t-test for unpaired measurements (C to F); n \u00bc 10 to 16/staining/group. Scale bar \u00bc 100 mm (10 mm in inserts in E).",
            "latex": null,
            "type": "figure"
        },
        "FIGREF87": {
            "text": "Triple immunofluorescence staining demonstrated PC-positive staining that co-localized with Mac-3positive macrophages within atherosclerotic lesions and CD31-positive endothelial cells covering the lesions (Figure 3). X19-mu TREATMENT PRESERVED CFR AND ENDOTHELIUM-MEDIATED VASODILATATION. The CFR was measured as the ratio of coronary flow velocity in the left coronary artery during adenosine stress and rest by Doppler ultrasound (Figure 3A).",
            "latex": null,
            "type": "figure"
        },
        "FIGREF88": {
            "text": "PC Epitope Is Present in Endothelial Cells and Macrophages in Atherosclerotic Lesions Representative section of the (A) aortic root showing immunofluorescence staining with phosphorylcholine (PC) antibody (PC-mAb), (B) Mac-3 antibody (macrophages), (C) CD31 antibody (endothelial cells), and (D) 4',6-diamino-2-phenylindole (DAPI, nuclei). White arrows indicate endothelial cells and yellow arrows macrophage-rich area. (E) PC-positive staining co-localizes with endothelial cells covering the lesion and macrophages (white color in merge). Scale bar \u00bc 75 mm. Abbreviation as in Figure 2. covariance for repeated measurements showed that the treatment with X19-mu was associated with a 33% improvement in CFR (p \u00bc 0.047) compared with vehicle during the 6-week study period (Figure 4B). Compared with week 0, CFR was 24 AE 20% lower after the 6-week treatment with vehicle (1.9 AE 0.29 vs. 1.4 AE 0.23; p \u00bc 0.006), whereas there was a trend toward a higher (9.0 AE 23%) CFR after treatment with X19-mu (1.6 AE 0.24 vs. 1.7 AE 0.24; p \u00bc 0.32) (Figure 4B). In healthy age-matched C57BL/6 mice, CFR was higher (2.1 AE 0.39) than in atherosclerotic mice after either vehicle or X19-mu treatment (p < 0.001 and p \u00bc 0.003, respectively). The absolute flow velocities are shown in the Supplemental Table 2. In a separate group of atherosclerotic ApoE \u00c0/\u00c0 mice, methacholine injection induced a transient reduction in arterial blood pressure (vasodilatory response) in X19-mu\u00c0treated mice, but not in the vehicle group (Supplemental Appendix, Supplemental Figure 3).",
            "latex": null,
            "type": "figure"
        },
        "FIGREF89": {
            "text": "Autoradiography showed focal uptake of 18 F-FDG in macrophage-rich atherosclerotic lesions within the aorta (Figures 6A to 6C). Compared with vehicle-treated mice and adjusted by sex, the average uptake of 18 F-FDG in atherosclerotic lesions normalized to activity in the lesion-free vessel wall (lesion-to-wall ratio) was significantly lower after the 6-week treatment with X19-mu (1.7 AE 0.24 vs. 1.5 AE 0.17, p \u00bc 0.002)",
            "latex": null,
            "type": "figure"
        },
        "FIGREF90": {
            "text": "X19-mu Treatment Preserves CFR (A) Blood flow in the left coronary artery (LCA) localized under color Doppler mapping (arrow) and the blood flow velocity profiles recorded by pulsed-wave Doppler at rest and during adenosine infusion. Coronary flow reserve (CFR) in individual mice at week 0 and after a 6-week treatment with vehicle or X19-mu. (B) Compared with vehicle, the CFR adjusted by the week 0 measurement was improved (p \u00bc 0.047) after a 6-week treatment with X19-mu. Results are expressed as individual data points with mean AE SD in the histogram; analysis for covariance for repeated measurements; n \u00bc 10/group. 6D). If analyzed separately, 18 F-FDG uptake was reduced after X19-mu treatment in both females (p \u00bc 0.023) and males (p \u00bc 0.034) compared with vehicle (Supplemental Figure 4). In comparison to the 18 F-FDG uptake at week 0 in the mice fed a high-fat diet (2.3 AE 0.24), the lesion-to-wall ratios were lower after the 6-week treatment on normal mouse chow in both the vehicle-(p < 0.001) and X19-mu\u00c0treated (p < 0.001) groups. The uptake of 18 F-FDG was further compared in lesions with low (average 22%), intermediate (29%), or high (35%) density of macrophages. The 18 F-FDG uptake was gradually increased in these lesions and was highest in lesions with high density of macrophages (p \u00bc 0.039). However, X19-mu treatment reduced 18 F-FDG uptake in lesions with low, intermediate. and high macrophage density compared with vehicle (p < 0.001) (Figure 6E). The 18 F-FDG uptake in other tissues is presented in Supplemental",
            "latex": null,
            "type": "figure"
        },
        "FIGREF91": {
            "text": "F-FDG uptake in atherosclerotic lesions in mice. These results provided evidence that the therapeutic antibody against PC had beneficial effects on coronary vascular function and inflammatory activity in the arterial wall in atherosclerosis. Furthermore, our results indicated that CFR and 18 F-FDG PET could be used as possible surrogate markers for the efficacy of PC antibody therapy in future clinical studies. Endothelial cell injury at early stages of atherosclerosis may lead to exposure of antigens, including OxPLs, that are normally hidden, eliciting an immune response and secretion of various disease-modifying antibodies (4,26). Previous studies indicated that OxPLs cause endothelial dysfunction with impairment of NO-mediated vasodilatation in arterial preparations",
            "latex": null,
            "type": "figure"
        },
        "FIGREF92": {
            "text": "PC-mAb Treatment Preserves NO Production in Human Aortic Endothelial Cells (A) Intracellular nitrate reflecting nitric oxide (NO) production was significantly decreased after 24-h stimulation with lipoprotein(a) [Lp(a)] in the presence of a nonspecific immunoglobulin-G (IgG) but preserved in the presence of PC-mAb. (B) The pro-inflammatory mediators, VCAM1, ICAM1, and IL8 gene-expression tended to be lower in the presence of PC-mAb than the nonspecific IgG antibody, but it was not statistically significant (B). Results are expressed as median with 25th and 75th percentiles for 3 independent experiments; Mann-Whitney U test; *p < 0.05. Ctrl \u00bc control; other abbreviations as in Figures 2 and 3. preserved CFR in vivo in response to adenosine in hypercholesterolemic mice that had impaired CFR, despite the absence of obstructive coronary artery disease (22). In HAECs stimulated with Lp(a), the main carrier of PC/OxPLs in the human plasma (11), the PC-mAb preserved NO production compared with that of a nonspecific IgG. In vivo, the methacholine provocation test further demonstrated enhanced vasodilatory response after X19-mu treatment. We previously showed that blood pressure response to methacholine could be blocked by pre-treatment with 50 mg/kg of the NO synthase inhibitor, L-Nitro-Arginine-Methyl Ester, which indicated NO-and endotheliummediated mechanisms (29). These results indicated that the beneficial effects of X19-mu on CFR were at least partly mediated via direct effects on endothelial cell NO metabolism. In line with that, our immunofluorescence stainings demonstrated PC-positive staining in the aortic root sections co-localizing with endothelial cells and macrophages. Alternatively,",
            "latex": null,
            "type": "figure"
        },
        "FIGREF93": {
            "text": "X19-mu Treatment Reduces 18 F-FDG Uptake in Atherosclerotic Lesions (A) A hematoxylin and eosin\u00c0stained longitudinal aortic cryosection, (B) corresponding autoradiograph, and (C) macrophage (Mac-3) staining. Black lines represent contours of the regions of interest defined in the atherosclerotic lesions and vessel wall without lesions. (D) The graph shows average 18-F-fluorodeoxyglucose ( 18 F-FDG) uptake in atherosclerotic lesions (normalized by the activity of vessel wall; lesion-to-wall ratio), which was lower after a 6-week treatment with X19-mu than with vehicle. (n \u00bc 16 mice/group; mean AE SD; sex-adjusted model). (E) The subanalysis showed that X19-mu treatment reduced 18 F-FDG uptake (lesion-to-wall ratios) in lesions with low, intermediate, and high macrophage density compared with vehicle. (n \u00bc 5 to 7 mice/group in each subcategory; mean AE SD; 2-way analysis for variance for the main effects of macrophage density and treatment). Scale bar \u00bc 0.5 mm. A \u00bc arch; AA \u00bc ascending aorta; B \u00bc brachiocephalic artery; D \u00bc descending thoracic aorta; L \u00bc lesion; LC \u00bc left common carotid artery; LS \u00bc left subclavian artery; W \u00bc wall. St\u00e5hle et al.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF94": {
            "text": "been shown that OxLDL stimulates macrophage18  F-FDG uptake(31), and that18  F-FDG uptake is particularly high in the early phase of foam cell formation (32). Recently, increased 18 F-FDG uptake in the arterial wall was found in patients with elevated Lp(a). Ex vivo experiments showed that the arterial inflammation was due to the OxPLs bound to Lp(a), because the E06 antibody prevented the proinflammatory effects of Lp(a) (11). The present study demonstrated that administration of a therapeutic antibody against PC reduced 18 F-FDG uptake in atherosclerotic lesions with different macrophage densities in vivo, which indicated reduced metabolic activity and possibly reduced anti-inflammatory effects in atherosclerosis. In line with this and a previous study (15), IL-1b was reduced in the lesions after X19-mu treatment. However, no changes in macrophage apoptosis was observed. The absolute amount of reduction in 18 F-FDG uptake (13%) was in line with the degree of reduction in arterial 18 F-FDG uptake seen in clinical studies that used cholesterol lowering intervention with atorvastatin (5% to 15%) , another immunogenic epitope onOxLDL, did not reduce arterial 18 F-FDG uptake in hypercholesterolemic minipigs(33)  or patients with stable inflammatory vascular lesions(34). These differences can be explained by differences in PC (phospholipid) and malondialdehyde (protein) epitopes, with the former being specifically associated with OxPLs (11) that are more prevalent in advanced, inflamed lesions(35).",
            "latex": null,
            "type": "figure"
        },
        "FIGREF95": {
            "text": "measured throughout the thoracic aorta in different regions(36). Aortic root is the most common and validated region for atherosclerosis quantification, but also contains the most advanced lesions(36). Finally, macrophages in the lesions were mainly of the reparative M2 type before therapy, and there was a high variation in the proportions of M1/ M2 polarized macrophages between mice; therefore, we could not exclude small effects of PC antibody treatment on macrophage phenotype. STUDY LIMITATIONS. We did not assess18  F-FDG uptake repeatedly in the same mice because high radiation exposure related to the high-resolution angiography might have influenced health of study animals, and the partial volume effects could have impaired the accuracy of quantification of the signal in the small atherosclerotic lesions in vivo (37). Although the LDLR \u00c0/\u00c0 ApoB 100/100 mouse is a widely used model of atherosclerosis, with a lipid profile that closely resembles human familial hypercholesterolemia, the findings could not be directly extrapolated to humans. Because of the high variation in CFR values observed in mice in general (from 1.2 to >2.2) (23,38) and in individual mice in our study, larger studies are needed to confirm the magnitude of the treatment effect on coronary vascular function. The high-fat diet was discontinued at the time of intervention, to prevent the toxic effects of high cholesterol and to mimic a clinical situation, where any therapy would be prescribed on top of cholesterol-lowering intervention. Chimeric mouse-human antibody was used in this study, because of the possible risk of formation of neutralizing antibodies with a fully human antibody in mice. Saline was used as a control treatment in the in vivo study because of challenges in the production of a corresponding mouse-human chimeric IgG1 not binding to PC, as well as to reduce the risk of interference of nonspecific IgG with the naturally occurring antibody responses (26). CONCLUSIONS Six weeks of treatment with X19-mu, in mice. The present findings provide evidence that X19-mu exerts therapeutic actions on endothelial cell function and inflammatory processes in the vessel wall, despite changes in lesion burden or cholesterol levels. Our results suggest that noninvasive imaging techniques, CFR and 18 F-FDG PET measures, represent translational tools to assess the effects of PC-targeted therapy on vascular function and atherosclerosis in clinical studies.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF96": {
            "text": "Iseme RA, Mcevoy M, Kelly B, et al. A role for autoantibodies in atherogenesis. Cardiovasc Res 2017;113:1102-12.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF97": {
            "text": "Shaw PX, H\u00f6rkk\u00f6 S, Chang MK, et al. Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity. J Clin Invest 2000;105:1731-40.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF98": {
            "text": "Fiskesund R, Su J, Bulatovic I, Vikstr\u00f6m M, de Faire U, Frosteg\u00e5rd J. IgM phosphorylcholine antibodies inhibit cell death and constitute a strong protection marker for atherosclerosis development, particularly in combination with other autoantibodies against modified LDL. Results Immunol 2012;2:13-8.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF99": {
            "text": "Gigante B, Leander K, Vikstr\u00f6m M, et al. Low levels of IgM antibodies against phosphorylcholine are associated with fast carotid intima media thickness progression and cardiovascular risk in men. Atherosclerosis 2014;236:394-9.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF100": {
            "text": "Caidahl K, Hartford M, Karlsson T, et al. IgMphosphorylcholine autoantibodies and outcome in acute coronary syndromes. Int J Cardiol 2012;167: 464-9.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF101": {
            "text": "Fiskesund R, Stegmayr B, Hallmans G, et al. Low levels of antibodies against phosphorylcholine predict development of stroke in a population-based study from Northern Sweden. Stroke 2010;41:607-12.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF102": {
            "text": "Imhof A, Koenig W, Jaensch A, Mons U, Brenner H, Rothenbacher D. Long-term prognostic value of IgM antibodies against phosphorylcholine for adverse cardiovascular events in patients with stable coronary heart disease. Atherosclerosis 2015;243:414-20.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF103": {
            "text": "11. van der Valk FM, Bekkering S, Kroon J, et al. Oxidized phospholipids on lipoprotein(a) elicit arterial wall inflammation and an inflammatory monocyte response in humans. Circulation 2016; 134:611-24.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF104": {
            "text": "Caligiuri G, Khallou-Laschet J, Vandaele M, et al. Phosphorylcholine-targeting immunization reduces atherosclerosis. J Am Coll Cardiol 2007; 50:540-6. and monitoring of coronary artery disease and microvascular health. J Am Coll Cardiol Img 2010; 3:623-40.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF105": {
            "text": "Gupta A, Taqueti V, van de Hoef T, et al. Integrated noninvasive physiological assessment of coronary circulatory function and impact on cardiovascular mortality in patients with stable coronary artery disease. Circulation 2017;136: 2325-36.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF106": {
            "text": "Pettersson K, Ewing MM, de Vries MR, et al. Abstract 15644: A fully human monoclonal IgG phosphorylcholine antibody prevents accelerated atherosclerosis in mice. Circulation 2011;124: A15644. 21. Ewing MM, Karper J, Nordzell M, et al. Chapter 6: Optimizing natural occurring IgM antibodies for therapeutic use: inflammatory vascular disease treatment with anti-phosphorylcholine IgG. Available at: https://openaccess.leidenuniv.nl/ PERSPECTIVES COMPETENCY IN MEDICAL KNOWLEDGE: Proinflammatory OxPLs that contain PC are a risk factor for cardiovascular disease. The present study demonstrated that treatment with a therapeutic monoclonal IgG1 antibody against PC on OxPLs affected NO metabolism in endothelial cells, preserved CFR, and attenuated atherosclerotic inflammation as determined by the uptake of 18 F-FDG in atherosclerotic mice. The results provided proof-ofconcept that a therapeutic antibody targeting PC might represent an approach to inhibit the atherogenic impact of OxPLs. TRANSLATIONAL OUTLOOK: The noninvasive imaging techniques represent translational tools to assess the effects of PC-targeted therapy on coronary artery function and atherosclerosis and appear to be possible surrogate markers for the efficacy of this therapy in clinical studies.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF107": {
            "text": "Tavakoli S, Zamora D, Ullevig S, Asmis R. Bioenergetic profiles diverge during macrophage polarization: implications for the interpretation of 18 F-FDG PET imaging of atherosclerosis. J Nucl Med 2013;54:1661-7.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF108": {
            "text": "Lee SJ, Hoa C, Quach T, et al. Oxidized low-density lipoprotein stimulates macrophage 18 F-FDG uptake via hypoxia-inducible factor-1a activation through Nox2-dependent reactive oxygen species generation. J Nucl Med 2016;55: 1699-706. 32. Ogawa M, Nakamura S, Saito Y, Kosugi M, Magata Y. What can be seen by F-18-FDG PET in atherosclerosis imaging? The effect of foam cell formation on F-18-FDG uptake to macrophages in vitro. J Nucl Med 2012;53:55-8.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF109": {
            "text": "K, et al. Treatment with a human recombinant monoclonal IgG antibody against oxidized LDL in atherosclerosis-prone pigs reduces cathepsin S in coronary lesions. Int J Cardiol 2016; 215:506-15.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF110": {
            "text": "Lehrer-Graiwer J, Singh P, Abdelbaky A, et al. FDG-PET imaging for oxidized LDL in stable atherosclerotic disease: a phase II study of safety, tolerability, and anti-inflammatory activity. J Am Coll Cardiol Img 2015;8:493-4. 35. van Dijk RA, Kolodgie F, Ravandi A, et al. Differential expression of oxidation-specific epitopes and apolipoprotein(a) in progressing and ruptured human coronary and carotid atherosclerotic lesions. J Lipid Res 2012;53:2773-90. 36. Witting PK, Pettersson K, Letters J, Stocker R. Site-specific antiatherogenic effect of probucol on apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2000;20:e26-33. 37. Hellberg S, Sippola S, Liljenb\u00e4ck H, et al. Effects of atorvastatin and diet interventions on atherosclerotic plaque inflammation and [18F]FDG uptake in Ldlr-/-Apob100/100 mice. Atherosclerosis 2016;263:369-76.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF111": {
            "text": "Wikstr\u00f6m J, Gr\u00f6nros J, Gan LM. Adenosine induces dilation of epicardial coronary arteries in mice: relationship between coronary flow velocity reserve and coronary flow reserve in vivo using transthoracic echocardiography. Ultrasound Med Biol 2008;34:1053-62. KEY WORDS atherosclerosis, coronary flow reserve, inflammation, 18 Ffluorodeoxyglucose positron emission tomography, phosphorylcholine APPENDIX For expanded Methods and Results sections and supplemental tables and figures, please see the online version of therosclerosis is a lipid-driven chronic inflammatory disease that results in the formation of atherosclerotic plaques, which on rupture or erosion lead to myocardial infarction and stroke. The recent clinical trial CANTOS (Canakinumab Anti-Inflammatory Thrombosis Outcome Study) has demonstrated the therapeutic value of immunomodulation in atherosclerotic cardiovascular disease (CVD) in humans and has paved the way toward the development of additional therapeutic strategies against the maladaptive immune response underlying atherosclerotic plaque formation (1). A crucial step in the initiation and progression of atherosclerosis is the oxidation of low-density lipoprotein (OxLDL) in the subendothelial space of arteries. OxLDL displays oxidation-specific epitopes (adducts generated on oxidative modification) that are immunogenic and are recognized by different cell types including endothelial cells, T cells, monocytes, and macrophages, resulting in the triggering of proinflammatory responses (2). Oxidation-specific epitopes include phosphorylcholine (PC)-containing oxidized phospholipids that are also present on OxLDL and apoptotic cells and exhibit a strong proinflammatory and proatherogenic effect in vivo (3). Natural immunoglobulin M (IgM) antibodies (preexisting germline-encoded products) are an important arm of humoral immunity and have the capacity to recognize oxidation-specific epitopes in both mice and humans. Mice lacking soluble IgM antibodies display dramatically accelerated atherosclerosis (4). Moreover, whereas the association of OxLDL-specific IgG levels in plasma with cardiovascular disease risk in humans requires further investigation, several epidemiological studies have demonstrated that anti-PC IgM levels in plasma are inversely associated with CVD (4). Thus, immunomodulatory strategies targeting PC may be beneficial in mitigating atherosclerosis. In this issue of JACC: Basic to Translational Science, St\u00e5hle et al. (5) investigated the effect of a monoclonal IgG1 anti-PC antibody (X19-mu) on inflammation and vascular function in established atherosclerosis in Ldlr \u00c0/\u00c0 ApoB 100/100 mice that were first fed an atherogenic diet for 12 weeks and then switched to regular chow diet for 6 weeks while they were treated weekly with the X19-mu antibody or saline. Treatment with the X19-mu antibody did not alter LDL, high-density lipoprotein, and blood glucose levels in plasma. Furthermore, the lesion size in mice treated with the X19-mu antibody was similar to lesions in the mice that received saline. In addition, X19-mu treatment did not alter the collagen deposition and total macrophage area as well as the proportions of M1-and M2-type macrophages in lesions. Despite similar macrophage and phagocytic cell content, mice that were treated with the X19-mu antibody displayed a modest reduction in interleukin (IL)-1b content in the lesions. Notably, compared with cells that were collected from control mice, peritoneal macrophages isolated from transgenic mice overexpressing a single chain variant of the anti-PC E06 antibody that had been injected with the oxidized phospholipid 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine (oxPAPC), displayed strongly reduced IL-1b expression (3",
            "latex": null,
            "type": "figure"
        },
        "FIGREF112": {
            "text": "X19-mu-treated mice compared with in lesions from control mice.It is important to point out a significant limitation of the study bySt\u00e5hle et al. (5): their study lacks of a group of mice treated with an isotype control antibody. This is particularly important because only the Fc portion of the X19-mu is of murine origin, and thus an immune reaction against X19-mu clone during the 6-week treatment cannot be excluded, which could also potentially limit the effect of the antibody.Furthermore, the different effector functions of the Fc portion of IgG antibodies that display different affinity to Fcg receptors may also determine the effect of such a therapeutic approach. Fcg receptors are divided into 2 main categories-the activating and inhibitory receptors-which confer both proatherogenic and atheroprotective effects (6). In addition, the capacity to activate the complement system differs among the different IgG classes and thus these properties could be of importance with respect to the efficacy of an anti-PC IgG-based therapeutic strategy (6). Previous studies have shown the atheroprotective effect of PC-based immunization or anti-PC IgM passive infusion strategies in the aortic root and veingraft atherosclerosis (4). St\u00e5hle et al. (5) showed that in contrast to saline-treated mice, treatment with the X19-mu antibody preserved the coronary flow reserve (on adenosine stress) in the left coronary artery before and after 6 weeks of treatment in mice with established atherosclerosis. These data show that anti-PC targeting has the capacity to improve coronary vascular function, which is highly relevant for human disease. To explore the underlying mechanism of the effect of X19-mu antibody intervention on coronary vascular function, St\u00e5hle et al. (5) treated human aortic endothelial cells with lipoprotein(a). Treatment with lipoprotein(a) led to a decreased intracellular nitrate concentration in endothelial cells treated with the isotype control antibody, whereas cells treated with the fully human PC-specific monoclonal antibody X19-A05, which has comparable binding affinity to PC as the X19-mu antibody, preserved intracellular nitrate concentration. These data are consistent with the protective effect of the PCspecific IgM E06 antibody in inhibiting IL-8 production by endothelial cells stimulated with apoptotic cells (6). In summary, the study by St\u00e5hle et al. (5) provides new insights into the therapeutic effect of anti-PC immunotherapy in atherosclerosis, particularly with respect to the homeostasis of the coronary vascular function. ADDRESS FOR CORRESPONDENCE: Dr. Dimitrios Tsiantoulas, Medical University of Vienna, Lazarettgasse 14, AKH BT 25.2, Vienna 1090, Austria. E-mail: dimitris.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF113": {
            "text": "brk1, nckap1, and wasf2 and the regulators of small GTPase signaling cul3a and racgap1 are critical to cardiac development. (J Am Coll Cardiol Basic Trans Science 2020;5:376-86) \u00a9 2020 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). the a Department of Pediatrics, Division of Pediatric Cardiology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania; b Department of Pharmacological Sciences, Mount Sinai Center for Bioinformatics, LINCS-BD2K DCIC, Icahn School of Medicine",
            "latex": null,
            "type": "figure"
        },
        "FIGREF114": {
            "text": "Variant calls were made using GATK Hap-lotypeCaller(8). De novo variants not meeting the following criteria after pooling from the 3 pipelines were filtered out: depth (minimum 10 reads total and 5 alternate allele reads), alternate allele balance (minimum 20% if alternate read depth $10 or minimum 28% if alternate read depth <10), and parental read characteristics (minimum depth of 10 reference reads and alternate allele balance <3.5%).Variant pathogenicity was assessed using in silico prediction from PredictSNP2 (Loschmidt Laboratories, Brno, Czech Republic), which employs an ensemble approach by integrating data from multiple in silico tools, for all variants other than frameshift mutations(10). As PredictSNP2 does not score frameshift mutations, we used Combined Annotation Dependent Depletion v1.4 for these variants(11).Combined Annotation Dependent Depletion, 1 of the tools which contributes to PredictSNP2, yields PHRED-scaled C scores, such that a score of $30 correlates to the top 0.1% of all possible variants and in prior studies has been used to discriminate pathogenic from tolerated frameshift variants(11).Variants were also filtered for those affecting HHE genes (4). The HHE gene set was previously identifiedusing RNA sequencing of isolated strain 129/SvEV mouse hearts including atria, ventricles, and all 4 valves at embryonic day 14.5 to dichotomize 16,676 genes with identified human-mouse orthologues with a minimum of 40 reads per million mapped reads into the top quartile of expression (4). The HHE gene list consists of 4,169 genes, and the low heart expression list consists of 12,507 genes.We considered that the low heart expression genes may contain some genes critical to cardiogenesis, so in an orthogonal variant filtering, we excluded genes unlikely to have a role in cardiovascular development based on knockout mouse phenotypes using the Mouse Genome Informatics (MGI) knockout phenotype gene library(12). Specifically, a gene was excluded if its knockout had been phenotyped, and the knockout was not found to cause any cardiovascular related phenotype, embryogenesis phenotype, or embryonic or postnatal lethality.Cardiac diagnoses were obtained from the PCGC Data Hub (13). Left ventricular outflow tract obstruction (LVOTO) (n \u00bc 802) included hypoplastic left heart syndrome, aortic coarctation, and aortic stenosis. Conotruncal defects (CTDs) (n \u00bc 1120) included D-transposition of the great arteries, tetralogy of Fallot, double outlet right ventricle, truncus arteriosus, ventricular septal defects, and abnormalities of the aortic arch patterning. Heterotaxy (HTX) (n \u00bc 274) included patients with left-right isomerism as the primary defect. The remaining patients not included in 1 of the 3 phenotype categories consisted of a heterogeneous group of defects including atrial septal defects and anomalous pulmonary venous connections, pulmonary valve lesions, atrioventricular canal defects, double inlet left ventricle, and tricuspid atresia. GENE SET ENRICHMENT ANALYSIS. We performed gene set enrichment analysis for Gene Ontology biological processes (GOBP) terms and Comprehensive Resource of Mammalian Protein Complexes (CORUM) using HHE in silico-and MGI library in silico-filtered variants and the hypergeometric test. Enrichment analyses were performed with Enrichr (Icahn School of Medicine at Mount Sinai, New York, New York), which, in addition to implementing the hypergeometric test, also employs a ranking method that combines the adjusted p value with a deviation from the expected rank based on enrichment analysis applied to random gene sets (z-score) (14). In addition, we repeated the enrichment analysis with the loading of 2 different background reference lists; 1 made of the 4,169 HHE genes and the other made of the entire human genome excluding the MGI library phenotype negative genes using WebGestalt (Vanderbilt University Medical Center, Nashville, Tennessee) with the default settings (15). The reference and background gene lists are available in supplemental information. A Benjamini-Hochbergadjusted p < 0.05 using both tools, Enrichr and WebGestalt, was used for significance with significant terms ranked by Enrichr's combined score. Gene Ontology enrichment analysis was performed for controls, all cases, and LVOTO, CTD, and HTX gene lists.Given that among the CHD phenotype-specific groups, significant enrichment was only observed for the LVOTO group, we performed a protein-protein interaction (PPI) network analysis only for this group to prioritize candidate genes. We generated an LVOTO-specific PPI network, using GeNets (BroadInstitute, Cambridge, Massachusetts), by inputting all LVOTO genes associated with all GOBP and CORUM terms identified as enriched including terms which were observed as enriched when using only Enrichr or WebGestalt enrichment analyses. Then we ranked genes associated with the consistently enriched terms by their number of connections identified in the LVOTO-specific PPI network. A flow diagram of the variant filtering and enrichment analyses is provided in Supplemental Figure 1.MODELING LOSS OF CANDIDATE GENES IN ZEBRAFISHEMBRYOS. Clustered regularly interspaced short palindromic repeats (CRISPR)-mediated knockdown experiments were performed for candidate genes in zebrafish F0 embryos to assess morphological phenotypes, as described previously(16). Briefly, wild-type AB strain zebrafish embryos were injected at the 1-to 2-cell stage with zebrafish-optimized Cas9 protein and CRISPR RNAs targeting abi1, brk1, cyfip1 cul3a, nckap1, racgap1, or wasf2. CRISPR design and construction were performed by the University of Utah Mutation Generation and Detection Core using standard best practice procedures. Single guide RNAs were designed for high efficiency and low off-target effects, and concentrations for single guide RNA and cas9 protein were also titrated for optimal impact.The mutagenic efficiency of each CRISPR and validation of double-stand breaks was assessed using high-resolution melting analysis performed on genomic DNA from individual injected embryos(17).CRISPR target sequences and high-resolution melting analysis primer sequences are listed in Supplemental",
            "latex": null,
            "type": "figure"
        },
        "FIGREF115": {
            "text": "Much less enrichment was observed for the CTD, HTX, and control gene lists, with no terms reaching statistical significance for the control or the HTX MGI library in silico or HHE in silico gene lists using either tool. For CTDs, only 1 GOBP term-pericardium development-was consistently enriched using the MGI library in silico-filtered genes. No term was consistently enriched using HHE in silicofiltered CTD genes. Complete results of patient phenotypes and variants and complete enrichment analyses results are included in the Supplemental Appendix. Across all enrichment analyses, LVOTO-driven WAVE2 complex enrichment demonstrated the highest Enrichr combined score and WebGestalt fold enrichment. Variants affecting 3 of the 5 genes encoding proteins within the WAVE2 complex and the direct regulator of WAVE2 (RAC1) were identified in LVOTO probands with none identified in other phenotypes: nonsense variants in ABI1 (p. R106X) and NCKAP1 (p. E1057X) and damaging missense variants in CYFIP1 (p. S35L) and RAC1 (p. R68C). PredictSNP2 scores ranged from 0.69 to 1.0 (maximum) and C scores were $32 (0.06% most damaging variants) for these 4 variants. The WAVE2 complex functions downstream of the small GTPase RAC1 to regulate branched actin synthesis and influence actin cytoskeleton organization in multiple cellular processes, including cell migration through formation of lamellipodia (18,19). In this context, it is notable that in addition to consistent enrichment observed for actin filament-based processes and regulation of small GTPase signaling, terms related to lamellipodium and actin cytoskeleton development were identified as enriched in at least 1 context. We considered that visualizing protein network interactions between genes associated with the LVOTO enriched terms would allow us to better prioritize candidate genes for downstream validation. To that end, we used Metanetwork v1.0 (Broad Institute) predicted protein-protein interactions available from GeNets to interrogate for interactions between the 35 genes associated with the 5 consistently enriched GOBP and CORUM terms and all genes associated with all LVOTO enriched terms (Figure 1) (20). These 35 genes had a median of 3 connections in this LVOTOspecific protein network with CUL3, CDC42, CYFIP1, NCKAP1, NF1, NOTCH1, RAC1, RACGAP1, and RAF1 being in the top quartile with 7 to 14 connections each.Unsurprisingly, most of these genes are already strongly implicated in cardiac development and CHD(21)(22)(23)(24)(25). Notably, both Cul3 -/and Racgap1 -/result in embryonic lethality, suggesting a possible role in heart development, which is further supported by a more recent cardiomyocyte-specific Cul3 -/of the WAVE2 complex, which consists of the 3 previously mentioned genes as well as BRICK1 and WASF2, in cardiogenesis is mostly unknown.Mouse knockout studies of Abi1, Brick1, and Cyfip1resulted in embryonic lethality, with the only reported cardiac phenotype being hemorrhagic pericardial edema or discontinuous cardiac tissue layers from loss of Abi1 (29-32). Additionally, loss of Wasf2 resulted in reversed cardiac looping in 1 of 2 mouse models and loss of Nckap1 resulted in cardia bifida in mice",
            "latex": null,
            "type": "figure"
        },
        "FIGREF116": {
            "text": "LVOTO Disease Gene NetworkBipartite graph generated using GeNets Metanetwork v1.0 protein-protein interactions connecting left ventricular outflow tract obstruction (LVOTO) genes associated with enriched terms using either high fetal heart expression (HHE) in silico or Mouse Genome Informatics (MGI) library in silico-filtered genes and either Enrichr or WebGestalt.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF118": {
            "text": "In this study, we used whole exome sequencing of 2,881 well-phenotyped, sporadic CHD trios and compared these with 900 control trios to identify de novo predicted damaging mutations using in silico, developmental heart expression, and previous implications in development or cardiac disease in knockout mouse phenotypes. As gene set enrichment analyses are sensitive to both the length of the genes list associated with each term and the background gene list, we performed enrichment analysis with different methods and considered not only statistical significance, but also consistency across tools and algorithms.Through phenotype-driven elaborate gene set enrichment analyses, we identified a novel association between the LVOTO phenotype and genes associated with the WAVE2 complex, actin-filament based processes, and small GTPase signal trans-identified CUL3 and RACGAP1 as mediators of small GTPase signaling. Placing the protein products of these genes within a PPI network we further highlight their strong connections within an LVOTO-specific network.In contrast to LVOTO, the other phenotype groups demonstrated significantly less term enrichment.Although CTDs had similar variant burden to LVOTO, we hypothesize that genetic and phenotypic hetero-geneity within this group may have limited our ability to identify consistent term enrichment with our approach. For HTX, we failed to identify a burden of mutations or identify any significant term enrichment using any combination of enrichment tools or gene filter. The smaller size of the HTX cohort compared with the other phenotypes may have limited our power for enrichment analysis, but limiting to de novo variants may also have missed significant genetic contributors. Recent results from the PCGC highlight that recessively inherited variants contribute substantially to pathogenesis of patients with CHD and laterality defects, suggesting that this model of inheritance needs to be incorporated into all future gene pathway enrichment studies for patients with HTX (7). CANDIDATE GENE VALIDATION IN ZEBRAFISH. Given consistency of LVOTO gene set enrichment, we selected candidate genes from this group for validation. We identified reversed cardiac looping with loss of brk1, cul3a, nckap1, and wasf2 and a small ventricle with atrial dilation and pericardial edema with loss of racgap1 in F0 zebrafish embryos. It is difficult to directly compare reversed cardiac looping in zebrafish with LVOTO defects in humans. Being comprised of only 2 chambers renders the developing zebrafish heart vulnerable to looping defects from mechanisms other than perturbed sidedness including altered myocardial cell polarity, cell number, or blood flow (37). Thus, while these results in zebrafish cannot definitively implicate these genes in LVOTO, we can conclude their critical nature to cardiac development and establish an association with mutations in these genes and LVOTO in humans. PROPOSED MOLECULAR MECHANISMS. Recently, the Lo lab has developed a mouse forward genetics screen coupled with fetal imaging and whole exome sequencing of founder mice exhibiting a cardiovascular malformation to identify recessively inherited variants in novel CHD genes (38). This model has illustrated a role for complex genetic inheritance in multiple CHD phenotypes including the severest form of LVOTO, hypoplastic left heart syndrome, in the Ohia mouse line (Sap130 m/m /Pcdha9 m/m ) (39). These genes were further validated in LVOTO pathogenesis after identifying mutations affecting SAP130 and a related gene, PCDHA13, in patients with hypoplastic left heart syndrome. Kyoto Encyclopedia of Genes and Genomes network analysis of differentially expressed genes in the Ohia right and left ventricular tissue by RNA sequencing and chromatin immunoprecipitation sequencing implicated multiple developmental pathways including Notch, Wnt, Tgfb, and hedgehog signaling, as well as biological processes including extracellular matrix receptors, regulation of actin cytoskeleton, axon guidance, and metabolism.WAVE2 is a highly conserved regulator of actin cytoskeleton and cell morphology during development, a process that is critical to regulating cell polarity, cell migration, cytokinesis, and tissue architecture(35,40,41). Interestingly, the noncanonical Wnt planar cell polarity pathway, which regulates cell polarity during development via small RhoGTPase regulation including RAC1, was identified as enriched using Enrichr with both MGI library in silico-and HHE in silico-filtered LVOTO gene lists and could provide a mechanistic link between altered WAVE2 complex activity and CHD(42).Knockout studies in mouse and zebrafish demonstrate that planar cell polarity genes influence heart development by regulating directional migration of progenitor cells, septation of the primitive heart tube, and patterning of cardiac structures(43). In loss of Wnt5a and mutants of Vangl2 and Dvl2 (which connect planar cell polarity to RhoGTPase signaling), abnormal outflow tract development, reduced cardiomyocyte polarity, and actin polymerization defects in cardiac progenitor cells are observed(44).",
            "latex": null,
            "type": "figure"
        },
        "FIGREF119": {
            "text": "Rac1 resulted in abnormal right ventricular cardiomyocyte polarity with inhibited second heart field progenitor cell migration and concomitant decreased expression of WAVE2 complex genes and Arp2/3 in embryonic right ventricular tissue(22).",
            "latex": null,
            "type": "figure"
        },
        "FIGREF120": {
            "text": "Lztr1 knockout in the mouse and loss of function LZTR1 mutations in humans have been implicated in Noonan syndrome through decreased CUL3-mediated RAS ubiquitination and ultimately increased RAS/MAPK signaling(47,48). Further, in the LVOTO-specific protein network generated in this study, the canonical ubiquitination regulator UBC demonstrated the highest number of connections including with CUL3. Thus, the mechanism of CUL3 loss leading to developmental cardiac defects might also be related to dysregulated ubiquitination. Finally, loss of cyfip1 and abi1a, unlike the other WAVE2 complex genes, was not found to impact zebrafish heart development. Zebrafish, unlike mouse or human, have 2 orthologs for ABI1 (abi1a and abi1b) with abi1b likely compensating to maintain normal cardiac development. Similarly, loss of cyfip1 may be compensated by irsp53, which in mice has been shown to also facilitate binding of activated Rac1 to WAVE2 (49). CONCLUSIONS Despite rigorous efforts to unravel the genetic mechanisms for severe forms of LVOTO pathogenesis, the etiology for most patients has largely remained elusive with only recent evidence confirming a role for SAP130 and PCDHA13 (39). Here, we exploited the strength of gene pathway enrichment analyses from whole exome sequencing results of sporadic, complex CHD trios to identify an association with LVOTO in humans and WAVE2 complex, actin-filament regulation, and small GTPase signaling genes. Furthermore, we confirmed a role for brk1, cul3a, nckap1, racgap1, and wasf2 in cardiac development using CRISPR mediated knockdown in zebrafish. Ultimately, we illustrate that combining phenotype-driven gene set enrichment analyses with validation in zebrafish is as an effective approach for identifying novel CHD genes. Given evidence linking planar cell polarity pathway to WAVE2 complex activity via small GTPase signaling, we propose this as a promising framework for future mechanistic investigation into LVOTO. ADDRESS FOR CORRESPONDENCE: Dr. Bruce D. Gelb, Mindich Child Health and Development Institute, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Place, Box 1040, New York, New York 10029. E-mail: bruce.gelb@mssm.edu.PERSPECTIVES COMPETENCY IN MEDICAL KNOWLEDGE: Genetic variants including single gene mutations or larger genomic changes, such as copy number variations or aneuploidy, contribute substantially to CHD pathogenesis. With the decreasing cost of nextgeneration sequencing, there is more widespread genetic testing, yet an unequivocal genetic cause is not identified in up to 80% of CHD patients. Closing this gap in our fund of knowledge has significant implications on genetic counseling for our patients and their families. TRANSLATIONAL OUTLOOK: Predicted damaging mutations affecting genes in the WAVE2 complex and related genes are probably causative of CHD and, more specifically, LVOTO. costs in drug development are in large part because of the high failure rates in clinical phase trials. The poor correlation of animal studies to human toxicity and efficacy have led many developers to question the value of requiring animal studies in determining which drugs should enter in-human trials. Part 1 of this 2-part series examined some of the data regarding the lack of concordance between animal toxicity studies and human trials, as well as some of the potential reasons behind it. This second part of the series focuses on some alternatives to animal trials (hereafter referred to as animal research) as well as current regulatory discussions and developments regarding such alternatives. (J Am Coll Cardiol Basic Trans Science 2020;5:387-97) \u00a9 2020 The Author. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license (http://creativecommons. org/licenses/by-nc-nd/4.0/). I ncreasingly, toxicologic testing in animals and preclinical animal studies in drug development have been questioned because of poor correlation with in-human results (1). In addition, public opinion plays a key role in determining how animal research is funded and regulated, and public opinion polls both in the United States and Europe demonstrate a steadily growing unease among the public sector for use of animals in industrial and pharmaceutical toxicity testing. Trends in public opinion regarding animal research in Great Britain, for example, demonstrated relatively steady approval (75%) of animal research between 1999 and 2010, so long as there was no alternative. However, public opinion began to shift significantly around 2012, with approval of animal research in the face of no alternative dropping to 66%, and less than one-half of the public agreeing that scientists could be trusted to be truthful about the experiments they were running (2). Annual Gallup polls in the United States demonstrated a steady decline in public opinion about the \"moral acceptability\" of animal research, from 65% approval in 2001 to 51% in 2017 (3). Opposition to animal research grew during the same period from 25% to 44%. Less than one-half of Americans 18 to 34 years of age felt that medical testing on animals was acceptable (4). In 2003, the seventh amendment to the European Union's Cosmetics Directive (5) stipulated an end to animal testing in the European Union for cosmetic purposes by 2009, regardless of the availability of alternative models by that time. In 2013, the National Institutes of Health (NIH) announced a program to phase out all research involving chimpanzees, passed by Congress and signed into law that required the Department of Veterans Affairs to suspend all dog research not specifically approved by the agency's secretary (8). In other parts of the globe, similar trends are demonstrated across Europe (9) and in New Zealand, Australia, and Japan (2). Animal research will not be entirely replaced by other methods anytime soon, but the potential for faster and ultimately less expensive commercialization of therapeutics, together with the reduction of animal use in the early phases of drug development, has helped to increase research funding for alternatives. Overall, the use of alternative methods for product testing and preclinical testing of medical drugs and devices has increased dramatically over the last quarter of a century. Between 1990 and 2015, the number of published papers using \"alternative animals\" (e.g., insects, fish, worms and shrimp) and in silico analysis increased over 900%. In 2015, more than 88,000 studies were published using in silico modeling, versus just 7,405 studies in 1990. Over the same period, testing and research use of guinea pigs and rabbits, previous favorites in the cosmetic industry, fell by 68% and 40%, respectively, although the use of rats and dogs remained stable, and the use of mice increased (10). ALTERNATIVES TO ANIMAL RESEARCH Predicting negative side effects of putative therapeutic agents is an important goal in drug development: prohibitive side effects or toxicity are a major reason why drugs that reach clinical trials fail to progress to market (lack of efficacy and lack of commercial interest are others). Animal toxicity testing fails to predict toxicity in almost 50% of drugs in the pipeline between Phase I trials and early post-market withdrawals (1), well after significant time and resources have been spent on what will prove to be a \"failed\" therapeutic. Testing that predicts probable late and expensive \"drop outs\" during drug development-termed a \"fail early\" strategy-would not only reduce costs, but also allow development resources to be redirected toward agents more likely to pass clinical trials. Alternative methods of drug testing that provide more consistent, rapid, and translatable results will also increase human safety. IN SILICO MODELING. Early prediction of human toxicity is critical in decreasing the costs of drug development, and in silico testing has recently been promoted as an important, human-based tool for preclinical evaluation (11). In silico, or computational, modeling refers to experiments or elements of experiments that are performed on computer computational models or via computer simulation. An in silico method is not simply a statistical analysis of known experimental data, but rather is a modeling approach using known characteristics of a chemical or chemical similar to it, information about the underlying chemical or biological system in which it will be used, and, when available, known preclinical and clinical data to predict untested system-level behaviors of a given chemical. Mayourian et al. (12) provide a detailed review of various in silico techniques particularly relevant to cardiovascular (CV) research. One of the most important advantages of in silico testing involves scale-in the number of chemicals that can be tested quickly (throughput), the types of endpoints and biological pathways covered, and the range of conditions that can be rapidly simulated. Computational research does not yet provide complete replacement of animal experimentation in drug development but can significantly increase the scale and speed of preclinical drug development, thus reducing expense in animal testing phases, leveraging information from fewer experimental animals to increase drug development, decreasing the timeline for new drugs to enter the market by reducing the time for preclinical testing, reducing overall costs of drug development, and improving access to new and novel therapies for patients in need. Today, practically all toxicological research already includes in silico elements (13).",
            "latex": null,
            "type": "figure"
        },
        "FIGREF121": {
            "text": "reintroduced into clinical trials for another indication. Repurposing of a drug (also called \"reposition-ing\" or \"reprofiling\") involves reapplying drugs that are either in clinical use already, or might have been retired from further development or marketingbecause of production of a more efficacious drug, risks of adverse effects, or commercialization considerations-to new indications. In both cases, preclinical phases and animal testing can often be bypassed altogether, and if human clinical phase",
            "latex": null,
            "type": "figure"
        },
        "FIGREF122": {
            "text": "found that a computer simulation of human heart cells was better able to predict risk of arrhythmogenicity of 62 drugs-including analgesics, antihistamines, and antibiotics-than animal testing (accuracy of 89% to 96% vs. 75% to 85%, respectively). In 2019,Moreno et al. (25)  used computational modeling to design a novel in silico mexiletine \"booster\" that may improve the efficacy of mexiletine in suppressing arrhythmias.There are a number of problems yet to solve regarding computational methods. As with animal research, lack of specificity could prompt unnecessary testing during drug development, or alternatively stop a safe and efficacious compound from progressing to further drug development because of false positive toxicity findings(26). Currently there is lack of widespread understanding of computational model construction, creating a \"black box effect\" that limits trust and acceptance of in silico data in preference to the familiarity of animal research, which may be less reliable. Additionally, a major challenge to computer modeling is achieving the computational power necessary to sufficiently simulate complex mechanical and physiological systems.The CompBiomed Project, initially funded by the European Union in 2016 and re-funded in 2020 for another 4-year period, has the goal of creating an entire in silico human organism for use in drug testing, disease modeling, and even personalized approaches to individual patient therapy based on patient-specific modeling and simulations(27).While the FDA has expressed interest in in silico testing for drug research(28), as of 2020, there are no guidances that allow in silico tests to replace preclinical animal testing in drug development, although in silico data can certainly be submitted in support of animal findings, and may reduce the number of animal experiments that are required.The FDA supports modeling and simulation research to help predict clinical outcomes, inform clinical trial design, support evidence of efficacy, identify the most relevant patients to study, and predict product safety(29). The FDA has published guidances on the formats for submitting in silico data in support of regulatory advancement of devices on its website(30). However, development of drug and biologicals and toxicological evaluation of metabolites of these entities is still vested in animal studies(31), which can be particularly problematic for testing metabolites that occur in human subjects but cannot be replicated in an animal model.ANIMAL-FREE RECOMBINANT ANTIBODIES. Not only are antibodies used in a variety of research, diagnostic, and regulatory applications, but also antibodies and other biologicals are increasingly becoming mainstream therapeutic agents themselves. Traditionally, the development of antibodies has required the expensive process of immunizing animals, and then sometimes fusing antibodyproducing B cells with \"immortalized\" cell cultures to increase supply. More than 300 companies now supply antibodies for such research and development, with an estimated market value in 2011 of $1.6 billion (32). However, antibodies produced from immunized animals exhibit variability in DNA sequencing and variability in target binding. The lack of reproducibility in research using animal-based antibodies has been deemed a \"crisis,\" with some scientists claiming that over one-half of all commercially available antibodies are unreliable in binding their intended targets (32). One proposed way to tackle the problems of variability in animal-produced antibody structure and targeting is the use of antibodies manufactured in engineered \"recombinant\" cells, and the use of antibodies from \"human antibody libraries\" (33). Advantages include faster production, more consistency in quality, and less biological variation with better potential for research and therapeutic reproducibility. Overall, costs would be eventually be reduced, but only after initial increased expenses of changing to recombinant antibody production from current methods. TISSUE ENGINEERING Perhaps one of the most \"futuristic\" approaches to drug and device development is represented by the emerging field of tissue engineering (TE). Unlike cell suspensions and \"tissue culture\" cellular monolayers, TE constructs have 3-dimensional (3D) structure. TE can more closely mimic the considerable influence that 3D cell-to-cell and cell-to-matrix interactions have over cell behavior in actual tissue and organ systems; something that cell and tissue cultures cannot. In addition, although a considerable body of TE research utilizes animal cells and tissues, TE can allow the creation of 3D tissue structures utilizing human cells-the actual therapeutic target-and likely increase the probability that activity in the engineered human tissue will more accurately reflect or predict the outcomes in human patients. Research regarding TE is burgeoning: the average annual number of published papers more than doubled between 1991 and 2010 (34). The largest body of publications presented various 3D constructions of human skin, made from human karyocytes-derived from neonatal foreskin and mammary tissue discarded after plastic surgery-that vary in complexity from more simple epidermal layers on collagen substrates, to tissue that included epidermis, dermis, and immune cells, and even vascularized skin equivalents with a vascular network (35). TE models have been created that mimic human corneal epithelium and stroma, urothelium, and human oral and vaginal mucosa. Emerging TE studies include engineered human liver tissue, and human neurospheres, as well as models for corneal innervation and the interaction between metastatic tumor cells and bone (34). TE AND THE HUMAN HEART. CV medicine, and the heart in particular, affords many challenges for reducing animal research, as it involves not merely the pharmacologic effects of drugs on the CV cells and systems, but also the effects of topographical properties, motion, and forces in cardiac and vascular shape and mechanical function. As a result, some of the most complex and dynamic alternative research is evolving in this field. The combination of TE with the methodology of 3D printing has resulted in some startling innovations with promise to revolutionize CV bioprosthetic interventions as well as pharmacologic testing and drug development.For more than 2 decades, biologists have been able to turn embryonic stem cells into beating heart muscle cells in a dish(36). Cardiac cells have to have intrinsic capacity to selfassemble into spontaneously beating spheroids, or syncytia (37)-making them particularly interesting with regard to 3D TE. Furthermore, cardiac constructs from primary cardiac myocytes develop a primitive vascular network with or without addition of endothelial cells(38).",
            "latex": null,
            "type": "figure"
        },
        "FIGREF123": {
            "text": ", used an engineered 3D cardiac microtissue model to characterize mechanisms of human toxicity of sunitibnib, a drug with considerable cardiotoxicity that is used widely to treat renal cell, gastrointestinal, and neuroendodrine tumors. However, the pharmaceutical industry has been slow to adopt such models as drug development tools, and regulatory agencies have not yet put forth guidances for how these technologies can or should be integrated into preclinical and clinical safety trials, nor whether they can begin to replace animal models in either capacity. The process of defining how engineered tissue might be approved and introduced as a therapy, in contrast, has quickly developed (45-48), but even the expedited processes available at the FDA for such therapeutics generally still follow the pathway of preclinical animal studies followed by human trials. HUMAN TISSUE-ON-CHIP ENGINEERING. Cell-based toxicity assays (via traditional \"tissue culture\" approach) are problematic in predicting drug toxicity in preclinical testing because cultivated cells often do not retain their original organ functions and morphologies when taken out of the context of intraorgan connection and interactions. In tissue culture, for example, it is difficult to maintain cellular functions for sustained periods of time. Tissue culture cells receive nutrients, oxygen and other substances almost solely by diffusion. However, in vivo, cells obtain oxygen, nutrients, and other substances that regulate their function via blood flow, and they experience and respond to physical stimulation such as stretching and sheer forces within their complex environments. Such differences may account for rapid deactivation, senescence, and cellular loss in many in vitro cultures. In addition, interactions between organs cannot be directly tested in tissue culture. Microfabrication techniques and microfluid technology combined with computer technology has led to a new type of in vitro organ model: the so-called",
            "latex": null,
            "type": "figure"
        },
        "FIGREF124": {
            "text": "Liver-on-Chip: Example of Organ-on-Chip Technology On the left is a chip about the size of an AA battery. Primary hepatocytes are grown in the upper parenchymal channel within an ECM sandwich, on top of an extracellular matrix (ECM)-coated, porous membrane that separates the 2 parallel microchannels. Relevant speciesspecific liver sinusoidal endothelial cells with or without liver Kupffer cells or stellate cells are cultured on the opposite side of the membrane in the lower vascular channel. Reprinted with permission from Jang KJ, Otieno MA, Ronxhi J, et al. Reproducing human and cross-species drug toxicities using a liver-chip. Sci Transl Med 2019; eaas5516 (68). Reprinted with permission from AAAS. organ-on-chip (OC), which has been further combined into multiorgan chip interactions to mimic wholebody responses, or \"body-on-chip\" (BC). Creating a hybrid of human tissue on a computer chip that can replicate the structure and function of human organs may seem like the realm of science fiction; however, this new technology not only is a current reality, but also is quickly entering the regulatory framework for assessing new therapeutic compounds. In OCs, transparent chips about the size of an AA battery contain microchannels that are lined with cultured human cells and have microsensor capabilities (e.g., photolithography). These channels allow microfluid (or air) flow that mimic breathing motions, muscle contractions, and other physiologic stressors (Figure 1). The chips are then placed into a research system similar to a computer, in which toxins, chemicals, and medicines can be introduced to test the OC's response and behavior. In recent developments, at the Wyss Institute at Harvard University, OCs have been connected together to mimic multiorgan interactions within a body (49). Software within the research system allows the investigator to manipulate cell architecture, tissue-to-tissue interfaces, mechanical forces in the environment, and biochemical changes within the environment of the OCs or BCs. Such OCs and BCs have undergone rapid advancement in the last 5 years. They include the \"lung-on-chip\" or \"breathing lung\" chip developed at Harvard University (48), in which the 2-layer channel structure of the microchip is separated by a microporous, stretchable silicone membrane on which alveolar cells and vascular endothelial cells are cultured. The chip mimics the physiological expansion and contraction of alveolar movement by altering pressure on both sides of the membrane via vacuum chambers (Figure 2). Researchers were able to reproduce inflammatory reactions, and even to allow neutrophils to enter via a side channel to respond to bacterial invasion. Other organs mimicked by OCs include the liver, kidney, and gut (50). In 2017, the FDA announced a multiyear research and development agreement with Emulate, Inc. (Cambridge, Massachusetts), a biotech spinout from the Wyss Institute specializing in OCs (51). Earlier this year, researchers from Wake Forest School of Medicine demonstrated that multiorganoid BC systems were both stable and capable of detecting hepatic and cardiotoxicity at human-relevant doses in almost all members of a panel of drugs they tested that had to be recalled by the FDA for hepatic or cardiotoxicity",
            "latex": null,
            "type": "figure"
        },
        "FIGREF125": {
            "text": "Lung-on-Chip With Breathing Motion preclinical animal studies and all phases of human clinical trials had failed to detect significant toxicity. HEART-ON-A-CHIP. Despite being the most frequent cause of death in the United States and a cause of almost 18 million deaths annually worldwide (53), the number of novel drug approvals for CV disease has undergone progressive decline (54). In 2019, just 2 drugs were approved under the classification of CV disease, both of which were for treatment of a rare form of cardiomyopathy-transthyretin-mediated amyloidosis (55). There were no new drug therapies approved for coronary artery disease and hypertensive cardiac disease, which is responsible for 60% of CV deaths (56). CV toxicity is a major cause of drug withdrawals from the market (16%), second only to hepatic toxicity (57). The ability to mimic physiologic and mechanical effects in the microchip environment has vastly extended the CV research applications of OC technology in the last 10 years (38,58,59). In 2011, Grosberg et al. (60) developed a \"heart-on-chip\" platform with anisotropically organized cardiomyocytes, which could be stimulated to mimic in vivo production of electrical impulses by pacemaker cellsdemonstrating that the heart-on-chip could be used to study and measure contractile behavior, cellular alignment, and functionality of cardiac cells, and suggesting that chip technology could be used to study and evaluate pharmacologic interventions on cardiac contractile function. A similar approach demonstrated that in vitro \"chip\" testing of pharmacologic effects of isoproterenol was comparable to results of in vivo studies in rats (61). McCain et al. (62) have successfully created a \"failing heart-on-chip\" platform, further suggesting that chip technology can be used to create disease models, and not merely as a high-throughput method of testing drugs. Ren et al. (63) fabricated a heart-on-chip to mimic hypoxic myocardial injury. Researchers are exploring chip technology as a means of evaluating the use of stem cells to assess therapies for myocardial repair, as well as to generate in vitro models of cardiac disease. In one case, an in vitro disease model of Barth syndrome was developed, and then used to test potential pharmacological and genetic therapeutic options (64). \"ACCURACY\" OF OCs IN PREDICTING HUMAN DRUG TOXICITY AND MODELING DISEASE.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF126": {
            "text": "Schlieren, Switzerland), a commercial developer of a liver chip assay, claims that the sensitivity of the test (in predicting human toxicity) over animal testing is increased by a factor of 2 (66). During development of a vascularized human bone marrow (BM) OC, researches demonstrated that it reproduced aspects of BM injury, including myeloerythroid toxicity after clinically relevant exposures to chemotherapeutic drugs and ionizing radiation, and myeloid recovery after drug-induced myelosuppression, suggesting that a BM OC system may be useful for predicting human toxicity and designing in-human trials. When the BM OC was constructed using cells from patients with a rare genetic disorder, it not only reproduced key hemopoietic defects of the disease, but also led to",
            "latex": null,
            "type": "figure"
        },
        "FIGREF127": {
            "text": "Goals of reducing the time and cost of drug development, together with reduced public support for animal research, are driving attempts to find alternatives to animal testing, which does not sufficiently identify human safety and toxicity for therapeutics. Reducing pursuit of drugs that prove in late phase of development to have intolerable human toxicity is an fail animal testing will likely increase potential effective therapeutics in human disease. Although alternatives to animal research, such as cell and tissue platforms, computational in silico modeling, 3D tissue platforms and OC research have shown great promise in facilitating drug development while decreasing time and expense, they have yet to make significant inroads as replacements for preclinical animal testing. Although both the United States and European Union have recognized the value of pursuing alternative methods of research, such methods still await wider regulatory acceptance to replace animal testing in drug approval processes. ADDRESS FOR CORRESPONDENCE: Dr. Gail A. Van Norman, Department of Anesthesiology and Pain Medicine, University of Washington, 2141 8th Avenue West, Seattle, Washington 98119. E-mail: gvn@uw.edu. STATE-OF-THE-ART REVIEW Targeting Vascular Calcification in Chronic Kidney Disease Adam J. Nelson, BMEDSC, MD, PHD, a Paolo Raggi, MD, b Myles Wolf, MD, MMSC, c Alexander M. Gold, MD, d,e Glenn M. Chertow, MD, MPH, e Matthew T. Roe, MD, MHS a",
            "latex": null,
            "type": "figure"
        },
        "FIGREF128": {
            "text": "Cardiovascular (CV) disease remains an important cause of morbidity and mortality for patients with chronic kidney disease (CKD). Although clustering of traditional risk factors with CKD is well recognized, kidney-specific mechanisms are believed to drive the disproportionate burden of CV disease. One perturbation that is frequently observed at high rates in patients with CKD is vascular calcification, which may be a central mediator for an array of CV sequelae. This review summarizes the pathophysiological bases of intimal and medial vascular calcification in CKD, current strategies for diagnosis and management, and posits vascular calcification as a risk marker and therapeutic target.(J Am Coll Cardiol Basic Trans Science 2020;5:398-412) \u00a9 2020 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).",
            "latex": null,
            "type": "figure"
        },
        "FIGREF129": {
            "text": "and often dense lesions on intravascular imaging are more common in patients with CKD(31).",
            "latex": null,
            "type": "figure"
        },
        "FIGREF130": {
            "text": "Categorical and Cardiovascular Disease Cause-Specific Mortality (A) Categorical and (B) cardiovascular disease (CVD) cause-specific mortality in an electronic health record-derived sample of >30,000 residents from Ohio with nondialysis chronic kidney disease (estimated glomerular filtration rate: 15 to 60 ml/min/1.73 m 2 ) (140). CeVD \u00bc cerebrovascular disease; HF \u00bc heart failure; IHD \u00bc ischemic heart disease.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF131": {
            "text": "Cardiovascular Disease Burden in a Sample of Medicare Beneficiaries Cardiovascular disease burden in a sample of Medicare beneficiaries in the United States Renal Data System 2016 sample. CAD \u00bc coronary artery disease; PAD \u00bc peripheral arterial disease; SCD \u00bc sudden cardiac death; TIA \u00bc transient ischemic attack; VA \u00bc ventricular arrhythmia;",
            "latex": null,
            "type": "figure"
        },
        "FIGREF133": {
            "text": "Linking Clinicopathological Calcification Flowchart linking clinicopathological calcification. Ca \u00bc calcium; LA \u00bc left atrial; LVH \u00bc left ventricular hypertrophy; PTH \u00bc parathyroid hormone.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF134": {
            "text": "regulated in states of vitamin K deficiency and had less affinity for calcium in the setting of hyperphosphatemia, which are 2 common abnormalities observed in CKD(80,81). MGP requires vitamin K\u00c0dependent carboxylation to assume its inhibitory qualities, thus a reduction in MGP activity may not necessarily relate to absolute levels but to functional decreases through persistence of a decarboxylated state. Supportive translational data demonstrated the administration of vitamin K antagonists (e.g., warfarin) was associated with increased rates of vascular calcification in cell lines, animal models, and patients(82,83). These findings subsequently spawned interest in the potential therapeutic capacity of vitamin K supplementation (see the following).Other known inhibitors of vascular calcification include pyrophosphate and osteopontin. Pyrophosphate is produced by arterial smooth muscle and directly inhibits hydroxyapatite formation(84).Osteopontin is a phosphoprotein that regulates mineralization through multiple functions, including mediating angiogenesis and responses to inflammation and mechanical stress. The relationship between osteopontin and vascular calcification appears complex. Although there is evidence of upregulation in calcified vessels(85), serum levels do not readily correlate with calcific burden(86).MATRIX VESICLES AND APOPTOSIS. Matrix vesicles, a form of extracellular vesicle observed in the vascular wall, have been more broadly implicated in both transdifferentiation of VSMCs and the calcification environment (87). Extracellular vesicles are phospholipid membrane-bound particles, have molecular cargo (protein, RNA, or lipid), and are released by many cells and cell types in response to cell activation or apoptosis. Under pro-calcifying conditions the vesicles released by VSMCs are altered and resemble those released by osteoblasts (88). These vesicles act as nucleating points that have the capacity for calcium binding and extracellular matrix production. There is emerging evidence that these vesicles may permit cross-talk among VSMCs but potentially also between endothelial cells and other vascular cells (89), lending biological support for bidirectional positive feedback between intimal and medial calcification (90). In vesicles that contain genotypic and/or phenotypic information such as microRNA, the content of the specific sequences released by VMSCs may either induce or inhibit nearby pro-calcific phenotypic change (91). An additional paracrine-type effect may be mediated through osteoblastic-and/or osteochrondoblastic-like cell activity on surrounding tissue. Subsequent changes in relative collagen composition and the degradation of elastin (92) have been shown to promote hydroxyapatite formation and provide scaffolding for further mineralization (93).FGF-23 AND KLOTHO. Most FGF-23 is produced by bone (94) and although the mediators of its release remain incompletely understood (95), associations with PTH (96), iron deficiency (97), calcium (98), and vitamin D (99) have been consistently observed. The primary function of FGF-23 is to orchestrate phosphate and calcium homeostasis by stimulating urinary phosphate excretion and suppressing circulating concentrations of calcitriol (100). The activity of FGF-23 to regulate phosphate homeostasis in the kidney requires the presence of klotho, a co-receptor that facilitates binding of FGF-23 to the FGF-receptor (101). FGF-23 excess is associated with poor outcomes in CKD (102), although its links to vascular calcification are less clear, and multiple studies have conveyed conflicting results. Human and animal VSMCs exposed to FGF-23 in the presence or absence of klotho, and in the presence of normal or high phosphate, showed increased, decreased, or no effect at all on vascular calcification (103\u00c0107). These conflicting results posit a more complex role of FGF-23 in vascular calcification; however, it is also possible that FGF-23 is not causal factor at all. Unlike FGF-23, in vitro and in vivo evidence support a protective role of klotho in vascular calcification. Addition of klotho to a rat VSMC line directly suppressed Pit-1 and Pit-2 activity and subsequently prevented phosphateinduced osteogenic transdifferentiation. In addition, klotho knockout models demonstrated increased expression of Pit-1 and Pit-2 receptors, which suggested that the progressive klotho deficiency observed in advancing CKD might result in investment into targeting intermediates of bone and mineral metabolism over several years has yielded little more than possible slowing of vascular calcification. Critically, neither evidence of halting nor evidence of regression has been observed. Further data questioning the validity of a passive (or restorative) therapeutic approach comes from elegant animal work in which calcified aortas from uremic mice were orthotopically transplanted into non-CKD mice and observed for 34 weeks (109). Although there was some superficial loss of calcium, there was no significant active resorption or regression of established calcified salts. Despite the failures to date, novel therapeutic approaches are emerging that actively target calcified material and may offer fresh insights into drug discovery in this area of unmet need. CALCIMIMETICS. The calcium-sensing receptor (CaR) is expressed in multiple tissues but particularly in the parathyroid glands, which makes it an effective target for treating secondary hyperparathyroidism and disordered mineral metabolism in patients with ESKD. Calcimimetics bind to the CaR and allosterically increase the parathyroid cell sensitivity to extracellular calcium, thereby suppressing the release of PTH and resulting in a reduction of serum calcium. In patients with ESKD, calcimimetics also decrease serum phosphate, presumably through a reduction in PTH-mediated bone resorption, which otherwise releases bone phosphate into the circulation. Beyond modulating PTH release, the CaR is also found on VSMCs (110) and its stimulation is associated with a reduction in phosphate-and calcium-driven vascular mineralization both in vitro and in animal models (111,112). These findings prompted the design and execution of 2 key clinical studies that evaluated cinacalcet: ADVANCE (A Randomised Study to Evaluate the Effects of Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects with Chronic Kidney Disease Receiving Hemodialysis) and EVOLVE (Evaluation of Cinacalcet Hydrochloride Therapy to Lower Cardiovascular Events). ADVANCE enrolled 360 patients who received hemodialysis across 3 continents with secondary hyperparathyroidism and CAC (113). Participants were randomized to openlabel cinacalcet and low-dose vitamin D analogs or flexible vitamin D therapy and were followed for 12 months. At follow-up, there was a smaller numerical increase (i.e., attenuation of progression) in the CAC score of the cinacalcet-treated patients compared with those treated with flexible vitamin D therapy; however, this did not reach statistical significance (progression of CAC: 24%; 95% CI: \u00c022% to 119% vs. 31% (95% CI: \u00c09% to 179%; p \u00bc 0.073). A secondary analysis by CAC volume score in the coronaries and the aortic valve suggested a potential beneficial effect of cinacalcet, although this was only of nominal significance. It remained unclear if excess vitamin D use might have mitigated the benefits of cinacalcet, or whether a 12-month follow-up might have been too short to observe a significant change.In comparison, the EVOLVE trial randomized 3,883 patients with secondary hyperparathyroidism on maintenance hemodialysis to cinacalcet or placebo in the setting of conventional therapy (e.g., phosphate binders and calcitriol or active vitamin D analogs)(114). After a median follow-up of 17 (placebo) to 21 (cinacalcet) months, there was an observed trend for relative reduction in the HR for the primary composite CV outcome (i.e., time until death, myocardial infarction, hospitalization for unstable angina, heart failure, or a peripheral vascular event) (HR: 0.93; 95% CI: 0.85 to 1.02; p \u00bc 0.11). Post hoc adjustment for age yielded lower relative HRs with nominally significant results in favor of cinacalcet, as did the analyses that accounted for differential withdrawal of study drug and commercial use of cinacalcet in the placebo arm.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF136": {
            "text": "SNF472: MYO-INOSITOL HEXAPHOSPHATE. A compound with promising results in early phase studies is SNF472, which is a hexasodium salt of the active",
            "latex": null,
            "type": "figure"
        },
        "FIGREF137": {
            "text": "Biologically plausible, temporal, and dose-dependent relationships exist between vascular calcification and CV outcomes in patients with CKD. Despite a large investment in potential therapeutic strategies, little more than slowing of calcification has been documented in only a handful of previous studies. The reasons for a lack of progress are multiple and varied. At a pre-clinical level, there are a lack of animal models that faithfully recapitulate a chronic, progressive CKD calcification process. The extension of pre-clinical findings derived from the current acute injury models may be misleading and translate to early clinical phase failure. The modification of an adenine murine model that does not require transgenic manipulation or surgical intervention appears promising (139). From an imaging perspective, a metric that reliably and quantitatively measures medial calcification with fidelity over time would be a welcome addition to trial endpoints of novel therapies. That said, currently enrolling studies have included imaging of multiple vascular beds or included functional assessments of arterial stiffness.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF138": {
            "text": "vention at a point of inexorable vascular damage, in which case trials such as IMPROVE-CKD may demonstrate the potential benefits of earlier, more preventative intervention. Alternatively, because of the multiple and synergistic processes involved in the development of vascular calcification in CKD, addressing individual upstream factors in isolation, even if dominant, may not be sufficient. Instead, actively targeting the final common pathway of calcification, such as with an anticalcifying agent agnostic to the upstream processes, may provide critical insight on this type of therapeutic approach. After decades of translational research fueling heated debate and polarized opinion, the next wave of evidence may finally provide the answer to whether arterial calcification, particularly in the",
            "latex": null,
            "type": "figure"
        },
        "FIGREF139": {
            "text": "Whom the Bell Tolls Douglas L. Mann, MD, Editor-in-Chief, JACC: Basic to Translational Science \"No man is an island, entire of itself; every man is a piece of the continent, a part of the main. If a clod be washed away by the sea, Europe is the less, as well as if a promontory were, as well as if a manor of thy friend's or of thine own were: any man's death diminishes me, because I am involved in mankind, and therefore never send to know for whom the bells tolls; it tolls for thee.\" -John Donne, Devotions Upon Emergent Occasions (1) I n mid-December 2019, Chinese physicians working in Wuhan, a port city of 11 million people in the central province of Hubei, reported several cases of an undisclosed pneumonia. Using a surveillance mechanism that was established following the 2003 severe acute respiratory syndrome (SARS) outbreak, the initial 4 reported cases of \"pneumonia of unknown etiology\" were linked to the Huanan Seafood Wholesale Market, which consequently was shut down on January 1, 2020. Based on the results of deep sequencing and investigations by 5 independent laboratories, Chinese officials reported on January 7, 2020, that the causative agent of the mystery pneumonia was a novel coronavirus (nCoV). Sequence analysis revealed that the 2019-nCoV possesses a typical genome structure of coronavirus belonging to the cluster of betacoronaviruses that includes Bat-SARS-like (SL)-ZC45, Bat-SL ZXC21, SARS-CoV, and Middle East respiratory syndrome-CoV. Based on the genomic content of coronavirus disease viruses, 2019-nCov appears to be more closely related to bat-SL-CoV ZC45 and bat-SL-CoV ZXC2, and more distantly related to SARS-CoV (2). On January 11, 2020, China reported the first death from nCoV in a 61-year-old man who purchased goods from the Huanan Seafood Wholesale Market. In the weeks that followed, the coronavirus outbreak spread across China, slithering into neighboring countries and continents. By January 13, the World Health Organization reported a case of 2019-nCoV in a woman in Thailand, who had arrived from Wuhan. Thus began what we now recognize as the coronavirus disease 2019 (COVID-19) pandemic. How the 2019-nCoV spread from a seafood market to become a worldwide pandemic that collapsed economies worldwide within a matter of months will continue to be the grist for the medical, economic, and political mills, now and for the foreseeable future. Certainly, there is plenty of blame to go around, beginning with the early handling of the outbreak by Chinese officials, as well as the agonizingly slow roll out of nCoV testing in the United States. Notwithstanding the reflexive finger-pointing and blame-gaming, there is an inspiring backstory of human sacrifice, heroism, and courage on the part of the health care workers in China, who were grappling with treating patients with SARS flu-like symptoms, but without any specific knowledge about the virulence or pathogenicity of the disease they were treating. Moreover, the frontline Chinese health care workers were providing care without proper personal protective equipment to shield them from harm. In a sobering article in the Los Angeles Times titled \"Doctors and Nurses Fighting Coronavirus in China Die of Both Infection and Fatigue\" (3), Alice Su reports that there were \"18 reported deaths of medical workers involved in the COVID-19 response as of Monday [February 24, 2020], including nurses and doctors who died not because of infection but because of cardiac arrest or other ailments due to overwork and fatigue.",
            "latex": null,
            "type": "figure"
        },
        "TABREF0": {
            "text": "Inclusion and Exclusion Criteria",
            "latex": null,
            "type": "table"
        },
        "TABREF1": {
            "text": "shows a detailed calendar of the procedures that are performed at each study visit.",
            "latex": null,
            "type": "table"
        },
        "TABREF2": {
            "text": "Overview of Study Visits and Examinations",
            "latex": null,
            "type": "table"
        },
        "TABREF3": {
            "text": "Recommended Medication Dose Titration Algorithm",
            "latex": null,
            "type": "table"
        },
        "TABREF4": {
            "text": "SPHERE-HF targets those patients who are most likely to develop pulmonary vascular remodeling and impaired RV function, and therefore, may potentially benefit most from b3AR stimulation. As opposed to other trials, the primary outcome measure in SPHERE-HF is the change in PVR rather than inhibition in a 1-year study.Circulation 2011;124:164-74. 15. Redfield MM, Chen HH, Borlaug BA, et al. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA 2013;309:1268-77.16. Hoendermis ES, Liu LC, Hummel YM, et al. Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial. Eur Heart J 2015;36:2565-73.17. Bermejo J, Yotti R, Garcia-Orta R, et al. Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: a multicenter, doubleblind, randomized clinical trial. Eur Heart J 2018;",
            "latex": null,
            "type": "table"
        },
        "TABREF5": {
            "text": "25. Garcia-Prieto J, Garcia-Ruiz JM, Sanz-Rosa D, et al. b3 adrenergic receptor selective stimulation MA, et al. A proof-of-concept study: mirabegron, a new therapy for overactive bladder. Neurourol Urodyn 2013;32:1116-22.33. Chapple CR, Dvorak V, Radziszewski P, et al. A phase II dose-ranging study of mirabegron in patients with overactive bladder. Int Urogynecol J 2013;24:1447-58. 34. Chapple CR, Kaplan SA, Mitcheson D, et al. 38. Bundgaard H, Axelsson A, Hartvig Thomsen J, et al. The first-in-man randomized trial of a beta3 adrenoceptor agonist in chronic heart failure: the BEAT-HF trial. Eur J Heart Fail 2017;19:566-75.50. Vanderpool RR, Naeije R. Progress in pulmonary hypertension with left heart failure. Beyond new definitions and acronyms. Am J Respir Crit Care Med 2015;192:1152-4.51. Packer M, McMurray J, Massie BM, et al. Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study. J Card Fail 2005;11:12-20. 52. Swiston JR, Johnson SR, Granton JT. Factors that prognosticate mortality in idiopathic pulmonary arterial hypertension: a systematic review of the literature. Respir Med 2010;104:1588-607.",
            "latex": null,
            "type": "table"
        },
        "TABREF6": {
            "text": "). A failure of histologic grade to correlate with a patient's imminent clinical trajectory can cause false reassurance in some cases and false alarm in others, with resultant treatment delays or overtreatment posing serious risks to patients. Because conventional ISHLT histologic grade never provides longerterm risk stratification, surveillance testing and immunosuppression-weaning protocols cannot be tailored to individual CAR risk. As a result, low-risk patients undergo more EMB procedures and more aggressive immunosuppression than are needed with attendant risks of infection and procedural complications. On the other hand, high-risk patients undergo premature weaning of immunosuppression, resulting in potentially avoidable rejection episodes. Both of these scenarios represent opportunities for better outcomes through improved diagnostic accuracy and greater prognostic insight. The traditional approach to morphologic CAR detection involves the identification and rough quantification of basophilic immune cells on hematoxylin and eosin-stained slides. This approach provides few insights into the specific types (and therefore, functions) of the immune cells present within EMB tissue. Expert panels have explicitly acknowledged the need for \"further characterization of the nature of the A B B R E V I A T I O N S A N D A C R O N Y M S CAR = cardiac allograft rejection CD = cluster of differentiation EMB = endomyocardial biopsy QmIF = quantitative multiplex immunofluorescence From the a Cardiovascular Research Institute, University of Pennsylvania, Philadelphia, Pennsylvania; b Akoya Biosciences, Hopkinton, Massachusetts; and the c Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. Research reported in this publication was supported by the Gund Family Fund at the University of Pennsylvania and the National Center for Advancing Translational Sciences of the National Institutes of Health under award number TL1TR001880. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Mr. Wang, Ms. Ishola, and Ms. Remeniuk are employed by Akoya Biosciences. Mr. Hoyt is employed by Akoya Biosciences; and owns Akoya Biosciences stock and stock options. Dr. Feldman is an equity holder and has technology licensed to both Elucid Bioimaging and Inspirata Inc.; has served as a scientific advisory consultant for Inspirata Inc.; served on the scientific Advisory Board of Inspirata Inc.; and has consulted for Phillips Healthcare, XFIN, and Virbio. Dr. Margulies has received research grants from Thoratec Corporation, Merck, Sanofi-Aventis USA, and GlaxoSmithKline; has served as a scientific consultant for American Regent; and has served as an Advisory Board member for Pfizer and MyoKardia. Dr. Peyster has reported that he has no relationships relevant to the contents of this paper to disclose. The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors' institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the JACC: Basic to Translational Science author instructions page. Manuscript received December 15, 2019; revised manuscript received January 24, 2020, accepted January 24, 2020.",
            "latex": null,
            "type": "table"
        },
        "TABREF7": {
            "text": "permit identification of clinically significant cases with greater sensitivity. By design, a subset of each clinical trajectory category represented an EMB with clinicalhistologic discordance (low-histologic grade meeting criteria for clinically evident rejection, or highhistologic grade with none of the criteria met for clinically evident rejection). All determinations of clinically evident versus clinically silent rejection were completed prior to the performance of immunostaining.",
            "latex": null,
            "type": "table"
        },
        "TABREF8": {
            "text": "). However, the checkpoint pathway has been recognized for its role in abrogating T-cell responses and promoting toler-Exposure times were set to avoid saturation.",
            "latex": null,
            "type": "table"
        },
        "TABREF9": {
            "text": "Criteria for Determining Clinically Evident RejectionAdmission to hospital for rejection treatment, along with 1 major or 2 minor criteria:Cardiac index #2.3, provided this represents a $20% decrease in cardiac index from baseline Right atrial pressure >10 mm Hg or pulmonary capillary wedge pressure >18 mm Hg provided this represents a $40% increase from baseline Absolute decrease in LVEF of $10% and to a level of #50% New arrhythmia-atrial fibrillation, flutter, or ventricular arrhythmia New low voltage ECG not due to pericardial effusion or pulmonary disease Cardiac troponin elevated $3\u00c2 the upper limit of normal and $3\u00c2 the patient's baseline, not due to coronary artery disease/graft vasculopathy Documented diagnosis of increased LV wall thickness and an LV wall thickness increase of >2 mm from baseline value ECG \u00bc electrocardiogram; LV \u00bc left ventricular; LVEF \u00bc left ventricular ejection fraction.",
            "latex": null,
            "type": "table"
        },
        "TABREF11": {
            "text": "",
            "latex": null,
            "type": "table"
        },
        "TABREF13": {
            "text": "QmIF Total Cell Count Results",
            "latex": null,
            "type": "table"
        },
        "TABREF14": {
            "text": "QmIF Results by Immune Cell Type With Cases Grouped by Clinical Rejection Trajectory and Conventional Histologic Grade EMB \u00bc endomyocardial biopsy; H-score \u00bc histology score; other abbreviations as Table 1.",
            "latex": null,
            "type": "table"
        },
        "TABREF17": {
            "text": "QmIF Results by Immune Cell Type, With Cases Grouped by Contingency Table Designation Based on Concordance Versus Discordance of Clinical Rejection C \u00bc concordance; D \u00bc discordance; High \u00bc high grade; ISHLT \u00bc International Society of Heart and Lung Transplantation; Low \u00bc low grade; other abbreviations as inTables 2 and 3.",
            "latex": null,
            "type": "table"
        },
        "TABREF18": {
            "text": "QmIF Results for Cases Associated With Future Serious Rejection and Those",
            "latex": null,
            "type": "table"
        },
        "TABREF19": {
            "text": "QmIF results for CD68\u00fe, FoxP3\u00fe, and PD-L1\u00fe cells, grouped by future CAR risk and temporal proximity to a high-grade, clinically evident rejection event. Never-CAR cases have markedly higher proportions of immune-modulating FoxP3 and PD-L1 than do future-CAR cases. Future-CAR cases when assessed by temporal proximity to a serious rejection event demonstrate an almost complete loss of detectable IF signal for each of these potentially allograft-protective",
            "latex": null,
            "type": "table"
        },
        "TABREF21": {
            "text": "venous ligation DVT model in the jugular vein, allowing us to monitor inflamed activity of DVT in the same animal using fluorodeoxyglucose-positron emission tomography(14). However, owing to its large thrombus size and pulsatile artifact, highresolution in vivo imaging at a single-cell level using intravital fluorescence microscopy was not feasible in jugular DVT.Establishment of novel VTE imaging model is critical to overcome these issues. In this study, we established a novel murine VTE model, which is suitable for real-time in vivo imaging of thrombus formation in the large lower extremity veins using",
            "latex": null,
            "type": "table"
        },
        "TABREF22": {
            "text": "). Results were expressed as median with IQR (25th, 75th percentiles). The statistical significance of differences between 2 groups were assessed using Mann-Whitney U test. Differences between more than 2 groups were evaluated using Kruskal-Wallis test followed by the Dunn multiple comparison post hoc test. A p value of <0.05 was considered statistically significant.FORMATION AT LIGATED FEMORAL/SAPHENOUS VEIN BY FLUORESCENCE MICROSCOPY. We initially tried to establish the stasis DVT model at the saphenous vein to allow in vivo imaging with fluorescence microscopy. However, due to multiple side branches and collateral formation within days, we failed to induce thrombus formation by ligation alone. We then tried to monitor the behavior of leukocytes and platelets after the ligation as they are reported to attach to the vein wall within several hours after the IVC ligation",
            "latex": null,
            "type": "table"
        },
        "TABREF23": {
            "text": "TWO-PHOTON IMAGING OF FORMED DVT. Recent advances in the 2-photon microscopy enabled fluorescence imaging of living deeper tissue such as, for example, brain, skin, bone, and heart(12,18,19). To the best of our knowledge, this is the first model visualizing erythrocyte-rich DVT in murine femoral vein with a single-cell level resolution. Highresolution imaging with 2-photon microscopy allows for a clear distinction between rhodamine 6G-labeled leukocytes and platelets by size(Figures 5A and 5B). harmonic generation can visualize collagen fibers; therefore, the vein wall and venous valve can be imaged without an exogenous labeling agent. DVT formed within venous valve pocket and surrounding platelets accumulation can be clearly imaged (Figures 5C to 5E).",
            "latex": null,
            "type": "table"
        },
        "TABREF25": {
            "text": "15. Min SK, Kim YH, Joh JH, et al. Diagnosis and treatment of lower extremity deep vein thrombosis: Korean practice guidelines. Vasc Specialist Int 2016;32:77-104.",
            "latex": null,
            "type": "table"
        },
        "TABREF27": {
            "text": "Pathology and Forensic Medicine, University of Turku, Turku, Finland; j Athera Biotechnologies AB, Stockholm, Sweden; k Turku PET Centre, Turku University Hospital, Turku, Finland; l Heart Center, Turku University Hospital, Turku, Finland; and the m Institute of Clinical Medicine, Turku University Hospital, Turku, Finland. The study was conducted within the Finnish Centre of Excellence in Cardiovascular and Metabolic Diseases supported by the Academy of Finland, University of Turku, Turku University Roivainen, and Saraste were supported by the Finnish Foundation for Cardiovascular Research. Drs. Roivainen and Saraste were supported by the Sigrid Jus\u00e9lius Foundation. Ms. St\u00e5hle was supported by the Instrumentarium Science Foundation, the Finnish Cultural Foundation, and the Drug Research Doctoral Programme, University of Turku Graduate School, Turku, Finland. Dr. Kroon was supported by the Netherlands Organization for Scientific Research VENI (91619098). Drs. Pettersson and T. Abrahamsson have received consultancy fees from and hold shares in Athera Biotechnologies AB. Dr. Pettersson is named as co-inventor on patent applications regarding therapeutic antibodies to PC assigned to Athera Biotechnologies AB. Dr. Knuuti has been a consultant for GE Healthcare and AstraZeneca. Dr. Saraste has been a member of the Advisory Board for AstraZeneca; and has received speaker fees from AstraZeneca, Bayer, Novartis, and Abbott. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors' institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the JACC: Basic to Translational Science author instructions page.",
            "latex": null,
            "type": "table"
        },
        "TABREF29": {
            "text": "Characteristics of LDLR \u00c0/\u00c0 ApoB 100/100 Mice at the Time ApoB \u00bc apolipoprotein-B; F \u00bc female; HDL \u00bc high-density lipoprotein; LDL \u00bc low-density lipoprotein; LDLR \u00bc low-density lipoprotein receptor; M \u00bc male.",
            "latex": null,
            "type": "table"
        },
        "TABREF33": {
            "text": "*Editorials published in JACC: Basic to Translational Science reflect the views of the authors and do not necessarily represent the views of JACC: Basic to Translational Science or the American College of Cardiology. From the Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria. Dr. Tsiantoulas has reported that he has no relationships relevant to the contents of this paper to disclose.",
            "latex": null,
            "type": "table"
        },
        "TABREF34": {
            "text": "at Mount Sinai, New York, New York; c Department of Molecular Physiology and Biophysics, Vanderbilt School of Medicine, Nashville, Tennessee; d Molecular Medicine Program, University of Utah School of Medicine, Salt Lake City, Utah; e Coriell Institute, Camden, New Jersey; f Gladstone Institute of Cardiovascular Disease, San Francisco, California; g Division of Pediatric Cardiology, Stanford University School of Medicine, Stanford University, Stanford, California; h Department of Cardiology, Great Ormond Street Hospital, University College London, London, United Kingdom; i Department of Pediatrics, University of Rochester Medical Center, University of Rochester School of Medicine and Dentistry, Rochester, New York; j Section of Cardio-Medical Center, New York, New York; s Department of Medicine, Columbia University Medical Center, New York, New York; t Nora Eccles Harrison Cardiovascular Research and Training Institute, University of Utah School of Medicine, Salt Lake City, Utah; Mindich Child Health and Development Institute, Icahn School of Medicine at Mount Sinai, New York, New York; and the Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, New York. This work was supported by a grant from the National Center for Research Resources and the National Center for Advancing Translational Sciences (U01 HL098153), Dr. Edwards was supported by National Institutes of Health Grant No. 5T32HL007915. Drs. Lifton and Seidman were supported by the Howard Hughes Medical Institute. Dr. Chung was supported by the Simons Foundation. Dr. Srivastava is co-founder and has served on the scientific advisory board for Tenaya Therapeutics. Dr. Lifton is director of Roche; has served on the scientific advisory board for Regeneron; and has served as a consultant for Johnson and Johnson. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors' institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the JACC: Basic to Translational Science author instructions page.that link variants to prioritize identification and lead to the discovery of novel candidate causal CHD genes.Validation of selected genes in model systems will ultimately expand our ability to detect genetic etiologies for patients.",
            "latex": null,
            "type": "table"
        },
        "TABREF35": {
            "text": "",
            "latex": null,
            "type": "table"
        },
        "TABREF36": {
            "text": ". The relatively low overlap in enriched terms",
            "latex": null,
            "type": "table"
        },
        "TABREF37": {
            "text": "Mutation Burden by Variant Filter and Phenotype CI \u00bc confidence interval; CTD \u00bc conotruncal defect; HHE \u00bc high fetal heart expression; HTX \u00bc heterotaxy; MGI \u00bc Mouse Genome Informatics; Var \u00bc variants.",
            "latex": null,
            "type": "table"
        },
        "TABREF38": {
            "text": "LVOTO Gene Set Enrichment",
            "latex": null,
            "type": "table"
        },
        "TABREF40": {
            "text": "Correlation of Liver Chip Results for Drugs Halted in Clinical Trials (i.e., Drugs That Had Passed Animal Toxicity Studies) Thus, the BM OC may be useful in discovering new, human-relevant therapeutic targets.In late 2019, Jang et al.(68)  developed a multispecies liver OC that was able to differentiate speciesspecific toxicities of test compounds in human, canine, and rat species. In one case, a proprietary test compound from Janssen Pharmaceuticals (Raritan, New Jersey), which had shown liver inflammation in rats and was subsequently discontinued from further development, showed replication of the rat findings but demonstrated a lack of toxicity in human cells.With a second proprietary compound, the canine portion of the canine chip was able to replicate the liver inflammation that had been found in dogs, and also suggested changes in human cells, suggesting a high likelihood of human toxicity. In addition, the authors tested their chip against drugs that had survived preclinical animal tests, only to be discontinued during human trials due to liver toxicity, and found that the chip accurately predicted human toxicity (Table 1). This is particularly intriguing news, as liver injury is the most frequent reason for post market withdrawal of drugs(69). Cross-species chips may be able to hone animal testing to only those species whose toxicity has been shown by chip analysis to be relevant to humans, sparing animals, time, and expense while preserving human safety.Despite academic enthusiasm for OC technology, industry has been cautious in adopting it for preclinical drug screening. In 2018, only about 20% of the top 50 pharmaceutical companies routinely used OC screening (66). OC technology is currently most widely applied in screening research for therapeutic targets, in preclinical testing in which no regulatory submissions are in question, than for toxicity testing, which at this time carries considerable regulatory uncertainty. A significant impediment is lack of standards for validation parameters for compounds, endpoints, exposure times, and thresholds for sensitivity and specificity, which contribute to the hesitance about acceptance/rejection criteria from the FDA and other regulators, including whether OC technology can at least partially replace animal testing in preclinical phases.In order to overcome some of these obstacles, theNIH National Center for Advancing Translational Sciences has collaborated with the FDA in the Tissue Chip for Drug Screening program to develop human tissue chips that accurately model the structure and function of human organs and predict drug safety in humans more rapidly and effectively.Updated information about funding opportunities for chip research can be found on their website (70). ADDITIONAL REGULATORY STEPS In December of 2017, the Toxicology Working Group at the U.S. FDA released its Predictive Technology Roadmap, which was formulated with a mission to strengthen the FDA's commitment to promoting the development and use of new technologies to better predict human, animal and environmental responses to a wide range of substances relevant to FDA's regulatory mission (71). In a September 2018, public hearing for stakeholder feedback on the roadmap, Commissioner Scott Gottlieb expressed a desire to apply OC technology across the life cycle of regulated product development, observing that \"results in animals are not always predictive of results in humans \" (66). Although the FDA has emphasized support for alternative research methods, to date most therapeutics require animal testing in the preclinical phases, and do not allow substitution of alternative methods. Under the 21st Century Cures Act (72), certain therapeutics wholly or partially including human cells, tissues, and \"therapeutic tissue engineering products\" may achieve status as \"regenerative medicine advanced therapies\" and be eligible for certain expedited pathways at the FDA for approval, including focused and expedited FDA review, acceptance of retrospective data in lieu of some clinical study requirements, and other measures (48). However, these programs do not yet generally allow substitution of alternative research for preclinical animal studies.In 2006, the European Union passed REACH (Registration, Evaluation, Authorization, and restriction of Chemicals) legislation that set a goal of reducing animal testing, and REACH does embrace some in silico methods(48,73). The European",
            "latex": null,
            "type": "table"
        },
        "TABREF41": {
            "text": "C hronic kidney disease (CKD) is a major global public health problem. Defined by the sus-CKD is believed to affect 10% to 15% of the population and is estimated to contribute to 5 to 10 million deaths annually(2,3). Despite improvements in the care of patients with CKD, life expectancy remains significantly reduced across all stages of kidney disease",
            "latex": null,
            "type": "table"
        },
        "TABREF42": {
            "text": "are all significantly increased across the spectrum of CKD. Clustering of traditional risk factors such as type 2 diabetes mellitus and hypertension were originally believed to drive propensity for CVD in these patients; however, meta-analyses have consistently identified significant residual, CKDspecific risk(17,18). Once CVD is established, CKD confers a significantly worse prognosis with a more aggressive disease phenotype, higher risk of complications, and premature cause-specific death(18).Reduced efficacy of proven secondary preventative therapies (e.g., statins) likely also contribute to the divergent outcomes experienced by patients with CKD (19\u00c021). Multiple systemic perturbations observed in CKD can lead to cardiac and vascular damage, and likely underscore the increased risk of CV events observed in this population. Vascular calcification, the pathological deposition of calcium salts in the arterial wall, has been observed among patients with CKD at between 2-and 5-fold the rate of age-matched non-CKD patients. A large body of evidence has subsequently supported biologically plausible, temporal (22), and dose\u00c0response (23) relations between vascular calcification and CV risk in patients with CKD. However, whether the regression or halting of vascular calcification is possible and subsequently results in improved CV outcomes remains to be determined. There are several distinct phenotypes of CV calcification-intimal vascular, medial vascular, and valvular. Although valvular calcification is increasingly recognized as an important contributor to morbidity and mortality in patients with CKD, particularly those on dialysis (24), for the purpose of this review we focused on the vascular entities of intimal and medial calcification. Intimal and medial vascular calcification are defined by their location within the arterial wall, which is a distinction that helps separate predisposing etiology, regional distribution, and clinical sequelae (Figure 3). Although this has intrinsic appeal, noninvasive imaging is unable to discern intimal from medial calcification; thus, our insights into the natural history and clinical relevance of each type of vascular calcification are limited. INTIMAL CALCIFICATION. Intimal calcification occurs almost exclusively in the context of atherosclerosis, which has a predilection for medium to large arteries and areas of abnormal flow, such as arterial vessel bifurcations.Although generally increased in patients with CKD, intimal calcification is not specific to CKD and instead is associated with traditional atherogenic risk factors such as dyslipidemia, diabetes, hypertension, and cigarette smoking(25). Of note, adolescents on dialysis who do not have traditional risk factors develop medial calcification almost exclusively(26,27), which is similar to animal models of CKD that are not exposed to an additional metabolic stimulus (e.g., through low-density lipoprotein (LDL) receptor knockout or a high cholesterol diet)(28). CKD may promote, accelerate, or catalyze an already established, synchronous atherosclerotic calcification process rather than incite it(29). Regardless, the complications of intimal calcification are believed to be local and mediated through the development of luminal stenosis, obstruction, and distal ischemia or infarction (i.e., myocardial infarction, stroke, or limb events). In general, intimal calcification appears to be dynamic and may be considered a barometer for the atherosclerotic cycle; microscopic flecks are visible during the earliest stages of intimal thickening and diffuse, confluent regions are observed in the most advanced fibrocalcific lesions(30). Although spotty calcification (approximately 1 mm in size) observed on both computed tomography (CT) and intravascular imaging has been associated with plaque instability and propensity for atherothrombotic events, confluent calcific lesions appear to be associated with a more stable phenotype(30)  and may instead represent a teleological response to injury(25). These confluent",
            "latex": null,
            "type": "table"
        },
        "TABREF43": {
            "text": "Whether the accelerated atherosclerotic or intimal calcification observed in CKD is causally linked to adverse CV outcomes or may be acting as a synchronous biomarker for medial calcification remains undetermined.MEDIAL CALCIFICATION. Unlike the often patchy distribution of intimal calcification, medial calcification tends to be more diffuse, forming sheets in topographic areas typically devoid of lipid or atherosclerotic change (26) (Central Illustration). Although medial calcification is seen in vessels of all calibers, it is conspicuous for location in territories usually spared from atherosclerosis, such as the internal mammary, radial, and digital arteries. Medial calcification is more specific to CKD because it appears to be abnormal bone and mineral metabolism, severity of CKD, and dialysis vintage. In addition to CKD, medial calcification is also observed with diabetes mellitus and advanced age; these 3 entities potentially share linking pathophysiology of chronic inflammation and cellular senescence(32). Compared with intimal calcification, medial calcification is rarely associated with local luminal compromise, and instead is linked to the systemic manifestations of increased arterial stiffness. Following seminal observations linking the presence of (mostly medial) vascular calcification with increased arterial stiffness(33,34), the latter has been considered a functional surrogate for the former. A reduction in vascular compliance augments systolic blood pressure, which increases cardiac work and causes left ventricular hypertrophy",
            "latex": null,
            "type": "table"
        },
        "TABREF44": {
            "text": "Most vascular calcification is detected incidentally through imaging obtained for other indications. In the research setting, several methods have been developed to quantitate vascular calcification and stratify risk. The most studied is the Agatston score (39) (often synonymous with \"calcium score\") for coronary artery calcification on CT scans. However, the Kauppila index (40) for abdominal aortic calcification and the Adragao score (41) for both lower abdominal aorta and peripheral arteries have also been shown to have a prognostic value. As alluded to earlier, noninvasive imaging is unable to discern intimal from medial calcification; a limitation that is amplified in CKD in which there is a greater degree of coexistence of both processes, particularly in the coronary arteries, peripheral arteries, and the aorta. For this reason, there has been enthusiasm for evaluating arterial beds that are generally devoid of atherosclerosis, thereby providing more specific measures of medial calcification. Another approach has been to assess the functional consequences of calcification by evaluating indexes of arterial stiffness, reviewed elsewhere in detail",
            "latex": null,
            "type": "table"
        },
        "TABREF45": {
            "text": "Over 30 years of data in the general population has shown that CT coronary artery calcification(CAC)    scoring with the Agatston score closely correlates with the atherosclerotic plaque burden, is linearly and independently associated with CV outcomes, and may outperform other established biomarkers for CV risk prognostication, including the ankle\u00c0brachial index, high-sensitivity C-reactive protein, and carotid intima media thickness(43). Seminal observations in the 1990s reported that patients with ESKD who received dialysis had an average CAC score that was an order of magnitude greater than what was generally considered a high-risk threshold (4,290 AE 1,509 Agatston units vs. >400 Agatston units)(44).Findings some years later affirmed the presence of a graded relationship between severity of CKD and CAC score(45,46). Until recently, data on the prognostic role of CAC in CKD was conflicting because of singlecenter studies, small sample sizes, or recruitment of narrow CKD severity grades(47). In the largest studyof patients with CKD published in 2017, investigators evaluated the CAC scores of 1,541 participants with an eGFRs of 20 to 70 ml/min/1.73 m 2 without established CVD as part of the CRIC Chronic Renal Insufficiency Cohort) trial (48). Over a median follow-up of 6 years, a total of 60 myocardial infarctions, 120 index heart failure events, 27 strokes, and 137 all-cause deaths occurred. There was a stepwise association between CAC severity (CAC score 0, 0 to 100, >100) and composite CV outcome. In multivariable modeling, the relative hazard ratios (HRs) associated with a 1 SD of log CAC were 1.40 (95% confidence interval [CI]: 1.16 to 1.69; p < 0.001) for the composite CVD outcome (myocardial infarction, heart failure, and stroke), 1.44 (95% CI: 1.02 to 2.02; p \u00bc 0.04) for myocardial infarction, and 1.39 (95% CI: 1.10 to 1.76; p \u00bc 0.006) for heart failure. CAC was not associated with all-cause mortality. This study from CRIC, as did another study (49), found CAC offered incremental prognostic value for CV events beyond traditional risk factors. The similar magnitude hazard ratios for atherosclerotic CVD and for HF suggest CAC scoring in the CKD population may be less specific for atherosclerotic burden and instead be an integrated marker of both medial and intimal calcification. This is consistent with autopsy findings of patients with established coronary artery disease in which high rates of coexistent medial calcification was observed only in those with CKD (50). Reduction in radiation dose, application of semiautomated scoring mechanisms, ease of access, and validated age-standardization have resulted in the CT CAC score becoming the gold standard endpoint for trials that evaluated change in vascular calcification. PLANE RADIOGRAPHY. The Kauppila score is a semiquantitative scoring method that attributes an ordinal value to calcification (0 to 3) at 8 sites along the abdominal aorta (total maximal score 24) as",
            "latex": null,
            "type": "table"
        },
        "TABREF46": {
            "text": "vertebral height with age (thus, length of quantified aorta) and superimposition of the vertebra on the aorta are known shortcomings. Studies in patients with ESKD have shown stepwise increases in abdominal aortic calcification (AAC) that correlate with CAC score(51)  and that associate with worse CV outcomes(52). However, there are few data to support its accuracy at discerning temporal trends, particularly in non-ESKD cohorts in which calcification may be more modest, nor has there been formal validation of the Kauppila score against a quantitative method. Another x-ray\u00c0based scoringsystem that was described by Adragao involves semiquantitative scoring of linear calcification on pelvic and hand radiographs (41). The deliberate focus on pattern of calcification and inclusion of hand vessels increases the specificity for medial calcification, which is a theory supported by its correlation with arterial stiffness. In 1 study of 742 participants with ESKD, an elevation in either the Adragao ($3) or Kauppila ($6) score was associated with all-cause and CV mortality; however, only the Adragao score remained significant after adjustment for covariates (HR: 3.46; 95% CI: 1.27 to 9.45; p \u00bc 0.02) (53).BREAST IMAGING. Breast arterial calcification is an attractive method for measuring exclusively medial artery calcification because atherosclerosis has not been shown to occur in these vessels. Studies in patients with advanced CKD confirm mammography is not only capable of sensitive, temporal measurement of breast arterial calcification compared with CT (54), but also demonstrates that breast arterial calcification is strongly associated with both measures of peripheral arterial calcification(55)  and CV outcomes(56).Although such a modality may inform mechanistic insights around the natural history of medial calcification, this is a modality limited to the assessment of women, and at present, has only been retrospectively analyzed.SCREENING. Proponents of routine screening for vascular calcification among patients with CKD suggest there is significant incremental value in identifying a high-risk CV cohort. Conversely, others",
            "latex": null,
            "type": "table"
        },
        "TABREF47": {
            "text": "have argued that all patients with CKD should be considered at the highest CV risk and, in the absence of specific vascular calcification therapies, screening for vascular calcification does not influence management. Routine vascular calcification screening using either lateral pelvic x-ray or CT imaging received a weak (level 2C) recommendation in the 2017 Kidney Disease Improving Global Outcomes guidelines, reflecting the paucity of outcomes-driven data (57,58). The wording used in the 2017 updated guidelines was nearly identical to that used in the 2009 Guidelines, highlighting the lack of progress in the search for specific therapies proven to reverse, arrest, or attenuate vascular calcification (59). Our understanding of vascular calcification has evolved from a benign, passive deposition of minerals CENTRAL ILLUSTRATION Distribution of Vascular Calcification With Attendant Clinical Consequences Nelson, A.J. et al. J Am Coll Cardiol Basic Trans Science. 2020;5(4):398-412.",
            "latex": null,
            "type": "table"
        },
        "TABREF48": {
            "text": "AND MINERAL METABOLISM. Phosphate excretion is regulated at the proximal tubule of the kidney; however, the balance of bone formation and resorption is an important determinant of serum levels. Hormonal regulation of phosphate at the renal and gastrointestinal levels via parathyroid hormone (PTH), fibroblast growth factor (FGF)-23, klotho and 1,25-dihydroxyvitamin D (calcitriol) maintains this mineral in a narrow serum range (2.5 to 4.5 mg/dl). As impaired kidney function progresses to advanced stages, with reduction in functional nephron mass, phosphate excretion is impaired, bone remodeling slows, and together with persistent dietary intake, serum phosphate concentrations rise. Multiple studies have suggested that there is a link between hyperphosphatemia and the propensity for accelerated vascular calcification (46,60), particularly in patients on hemodialysis (61,62). Because phosphate is a key building block of hydroxyapatite crystals, it is conceivable that increased serum levels alone in the context of CKD could contribute directly to precipitation of hydroxyapatite in tissue (63). Although this may occur to some degree, not all patients with sustained hyperphosphatemia develop vascular calcification; seminal in vitro observations suggest a more active process wherein exposure to elevated phosphate induces a dose-and time-dependent phenotypic change in vascular smooth muscle cells (VSMCs) (64). The presence of a pro-calcific CKD milieu permits (and potentially promotes) the upregulation of phosphate channels (Pit-1 and Pit-2) which, in the context of hyperphosphatemia, mediates transdifferentiation of VSMCs to an osteochodrogenic cell phenotype (65); an event that can be, in part, inhibited by competitive antagonism of Pit-1 (64). Beyond phosphate, other metabolic features of the mineral-bone axis have been implicated in vascular calcification, including calcium and PTH, although their effects may be more complex. Several lines of evidence support a direct role of PTH: elevated PTH is associated with higher rates of vascular calcification (66); and animal models of synthetic PTH infusion develop extensive calcification regardless of subtotal nephrectomy/sham and independent of presence or absence of hypercalcemia (67). In subtotally nephrectomized rats, submaximal suppression of PTH by treatment with a calcimimetic or parathyroidectomy slows rates of aortic calcification independent of serum calcium and phosphate concentrations (68). That stated, vascular calcification may also be potentiated in the setting of overzealous treatment of hyperparathyroidism, especially with excessive use of calcium-containing phosphate binders, which results in low bone turnover and reduced mineralization (69). Although complex and incompletely understood, states of low bone turnover and reduced mineralization are likely to attenuate the skeletal capacity for effective calcium and phosphate homeostasis. A reduction in skeletal buffering capacity may expose the vasculature to greater fluctuations in extracellular calcium and phosphate, thereby increasing the propensity for vascular calcification (70). . As alluded to, the transdifferentiation of VSMCs into an osteoblast-like secretory phenotype is central to the underlying pathophysiology of vascular calcification. This process is marked by downregulation of smooth muscle genes and subsequent expression of bone markers Runx2, osteopontin, osteocalcin, and alkaline phosphatase. The biology governing VSMC phenotypic switching remains to be fully appreciated; however, a number of triggers have been identified, including oxidative stress, imbalance of pro-calcific and/or anticalcific mediators (see the following), pro-calcific microRNAs, advanced glycation end products, cellular senescence [potentially through Prelamin A (71)], and hyperphosphatemia (as previously described). Once established, these osteoblast and/or chondrocyte-like cells behave in a manner consistent with other bone-forming cells by producing a collagen matrix through the secretion of calcium and phosphorous-laden vesicles (see the following). OF INHIBITORY MECHANISMS. Mineralization occurs throughout the body at physiological calcium and phosphate levels; thus, a dynamic balance of promoters and inhibitors are required to ensure mineralization is supported at desired sites (bone) and is prevented from occurring elsewhere (ectopic, metastatic). Two prominent inhibitors are fetuin-A and matrix Gla protein (MGP). Fetuin-A is a glycoprotein synthesized in the liver that is recycled by VSMCs where it acts as a mineral chaperone, binding serum calcium in calciprotein complexes and preventing it from crystallization (72). Mice deficient in fetuin-A develop widespread calcification (73), whereas the addition of fetuin-A to bovine VSMC",
            "latex": null,
            "type": "table"
        },
        "TABREF49": {
            "text": "The primary endpoint is progression of thoracic aortic calcification and CAC at 18 months. Major adverse CV events will be assessed at 3 to 5 years after treatment initiation; results are expected towards the end of 2020. The other way of testing this hypothesis is to evaluate for differential effects on vascular calcification in patients who receive direct acting oral anticoagulants compared with vitamin K antagonists (e.g., warfarin).The largest trial evaluating this hypothesis is the IRIVASC-Trial (Rivaroxaban Compared to Vitamin K Antagonist Treatment Upon Development of Cardiovascular Calcification; NCT02066662), which has enrolled participants with an eGFR >15 ml/ min/1.73 m 2 and who have either atrial fibrillation or pulmonary embolism that requires systemic anticoagulation. PHOSPHATE BINDERS. Patients with advanced CKD who have developed hyperphosphatemia frequently require treatment with phosphate binders when dietary restriction is inadequate. Because phosphate and the attendant increase in FGF-23 and PTH have been linked to vascular calcification (46,64) (as previously described), lowering or even maintaining stable phosphate levels near normal could be associated with favorable overall vascular outcomes.Serum phosphate can be reduced with either calcium-containing binders (acetate, carbonate) or calcium-free binders (sevelamer, lanthanum, iron compounds, magnesium). In the dialysis population, the totality of data suggest exposure to exogenous calcium through calcium-containing binders is associated with higher rates of vascular calcification(62,122,123). Although subsequent meta-analyses have shown a mortality benefit for calcium-free binders(124), it remains unclear whether this is due to increased risk in the comparator arms due to excess calcium loading or to an absolute benefit in the calcium free arms. Moreover, because of the degree of phosphate lowering has been similar across most patients in the trials, it is unclear whether any benefits at all are due to the management of phosphatemia (or potentially its effect on intermediates, such as FGF-23) or are instead due to agent-specific effects, such as improvements in lipid profile and C-reactive protein observed with sevalemer. Importantly, no clinical trial has demonstrated a long-term benefit of phosphate binders on clinical outcomes in ESKD nor has any trial established the optimal serum phosphate target for ESKD. In the nondialysis CKD population, data are even less convincing. A recent trial that compared phosphate control with either calcium-containing or calcium-free binders against placebo in patients with stage 3 to 4 CKD showed only a modest reduction in phosphate and a paradoxical increase in CAC (albeit largest in those receiving calcium-containing binders) (125). A further trial is currently underway, IMPROVE-CKD (Impact of Phosphate Reduction on Vascular Endpoints in Chronic Kidney Disease), which is comparing lanthanum against placebo in patients with stage 3 to 4 CKD. This trial will evaluate arterial stiffness as the primary endpoint in 488 participants at 96 weeks with secondary endpoints that include aortic calcification, left ventricular mass using magnetic resonance imaging, and bone and/or phosphate markers among others (126). Whether IMPROVE-CKD will fill the evidence gap between control (or reduction) of serum phosphate with slowing or halting of vascular calcification, or potentially further highlight the limitations of serum phosphate as an overall measure of the total phosphate pool (and thus, propensity to calcification) remains to be seen. Adding complexity is the recently completed COMBINE (CKD Optimal Management With Binders and Nicotinamide study) trial that evaluated a similar cohort of patients with stage 3 to 4 CKD; not only was lanthanum poorly tolerated (despite the addition of nicotinamide), there was minimal effect on phosphate or FGF-23 over 12 months (127). MAGNESIUM. Recent studies have highlighted a potential role for magnesium to prevent vascular calcification. In vitro (128\u00c0130) and animal studies (131) showed that magnesium modulates the development of phosphate-induced calcification in a dosedependent manner. Small human clinical studies have shown that oral administration of magnesium to patients with moderate CKD through to ESKD, either as a phosphate binder or as a supplement, directly slowed CAC progression or indirectly reduced the propensity for calcification (132\u00c0134). Based on this controlled trial evaluated the effect of magnesium oxide on CAC progression in patients with CKD stages 3 to 4 (135). The trial was stopped early when the control arm demonstrated a median CAC change of 39.5% (interquartile range: 19.0% to 81.3%), whereas the magnesium arm showed a progression of only 11.3% (interquartile range: 0% to 30.8%; p < 0.001).",
            "latex": null,
            "type": "table"
        },
        "TABREF50": {
            "text": "Vascular Calcification in CKD ingredient, myo-inositol hexaphosphate (IP6), or phytate. SNF472 inhibits the development and progression of calcification by binding to growth sites of hydroxyapatite crystal; this mechanism appears to be agnostic to the underlying cause of calcification and may represent an opportunity to inhibit the final common pathway of vascular calcification. Pre-clinical studies demonstrated that the intravenous administration of SNF472 to vitamin D\u00c0supplemented rodent models reduced the development of CV calcification (136) and prevented progression of established calcification (137). Recently, the results of the CaLIPSO (Cal for calcium and ipso meaning the item itself) trial were reported; in this Phase IIb study, 274 patients with ESKD who underwent dialysis were randomized to SNF472 administered at 2 different doses (300 mg or 600 mg) or placebo (1:1:1) for 52 weeks (138). For the primary endpoint at 12 months, using data from the combined dose group, administration of SNF472 resulted in significant slowing of progression of CAC (11%: 95% CI: 7% to 15% vs. 20%; 95% CI 14% to 26%; p \u00bc 0.016). Secondary endpoints also showed slowing of progression of aortic valve calcification (14%; 95% CI: 5% to 24% vs. 98%; 95% CI: 77% to 123%; p < 0.001) and a directionally consistent but nonsignificant difference in progression of thoracic aorta calcification (23%; 95% CI: 16% to 30% vs. 28%; 95% CI: 19% to 38%; p \u00bc 0.40). Notwithstanding these promising data, larger studies are required to delineate the clinical efficacy and safety of this compound.",
            "latex": null,
            "type": "table"
        },
        "TABREF51": {
            "text": "Key Mediators of Medial Vascular CalcificationPhosphate, bone, and mineral metabolism Failure of/reduction in calcification inhibitors FGF \u00bc fibroblast growth factor; miRNA \u00bc micro RNA; VSMC \u00bc vascular smooth muscle cell.",
            "latex": null,
            "type": "table"
        },
        "TABREF52": {
            "text": "One victim was hit by a car while taking temperatures on a highway.\" The article also mentions Dr. Peng Yinhua (age 29), who postponed his planned wedding on February 1, so that he could continue to provide care to COVID-19 patients. Dr. Yinhua promised his pregnant fianc\u00e9e that they would have a ceremony after the outbreak had passed: he died of COVID-19 on February 21. In his epic work Devotions Upon Emergent Occasions, John Donne argues that the death of any individual is something others can learn from, should they understand it properly (1,4). Fully understanding the COVID-19-attributable deaths of health care workers in China, and for that matter, the COVID-19-attributable deaths of health care workers all around the world will take some time to process, insofar as many of these deaths were preventable. As noted, there is plenty of blame to go around. The unbelievable courage of the men and women who provided care to COVID-19 patients, knowing that they might die from the same mysterious illness that was killing their patients, is an example of what is truly remarkable and best about humanity. Their lesson of sacrifice and selfless caring is one that can never be washed away, nor ever diminished. Not ever. To this end, we dedicate this issue of JACC: Basic to Translational Science to the Chinese health care workers who died from COVID-19, as well as all of the other health care workers around the world who are caring for COVID-19 patients. A partial list of the names of the frontline Chinese physicians and nurses who died of COVID-19 (online search date March 20, 2020) follows at the end of this Editor's Page. ADDRESS FOR CORRESPONDENCE: Dr. Douglas L. Mann, Editor-in-Chief JACC: Basic to Translational Science, American College of Cardiology, 2400 N. Street NW, Washington, DC 20037. E-mail: jaccbts@acc.org.",
            "latex": null,
            "type": "table"
        }
    },
    "back_matter": []
}